<!DOCTYPE html>
<html lang="en-US" data-bt-theme="Industrial 1.3.1">
<head>

<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="robots" content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1">
<script type="06cd7e663a0e46d4271fe72d-text/javascript">if(navigator.userAgent.match(/MSIE|Internet Explorer/i)||navigator.userAgent.match(/Trident\/7\..*?rv:11/i)){var href=document.location.href;if(!href.match(/[?&]nowprocket/)){if(href.indexOf("?")==-1){if(href.indexOf("#")==-1){document.location.href=href+"?nowprocket=1"}else{document.location.href=href.replace("#","?nowprocket=1#")}}else{if(href.indexOf("#")==-1){document.location.href=href+"&nowprocket=1"}else{document.location.href=href.replace("#","&nowprocket=1#")}}}}</script><script type="06cd7e663a0e46d4271fe72d-text/javascript">class RocketLazyLoadScripts{constructor(e){this.triggerEvents=e,this.eventOptions={passive:!0},this.userEventListener=this.triggerListener.bind(this),this.delayedScripts={normal:[],async:[],defer:[]},this.allJQueries=[]}_addUserInteractionListener(e){this.triggerEvents.forEach((t=>window.addEventListener(t,e.userEventListener,e.eventOptions)))}_removeUserInteractionListener(e){this.triggerEvents.forEach((t=>window.removeEventListener(t,e.userEventListener,e.eventOptions)))}triggerListener(){this._removeUserInteractionListener(this),"loading"===document.readyState?document.addEventListener("DOMContentLoaded",this._loadEverythingNow.bind(this)):this._loadEverythingNow()}async _loadEverythingNow(){this._delayEventListeners(),this._delayJQueryReady(this),this._handleDocumentWrite(),this._registerAllDelayedScripts(),this._preloadAllScripts(),await this._loadScriptsFromList(this.delayedScripts.normal),await this._loadScriptsFromList(this.delayedScripts.defer),await this._loadScriptsFromList(this.delayedScripts.async),await this._triggerDOMContentLoaded(),await this._triggerWindowLoad(),window.dispatchEvent(new Event("rocket-allScriptsLoaded"))}_registerAllDelayedScripts(){document.querySelectorAll("script[type=rocketlazyloadscript]").forEach((e=>{e.hasAttribute("src")?e.hasAttribute("async")&&!1!==e.async?this.delayedScripts.async.push(e):e.hasAttribute("defer")&&!1!==e.defer||"module"===e.getAttribute("data-rocket-type")?this.delayedScripts.defer.push(e):this.delayedScripts.normal.push(e):this.delayedScripts.normal.push(e)}))}async _transformScript(e){return await this._requestAnimFrame(),new Promise((t=>{const n=document.createElement("script");let i;[...e.attributes].forEach((e=>{let t=e.nodeName;"type"!==t&&("data-rocket-type"===t&&(t="type",i=e.nodeValue),n.setAttribute(t,e.nodeValue))})),e.hasAttribute("src")&&this._isValidScriptType(i)?(n.addEventListener("load",t),n.addEventListener("error",t)):(n.text=e.text,t()),e.parentNode.replaceChild(n,e)}))}_isValidScriptType(e){return!e||""===e||"string"==typeof e&&["text/javascript","text/x-javascript","text/ecmascript","text/jscript","application/javascript","application/x-javascript","application/ecmascript","application/jscript","module"].includes(e.toLowerCase())}async _loadScriptsFromList(e){const t=e.shift();return t?(await this._transformScript(t),this._loadScriptsFromList(e)):Promise.resolve()}_preloadAllScripts(){var e=document.createDocumentFragment();[...this.delayedScripts.normal,...this.delayedScripts.defer,...this.delayedScripts.async].forEach((t=>{const n=t.getAttribute("src");if(n){const t=document.createElement("link");t.href=n,t.rel="preload",t.as="script",e.appendChild(t)}})),document.head.appendChild(e)}_delayEventListeners(){let e={};function t(t,n){!function(t){function n(n){return e[t].eventsToRewrite.indexOf(n)>=0?"rocket-"+n:n}e[t]||(e[t]={originalFunctions:{add:t.addEventListener,remove:t.removeEventListener},eventsToRewrite:[]},t.addEventListener=function(){arguments[0]=n(arguments[0]),e[t].originalFunctions.add.apply(t,arguments)},t.removeEventListener=function(){arguments[0]=n(arguments[0]),e[t].originalFunctions.remove.apply(t,arguments)})}(t),e[t].eventsToRewrite.push(n)}function n(e,t){let n=e[t];Object.defineProperty(e,t,{get:()=>n||function(){},set(i){e["rocket"+t]=n=i}})}t(document,"DOMContentLoaded"),t(window,"DOMContentLoaded"),t(window,"load"),t(window,"pageshow"),t(document,"readystatechange"),n(document,"onreadystatechange"),n(window,"onload"),n(window,"onpageshow")}_delayJQueryReady(e){let t=window.jQuery;Object.defineProperty(window,"jQuery",{get:()=>t,set(n){if(n&&n.fn&&!e.allJQueries.includes(n)){n.fn.ready=n.fn.init.prototype.ready=function(t){e.domReadyFired?t.bind(document)(n):document.addEventListener("rocket-DOMContentLoaded",(()=>t.bind(document)(n)))};const t=n.fn.on;n.fn.on=n.fn.init.prototype.on=function(){if(this[0]===window){function e(e){return e.split(" ").map((e=>"load"===e||0===e.indexOf("load.")?"rocket-jquery-load":e)).join(" ")}"string"==typeof arguments[0]||arguments[0]instanceof String?arguments[0]=e(arguments[0]):"object"==typeof arguments[0]&&Object.keys(arguments[0]).forEach((t=>{delete Object.assign(arguments[0],{[e(t)]:arguments[0][t]})[t]}))}return t.apply(this,arguments),this},e.allJQueries.push(n)}t=n}})}async _triggerDOMContentLoaded(){this.domReadyFired=!0,await this._requestAnimFrame(),document.dispatchEvent(new Event("rocket-DOMContentLoaded")),await this._requestAnimFrame(),window.dispatchEvent(new Event("rocket-DOMContentLoaded")),await this._requestAnimFrame(),document.dispatchEvent(new Event("rocket-readystatechange")),await this._requestAnimFrame(),document.rocketonreadystatechange&&document.rocketonreadystatechange()}async _triggerWindowLoad(){await this._requestAnimFrame(),window.dispatchEvent(new Event("rocket-load")),await this._requestAnimFrame(),window.rocketonload&&window.rocketonload(),await this._requestAnimFrame(),this.allJQueries.forEach((e=>e(window).trigger("rocket-jquery-load"))),window.dispatchEvent(new Event("rocket-pageshow")),await this._requestAnimFrame(),window.rocketonpageshow&&window.rocketonpageshow()}_handleDocumentWrite(){const e=new Map;document.write=document.writeln=function(t){const n=document.currentScript;n||console.error("WPRocket unable to document.write this: "+t);const i=document.createRange(),r=n.parentElement;let a=e.get(n);void 0===a&&(a=n.nextSibling,e.set(n,a));const o=document.createDocumentFragment();i.setStart(o,0),o.appendChild(i.createContextualFragment(t)),r.insertBefore(o,a)}}async _requestAnimFrame(){return new Promise((e=>requestAnimationFrame(e)))}static run(){const e=new RocketLazyLoadScripts(["keydown","mousemove","touchmove","touchstart","touchend","wheel"]);e._addUserInteractionListener(e)}}RocketLazyLoadScripts.run();
</script>
<title>Active pharmaceutical ingredients - Ikigai&reg; Corporation</title>
<link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CMontserrat%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CMontserrat%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CRoboto%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CMontserrat%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CRoboto%3A100%2C100italic%2C200%2C200italic%2C300%2C300italic%2C400%2C400italic%2C500%2C500italic%2C600%2C600italic%2C700%2C700italic%2C800%2C800italic%2C900%2C900italic%7CRoboto%20Slab%3A100%2C100italic%2C200%2C200italic%2C300%2C300italic%2C400%2C400italic%2C500%2C500italic%2C600%2C600italic%2C700%2C700italic%2C800%2C800italic%2C900%2C900italic&#038;subset=latin%2Clatin-ext&#038;display=swap">
<link rel="stylesheet" href="./../../../../wp-content/cache/min/1/94ef57cb2a7e04898d8df31f764bfef2.css" media="all" data-minify="1">
<meta name="description" content="API (Active Pharmaceutical Ingredient) determines the active component which is included in the medicine. CATEGORY :ALLAPI. ANTIBIOTICSAPI. BOLDENONE SERIESAPI. CANRENONE DERIVATIVESAPI. CORTICAL STEROIDAPI. DHEA &amp; DERIVATIVESAPI. ESTROGENAPI. NANDROLONE SERIESAPI. OTHERSAPI. PROGESTERONE &amp; INTERMEDIATEAPI. STARTING MATERIALAPI. TESTOSTERONE SERIES">
<link rel="canonical" href="./index.html">
<meta property="og:locale" content="en_US">
<meta property="og:type" content="article">
<meta property="og:title" content="Active pharmaceutical ingredients - Ikigai&reg; Corporation">
<meta property="og:description" content="API (Active Pharmaceutical Ingredient) determines the active component which is included in the medicine. CATEGORY :ALLAPI. ANTIBIOTICSAPI. BOLDENONE SERIESAPI. CANRENONE DERIVATIVESAPI. CORTICAL STEROIDAPI. DHEA &amp; DERIVATIVESAPI. ESTROGENAPI. NANDROLONE SERIESAPI. OTHERSAPI. PROGESTERONE &amp; INTERMEDIATEAPI. STARTING MATERIALAPI. TESTOSTERONE SERIES">
<meta property="og:url" content="./active-pharmaceutical-ingredients/">
<meta property="og:site_name" content="Ikigai&reg; Corporation">
<meta property="article:modified_time" content="2021-01-28T12:32:49+00:00">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:label1" content="Est. reading time">
<meta name="twitter:data1" content="1 minute">
<script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"WebSite","@id":"./#website","url":"./","name":"Ikigai&reg; Corporation","description":"Leading suppliers of API (active pharmaceutical ingredients)","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"./?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"WebPage","@id":"./active-pharmaceutical-ingredients/#webpage","url":"./active-pharmaceutical-ingredients/","name":"Active pharmaceutical ingredients - Ikigai&reg; Corporation","isPartOf":{"@id":"./#website"},"datePublished":"2020-01-30T19:55:43+00:00","dateModified":"2021-01-28T12:32:49+00:00","description":"API (Active Pharmaceutical Ingredient) determines the active component which is included in the medicine. CATEGORY :ALLAPI. ANTIBIOTICSAPI. BOLDENONE SERIESAPI. CANRENONE DERIVATIVESAPI. CORTICAL STEROIDAPI. DHEA & DERIVATIVESAPI. ESTROGENAPI. NANDROLONE SERIESAPI. OTHERSAPI. PROGESTERONE & INTERMEDIATEAPI. STARTING MATERIALAPI. TESTOSTERONE SERIES","breadcrumb":{"@id":"./active-pharmaceutical-ingredients/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["./active-pharmaceutical-ingredients/"]}]},{"@type":"BreadcrumbList","@id":"./active-pharmaceutical-ingredients/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"./"},{"@type":"ListItem","position":2,"name":"Active pharmaceutical ingredients"}]}]}</script>

<link rel="dns-prefetch" href="https://use.fontawesome.com">
<link rel="dns-prefetch" href="https://fonts.googleapis.com">
<link href="https://fonts.gstatic.com" crossorigin rel="preconnect">
<style type="text/css">img.wp-smiley,
img.emoji {
	display: inline !important;
	border: none !important;
	box-shadow: none !important;
	height: 1em !important;
	width: 1em !important;
	margin: 0 .07em !important;
	vertical-align: -0.1em !important;
	background: none !important;
	padding: 0 !important;
}</style>

<style id="industrial-style-inline-css" type="text/css">select, input{font-family: Roboto;} input:not([type='checkbox']):not([type='radio']), textarea, select{ font-family: "Montserrat";} input:not([type='checkbox']):not([type='radio']):not([type='submit']):focus, textarea:focus{-webkit-box-shadow: 0 0 4px 0 #58a0d3; box-shadow: 0 0 4px 0 #58a0d3;} html a:hover, .btLightSkin a:hover, .btDarkSkin .btLightSkin a:hover, .btLightSkin .btDarkSkin .btLightSkin a:hover, .btDarkSkin a:hover, .btLightSkin .btDarkSkin a:hover, .btDarkSkin.btLightSkin .btDarkSkin a:hover{ color: #58a0d3;} .btLightSkin .btText a, .btDarkSkin .btLightSkin .btText a, .btLightSkin .btDarkSkin .btLightSkin .btText a, .btDarkSkin .btText a, .btLightSkin .btDarkSkin .btText a, .btDarkSkin.btLightSkin .btDarkSkin .btText a{color: #58a0d3;} body{font-family: "Roboto",Arial,sans-serif;} .btContentHolder cite{ font-family: Montserrat;} h1, h2, h3, h4, h5, h6{font-family: "Montserrat";} .btContentHolder table thead th{ background-color: #58a0d3; font-family: Montserrat;} .btAccentColorBackground{background-color: #58a0d3 !important;} .btAccentColorBackground .headline b.animate.animated{color: #1a86d3;} .btAccentColorBackground .btDash.bottomDash .dash:after{border-color: #1a86d3;} .btAccentDarkColorBackground{background-color: #2e7ab0 !important;} .btAccentDarkColorBackground .headline b.animate.animated{color: #1a86d3;} .btAccentVeryDarkColorBackground{background-color: #19425f !important;} .btAccentLightColorBackground{background-color: rgba(88,160,211,0.7) !important;} .btAlternateColorBackground{background-color: #1a86d3 !important;} .btAlternateDarkColorBackground{background-color: #125b8f !important;} .btAlternateVeryDarkColorBackground{background-color: #0c3e61 !important;} .btAlternateLightColorBackground{background-color: rgba(26,134,211,0.6) !important;} .btAccentDarkHeader .btPreloader .animation > div:first-child, .btLightAccentHeader .btPreloader .animation > div:first-child{ background-color: #2e7ab0;} .btPreloader .animation .preloaderLogo{height: 100px;} .mainHeader{ font-family: "Montserrat";} .btMenuVertical.btAccentDarkHeader .mainHeader, .btMenuVertical.btLightAccentHeader .mainHeader{background-color: #58a0d3;} .btMenuVertical.btLightAlternateHeader .mainHeader{background-color: #1a86d3;} .menuPort{font-family: "Montserrat";} .menuPort nav ul li a:hover{color: #58a0d3 !important;} .menuPort nav > ul > li > a{line-height: 100px;} .btTextLogo{ line-height: 100px;} .btLogoArea .logo img{height: 100px;} .btHorizontalMenuTrigger{ line-height: 100px;} .btMenuHorizontal .menuPort nav > ul > li.current-menu-ancestor > a:after, .btMenuHorizontal .menuPort nav > ul > li.current-menu-item > a:after{ background-color: #58a0d3;} .btAccentDarkHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-ancestor > a:after, .btAccentDarkHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-item > a:after, .btAccentLightHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-ancestor > a:after, .btAccentLightHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-item > a:after{background-color: #1a86d3;} .btMenuHorizontal .menuPort nav > ul > li > ul li.current-menu-ancestor > a, .btMenuHorizontal .menuPort nav > ul > li > ul li.current-menu-item > a{color: #58a0d3 !important;} body.btMenuHorizontal .subToggler{ line-height: 100px;} .btMenuHorizontal .topBarInMenu{ height: 100px;} .btLightSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btLightSkin.btAccentLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .btBelowLogoArea, .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .topBar, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .btBelowLogoArea, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .topBar{background-color: #58a0d3;} .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .btBelowLogoArea:before, .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .topBar:before, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .btBelowLogoArea:before, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .topBar:before{ background-color: #58a0d3;} .btAccentLightHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .btBelowLogoArea, .btAccentLightHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .topBar{background-color: #58a0d3;} .btLightSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btLightSkin.btLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btLightSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .menuPort > nav > ul > li > a:hover, .btDarkSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btAccentDarkHeader.btMenuHorizontal:not(.btBelowMenu) .mainHeader, .btAccentDarkHeader.btMenuHorizontal.btStickyHeaderActive .mainHeader{background-color: #58a0d3;} .btAccentDarkHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .port .btLogoArea{background-color: #58a0d3;} .btLightSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btLightAccentHeader.btMenuHorizontal:not(.btBelowMenu) .mainHeader, .btLightAccentHeader.btMenuHorizontal.btStickyHeaderActive .mainHeader{background-color: #58a0d3;} .btLightAccentHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .port .btLogoArea{background-color: #58a0d3;} .btLightSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover{color: #58a0d3 !important;} .btLightAlternateHeader.btMenuHorizontal:not(.btBelowMenu) .mainHeader, .btLightAlternateHeader.btMenuHorizontal.btStickyHeaderActive .mainHeader{background-color: #1a86d3;} .btLightAlternateHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .port .btLogoArea{background-color: #1a86d3;} .btAccentDarkHeader.btMenuVertical > .menuPort .logo, .btLightAccentHeader.btMenuVertical > .menuPort .logo{background-color: #58a0d3;} .btLightAlternateHeader.btMenuVertical > .menuPort .logo{background-color: #1a86d3;} .btMenuVertical > .menuPort .btCloseVertical:before:hover{color: #58a0d3;} @media (min-width: 1200px){.btMenuVerticalOn .btVerticalMenuTrigger .btIco a:before{color: #58a0d3 !important;} }.btMenuHorizontal .topBarInLogoArea{ height: 100px;} .btMenuHorizontal .topBarInLogoArea .topBarInLogoAreaCell{border: 0 solid #58a0d3;} .btSearchInner.btFromTopBox{ background: #58a0d3;} .btSearchInner.btFromTopBox form button:hover:before{color: #58a0d3;} .btDarkSkin .btSiteFooter .port:before, .btLightSkin .btDarkSkin .btSiteFooter .port:before, .btDarkSkin.btLightSkin .btDarkSkin .btSiteFooter .port:before{background-color: #58a0d3;} .btMediaBox.btQuote, .btMediaBox.btLink{ background-color: #58a0d3;} .btArticleListItem .headline a:hover{color: #58a0d3;} .btCommentsBox .vcard .posted{ font-family: "Montserrat";} .btCommentsBox .commentTxt p.edit-link, .btCommentsBox .commentTxt p.reply{ font-family: "Montserrat";} .comment-respond .btnOutline button[type="submit"]{font-family: "Montserrat";} a#cancel-comment-reply-link:hover{color: #58a0d3;} .post-password-form input[type="submit"]{ background: #58a0d3; font-family: "Montserrat";} .btPagination{font-family: "Montserrat";} .btPagination .paging a:hover:after{border-color: #58a0d3;} span.btHighlight{ background-color: #58a0d3;} .btArticleCategories a:not(:first-child):before{ background-color: #58a0d3;} .btArticleMeta{font-family: "Montserrat";} body:not(.btNoDashInSidebar) .btBox > h4:after, body:not(.btNoDashInSidebar) .btCustomMenu > h4:after, body:not(.btNoDashInSidebar) .btTopBox > h4:after{ border-bottom: 3px solid #58a0d3;} .btBox ul li.current-menu-item > a, .btCustomMenu ul li.current-menu-item > a, .btTopBox ul li.current-menu-item > a{color: #58a0d3;} .btBox .ppTxt .header .headline a a:hover, .btCustomMenu .ppTxt .header .headline a a:hover, .btTopBox .ppTxt .header .headline a a:hover{color: #58a0d3;} .btBox p.posted, .btBox .quantity, .btCustomMenu p.posted, .btCustomMenu .quantity, .btTopBox p.posted, .btTopBox .quantity{ font-family: Montserrat;} .widget_calendar table caption{background: #58a0d3; font-family: "Montserrat";} .widget_rss li a.rsswidget{font-family: "Montserrat";} .fancy-select .trigger.open{color: #58a0d3;} .fancy-select ul.options li:hover{color: #58a0d3;} .widget_shopping_cart .total{ font-family: Montserrat;} .widget_shopping_cart .widget_shopping_cart_content .mini_cart_item .ppRemove a.remove{ background-color: #58a0d3;} .widget_shopping_cart .widget_shopping_cart_content .mini_cart_item .ppRemove a.remove:hover{background-color: #1a86d3;} .menuPort .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetIcon span.cart-contents, .topTools .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetIcon span.cart-contents, .topBarInLogoArea .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetIcon span.cart-contents{ background-color: #1a86d3; font: normal 10px/1 Montserrat;} .btMenuVertical .menuPort .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetInnerContent .verticalMenuCartToggler, .btMenuVertical .topTools .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetInnerContent .verticalMenuCartToggler, .btMenuVertical .topBarInLogoArea .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetInnerContent .verticalMenuCartToggler{ background-color: #58a0d3;} .widget_recent_reviews{font-family: Montserrat;} .widget_price_filter .price_slider_wrapper .ui-slider .ui-slider-handle{ background-color: #58a0d3;} .btBox .tagcloud a, .btTags ul a{ background: #58a0d3; font-family: "Montserrat";} .btSidebar .btIconWidget:hover .btIconWidgetText, footer .btIconWidget:hover .btIconWidgetText{color: #58a0d3;} .btTopBox.widget_bt_text_image .widget_sp_image-description{ font-family: 'Roboto',arial,sans-serif;} .btMenuHorizontal .topTools .btIconWidget:hover, .btMenuHorizontal .topBarInMenu .btIconWidget:hover{color: #58a0d3;} .btMenuHorizontal .topTools .btAccentIconWidget, .btMenuHorizontal .topBarInMenu .btAccentIconWidget{background-color: #58a0d3;} .btTopToolsInMenuArea.btMenuHorizontal .topTools .btAccentIconWidget, .btTopToolsInMenuArea.btMenuHorizontal .topBarInMenu .btAccentIconWidget{background-color: #1a86d3;} .btTopToolsInMenuArea.btMenuHorizontal .topTools .btAccentIconWidget:hover, .btTopToolsInMenuArea.btMenuHorizontal .topBarInMenu .btAccentIconWidget:hover{color: #58a0d3;} .btAccentLightHeader.btMenuHorizontal .topTools .btAccentIconWidget, .btLightAccentHeader.btMenuHorizontal .topTools .btAccentIconWidget, .btAccentLightHeader.btMenuHorizontal .topBarInMenu .btAccentIconWidget, .btLightAccentHeader.btMenuHorizontal .topBarInMenu .btAccentIconWidget{background-color: #1a86d3;} .btMenuHorizontal .topTools .btAccentIconWidget:hover, .btMenuHorizontal .topBarInMenu .btAccentIconWidget:hover{color: #1a86d3;} .btTopToolsInMenuArea.btLightAccentHeader.btMenuHorizontal .topTools .btAccentIconWidget:hover, .btTopToolsInMenuArea.btLightAccentHeader.btMenuHorizontal .topBarInMenu .btAccentIconWidget:hover{background-color: #58a0d3;} .btLightSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btLightSkin.btAccentLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before, .btLightSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btLightSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before{color: #1a86d3;} .btLightSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType .btIcoHolder:hover:before, .btDarkSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before{color: #1a86d3;} .btLightSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before, .btDarkSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before{color: #58a0d3;} .btLightSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before, .btDarkSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before{color: #58a0d3;} .btSpecialHeaderIcon .btIco .btIcoHolder:before, .btSpecialHeaderIcon .btIconWidgetTitle, .btSpecialHeaderIcon .btIconWidgetText{color: #58a0d3 !important;} .btLightSkin .btBox .btSearch button:hover, .btDarkSkin .btLightSkin .btBox .btSearch button:hover, .btLightSkin .btDarkSkin .btLightSkin .btBox .btSearch button:hover, .btDarkSkin .btBox .btSearch button:hover, .btLightSkin .btDarkSkin .btBox .btSearch button:hover, .btDarkSkin.btLightSkin .btDarkSkin .btBox .btSearch button:hover, .btLightSkin form.woocommerce-product-search button:hover, .btDarkSkin .btLightSkin form.woocommerce-product-search button:hover, .btLightSkin .btDarkSkin .btLightSkin form.woocommerce-product-search button:hover, .btDarkSkin form.woocommerce-product-search button:hover, .btLightSkin .btDarkSkin form.woocommerce-product-search button:hover, .btDarkSkin.btLightSkin .btDarkSkin form.woocommerce-product-search button:hover{background: #58a0d3 !important; border-color: #58a0d3 !important;} .topTools .widget_search button, .topBarInMenu .widget_search button{ background: #58a0d3;} .topTools .widget_search button:before, .topBarInMenu .widget_search button:before{ color: #58a0d3;} .topTools .widget_search button:hover, .topBarInMenu .widget_search button:hover{background: #2e7ab0;} .btIcoFilledType.btIcoAccentColor.btIconHexagonShape.btIco .btIcoHolder .hex{fill: #58a0d3;} .btIcoFilledType.btIcoAlternateColor.btIconHexagonShape.btIco .btIcoHolder .hex{fill: #1a86d3;} .btIcoOutlineType.btIcoAccentColor.btIconHexagonShape.btIco .btIcoHolder .hex{ stroke: #58a0d3;} .btIcoOutlineType.btIcoAlternateColor.btIconHexagonShape.btIco .btIcoHolder .hex{ stroke: #1a86d3;} .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex{fill: #58a0d3; stroke: #58a0d3;} .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex{fill: #1a86d3; stroke: #1a86d3;} .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex{ stroke: #1a86d3;} .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex{ stroke: #58a0d3;} .btIconHexagonShape .btIco.btIcoFilledType .btIcoHolder svg .hex{ fill: #58a0d3;} .btIconHexagonShape .btIco.btIcoFilledType:hover .btIcoHolder svg .hex{stroke: #58a0d3;} .btIconHexagonShape .btIco.btIcoOutlineType .btIcoHolder svg .hex{stroke: #58a0d3;} .btIconHexagonShape .btIco.btIcoOutlineType:hover .btIcoHolder svg .hex{stroke: #58a0d3; fill: #58a0d3;} .btIco.btIcoFilledType.btIcoAccentColor .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAccentColor:hover .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1em #58a0d3 inset; box-shadow: 0 0 0 1em #58a0d3 inset;} .btIco.btIcoFilledType.btIcoAccentColor:hover .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAccentColor .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset; box-shadow: 0 0 0 1px #58a0d3 inset; color: #58a0d3;} .btIco.btIcoFilledType.btIcoAlternateColor .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAlternateColor:hover .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1em #1a86d3 inset; box-shadow: 0 0 0 1em #1a86d3 inset;} .btIco.btIcoFilledType.btIcoAlternateColor:hover .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAlternateColor .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1px #1a86d3 inset; box-shadow: 0 0 0 1px #1a86d3 inset; color: #1a86d3;} .btLightSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btLightSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btLightSkin .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btDarkSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btDarkSkin.btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before{color: #58a0d3;} .btLightSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btDarkSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btDarkSkin.btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before{color: #1a86d3;} .btIcoAccentColor span{color: #58a0d3;} .btIcoAlternateColor span{color: #1a86d3;} .btIcoDefaultColor:hover span{color: #58a0d3;} .btBtn{ font-family: "Montserrat";} .btnFilledStyle.btnAccentColor, .btnOutlineStyle.btnAccentColor:hover{background-color: #58a0d3; border: 2px solid #58a0d3;} .btnOutlineStyle.btnAccentColor, .btnFilledStyle.btnAccentColor:hover{ border: 2px solid #58a0d3; color: #58a0d3;} .btnOutlineStyle.btnAccentColor span, .btnFilledStyle.btnAccentColor:hover span, .btnOutlineStyle.btnAccentColor span:before, .btnFilledStyle.btnAccentColor:hover span:before, .btnOutlineStyle.btnAccentColor a, .btnFilledStyle.btnAccentColor:hover a, .btnOutlineStyle.btnAccentColor .btIco a:before, .btnFilledStyle.btnAccentColor:hover .btIco a:before, .btnOutlineStyle.btnAccentColor button, .btnFilledStyle.btnAccentColor:hover button{color: #58a0d3 !important;} .btnBorderlessStyle.btnAccentColor span, .btnBorderlessStyle.btnNormalColor:hover span, .btnBorderlessStyle.btnAccentColor span:before, .btnBorderlessStyle.btnNormalColor:hover span:before, .btnBorderlessStyle.btnAccentColor a, .btnBorderlessStyle.btnNormalColor:hover a, .btnBorderlessStyle.btnAccentColor .btIco a:before, .btnBorderlessStyle.btnNormalColor:hover .btIco a:before, .btnBorderlessStyle.btnAccentColor button, .btnBorderlessStyle.btnNormalColor:hover button{color: #58a0d3;} .btnFilledStyle.btnAlternateColor, .btnOutlineStyle.btnAlternateColor:hover{background-color: #1a86d3; border: 2px solid #1a86d3;} .btnOutlineStyle.btnAlternateColor, .btnFilledStyle.btnAlternateColor:hover{ border: 2px solid #1a86d3; color: #1a86d3;} .btnOutlineStyle.btnAlternateColor span, .btnFilledStyle.btnAlternateColor:hover span, .btnOutlineStyle.btnAlternateColor span:before, .btnFilledStyle.btnAlternateColor:hover span:before, .btnOutlineStyle.btnAlternateColor a, .btnFilledStyle.btnAlternateColor:hover a, .btnOutlineStyle.btnAlternateColor .btIco a:before, .btnFilledStyle.btnAlternateColor:hover .btIco a:before, .btnOutlineStyle.btnAlternateColor button, .btnFilledStyle.btnAlternateColor:hover button{color: #1a86d3 !important;} .btnBorderlessStyle.btnAlternateColor span, .btnBorderlessStyle.btnAlternateColor span:before, .btnBorderlessStyle.btnAlternateColor a, .btnBorderlessStyle.btnAlternateColor .btIco a:before, .btnBorderlessStyle.btnAlternateColor button{color: #1a86d3;} .btCounterHolder{font-family: "Montserrat";} .btCounterHolder .btCountdownHolder .days_text, .btCounterHolder .btCountdownHolder .hours_text, .btCounterHolder .btCountdownHolder .minutes_text, .btCounterHolder .btCountdownHolder .seconds_text{ font-family: Montserrat; color: #58a0d3;} .btProgressContent{font-family: "Montserrat";} .btProgressContent .btProgressAnim{ background-color: #58a0d3;} .btShowTitle{ border-left: 4px solid #58a0d3;} .btAccentColorBackground .btShowTitle{border-left: 4px solid #1a86d3;} .btPriceTable .btPriceTableHeader{background: #58a0d3;} .btPriceTableSticker{ font-family: "Montserrat";} .header .btSuperTitle{font-family: "Montserrat";} .header .btSubTitle{font-family: "Roboto";} .btDash.bottomDash .dash:after{ border-bottom: 4px solid #58a0d3;} .btDash.topDash .btSuperTitle:after, .btDash.topDash .btSuperTitle:before{ border-top: 1px solid #58a0d3;} .btNoMore{ font-family: Montserrat;} .btGridContent .header .btSuperTitle a:hover{color: #58a0d3;} .btCatFilter{ font-family: Montserrat;} .btCatFilter .btCatFilterItem:hover{color: #58a0d3;} .btCatFilter .btCatFilterItem.active{color: #58a0d3;} .nbs a .nbsItem .nbsDir{ font-family: "Montserrat";} .btLightSkin .btSimpleArrows .nbs a:hover:before, .btDarkSkin .btLightSkin .btSimpleArrows .nbs a:hover:before, .btLightSkin .btDarkSkin .btLightSkin .btSimpleArrows .nbs a:hover:before, .btDarkSkin .btSimpleArrows .nbs a:hover:before, .btLightSkin .btDarkSkin .btSimpleArrows .nbs a:hover:before, .btDarkSkin.btLightSkin .btDarkSkin .btSimpleArrows .nbs a:hover:before{color: #58a0d3 !important;} .neighboringArticles .nbs a .nbsItem .nbsDir{ font-family: 'Roboto',arial,sans-serif;} .neighboringArticles .nbs a:hover .nbsDir{color: #58a0d3;} .recentTweets small:before{ color: #58a0d3;} .btInfoBar .btInfoBarMeta p strong{color: #58a0d3;} .tabsHeader li{ font-family: "Montserrat";} .tabsVertical .tabAccordionTitle{ font-family: "Montserrat";} .btVisualizer{font-family: Montserrat;} form.wpcf7-form .wpcf7-submit{ background-color: #58a0d3;} .btAnimNav li.btAnimNavDot{ font-family: Montserrat;} .btAnimNav li.btAnimNavNext:hover, .btAnimNav li.btAnimNavPrev:hover{border-color: #58a0d3; color: #58a0d3;} .headline b.animate.animated{ color: #58a0d3;} .headline em.animate{ font-family: Roboto;} p.demo_store{ background-color: #58a0d3;} .woocommerce .woocommerce-info a: not(.button), .woocommerce .woocommerce-message a: not(.button), .woocommerce-page .woocommerce-info a: not(.button), .woocommerce-page .woocommerce-message a: not(.button){color: #58a0d3;} .woocommerce .woocommerce-message:before, .woocommerce .woocommerce-info:before, .woocommerce-page .woocommerce-message:before, .woocommerce-page .woocommerce-info:before{ color: #58a0d3;} .woocommerce a.button, .woocommerce input[type="submit"], .woocommerce button[type="submit"], .woocommerce input.button, .woocommerce input.alt:hover, .woocommerce a.button.alt:hover, .woocommerce .button.alt:hover, .woocommerce button.alt:hover, .woocommerce-page a.button, .woocommerce-page input[type="submit"], .woocommerce-page button[type="submit"], .woocommerce-page input.button, .woocommerce-page input.alt:hover, .woocommerce-page a.button.alt:hover, .woocommerce-page .button.alt:hover, .woocommerce-page button.alt:hover{ font-family: Montserrat;} .woocommerce a.button:hover, .woocommerce input[type="submit"]:hover, .woocommerce .button:hover, .woocommerce button:hover, .woocommerce input.alt, .woocommerce a.button.alt, .woocommerce .button.alt, .woocommerce button.alt, .woocommerce-page a.button:hover, .woocommerce-page input[type="submit"]:hover, .woocommerce-page .button:hover, .woocommerce-page button:hover, .woocommerce-page input.alt, .woocommerce-page a.button.alt, .woocommerce-page .button.alt, .woocommerce-page button.alt{ font-family: "Montserrat";} .woocommerce p.lost_password:before, .woocommerce-page p.lost_password:before{ color: #58a0d3;} .woocommerce form.login p.lost_password a:hover, .woocommerce-page form.login p.lost_password a:hover{color: #58a0d3;} .woocommerce .added:after, .woocommerce .loading:after, .woocommerce-page .added:after, .woocommerce-page .loading:after{ background-color: #58a0d3;} .woocommerce form .form-row .select2-container, .woocommerce-page form .form-row .select2-container{ font-family: "Montserrat";} .woocommerce div.product p.price, .woocommerce div.product span.price, .woocommerce-page div.product p.price, .woocommerce-page div.product span.price{ font-family: "Montserrat"; color: #58a0d3;} .woocommerce div.product .stock, .woocommerce-page div.product .stock{color: #58a0d3;} .woocommerce div.product a.reset_variations:hover, .woocommerce-page div.product a.reset_variations:hover{color: #58a0d3;} .woocommerce .added_to_cart, .woocommerce-page .added_to_cart{ font-family: Montserrat;} .woocommerce .products ul li.product .btPriceTableSticker, .woocommerce ul.products li.product .btPriceTableSticker, .woocommerce-page .products ul li.product .btPriceTableSticker, .woocommerce-page ul.products li.product .btPriceTableSticker{ background: #1a86d3;} .woocommerce .products ul li.product .price, .woocommerce ul.products li.product .price, .woocommerce-page .products ul li.product .price, .woocommerce-page ul.products li.product .price{ font-family: "Montserrat";} .woocommerce nav.woocommerce-pagination, .woocommerce-page nav.woocommerce-pagination{ font-family: "Montserrat";} .woocommerce nav.woocommerce-pagination ul li a:focus, .woocommerce nav.woocommerce-pagination ul li a:hover, .woocommerce nav.woocommerce-pagination ul li a.next, .woocommerce nav.woocommerce-pagination ul li a.prev, .woocommerce nav.woocommerce-pagination ul li span.current, .woocommerce-page nav.woocommerce-pagination ul li a:focus, .woocommerce-page nav.woocommerce-pagination ul li a:hover, .woocommerce-page nav.woocommerce-pagination ul li a.next, .woocommerce-page nav.woocommerce-pagination ul li a.prev, .woocommerce-page nav.woocommerce-pagination ul li span.current{background: #58a0d3;} .woocommerce .star-rating span:before, .woocommerce-page .star-rating span:before{ color: #58a0d3;} .woocommerce p.stars a[class^="star-"].active:after, .woocommerce p.stars a[class^="star-"]:hover:after, .woocommerce-page p.stars a[class^="star-"].active:after, .woocommerce-page p.stars a[class^="star-"]:hover:after{color: #58a0d3;} .woocommerce-cart table.cart td.product-remove a.remove{ color: #58a0d3; border: 1px solid #58a0d3;} .woocommerce-cart table.cart td.product-remove a.remove:hover{background-color: #58a0d3;} .woocommerce-cart .cart_totals .discount td{color: #58a0d3;} .woocommerce-account header.title .edit{ color: #58a0d3;} .woocommerce-account header.title .edit:before{ color: #58a0d3;} .btLightSkin.woocommerce-page .product .headline a:hover, .btDarkSkin .btLightSkin.woocommerce-page .product .headline a:hover, .btLightSkin .btDarkSkin .btLightSkin.woocommerce-page .product .headline a:hover, .btDarkSkin.woocommerce-page .product .headline a:hover, .btLightSkin .btDarkSkin.woocommerce-page .product .headline a:hover, .btDarkSkin.btLightSkin .btDarkSkin.woocommerce-page .product .headline a:hover{color: #58a0d3;} .btQuoteBooking .btTotalNextWrapper{ font-family: "Montserrat";} .btQuoteBooking .btContactNext{ border: #58a0d3 2px solid; color: #58a0d3;} .btQuoteBooking .btContactNext:hover, .btQuoteBooking .btContactNext:active{background-color: #58a0d3 !important;} .btQuoteBooking .btQuoteSwitch:hover{-webkit-box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btQuoteSwitch.on .btQuoteSwitchInner{ background: #58a0d3;} .btQuoteBooking .dd.ddcommon.borderRadiusTp .ddTitleText, .btQuoteBooking .dd.ddcommon.borderRadiusBtm .ddTitleText{ -webkit-box-shadow: 5px 0 0 #58a0d3 inset,0 2px 10px rgba(0,0,0,.2); box-shadow: 5px 0 0 #58a0d3 inset,0 2px 10px rgba(0,0,0,.2);} .btQuoteBooking .ui-slider .ui-slider-handle{ background: #58a0d3;} .btQuoteBooking .btQuoteBookingForm .btQuoteTotal{ background: #58a0d3;} .btQuoteBooking .btContactFieldMandatory.btContactFieldError input, .btQuoteBooking .btContactFieldMandatory.btContactFieldError textarea{border: 1px solid #58a0d3; -webkit-box-shadow: 0 0 0 1px #58a0d3 inset; box-shadow: 0 0 0 1px #58a0d3 inset;} .btQuoteBooking .btContactFieldMandatory.btContactFieldError .dd.ddcommon.borderRadius .ddTitleText{border: 1px solid #58a0d3; -webkit-box-shadow: 0 0 0 1px #58a0d3 inset; box-shadow: 0 0 0 1px #58a0d3 inset;} .btQuoteBooking .btContactFieldMandatory.btContactFieldError input:hover, .btQuoteBooking .btContactFieldMandatory.btContactFieldError textarea:hover{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btContactFieldMandatory.btContactFieldError .dd.ddcommon.borderRadius:hover .ddTitleText{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btContactFieldMandatory.btContactFieldError input:focus, .btQuoteBooking .btContactFieldMandatory.btContactFieldError textarea:focus{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btContactFieldMandatory.btContactFieldError .dd.ddcommon.borderRadiusTp .ddTitleText{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btSubmitMessage{color: #58a0d3;} .btDatePicker .ui-datepicker-header{ background-color: #58a0d3;} .btQuoteBooking .btContactSubmit{font-family: "Montserrat"; background-color: #58a0d3; border: 1px solid #58a0d3;} .btQuoteBooking .btContactSubmit:hover{ color: #58a0d3;} .btPayPalButton:hover{-webkit-box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} #btSettingsPanel #btSettingsPanelToggler:before{ color: #58a0d3;} #btSettingsPanel h4{ background-color: #58a0d3;} #btSettingsPanel .btSettingsPanelRow.btAccentColorRow .trigger, #btSettingsPanel .btSettingsPanelRow.btAccentColorRow select{border-color: #58a0d3;} #btSettingsPanel .btSettingsPanelRow.btAlternateColorRow .trigger, #btSettingsPanel .btSettingsPanelRow.btAlternateColorRow select{border-color: #1a86d3;} .wp-block-button__link:hover{color: #58a0d3 !important;}
.tagcloud a { color: #ffffff; } .btTopToolsInMenuArea.btMenuHorizontal .topTools .btAccentIconWidget, .btTopToolsInMenuArea.btMenuHorizontal .topBarInMenu .btAccentIconWidget { background-color: #02b3f9; }</style>
<link rel="stylesheet" id="industrial-print-css" href="./../../../../wp-content/themes/industrial/print.css?ver=5.8" type="text/css" media="print">
<style id="elementor-frontend-inline-css" type="text/css">@font-face{font-family:eicons;src:url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.eot?5.10.0);src:url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.eot?5.10.0#iefix) format("embedded-opentype"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.woff2?5.10.0) format("woff2"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.woff?5.10.0) format("woff"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.ttf?5.10.0) format("truetype"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.svg?5.10.0#eicon) format("svg");font-weight:400;font-style:normal}</style>
<style id="font-awesome-official-v4shim-inline-css" type="text/css">@font-face {
font-family: "FontAwesome";
font-display: block;
src: url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.eot"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.eot?#iefix") format("embedded-opentype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.woff2") format("woff2"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.woff") format("woff"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.ttf") format("truetype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.svg#fontawesome") format("svg");
}

@font-face {
font-family: "FontAwesome";
font-display: block;
src: url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.eot"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.eot?#iefix") format("embedded-opentype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.woff2") format("woff2"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.woff") format("woff"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.ttf") format("truetype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.svg#fontawesome") format("svg");
}

@font-face {
font-family: "FontAwesome";
font-display: block;
src: url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.eot"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.eot?#iefix") format("embedded-opentype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.woff2") format("woff2"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.woff") format("woff"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.ttf") format("truetype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.svg#fontawesome") format("svg");
unicode-range: U+F004-F005,U+F007,U+F017,U+F022,U+F024,U+F02E,U+F03E,U+F044,U+F057-F059,U+F06E,U+F070,U+F075,U+F07B-F07C,U+F080,U+F086,U+F089,U+F094,U+F09D,U+F0A0,U+F0A4-F0A7,U+F0C5,U+F0C7-F0C8,U+F0E0,U+F0EB,U+F0F3,U+F0F8,U+F0FE,U+F111,U+F118-F11A,U+F11C,U+F133,U+F144,U+F146,U+F14A,U+F14D-F14E,U+F150-F152,U+F15B-F15C,U+F164-F165,U+F185-F186,U+F191-F192,U+F1AD,U+F1C1-F1C9,U+F1CD,U+F1D8,U+F1E3,U+F1EA,U+F1F6,U+F1F9,U+F20A,U+F247-F249,U+F24D,U+F254-F25B,U+F25D,U+F267,U+F271-F274,U+F279,U+F28B,U+F28D,U+F2B5-F2B6,U+F2B9,U+F2BB,U+F2BD,U+F2C1-F2C2,U+F2D0,U+F2D2,U+F2DC,U+F2ED,U+F328,U+F358-F35B,U+F3A5,U+F3D1,U+F410,U+F4AD;
}</style>
<script  data-rocket-type="text/javascript" src="./../../../../wp-includes/js/jquery/jquery.min.js?ver=3.6.0" id="jquery-core-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-includes/js/jquery/jquery-migrate.min.js?ver=3.3.2" id="jquery-migrate-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/bold-page-builder/script_fe.js?ver=1620657753" id="bt_bb_fe-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/bt_elements.js?ver=1620657753" id="bt_plugin_enqueue-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/modal-for-elementor/js/jquery.cookie.js?ver=1620657753" id="jquery-cookie-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/html5shiv.min.js?ver=1" id="html5shiv-min-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/respond.min.js?ver=1" id="respond-min-js" defer></script>
<script  data-rocket-type="text/javascript" id="industrial-header-misc-js-before">
window.BoldThemesURI = "./wp-content/themes/industrial"; window.BoldThemesAJAXURL = "./wp-admin/admin-ajax.php";window.boldthemes_text = [];window.boldthemes_text.previous = 'previous';window.boldthemes_text.next = 'next';
</script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/header.misc.js?ver=1620657753" id="industrial-header-misc-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/sticky-header-effects-for-elementor/assets/js/she-header.js?ver=1620657753" id="she-header-js" defer></script>
<link rel="https://api.w.org/" href="./../../../../wp-json/index.html">
<link rel="alternate" type="application/json" href="./../../../../wp-json/wp/v2/pages/3408/index.html">
<meta name="generator" content="WordPress 5.8">
<link rel="shortlink" href="./../../../../index.html?p=3408">
<link rel="alternate" type="application/json+oembed" href="./../../../../wp-json/oembed/1.0/embed/index.html?url=https%3A%2F%2F%2Factive-pharmaceutical-ingredients%2F">
<link rel="alternate" type="text/xml+oembed" href="./../../../../wp-json/oembed/1.0/embed/index.html?url=https%3A%2F%2F%2Factive-pharmaceutical-ingredients%2F&#038;format=xml">
<script  data-rocket-type="text/javascript">
            ( function () {
                window.lae_fs = { can_use_premium_code: false};
            } )();
        </script>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Productivity.woff?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Development.ttf?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Construction.ttf?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/CraftEssential.ttf?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Pe-icon-7-stroke.woff?d7yf1v" crossorigin>
<link rel="icon" href="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-32x32.jpg" sizes="32x32">
<link rel="icon" href="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-192x192.jpg" sizes="192x192">
<link rel="apple-touch-icon" href="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-180x180.jpg">
<meta name="msapplication-TileImage" content="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-270x270.jpg">
<noscript><style id="rocket-lazyload-nojs-css">.rll-youtube-player, [data-lazy-src]{display:none !important;}</style></noscript>

<script  async src="https://www.googletagmanager.com/gtag/js?id=UA-124610061-1"></script>
<script >
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'UA-124610061-1');
	
</script>

<script  async src="https://www.googletagmanager.com/gtag/js?id=AW-634803173"></script>
<script >
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'AW-634803173');
</script>

<script >
  gtag('event', 'conversion', {'send_to': 'AW-634803173/aDeACK-KstABEOWn2a4C'});
</script>

<script >(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-KJ8SPBQ');</script>

<script async src="./../../../../cdn-cgi/bm/cv/669835187/api.js"></script>
</head>
<body class="page-template-default page page-id-3408 bt_bb_plugin_active bt_bb_fe_preview_toggle has-navmenu has-megamenu bodyPreloader btMenuLeftEnabled btMenuBelowLogo btStickyEnabled btHideHeadline btLightSkin btTopToolsInMenuArea btRemovePreloader btSoftRoundedButtons btLightAlternateHeader btNoSidebar cookies-not-set elementor-default elementor-kit-3445 elementor-page elementor-page-3408" data-autoplay="0">

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KJ8SPBQ" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>

<div class="btPageWrap" id="top">
<header class="mainHeader btClear gutter ">
<div class="port">
<div class="btLogoArea menuHolder btClear">
<span class="btVerticalMenuTrigger">&nbsp;<span class="btIco btIcoDefaultType"><a href="#" target="_self" data-ico-fa="&#xf0c9;" class="btIcoHolder"></a></span></span>
<span class="btHorizontalMenuTrigger">&nbsp;<span class="btIco btIcoDefaultType"><a href="#" target="_self" data-ico-fa="&#xf0c9;" class="btIcoHolder"></a></span></span>
<div class="logo">
<span>
<a href="./../../../../index.html"><img class="btMainLogo" data-hw="1" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ikigai&reg; Corporation" data-lazy-src="./../../../../wp-content/uploads/2020/05/logo-2.png"><noscript><img class="btMainLogo" data-hw="1" src="./../../../../wp-content/uploads/2020/05/logo-2.png" alt="Ikigai&reg; Corporation"></noscript>
<img class="btAltLogo" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ikigai&reg; Corporation" data-lazy-src="./../../../../wp-content/uploads/2018/10/cropped-imgonline-com-ua-Compressed-09lij2UbRT-com.jpg"><noscript><img class="btAltLogo" src="./../../../../wp-content/uploads/2018/10/cropped-imgonline-com-ua-Compressed-09lij2UbRT-com.jpg" alt="Ikigai&reg; Corporation"></noscript></a> </span>
</div>
<div class="topBarInLogoArea">
<div class="topBarInLogoAreaCell">
<span class="btIconWidget btAccentIconWidget btWidgetWithText"><span class="btIconWidgetIcon"><span class="btIco btIcoDefaultType btIcoDefaultColor"><span data-ico-pr="&#xf10f;" class="btIcoHolder"></span></span></span><span class="btIconWidgetContent"><span class="btIconWidgetTitle">Working hours:</span><span class="btIconWidgetText">Mon - Fri 9.00 - 18.00</span></span></span> </div>
</div>
</div>
<div class="btBelowLogoArea btClear"> <div class="menuPort">
<div class="topBarInMenu">
<div class="topBarInMenuCell">
<span id="time610e3a31c10e7" class="btIconWidget"><span class="btIconWidgetIcon"><span class="btIco btIcoDefaultType btIcoDefaultColor"><span data-ico-fa="&#xf017;" class="btIcoHolder"></span></span></span><span class="btIconWidgetContent"><span class="btIconWidgetTitle">Hong Kong time</span><span class="btIconWidgetText"></span></span></span><div class="btTopBox widget_search">
<h2 class="widgettitle">Search</h2>
<div class="btSearch">
<span class="btIco btIcoDefaultType btIcoDefaultColor"><a href="#" target="_self" data-ico-fa="&#xf002;" class="btIcoHolder" style="color:#fff"></a></span>
<div class="btSearchInner gutter" role="search">
<div class="btSearchInnerContent port">
 <form action="./index.html" method="get">
<div class="col-lg-12 form-control-group"><input type="text" id="elastic"placeholder="Looking for..."></div>
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/azithromycin/"style="
    color: #fff;
"><li class="hide">Azithromycin</li></a>
	<a href="./../../../../portfolio/doxycycline/"style="
    color: #fff;
"><li class="hide">Doxycycline</li></a>
	<a href="./../../../../portfolio/levofloxacin/"style="
    color: #fff;
"><li class="hide">Levofloxacin</li></a>
	<a href="./../../../../portfolio/metronidazole/"style="
    color: #fff;
"><li class="hide">Metronidazole</li></a>
	<a href="./../../../../portfolio/trimethoprim/"style="
    color: #fff;
"><li class="hide">Trimethoprim</li></a>
	<a href="./../../../../portfolio/sulfamethoxazole/"style="
    color: #fff;
"><li class="hide">Sulfamethoxazole</li></a>
	<a href="./../../../../portfolio/ciprofloxacin/"style="
    color: #fff;
"><li class="hide">Ciprofloxacin</li></a>
	<a href="./../../../../portfolio/cephalexin/"style="
    color: #fff;
"><li class="hide">Cephalexin</li></a>
	<a href="./../../../../portfolio/clindamycin/"style="
    color: #fff;
"><li class="hide">Clindamycin</li></a>
	<a href="./../../../../portfolio/clavulanic-acid/"style="
    color: #fff;
"><li class="hide">Clavulanic acid</li></a>



</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/amoxicillin/"style="
    color: #fff;
"><li class="hide">Amoxicillin</li></a>
	<a href="./../../../../portfolio/boldenone-cypionate/"style="
    color: #fff;
"><li class="hide">Boldenone cypionate</li></a>
	<a href="./../../../../portfolio/boldenone-propionate/"style="
    color: #fff;
"><li class="hide">Boldenone propionate</li></a>
	<a href="./../../../../portfolio/boldenone-acetate/"style="
    color: #fff;
"><li class="hide">Boldenone acetate</li></a>
	<a href="./../../../../portfolio/boldenone-undecylenate/"style="
    color: #fff;
"><li class="hide">Boldenone undecylenate</li></a>
	<a href="./../../../../portfolio/boldenone/"style="
    color: #fff;
"><li class="hide">Boldenone</li></a>
	<a href="./../../../../portfolio/spironolactone/"style="
    color: #fff;
"><li class="hide">Spironolactone</li></a>
	<a href="./../../../../portfolio/11a-hydroxy-canrenone/"style="
    color: #fff;
"><li class="hide">11a Hydroxy Canrenone</li></a>
	<a href="./../../../../portfolio/canrenone/"style="
    color: #fff;
"><li class="hide">Canrenone</li></a>
	<a href="./../../../../portfolio/prednisolone-acetate/"style="
    color: #fff;
"><li class="hide">Prednisolone acetate</li></a>



</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/prednisolone/"style="
    color: #fff;
"><li class="hide">Prednisolone</li></a>
	<a href="./../../../../portfolio/anecortave-acetate/"style="
    color: #fff;
"><li class="hide">Anecortave acetate</li></a>
	<a href="./../../../../portfolio/prednisone-acetate/"style="
    color: #fff;
"><li class="hide">Prednisone acetate</li></a>
	<a href="./../../../../portfolio/prednisone/"style="
    color: #fff;
"><li class="hide">Prednisone</li></a>
	<a href="./../../../../portfolio/hydrocortisone-acetate/"style="
    color: #fff;
"><li class="hide">Hydrocortisone Acetate</li></a>
	<a href="./../../../../portfolio/hydrocortisone/"style="
    color: #fff;
"><li class="hide">Hydrocortisone</li></a>
	<a href="./../../../../portfolio/cortisone-acetate/"style="
    color: #fff;
"><li class="hide">Cortisone Acetate</li></a>
	<a href="./../../../../portfolio/cortisone/"style="
    color: #fff;
"><li class="hide">Cortisone</li></a>
	<a href="./../../../../portfolio/7-keto-dhea/"style="
    color: #fff;
"><li class="hide">7-Keto DHEA</li></a>
	<a href="./../../../../portfolio/androstanolone/"style="
    color: #fff;
"><li class="hide">Androstanolone</li></a>
	


</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/mestanolone/"style="
    color: #fff;
"><li class="hide">Mestanolone</li></a>
	<a href="./../../../../portfolio/epiandrosterone/"style="
    color: #fff;
"><li class="hide">Epiandrosterone</li></a>
	<a href="./../../../../portfolio/estradiol-valerate/"style="
    color: #fff;
"><li class="hide">Estradiol Valerate</li></a>
	<a href="./../../../../portfolio/estradiol-cypionate/"style="
    color: #fff;
"><li class="hide">Estradiol Cypionate</li></a>
	<a href="./../../../../portfolio/estradiol-enanthate/"style="
    color: #fff;
"><li class="hide">Estradiol Enanthate</li></a>
<a href="./../../../../portfolio/estradiol-benzoate/"style="
    color: #fff;
"><li class="hide">Estradiol Benzoate</li></a>
	<a href="./../../../../portfolio/estriol/"style="
    color: #fff;
"><li class="hide">Estriol</li></a>
	<a href="./../../../../portfolio/estradiol/"style="
    color: #fff;
"><li class="hide">Estradiol</li></a>
	<a href="./../../../../portfolio/estrone/"style="
    color: #fff;
"><li class="hide">Estrone</li></a>
	<a href="./../../../../portfolio/dehydronandrolone-acetate/"style="
    color: #fff;
"><li class="hide">Dehydronandrolone Acetate</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/nandrolone-undecanoate/"style="
    color: #fff;
"><li class="hide">Nandrolone Undecanoate</li></a>
	<a href="./../../../../portfolio/nandrolone-cypionate/"style="
    color: #fff;
"><li class="hide">Nandrolone Cypionate</li></a>
	<a href="./../../../../portfolio/nandrolone-propionate/"style="
    color: #fff;
"><li class="hide">Pandrolone Propionate</li></a>
	<a href="./../../../../portfolio/nandrolone-phenylpropionate/"style="
    color: #fff;
"><li class="hide">Nandrolone Phenylpropionate</li></a>
	<a href="./../../../../portfolio/nandrolone-decanoate/"style="
    color: #fff;
"><li class="hide">Nandrolone Decanoate</li></a>
<a href="./../../../../portfolio/nandrolone-base-（19-nor-testosterone）/"style="
    color: #fff;
"><li class="hide">Nandrolone</li></a>
	<a href="./../../../../portfolio/drostanolone-enanthate/"style="
    color: #fff;
"><li class="hide">Drostanolone Enanthate</li></a>
	<a href="./../../../../portfolio/drostanolone-propionate/"style="
    color: #fff;
"><li class="hide">Drostanolone Propionate</li></a>
	<a href="./../../../../portfolio/metenolone-acetate/"style="
    color: #fff;
"><li class="hide">Metenolone Acetate</li></a>
	<a href="./../../../../portfolio/trenbolone-enanthate/"style="
    color: #fff;
"><li class="hide">Trenbolone Enanthate</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/trenbolone-acetate/"style="
    color: #fff;
"><li class="hide">Trenbolone Acetate</li></a>
	<a href="./../../../../portfolio/fluoxymesterone/"style="
    color: #fff;
"><li class="hide">Fluoxymesterone</li></a>
	<a href="./../../../../portfolio/mesterolone/"style="
    color: #fff;
"><li class="hide">Mesterolone</li></a>
<a href="./../../../../portfolio/altrenogest//"style="
    color: #fff;
"><li class="hide">Altrenogest</li></a>
	<a href="./../../../../portfolio/exemestane/"style="
    color: #fff;
"><li class="hide">Exemestane</li></a>
	<a href="./../../../../portfolio/oxandrolone/"style="
    color: #fff;
"><li class="hide">Oxandrolone</li></a>
	<a href="./../../../../portfolio/methandienone/"style="
    color: #fff;
"><li class="hide">Methandienone</li></a>
	<a href="./../../../../portfolio/oxymetholone/"style="
    color: #fff;
"><li class="hide">Oxymetholone</li></a>
	<a href="./../../../../portfolio/stanozolol/"style="
    color: #fff;
"><li class="hide">Stanozolol</li></a>
	<a href="./../../../../portfolio/methenolone-enanthate/"style="
    color: #fff;
"><li class="hide">Methenolone Enanthate</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/progesterone/"style="
    color: #fff;
"><li class="hide">Progesterone</li></a>
	<a href="./../../../../portfolio/20-formylpregn-4-en-3-one/"style="
    color: #fff;
"><li class="hide">20-Formylpregn-4-en-3-one</li></a>
	<a href="./../../../../portfolio/14-androstadienedioneadd/"style="
    color: #fff;
"><li class="hide">1,4-Androstadienedione(add)</li></a>
	<a href="./../../../../portfolio/4-androstenedione4-ad/"style="
    color: #fff;
"><li class="hide">4-Androstenedione (4-AD)</li></a>
	<a href="./../../../../portfolio/1-testosterone/"style="
    color: #fff;
"><li class="hide">1-Testosterone</li></a>
	<a href="./../../../../portfolio/methyl-1-testosterone/"style="
    color: #fff;
"><li class="hide">Methyl-1-Testosterone</li></a>
	<a href="./../../../../portfolio/testosterone-undecanoate/"style="
    color: #fff;
"><li class="hide">Testosterone Undecanoate</li></a>
	<a href="./../../../../portfolio/testosterone-isocaproate/"style="
    color: #fff;
"><li class="hide">Testosterone Isocaproate</li></a>
	<a href="./../../../../portfolio/testosterone-propionate/"style="
    color: #fff;
"><li class="hide">Testosterone Propionate</li></a>
	<a href="./../../../../portfolio/testosterone-phenylpropionate/"style="
    color: #fff;
"><li class="hide">Testosterone Phenylpropionate</li></a>



</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/sitolactone/"style="
    color: #fff;
"><li class="hide">Sitolactone</li></a>
	<a href="./../../../../portfolio/testosterone-enanthate/"style="
    color: #fff;
"><li class="hide">Testosterone Enanthate</li></a>
	<a href="./../../../../portfolio/testosterone-decanoate/"style="
    color: #fff;
"><li class="hide">Testosterone Decanoate</li></a>
	<a href="./../../../../portfolio/testosterone-cypionate/"style="
    color: #fff;
"><li class="hide">Testosterone Cypionate</li></a>
	<a href="./../../../../portfolio/testosterone-acetate/"style="
    color: #fff;
"><li class="hide">Testosterone Acetate</li></a>
	<a href="./../../../../portfolio/methyltestosterone/"style="
    color: #fff;
"><li class="hide">Methyltestosterone</li></a>
	<a href="./../../../../portfolio/testosterone/"style="
    color: #fff;
"><li class="hide">Testosterone</li></a>
	<a href="./../../../../portfolio/magnesium-stearate/"style="
    color: #fff;
"><li class="hide">Magnesium Stearate</li></a>
	<a href="./../../../../portfolio/bis4-nitrophenylsulfane/"style="
    color: #fff;
"><li class="hide">Bis(4-nitrophenylsulfane)</li></a>
	<a href="./../../../../portfolio/n-benzhydrylpiperazine/"style="
    color: #fff;
"><li class="hide">N-Benzhydrylpiperazine</li></a>

	



</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	
<a href="./../../../../portfolio/zinc-stearate/"style="
    color: #fff;
"><li class="hide">Zinc stearate</li></a>
	<a href="./../../../../portfolio/sodium-starch-glycolate/"style="
    color: #fff;
"><li class="hide">Sodium starch glycolate</li></a>
	<a href="./../../../../portfolio/microcrystalline-cellulose/"style="
    color: #fff;
"><li class="hide">microcrystalline Cellulose</li></a>
	<a href="./../../../../portfolio/croscarmellose-sodium/"style="
    color: #fff;
"><li class="hide">CROSCARMELLOSE SODIUM</li></a>
	<a href="./../../../../portfolio/calcium-stearate/"style="
    color: #fff;
"><li class="hide">Calcium stearate</li></a>
	<a href="./../../../../portfolio/calcium-lactate/"style="
    color: #fff;
"><li class="hide">Calcium lactate</li></a>
	<a href="./../../../../portfolio/calcium-acetate/"style="
    color: #fff;
"><li class="hide">Calcium acetate</li></a>
	<a href="./../../../../portfolio/1-aminoindan/"style="
    color: #fff;
"><li class="hide">1-Aminoindan</li></a>
	<a href="./../../../../portfolio/44-sulfonylbisnitrobenzene/"style="
    color: #fff;
"><li class="hide">4,4′-sulfonylbis(nitrobenzene)</li></a>
	<a href="./../../../../portfolio/dehydroepiandrosterone-enanthate/"style="
    color: #fff;
"><li class="hide">Dehydroepiandrosterone Enanthate</li></a>




</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/11a17a-dihydroxyprogesterone/"style="
    color: #fff;
"><li class="hide">11a,17a-Dihydroxyprogesterone</li></a>
	<a href="./../../../../portfolio/17a-hydroxyprogesterone-hpg/"style="
    color: #fff;
"><li class="hide">17a-Hydroxyprogesterone (HPG)</li></a>
    <a href="./../../../../portfolio/dehydroepiandrosterone-acetate-prasterone-acetate/"style="
    color: #fff;
"><li class="hide">Dehydroepiandrosterone Acetate Prasterone Acetate</li></a>
	<a href="./../../../../portfolio/dehydroepiandrosterone-dheaprasterone/"style="
    color: #fff;
"><li class="hide">Dehydroepiandrosterone DHEA, Prasterone</li></a>
	<a href="./../../../../portfolio/trenbolone-cyclohexylmethylcarbonate/"style="
    color: #fff;
"><li class="hide">Trenbolone Cyclohexylmethylcarbonate</li></a>
	<a href="./../../../../portfolio/4-chlorodehydromethyltestosterone/"style="
    color: #fff;
"><li class="hide">4-Chlorodehydromethyltestosterone</li></a>
	<a href="./../../../../portfolio/21-hydroxy-20-methylpregn-4-en-3-one/"style="
    color: #fff;
"><li class="hide">21-Hydroxy-20-methylpregn-4-en-3-one</li></a>
	<a href="./../../../../portfolio/9a-hydroxy-4-androstenedione-（9a-ohad）/"style="
    color: #fff;
"><li class="hide">9a-Hydroxy-4-androstenedione（9a-OHAD)</li></a>
	<a href="./../../../../portfolio/44-difluorobenzhydrylpiperazine/"style="
    color: #fff;
"><li class="hide">4,4′-Difluorobenzhydrylpiperazine</li></a>
	<a href="./../../../../portfolio/ethyl-6-4-iodophenyl-1/"style="
    color: #fff;
"><li class="hide">Ethyl 6-(4-iodophenyl)-1-(4-methoxy phenyl)-7- oxo-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4- c]pyridine-3-carboxylate</li></a>
	



</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
		<a href="./../../../../portfolio/ethyl-1-4-methoxyphenyl-7/"style="
    color: #fff;
"><li class="hide">Ethyl 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro1H-pyrazolo[3,4-c]pyridine-3-carboxylate</li></a>
		<a href="./../../../../portfolio/5-bromo-2-chloro4ethoxydiphenylmethane/"style="
    color: #fff;
"><li class="hide">5-Bromo-2-chloro4’ethoxydiphenylmethane</li></a>
	<a href="./../../../../portfolio/15-anhydro-1-c-4-chloro-3/"style="
    color: #fff;
"><li class="hide">1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-,2,3,4,6-tetraacetate, (1S)- D-Glucitol</li></a>
	<a href="./../../../../portfolio/2346-tetra-o-trimethylsilyl-s-d-glucolactone/"style="
    color: #fff;
"><li class="hide">2,3,4,6-tetra-O-trimethylsilyl-ß-D-glucolactone</li></a>
	<a href="./../../../../portfolio/carbamic-acid-n-1s2r/"style="
    color: #fff;
"><li class="hide">Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1- (phenylmethyl)propyl]-,1,1-dimethylethylester</li></a>
	<a href="./../../../../portfolio/10s-1011-dihydro-10-hydroxy/"style="
    color: #fff;
"><li class="hide">(10S)-10,11-Dihydro-10-hydroxy-5Hdibenz[b,f]azepine-5-carboxamide</li></a>
	<a href="./../../../../portfolio/1011-dihydro-10-hydroxy-5h/"style="
    color: #fff;
"><li class="hide">10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide</li></a>
	<a href="./../../../../portfolio/3-3-dichloro-1-4-iodophenyl-piperidin-2-one/"style="
    color: #fff;
"><li class="hide">3, 3-dichloro-1-(4-iodophenyl) piperidin-2-one</li></a>
	<a href="./../../../../portfolio/1-23-dichlorophenyl-piperazine/"style="
    color: #fff;
"><li class="hide">1-(2,3-Dichlorophenyl) Piperazine HCl</li></a>
	<a href="./../../../../portfolio/1e-n-hydroxy-5-methoxy-1/"style="
    color: #fff;
"><li class="hide">(1E)-N-Hydroxy-5-Methoxy-1-(4-Trifluoromethylphenyl)Pentan-1-Imine</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/2-bromo-4-benzyloxy-3-nitroacetophenone/"style="
    color: #fff;
"><li class="hide">2-Bromo-4′-benzyloxy-3′-nitroacetophenone</li></a>
	<a href="./../../../../portfolio/24-dihydro-4-4-4-4-methoxyphenyl-1/"style="
    color: #fff;
"><li class="hide">2,4-Dihydro-4-[4-[4-(4-methoxyphenyl)-1- piperazinyl]phenyl]-2-(1-methyl propyl)-3H-1,2,4-triazol-3-one</li></a>
	<a href="./../../../../portfolio/1-acetyl-4-4-hydroxyphenyl-piperazine/"style="
    color: #fff;
"><li class="hide">1-Acetyl-4-(4-hydroxyphenyl) piperazine</li></a>
	<a href="./../../../../portfolio/1r-2-2-4-nitrophenylethylamino-1/"style="
    color: #fff;
"><li class="hide">(1R)-2-{[2-(4-nitrophenyl)ethyl]amino}-1-phenylethanol</li></a>
	<a href="./../../../../portfolio/5-methylpyridin-21h-one-2-hydroxy-5/"style="
    color: #fff;
"><li class="hide">5-methylpyridin-2(1H)-one/2-Hydroxy-5- methylpyridine</li></a>
	<a href="./../../../../portfolio/dibenzo-b-f-1-4-thiazepin-1110h-one/"style="
    color: #fff;
"><li class="hide">Dibenzo [b, f] [1, 4] thiazepin- 11(10H)-one</li></a>
	<a href="./../../../../portfolio/4-4-5s-5-aminomethyl-2-oxo-13/"style="
    color: #fff;
"><li class="hide">4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one hydrochloride</li></a>
<a href="./../../../../portfolio/2-5s-2-oxo-3-4-3-oxomorpholin-4-yl/"style="
    color: #fff;
"><li class="hide">2-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl}methyl)-1H-isoindole-1,3(2H)-dione</li></a>
	<a href="./../../../../portfolio/2-3ar4s6r6as-6/"style="
    color: #fff;
"><li class="hide">2-(((3aR,4S,6R,6aS)-6-((5-amino-6-chlo ro-2-(propylthio)pyrimidin-4-yl)amino) -2,2-dimethyltetrahydro-3aH-cyclo penta[d][1,3]dioxol-4-yl)oxy)ethanol</li></a>
	<a href="./../../../../portfolio/1-acetamido-35-dimethyl-adamantane/"style="
    color: #fff;
"><li class="hide">1-Acetamido 3,5-dimethyl Adamantane*</li></a>
	



</ul></div> 

</form>
<div class="btSearchInnerClose"><span class="btIco "><a href="#" target="_self" data-ico-fa="&#xf00d;" class="btIcoHolder" style="color:#fff"></a></span></div>
</div>
</div>
</div>
</div> </div>
</div>
<nav>
<ul id="menu-primary-menu" class="menu">
<li id="menu-item-3253" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-3253"><a title="						" href="./../../../../index.html">Home</a></li>
<li id="menu-item-3403" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3403">
<a href="./../../../../about-us/index.html">About us</a><ul class="sub-menu">
<li id="menu-item-3399" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3399"><a href="./../../../../about-us/index.html#company_profile">Company Profile/ Who we are?</a></li>
<li id="menu-item-3400" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3400"><a href="./../../../../about-us/index.html#vision&#038;values">Vision &#038; Values</a></li>
<li id="menu-item-3401" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3401"><a href="./../../../../about-us/index.html#business_segment">Business Segments</a></li>
<li id="menu-item-3402" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3402"><a href="./../../../../about-us/index.html#geographic_spread">Geographic spread</a></li>
</ul>
</li>
<li id="menu-item-3459" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3459"><a href="./../../../../our-technology/index.html">Our Technology</a></li>
<li id="menu-item-3256" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-ancestor current-menu-parent current_page_parent current_page_ancestor menu-item-has-children menu-item-3256">
<a title="						" href="./../../../../services/index.html">Product Portfolio</a><ul class="sub-menu">
<li id="menu-item-3415" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-3408 current_page_item menu-item-3415"><a href="./../../../../active-pharmaceutical-ingredients/index.html" aria-current="page">Active pharmaceutical ingredients</a></li>
<li id="menu-item-3868" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3868"><a href="./../../../../pharmaceutical_intermediates/index.html">Pharmaceutical intermediates</a></li>
<li id="menu-item-3414" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3414"><a href="./../../../../pharmaceutical_excipients/index.html">Pharmaceutical excipients</a></li>
</ul>
</li>
<li id="menu-item-3872" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3872">
<a href="./../../../../policies/index.html">Policies</a><ul class="sub-menu">
<li id="menu-item-3497" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-privacy-policy menu-item-3497"><a href="./../../../../services/privacy-policy/index.html">Privacy Statement</a></li>
<li id="menu-item-3739" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3739"><a href="./../../../../services/ordering-details-terms-and-conditions/index.html">Ordering Details, Terms, and Conditions</a></li>
<li id="menu-item-3738" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3738"><a href="./../../../../services/browser-recommendation/index.html">Browser Recommendation</a></li>
<li id="menu-item-3737" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3737"><a href="./../../../../services/new-product-suggestion/index.html">New Product Suggestion</a></li>
</ul>
</li>
<li id="menu-item-3594" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3594"><a href="./../../../../services/partner_with_us/index.html">Partner with us</a></li>
<li id="menu-item-3494" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3494"><a href="./../../../../careers/index.html">Careers</a></li>
<li id="menu-item-4734" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4734"><a href="./../../../../library/index.html">Library</a></li>
<li id="menu-item-3438" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3438"><a href="./../../../../contact/index.html">Contact</a></li>
</ul> </nav>
</div>
</div>
</div>
</header>


<!--page-content-here-->
<div class="btContentWrap btClear" bis_skin_checked="1" style="padding-top: 61.4844px;">
<section class="boldSection bottomSemiSpaced btPageHeadline gutter  topSemiSpaced btTextLeft " data-parallax="0" data-parallax-offset="0"><div class="port" bis_skin_checked="1"><header class="header btClear large"><div class="btSuperTitle" bis_skin_checked="1"><span><div class="btBreadCrumbs" bis_skin_checked="1"><nav><ul><li><a href="/../../../../">Home</a></li><li>Category</li></ul></nav></div></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline">Articles Archives - Page 3 of 4 - Ikigai® Corporation</span></h2></div></header></div></section> <div class="btContentHolder" bis_skin_checked="1">
<div class="btContent" bis_skin_checked="1">
<article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5183 post type-post status-publish format-standard hentry category-articles animated"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g" class="avatar avatar-144 photo lazyloaded" height="144" width="144" srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" data-ll-status="loaded"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>01.04.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/04/01/simultaneous-identification-and-quantification-of-canrenone-and-11-%ce%b1-hydroxy-canrenone-by-lc-ms-and-hplc-uvd/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/04/01/simultaneous-identification-and-quantification-of-canrenone-and-11-%ce%b1-hydroxy-canrenone-by-lc-ms-and-hplc-uvd/">Simultaneous Identification and Quantification of Canrenone and 11-α-Hydroxy-Canrenone by LC-MS and HPLC-UVD</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p><span class="">Da-Ming Huang,<sup>1</sup>&nbsp;</span><span class="">Tian-Zhen Zhang,<sup>1</sup>&nbsp;</span><span class=""><b>Feng-Jie Cui</b>,<sup>1</sup>&nbsp;</span><span class="">Wen-Jing Sun,<sup>1,2</sup>&nbsp;</span><span class=""><b>Li-Ming Zhao</b>,<sup>3</sup>&nbsp;</span><span class="">Meng-Yi Yang,<sup>1</sup>&nbsp;and&nbsp;</span><span class="">Ya-Juan Wang<sup>1</sup></span></p>
<p>&nbsp;</p>
<h4 id="abstract" class="header">Abstract</h4>
<hr>
<p>&nbsp;</p>
<p>A procedure for simultaneous identification and quantification of canrenone and its biotransformed product 11-<i>α</i>-hydroxy-canrenone by high-performance liquid chromatography with ultraviolet detector (HPLC-UVD) and mass spectrometry (LC-MS) methods was proposed. The optimal determination variables on the HPLC-UVD or LC-MS coupled with a ZORBAX Eclipse XDB-C18 column (150 mm × 4.6 mm, 5 <i>μ</i>m) were set as follows: detection wavelength of 280 nm, mobile phase of water and methanol gradient elution, temperature for the chromatographic column of 30°C, flow rate of mobile phase of 0.8 mL/min, sample injection volume of 5 <i>μ</i>L, and elution time of 40 min. The MS conditions were set as follows: the flow rate of sheath gas, aux gas, and sweep gas were kept at 35 arb, 5 arb, and 0 arb, respectively. The temperature of capillary was held at 300°C, and capillary voltage was set at 30.00 V. Tube lens were performed at 100.00 V. The proposed method was validated by linearity (&nbsp;≥ 0.9910), average recovery (94.93%, RSD1.21%), precision (RSD ≤ 1.31%), limit of detection, and limit of quantification (LOD 0.1~0.12 mg/L, LOQ 0.5~0.67 mg/L), which proved to be affordable for simultaneously determining canrenone and its bio-transformed product 11-<i>α</i>-hydroxy-canrenone.</p>
<p>&nbsp;</p>
<h4 id="introduction">1. Introduction</h4>
<hr>
<p>&nbsp;</p>
<p>Canrenone (CR), a cardiovascular drug, a sort of steroid, is spironolactone’s major metabolite and has been widely used as a nonselective aldosterone receptor antagonist clinically to treat heart failure, high blood pressure, edema, liver ascites, and other cardiovascular diseases [<a class="refAnchor">1</a>,&nbsp;<a class="refAnchor">2</a>]. However, canrenone also has the significant side effects including ataxia, mental confusion, and hirsutism. To enhance curative effect and reduce those side effects, hydroxylation and/or nitration steps were developed to synthesize its derivatives [<a class="refAnchor">3</a>,&nbsp;<a class="refAnchor">4</a>]. Eplerenone is the first agent in a new class of drugs known as the selective aldosterone-receptor antagonists (SARAs), and has a 15- to 20-fold lower affinity for the mineralocorticoid receptor; however, fewer adverse events occur due to its specific binding to aldosterone [<a class="refAnchor">5</a>–<a class="refAnchor">8</a>]. Eplerenone can be semichemically synthesized from canrenone, which involves the 11-<i>α</i>-hydroxylation as the first step and one of the most key steps [<a class="refAnchor">9</a>,&nbsp;<a class="refAnchor">10</a>]. The production of 11-<i>α</i>-hydroxy-canrenone by the 11-<i>α</i>-hydroxylation reaction can be conducted by chemical synthesis or microbial transformation (Figure&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/fig1/" target="_blank" rel="noopener">1</a>). Chemical synthesis will lead to some problems including low stereo- and region-selectivity, strict reaction condition environmental pollution, and complicated and expensive production processes, while microbial transformation process can be considered as a “green” producing alternative that overcomes the above problems from chemical synthesis [<a class="refAnchor">11</a>–<a class="refAnchor">14</a>].</p>
<p>&nbsp;</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.001.jpg"><noscript><img src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.001.jpg" /></noscript></p>
<div class="floats-partial-caption" bis_skin_checked="1"><span class="caption-text">Figure 1</span><a class="caption-partial-url" title="full view" href="https://www.hindawi.com/journals/bmri/2011/917232/fig1/" target="_blank" rel="noopener" aria-label="full view">&nbsp;</a></div>
<div class="floats-partial-caption-text" bis_skin_checked="1">11-<i>α</i>-hydroxylation of canrenone by microbial transformation.</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<p>The hydroxylation of steroids by fungal biocatalysts has been known for many years, this procedure remains one of the most useful preparative methods for the introduction of hydroxyl groups at sites of the steroid nucleus remote from other functionality, and the value of microbial steroid hydroxylation in the preparation of pharmacologically active steroids is well established. In our primary experiments, a fungus of&nbsp;<i>Rhizopus sp</i>&nbsp;UJS-0602 was screened for producing the 11-<i>α</i>-hydroxy-canrenone from canrenone. However, a key step of proposing a reliable assay method for determining canrenone and 11-<i>α</i>-hydroxy-canrenone was necessary to evaluate productivity of 11-<i>α</i>-hydroxy-canrenone, consuming rate of canrenone, and biotransformating yield. However, few references were provided for simultaneously determining 11-<i>α</i>-hydroxy-canrenone and canrenone in biotransformation by high-performance liquid chromatography (HPLC), but few related works dealing with the simultaneous quantitation of spironolactone and canrenone in human [<a class="refAnchor">15</a>–<a class="refAnchor">18</a>] and rat [<a class="refAnchor">19</a>] plasma samples, in urine samples [<a class="refAnchor">20</a>,&nbsp;<a class="refAnchor">21</a>], or in tablets [<a class="refAnchor">22</a>]. Similar structure between 11-<i>α</i>-hydroxy-canrenone and canrenone also increases the difficulties for accurate determination of the two substances by the other methods such as colorimetry or thin-layer chromatography (TLC).</p>
<p>The aim of the present study was to propose a simple, quick, accurate, and feasible determining procedure for simultaneous identification and quantification of canrenone and 11-<i>α</i>-hydroxy-canrenone by two novel reversed-phase LC-MS and HPLC-UV.</p>
</div>
<h4 id="experimental-chemicals-and-reagents">2. Experimental Chemicals and Reagents</h4>
<hr>
<p>&nbsp;</p>
<p>Standard canrenone and 11-<i>α</i>-hydroxy-canrenone were purchased from the Fisher Scientific International Inc. (Hampton, New Hampshire, USA). For microbial transformation, substrate canrenone with purity ≥97% was purchased from TaiYuan RHF Co. (Shanxi, China). Methanol (Tedia, Baker, USA) was of HPLC grade and all other chemicals were of analytical reagent grade.</p>
<p>&nbsp;</p>
<h4 id="microbial-transformation-procedure">3. Microbial Transformation Procedure</h4>
<hr>
<p>Microorganism&nbsp;<i>Rhizopus sp</i>&nbsp;UJS-0602 was activated on the PDA slants for 5 d at 28°C, then washed out with sterile water and transferred to fresh liquid medium a 500 mL erlenmeyer flask with 100 mL liquid culture medium, and cultured for 33 h at 28°C with the shaking rate of 160 r/min. Further, the substrate canrenone dissolved in dimethyl formamide (DMF; 3.6 g/l) was added into the cultured broth and transformed for another 48 hours at the same culture conditions.</p>
<h5 id="sec3.1">3.1. Sample Preparation</h5>
<p>Mixed standard stock solution of canrenone and 11-<i>α</i>-hydroxy-canrenone (10 g/L) was prepared by accurately weighing 10 mg of canrenone and 11-<i>α</i>-hydroxy-canrenone standards, dissolving into 1 mL of HPLC-grade methanol. The working standard solutions were prepared by diluting the mixed standard solution with methanol to a series of proper concentrations (3 g/L, 1.5 g/L, 0.75 g/L, 0.3 g/L, and 0.1 g/L). The standard stock solution and working solutions were all stored at 4°C.</p>
<p>The microbial transformed broth was filtered into two fractions of mycelia and filtrate which were further extracted with ethyl acetate in an amount five-times its volume for three times, respectively. The microbial transformed sample was obtained by collecting and concentrating the organic phases to dry, redissolving, and diluting with methanol to volume of 100 mL for HPLC analysis.</p>
<h5 id="sec3.2">3.2. LC-MS and HPLC-UV Analysis</h5>
<p>The LC-MS qualitative analysis was carried out on an ion trap Thermo LXQ Finnigan SURYEYOR (USA). The separation was performed using a ZORBAX Eclipse XDB-C18 column (150 mm × 4.6 mm, 5 <i>μ</i>m) supplied by Agilent Technologies, USA. The qualitative gradient elution system consisted of methanol (<i>Mobile Phase A</i>) and water (<i>Mobile Phase B</i>). The separation was achieved using the following gradient program: 0–40 min (10%~50%<i>&nbsp;Mobile Phase A</i>), 40–60 min (50%~100%<i>&nbsp;Mobile Phase A</i>). The flowrate was set at 0.8 mL/min and the samples were injected automatically (5.0 <i>μ</i>L of each other). The column was thermostatically controlled at 30°C and the chromatogram was monitored at 280 nm. The flow rate of sheath gas, aux gas, and sweep gas were kept at 35 arb, 5 arb, and 0 arb, respectively. The temperature of capillary was held at 300°C and capillary voltage was set at 30.00 V. Tube lens were performed at 100.00 V.</p>
<p>The HPLC-UV analysis was carried out on a Waters Alliance LC-20AT (SHIMADZU, Japan) liquid chromatograph connected to a model 2996 (DAD) diode array detector and controlled by LC Driver Ver.2.0 for Waters Empower software. The optimized gradients employed were 0–40 min, 10%~100% methanol, and 90%~0% water. The column and other chromatographic conditions were the same as those used for the LC-MS analysis. Data were processed using Waters Empower software.</p>
<h5 id="sec3.3">3.3. Calibration Curves</h5>
<p>The working standard solutions were brought to room temperature and an aliquot of 5.0 <i>μ</i>L was injected into HPLC for construction of calibration curves. The column and chromatographic condition were the same as described in Section&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/#sec3.3">3.3</a>&nbsp;of HPLC-UV. The five concentrations of working standard solutions were analyzed in triplicate and calculating the calibration curves were calculated by linear regression of the double logarithmic plots of the peak area versus the concentration of the working standard solution injected.</p>
<p>The linearity was determined by the correlation coefficients of the analytical curves generated by injections of the working solutions at five concentration levels. In the method for quantification of canrenone and 11-<i>α</i>-hydroxy-canrenone in microbial transformation fluid, the analytical curves were constructed in triplicate by diluting the mixed standard solutions with methanol, which resulted in the final concentrations of 3 g/L, 1.5 g/L, 0.75 g/L, 0.3 g/L, and 0.1 g/L.</p>
<h5 id="sec3.4">3.4. Accuracy</h5>
<p>Standard addition method was performed to evaluate the accuracy of the HPLC method. The procedure was summarized as follows: to determine 1 mL sample solution with the same concentration prepared in Section&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/#sec3.1">3.1</a>&nbsp;for 5 parts accurately, and 1 mL of 10% canrenone standard solution was added to each sample solution. The prepared 5 samples above were analyzed in turn by HPLC-UV. The average recoveries were calculated by the following formula:</p>
<p>with relative standard deviations (RSD%) = (SD/mean) × 100%.</p>
<p>&nbsp;</p>
<h5 id="sec3.5">3.5. Repeatability</h5>
<p>For repeatability test, five independent analytical sample solutions from the same batch of sample were prepared in same procedures noted in Section&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/#sec3.1">3.1</a>, RSD% values of the obtained contents of each analyte were used to estimate repeatability.</p>
<h5 id="sec3.6">3.6. Precision and Intermediate Precision</h5>
<p>The stability test was chosen to determine the precision of the HPLC-UV method. The same sample solution prepared in Section&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/#sec3.1">3.1</a>&nbsp;was analyzed as described in Section&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/#sec3.3">3.3</a>&nbsp;of HPLC-UV in 6 different hours: 0 h, 4 h, 8 h, 12 h, 18 h, and 24 h throughout a day. Variations of the peak area were taken as the measures of precision and expressed as RSD%. Intermediate precision was determined by analyzing the mixed standard solution with the same concentration employed in Section&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/#sec3.1">3.1</a>&nbsp;continuously for 5 times. Precision was expressed in terms of RSD%.</p>
<h5 id="sec3.7">3.7. Limit of Detection (LOD) and Limit of Quantitation (LOQ)</h5>
<p>LOD and LOQ were estimated experimentally by injecting standard solutions of canrenone and 11-<i>α</i>-hydroxy-canrenone diluted in methanol under the above chromatographic conditions in Section&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/#sec3.2">3.2</a>&nbsp;of HPLC-UV until the signal-to-noise ratio for the standards reached a 3 : 1 ratio for LOD and 10 : 1 for LOQ.</p>
<p>&nbsp;</p>
<h4 id="results-and-discussion">4. Results and Discussion</h4>
<hr>
<p>&nbsp;</p>
<h5 id="sec4.1">4.1. Identification of Canrenone and 11-<i>α</i>-Hydroxy-Canrenone by LC-MS</h5>
<p>For the purpose of correct identification, an LC-MS analysis was performed on standard under the LC-MS conditions. The previous chromatographic conditions for determination of the two sterols in microbial transformation fluid by LC-MS were used as the basis for mobile phase selection and optimization. Unfortunately, the reported gradient elution of methanol-water could not be applied to the separation of canrenone and 11-<i>α</i>-hydroxy-canrenone. Under this circumstance, the gradient elution program was carefully adjusted and after several trials the new gradient program was selected until it permitted the best separation ability for the two sterols. Figure&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/fig2/" target="_blank" rel="noopener">2</a>&nbsp;shows that under the optimized LC-MS conditions, canrenone and 11-<i>α</i>-hydroxy-canrenone were separated and identified by analysing their mass spectra. The results of MS spectrogram are shown in Figure&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/fig2/" target="_blank" rel="noopener">2</a>. Comparing the standards of 11-<i>α</i>-hydroxylation of canrenone Figure&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/fig2/" target="_blank" rel="noopener">2</a>(A) and canrenone Figure&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/fig2/" target="_blank" rel="noopener">2</a>(B), the mass-to-charge ratios of each molecular ion peak (M + H) were 357.4 and 341.4, respectively. According to the references, the molecular weight of 11-<i>α</i>-hydroxylation of canrenone and canrenone are 356.4 and 340.4, which meant that the molecular weight of 11-<i>α</i>-hydroxylation is 16 more than canrenone. Hence, the hydroxylation of canrenone has occurred by the selected biotransforming strain&nbsp;<i>Rhizopus sp</i>&nbsp;UJS-0602.</p>
<p>&nbsp;</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="917232.fig.002a" data-lazy-src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.002a.jpg"><noscript><img src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.002a.jpg" alt="917232.fig.002a" /></noscript></p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="917232.fig.002b" data-lazy-src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.002b.jpg"><noscript><img src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.002b.jpg" alt="917232.fig.002b" /></noscript></p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="917232.fig.002c" data-lazy-src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.002c.jpg"><noscript><img src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.002c.jpg" alt="917232.fig.002c" /></noscript></p>
<p>&nbsp;</p>
<div class="floats-partial-caption" bis_skin_checked="1"><span class="caption-text">Figure 2</span><a class="caption-partial-url" title="full view" href="https://www.hindawi.com/journals/bmri/2011/917232/fig2/" target="_blank" rel="noopener" aria-label="full view">&nbsp;</a></div>
<div class="floats-partial-caption-text" bis_skin_checked="1">LC-MS chromatograms of mixed standards (a) and (b) in negative-ion mode. HPLC was performed on a ZORBAX Eclipse XDB-C18 column (150 mm × 4.6 mm, 5 <i>μ</i>m) at the column temperature of 30°C. The separation was achieved using the following gradient program: 0–40 min (10%~50% methanol), 40–60 min (50%~100% methanol). The flowrate was at 0.8 mL/min and the sample injection volume was 5.0 <i>μ</i>L. Peak assignments: (a) canrenone; (b) 11-<i>α</i>-hydroxy-canrenone. MS spectrograms (A) and (B) stand for the molecular weight of the peak (a) and (b) at 357.44 and 341.40 amu, respectively.</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h5 id="sec4.2">4.2. Quantitative Analysis of Canrenone and 11-<i>α</i>-Hydroxy-Canrenone by HPLC-UV</h5>
<p>The proposed LC-MS method was successfully applied to simultaneous determination of canrenone and 11-<i>α</i>-hydroxy-canrenone in microbial transformation fluid. But it cost a lot of time under the LC-MS conditions described in Section&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/#sec3.3">3.3</a>. The optimal condition for the extraction by HPLC-UV of canrenone and 11-<i>α</i>-hydroxy-canrenone was selected and presented in details in Section&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/#sec3.3">3.3</a>.</p>
<p>As shown in Figure&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/fig3/" target="_blank" rel="noopener">3</a>, canrenone and 11-<i>α</i>-hydroxy-canrenone were comprehensively separated and their retention times were at 29 min and 33 min severally. From the picture, we can see that the peak of canrenone at 33 min reduced radically after transformation reaction when the peak of 11-<i>α</i>-hydroxy-canrenone at 29 min raised sharply, which demonstrated that the transformation reaction through microorganism was successfully completed.</p>
</div>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="917232.fig.003a" data-lazy-src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.003a.jpg"><noscript><img src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.003a.jpg" alt="917232.fig.003a" /></noscript></p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="917232.fig.003b" data-lazy-src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.003b.jpg"><noscript><img src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.003b.jpg" alt="917232.fig.003b" /></noscript></p>
<p>&nbsp;</p>
<div class="floats-partial-caption" bis_skin_checked="1"><span class="caption-text">Figure 3</span><a class="caption-partial-url" title="full view" href="https://www.hindawi.com/journals/bmri/2011/917232/fig3/" target="_blank" rel="noopener" aria-label="full view">&nbsp;</a></div>
<div class="floats-partial-caption-text" bis_skin_checked="1">Typical HPLC-UV chromatogram (<i>λ</i>&nbsp;= 280 nm) of (C) mixed standards of canrenone and 11-<i>α</i>-hydroxy-canrenone and (D) samples extracted from microbial transformed fluid. The quantitative gradient elution system consist of methanol and water. The gradient program: 0–40 min, 10%~100% methanol, and 90%~0% water. For other chromatographic conditions were the same as those in Section&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/#sec3.3">3.3</a>. Peak assignments: (a) canrenone; (b) 11-<i>α</i>-hydroxy-canrenone.</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h5 id="sec4.3">4.3. Validation of the Proposed Method</h5>
<h6 id="sec4.3.1">4.3.1. Linearity, LOD, and LOQ</h6>
<p>According to the data in Table&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/tab1/" target="_blank" rel="noopener">1</a>, acceptable results of the regression analysis, the correlation coefficients (), LODs, and LOQs were obtained for all the analytes: both of the calibration curves showed good linear regression (&nbsp;≥ 0.9911) within the test range; the LODs and LOQs of the two sterols were in the range of 0.1~0.12 mg/L and 0.5~0.67 mg/L, respectively.</p>
</div>
<h2>Table 1</h2>
<div class="floats-full-page-caption" bis_skin_checked="1">Parameters of the analytical curves, LOD, and LOQ for canrenone and 11-<i>α</i>-hydroxy-canrenone quantification by HPLC-UV.</div>
<div class="floats-full-page-content" bis_skin_checked="1">
<table id="tab1" class="table-group">
<tbody>
<tr>
<td>
<table class="table">
<tbody>
<tr>
<td class="thead-hr" colspan="6">
<hr>
</td>
</tr>
<tr class="thead">
<td align="left">Standard</td>
<td align="center">Concentratio<i>n</i>&nbsp;range (g/L)</td>
<td align="center">Calibration curve<sup>a</sup></td>
<td align="center">Correlatio<i>n</i>&nbsp;coefficient<i>s</i> (r2)</td>
<td align="center">LOD<sup>b</sup></td>
<td align="center">LOQ<sup>c</sup></td>
</tr>
<tr>
<td class="thead-hr" colspan="6">
<hr>
</td>
</tr>
<tr>
<td align="left">Canrenone</td>
<td align="center">0.1~3.0</td>
<td align="center"><i>y</i>&nbsp;= 0.4587 + 1.2879<i>x</i></td>
<td align="center">0.9910</td>
<td align="center">0.1 mg/L</td>
<td align="center">0.5 mg/L</td>
</tr>
<tr>
<td align="left">11-<i>α</i>-hydroxy-canrenone</td>
<td align="center">0.1~3.0</td>
<td align="center"><i>y</i>&nbsp;= 0.3681 + 1.2274<i>x</i></td>
<td align="center">0.9928</td>
<td align="center">0.12 mg/L</td>
<td align="center">0.67 mg/L</td>
</tr>
<tr class="table-tr">
<td colspan="6">
<hr class="tbody-hr">
</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr class="table-fn">
<td><sup>a</sup><i>y</i>&nbsp;and&nbsp;<i>x</i>&nbsp;stand for logarithmic values of peak area and concentration (g/L), respectively.<br>
<sup>b</sup>Limit of detection (S/N=3).<br>
<sup>c</sup>Limit of quantification (S/N=10).</td>
</tr>
</tbody>
</table>
</div>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p><span class="statement-title"><i class="statement-title">Accuracy, Repeatability, Precision, and Intermediate Precision</i></span><br>
Table&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/tab2/" target="_blank" rel="noopener">2</a>&nbsp;presents that the developed method had good accuracy with the overall recovery of 91.75~97.94%, with the RSD 1.21%. The results of the repeatability test shown in Table&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/tab3/" target="_blank" rel="noopener">3</a>&nbsp;demonstrated that the developed assay was reproducible (RSD = 1.21%), and the intermediate precision of this method was also acceptable (RSD = 1.37% and 1.21%). The stability test was chosen to determine the precision of the HPLC-UV method. For the stability test (Table&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/tab4/" target="_blank" rel="noopener">4</a>), the analysis was performed by injecting the same sample solution prepared in Section&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/#sec3.2">3.2</a>&nbsp;in 6 different hours: 0 h, 4 h, 8 h, 12 h, 18 h, and 24 h throughout a day, and it was found to be rather stable daylong (RSD = 1.03% and 1.35%). These results indicated that the HPLC-UVD method is accurate, precise, and sensitive for quantitative determination of canrenone and 11-<i>α</i>-hydroxy-canrenone in the microbial transformation fluid.</p>
<p>&nbsp;</p>
<h2>Table 2</h2>
<div class="floats-full-page-caption" bis_skin_checked="1">Accuracy of HPLC-UV method for canrenone.</div>
<div class="floats-full-page-content" bis_skin_checked="1">
<table id="tab2" class="table-group">
<tbody>
<tr>
<td>
<table class="table">
<tbody>
<tr>
<td class="thead-hr" colspan="7">
<hr>
</td>
</tr>
<tr class="thead">
<td align="left">Samples</td>
<td align="center">Original (g)</td>
<td align="center">Added (g)</td>
<td align="center">Found (g)</td>
<td align="center">Recovery<sup>a</sup>&nbsp;(%)</td>
<td align="center">Mean Recovery (%)</td>
<td align="center">RSD<sup>b</sup>&nbsp;(%)</td>
</tr>
<tr>
<td class="thead-hr" colspan="7">
<hr>
</td>
</tr>
<tr>
<td align="left">1</td>
<td align="center">0.0014</td>
<td align="center">0.0097</td>
<td align="center">0.0107</td>
<td align="center">95.88</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">2</td>
<td align="center">0.0015</td>
<td align="center">0.0097</td>
<td align="center">0.0104</td>
<td align="center">91.75</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">3</td>
<td align="center">0.0014</td>
<td align="center">0.0097</td>
<td align="center">0.0106</td>
<td align="center">94.85</td>
<td align="center">94.93</td>
<td align="center">1.21</td>
</tr>
<tr>
<td align="left">4</td>
<td align="center">0.0013</td>
<td align="center">0.0097</td>
<td align="center">0.0108</td>
<td align="center">97.94</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">5</td>
<td align="center">0.0014</td>
<td align="center">0.0097</td>
<td align="center">0.0105</td>
<td align="center">93.81</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="table-tr">
<td colspan="7">
<hr class="tbody-hr">
</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr class="table-fn">
<td><sup>a</sup>Recovery (%) = ((canrenone amount found−original canrenone amount in sample solution)/canrenone added amount) × 100%.<br>
<sup>b</sup>(RSD%) = (S.D./mean) × 100%.<p></p>
<h2>Table 3</h2>
<div class="floats-full-page-caption" bis_skin_checked="1">Repeatabilities and intermediate precisions of HPLC-UV method for canrenone and 11-<i>α</i>-hydroxy-canrenone.</div>
<div class="floats-full-page-content" bis_skin_checked="1">
<table id="tab3" class="table-group">
<tbody>
<tr>
<td>
<table class="table">
<tbody>
<tr>
<td class="thead-hr" colspan="9">
<hr>
</td>
</tr>
<tr>
<td align="left"></td>
<td colspan="4" align="center">Repeatability<sup>e</sup> (n=5)</td>
<td colspan="4" align="center">Intermediate precision<sup>f</sup> (n=5)</td>
</tr>
<tr>
<td align="left">Samples</td>
<td colspan="2" align="center">Content (g/L)</td>
<td colspan="2" align="center">RSD%</td>
<td colspan="2" align="center">Content (g/L)</td>
<td colspan="2" align="center">RSD%</td>
</tr>
<tr>
<td align="left"></td>
<td align="center">a</td>
<td align="center">b</td>
<td align="center">a</td>
<td align="center">b</td>
<td align="center">a</td>
<td align="center">b</td>
<td align="center">a</td>
<td align="center">b</td>
</tr>
<tr>
<td colspan="9" align="center">
<hr>
</td>
</tr>
<tr>
<td align="left">1</td>
<td align="center">1.3813</td>
<td align="center">1.8343</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">2.2379</td>
<td align="center">2.2127</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">2</td>
<td align="center">1.3726</td>
<td align="center">1.8387</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">2.2267</td>
<td align="center">2.1567</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">3</td>
<td align="center">1.3792</td>
<td align="center">1.8814</td>
<td align="center">0.99</td>
<td align="center">1.03</td>
<td align="center">2.2140</td>
<td align="center">2.1479</td>
<td align="center">1.37</td>
<td align="center">1.21</td>
</tr>
<tr>
<td align="left">4</td>
<td align="center">1.4029</td>
<td align="center">1.8471</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">2.2725</td>
<td align="center">2.1704</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">5</td>
<td align="center">1.4011</td>
<td align="center">1.8609</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">2.2086</td>
<td align="center">2.1914</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="table-tr">
<td colspan="9">
<hr class="tbody-hr">
</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr class="table-fn">
<td><sup>a</sup>Canrenone.<br>
<sup>b</sup>11-<i>α</i>-hydroxy-canrenone.<br>
<sup>e</sup>Five samples was analyzed, and contents of each solution were used to access repeatability.<br>
<sup>f</sup>The mixed standard solutions with the same concentration were analyzed, and their contents were used to access intermediate precision.</td>
</tr>
</tbody>
</table>
</div>
</td>
</tr>
</tbody>
</table>
</div>
<p>&nbsp;</p>
<h2>Table 4</h2>
<div class="floats-full-page-caption" bis_skin_checked="1">Precisions of HPLC-UV method for canrenone and 11-<i>α</i>-Hydroxy-canrenone.</div>
<div class="floats-full-page-content" bis_skin_checked="1">
<table id="tab4" class="table-group">
<tbody>
<tr>
<td>
<table class="table">
<tbody>
<tr>
<td class="thead-hr" colspan="7">
<hr>
</td>
</tr>
<tr>
<td rowspan="2" align="left">Time (h)</td>
<td colspan="2" align="center">Content (g/L)</td>
<td colspan="2" align="center">Mean content (g/L)</td>
<td colspan="2" align="center">RSD%</td>
</tr>
<tr>
<td align="center">a</td>
<td align="center">b</td>
<td align="center">a</td>
<td align="center">b</td>
<td align="center">a</td>
<td align="center">b</td>
</tr>
<tr>
<td colspan="7" align="center">
<hr>
</td>
</tr>
<tr>
<td align="left">0<br>
4<br>
8<br>
12<br>
18<br>
24</td>
<td align="center">1.3813<br>
1.3842<br>
1.3930<br>
1.3516<br>
1.3760<br>
1.3844</td>
<td align="center">1.8343<br>
1.9036<br>
1.8679<br>
1.8650<br>
1.8834<br>
1.8444</td>
<td align="center">1.3784</td>
<td align="center">1.8664</td>
<td align="center">1.03</td>
<td align="center">1.35</td>
</tr>
<tr class="table-tr">
<td colspan="7">
<hr class="tbody-hr">
</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr class="table-fn">
<td><sup>a</sup>Canrenone.<br>
<sup>b</sup>11-<i>α</i>-hydroxy-canrenone.</td>
</tr>
</tbody>
</table>
</div>
<h5 id="sec4.4">4.4. Application</h5>
<p>The method was used to determine biotransformation broth of canrenone and 11<i>α</i>-hydroxy-canrenone obtained after transformation simultaneously. Figure&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/fig4/" target="_blank" rel="noopener">4</a>&nbsp;showed the representative chromatograms of substrate canrenone before transformation (Figure&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/fig4/" target="_blank" rel="noopener">4</a><i>α</i>), and of bioconversion broth obtained after conversion for 48 h (Figure&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/fig4/" target="_blank" rel="noopener">4</a><i>β</i>), and of blank (Figure&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/fig4/" target="_blank" rel="noopener">4</a><i>γ</i>). Comparing with the representative chromatograms of standard solution by LC-MS/HPLC-UVD shown in Figure&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/fig2/" target="_blank" rel="noopener">2</a>&nbsp;and Figure&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/fig3/" target="_blank" rel="noopener">3</a>(C), it could be seen that canrenone and 11<i>α</i>-hydroxy-canrenone were eluted at 29.05 min and 33.33 min without carryover, and 11-<i>α</i>-hydroxy-canrenone existed as product in biotransformation system. No other impurity peaks were found in Figure&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/fig3/" target="_blank" rel="noopener">3</a>(C) and Figure&nbsp;<a href="https://www.hindawi.com/journals/bmri/2011/917232/fig3/" target="_blank" rel="noopener">3</a>(D). The obtained results indicated that the detecting results were satisfactory, and the proposed method could be applied to the following researches of biotransformation of canrenone to 11-<i>α</i>-hydroxy-canrenone in our laboratory.</p>
<p>&nbsp;</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="917232.fig.004a" data-lazy-src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.004a.jpg"><noscript><img src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.004a.jpg" alt="917232.fig.004a" /></noscript></p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="917232.fig.004b" data-lazy-src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.004b.jpg"><noscript><img src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.004b.jpg" alt="917232.fig.004b" /></noscript></p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="917232.fig.004c" data-lazy-src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.004c.jpg"><noscript><img src="https://static-01.hindawi.com/articles/bmri/volume-2011/917232/figures/917232.fig.004c.jpg" alt="917232.fig.004c" /></noscript></p>
<p>&nbsp;</p>
<h4 id="conclusions">5. Conclusions</h4>
<hr>
<p>&nbsp;</p>
<p>In this study, an HPLC coupled with MS and UVD method has been proposed for simultaneous identification and quantification of canrenone and 11-<i>α</i>-hydroxy-canrenone in the microbial transformation broth. The parameters evaluated here demonstrated that the methods offer good specificity, linearity, accuracy, and precision within acceptable limits while the LODs and LOQs confirmed the efficiency of the methodologies in quantifying low concentrations of sterols. These results are definitely helpful to control the quality of canrenone and 11-<i>α</i>-hydroxy-canrenone, and provide a scientific basis for the search for the improvement the quality of sterols products and transformation efficiency in the production.</p>
<p>&nbsp;</p>
<h4 id="acknowledgments">Acknowledgments</h4>
<hr>
<p>&nbsp;</p>
<p>This paper was financially supported by funding from the National Natural Science Foundation of China (NSFC 31101269), International Foundation for Science Grant Program (no. F 4930-1), Technological Research and Development Program of Zhenjiang City (GY2011006), Jiangxi Provincial Engineering and Technology Research Center for Food Additives Bioproduction; Research Foundation for Advanced Talents of Jiangsu University (08JDG029), Leaders of Disciplines and Science Cultivation Program of Jiangxi Province (2008DD00600), Science and Technology Program of Jiangxi Province (2010DQB00800 and no. (2008147), Science and Technology Platform Construction Program of Jiangxi Province, Priority Academic Program Development of Jiangsu Higher Education Institutions, and Student Research Grant Program of Jiangsu University (no. Y10A075).</p>
<p>&nbsp;</p>
<h4 id="references" class="references">References</h4>
<hr>
<p>&nbsp;</p>
<p>S. Werner, M. Christine, B. Eber, E. Barbara et al., “Intoxication due to negative canrenone interference in digoxin drug monitoring,” The Lancet, vol. 354, no. 9185, pp. 1176–1177, 1999.<br>
View at: Publisher Site | Google Scholar<br>
B. Marrs, S. Delagrave, and D. Murphy, “Novel approaches for discovering industrial enzymes,” Current Opinion in Microbiology, vol. 2, no. 3, pp. 241–245, 1999.<br>
View at: Publisher Site | Google Scholar<br>
C. L. Preisig, J. A. Laakso, U. M. Mocek, P. T. Wang, J. Baez, and G. Byng, “Biotransformations of the cardiovascular drugs mexrenone and canrenone,” Journal of Natural Products, vol. 66, no. 3, pp. 350–356, 2003.<br>
View at: Publisher Site | Google Scholar<br>
R. Megges, J. Weiland, B. Undeutsch, H. Büchting, and R. Schön, “The nitration of canrenone with acetic anhydride/nitric acid,” Steroids, vol. 62, no. 12, pp. 762–766, 1997.<br>
View at: Publisher Site | Google Scholar<br>
E. G. McMahon, “Recent studies with eplerenone, a novel selective aldosterone receptor antagonist,” Current Opinion in Pharmacology, vol. 1, no. 2, pp. 190–196, 2001.<br>
View at: Publisher Site | Google Scholar<br>
E. D. Burgess, Y. Lacourciere, L. M. Ruilope-Urioste et al., “Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension,” Clinical Therapeutics, vol. 25, no. 9, pp. 2388–2404, 2003.<br>
View at: Publisher Site | Google Scholar<br>
K. L. Davis and J. M. Nappi, “The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist,” Clinical Therapeutics, vol. 25, no. 11, pp. 2647–2668, 2003.<br>
View at: Publisher Site | Google Scholar<br>
W. B. White, A. A. Carr, S. Krause, R. Jordan, B. Roniker, and W. Oigman, “Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension,” The American Journal of Cardiology, vol. 92, no. 1, pp. 38–42, 2003.<br>
View at: Publisher Site | Google Scholar<br>
S. Gladiali, A. Gallotti, R. Vitali, and R. Gardi, “Facilitated reduction of 11-ketone in corticosteroid 17,21-diacetates,” Chemistry and Industry, vol. 24, pp. 982–983, 1977.<br>
View at: Google Scholar<br>
M. Nussium and F. Sondheimer, “New synthesis of 11-oxygenated steroids,” Chemistry &amp; Industry, vol. 4, pp. 400–401, 1960.<br>
View at: Google Scholar<br>
L. X. Du, S. J. Jia, and F. P. Lu, “Morphological changes of Rhizopus chinesis 12 in submerged culture and its relationship with antibiotic production,” Process Biochemistry, vol. 38, no. 12, pp. 1643–1646, 2003.<br>
View at: Publisher Site | Google Scholar<br>
A. J. Reyes, W. P. Leary, P. Crippa et al., “The aldosterone antagonist and facultative diuretic eplerenone: a critical review,” European Journal of Internal Medicine, vol. 16, no. 1, pp. 3–11, 2005.<br>
View at: Publisher Site | Google Scholar<br>
E. Gharaee Fathabad, M. TabatabaeiYazdi, M. A. Faramarzi et al., “Biotransformation of Hydroeortisone by Neurospora crassa,” Journal of Sciences, Islamic Republic of Iran, vol. 17, no. 4, pp. 309–312, 2006.<br>
View at: Google Scholar<br>
A. Romano, D. Romano, E. Ragg et al., “Steroid hydroxylations with Botryodiplodia malorum and Colletotrichum lini,” Steroids, vol. 71, no. 6, pp. 429–434, 2006.<br>
View at: Publisher Site | Google Scholar<br>
D. I. Sora, S. Udrescu, F. Albu, V. David, and A. Medvedovici, “Analytical issues in HPLC/MS/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples,” Journal of Pharmaceutical and Biomedical Analysis, vol. 52, no. 5, pp. 734–740, 2010.<br>
View at: Publisher Site | Google Scholar<br>
J. M. Sandall, J. S. Millership, P. S. Collier, and J. C. McElnay, “Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples,” Journal of Chromatography B, vol. 839, no. 1-2, pp. 36–44, 2006.<br>
View at: Publisher Site | Google Scholar<br>
H. Zhang and J. T. Stewart, “Liquid chromatographic determination of canrenone in human serum using solid-phase extraction,” Journal of Pharmaceutical and Biomedical Analysis, vol. 11, no. 11-12, pp. 1341–1344, 1993.<br>
View at: Publisher Site | Google Scholar<br>
A. Jankowski, A. Skorek-Jankowska, and H. Lamparczyk, “Simultaneous determination of spironolactone and its metabolites in human plasma,” Journal of Pharmaceutical and Biomedical Analysis, vol. 14, no. 8-10, pp. 1359–1365, 1996.<br>
View at: Publisher Site | Google Scholar<br>
A. M. Kaukonen, P. Vuorela, H. Vuorela, and J. P. Mannermaa, “High-performance liquid chromatography methods for the separation and quantitation of spironolactone and its degradation products in aqueous formulations and of its metabolites in rat serum,” Journal of Chromatography A, vol. 797, no. 1-2, pp. 271–281, 1998.<br>
View at: Publisher Site | Google Scholar<br>
E. Martin, A. I. Jimenez, O. Hernandez et al., “Simultaneous kinetic spectrophotome- tric determination of spironolactone and canrenone in urine using partial least-squares regression,” Talanta, vol. 49, no. 1, pp. 143–154, 1999.<br>
View at: Google Scholar<br>
R. Herraez-Hernandez, E. Soriano-Vega, and P. Campins-Falco, “High-performance liquid chromatographic determination of spironolactone and its major metabolite canrenone in urine using ultraviolet detection and column-switching,” Journal of Chromatography B, vol. 658, no. 2, pp. 303–310, 1994.<br>
View at: Publisher Site | Google Scholar<br>
F. De Croo, W. Van den Bossche, and P. De Moerloose, “Simultaneous quantitative determination of butizide, potassium canrenoate and canrenone in tablets by high-performance liquid chromatography,” Journal of Chromatography A, vol. 354, pp. 367–373, 1986.<br>
View at: Google Scholar</p>
<p>&nbsp;</p>
<h2>Source</h2>
<hr>
<p>&nbsp;</p>
<p>https://www.hindawi.com/journals/bmri/2011/917232/</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/04/01/simultaneous-identification-and-quantification-of-canrenone-and-11-%ce%b1-hydroxy-canrenone-by-lc-ms-and-hplc-uvd/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/04/01/simultaneous-identification-and-quantification-of-canrenone-and-11-%ce%b1-hydroxy-canrenone-by-lc-ms-and-hplc-uvd/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5180 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>25.03.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/03/25/evaluation-of-boldenone-as-a-growth-promoter-in-broilers-safety-and-meat-quality-aspects/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/03/25/evaluation-of-boldenone-as-a-growth-promoter-in-broilers-safety-and-meat-quality-aspects/">Evaluation of boldenone as a growth promoter in broilers: safety and meat quality aspects</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p><span class="sr-only">Author links open overlay panel</span><span class="content"><span class="text given-name">Abdelrazzag</span><span class="text surname">Elmajdoub</span><span id="baff1" class="author-ref"><sup>a</sup></span></span> <span class="content"><span class="text given-name">Aboubaker</span><span class="text surname">Garbaj</span><span id="baff2" class="author-ref"><sup>b</sup></span></span> <span class="content"><span class="text given-name">Said</span><span class="text surname">Abolghait</span><span id="baff3" class="author-ref"><sup>c</sup></span></span> <span class="content"><span class="text given-name">Abubakr</span><span class="text surname">El-Mahmoudy</span><span id="baff4" class="author-ref"><sup>d</sup></span></span></p>
<h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">Abstract</h2>
<hr>
<p>&nbsp;</p>
<p>The object of this study was to evaluate the safety and meat quality criteria in&nbsp;broilers&nbsp;following&nbsp;intramuscular injection&nbsp;of&nbsp;boldenone. Twenty-four broiler chicks, divided into two groups, were used in the present study. Boldenone was injected intramuscularly at a single-dose level of 5&nbsp;mg/kg body weight into 12 broiler chicks at 2&nbsp;weeks old; the other 12 chicks were injected with&nbsp;sesame oil&nbsp;and kept as controls. Blood samples were collected from the wing and metatarsal veins after 1, 2, and 3&nbsp;weeks through the experimental course for hematological and clinic-chemical safety parameters. On the last day, chicks were humanely sacrificed and livers and kidneys were removed for histopathological examination. Breast muscles were also removed to assess meat-quality parameters. Boldenone significantly (<em>p</em>&nbsp;&lt; 0.05) increased total erythrocytic count and&nbsp;hemoglobin&nbsp;and hematocrit values, while mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration indices decreased. Leukogram showed&nbsp;<a title="Learn more about Leukopenia from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/leukopenia">leukopenia</a>,&nbsp;<a title="Learn more about Lymphocytopenia from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/lymphocytopenia">lymphopenia</a>, and&nbsp;<a title="Learn more about Granulocytosis from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/granulocytosis">granulocytosis</a>&nbsp;(<em>p</em>&nbsp;&lt; 0.05) as compared to control. Hepatorenal biomarkers, including&nbsp;alkaline phosphatase,&nbsp;aspartate aminotransferase,&nbsp;alanine aminotransferase, urea, and&nbsp;creatinine&nbsp;were significantly (<em>p</em>&nbsp;&lt; 0.05) higher than the corresponding control values. Additionally, boldenone significantly (<em>p</em>&nbsp;&lt; 0.05) increased metabolic markers, including total protein,&nbsp;globulins, cholesterol,&nbsp;triacylglycerols, and glucose, with parallel decreases in&nbsp;albumin&nbsp;and albumin/globulin ratio. Degenerative changes were recorded in liver and kidney tissues from chicks treated with boldenone. Muscle samples exhibited raised pH values and higher microbial counts as compared to the corresponding control. These data may discourage the use of boldenone as a&nbsp;growth promoter&nbsp;in broilers due to safety and meat quality reasons.</p>
<p>&nbsp;</p>
<p class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">Keywords: Broilers, Boldenone, Clinicochemical, Meat quality, Safety</p>
<p>&nbsp;</p>
<h2 id="sectitle0020" class="u-h3 u-margin-l-top u-margin-xs-bottom">1.&nbsp;Introduction</h2>
<hr>
<p>&nbsp;</p>
<p id="p0010">Anabolic&nbsp;androgenic steroids&nbsp;are synthetic derivatives structurally related to androgens (the male sex hormones). These agents promote development of male sexual characteristics (androgenic effects) and, thus, are used in treating&nbsp;delayed puberty, impotence, and related conditions. They also promote growth of skeletal muscle (anabolic effects) and can be used in repairing wasting of the body caused by some emaciating diseases&nbsp;[1]. However, these&nbsp;anabolic steroids&nbsp;can be abused in human and animal sports for better performance&nbsp;[2]. Also, they can be used for increasing body weight in livestock as&nbsp;growth-promoting agents&nbsp;either legally or illegally.</p>
<p id="p0015">Growth-promoting implants have been used in the production of cattle and sheep for &gt;40&nbsp;years. Such implants may improve growth rates (approx. 10–30%), feed efficiency (approx. 5–15%), and carcass leanness (approx. 5–8%). Historically, the earliest use of hormones as growth enhancers in farm animal production included iodinated proteins in&nbsp;dairy cows&nbsp;for increased milk production and estrogen implants (diethylstilbestrol and dienestrol) in&nbsp;broilers&nbsp;for enhanced fat deposition&nbsp;[3]. The first hormone used in beef cattle and sheep for growth, efficiency, and lean meat promotion was&nbsp;diethylstilbestrol&nbsp;in 1954&nbsp;[4]. However, because of potential&nbsp;carcinogenicity&nbsp;from the use of diethylstilbestrol in humans, this compound was banned for use in 1979 by the Food and Drug Administration (FDA). Parallel to this trend, most hormonal growth promoters have been banned, and the restricted use of only a few agents have been permitted. Many countries permit the use of a short list of growth-promoting&nbsp;steroid hormones&nbsp;to bulk up animals and increase the yield of meat. The USA and Canada, in addition to all developing countries, follow this practice; however, the EU has banned the use of hormones in food-producing animals due to health concerns&nbsp;[5].</p>
<p id="p0020">Boldenone&nbsp;is an anabolic steroid that differs from&nbsp;testosterone&nbsp;by its high anabolic and low androgenic activities. Therefore, it has been produced as a veterinary product as boldenone undecylenate under various trade names for improving meat mass in cattle and&nbsp;veal&nbsp;calves. Boldenone is restricted to veterinary purposes only in some countries; nonetheless, sports competitors and bodybuilders have been known to administer this anabolic steroid. It was approved by the U.S. FDA for use in horses; however, in most countries worldwide, it is forbidden for meat production and human use&nbsp;[6]. The control of boldenone for illegal uses was based on the identification of either 17β-boldenone or 17α-boldenone (the main metabolite in cattle) in edible tissues, hair, feces, or urine&nbsp;[7]. Boldenone has been increasingly detected in a number of biological samples in different EU member states. The question arose concerning whether this increased number of boldenone findings was due to the illegal treatment of animals or whether, in some circumstances, boldenone could be of endogenous origin. For instance, it was demonstrated that boldenone could be formed from&nbsp;phytosterols&nbsp;present in vegetable fat&nbsp;[8],&nbsp;[9]. Previous studies were conducted to study the effects and metabolism of boldenone in various species, including horses&nbsp;[10], cattle&nbsp;[11], veal calves&nbsp;[12], weaned lambs&nbsp;[13], rabbits&nbsp;[14],&nbsp;[15], and human volunteers&nbsp;[16].</p>
<p id="p0025">No data are available concerning the altering effects of boldenone administration to broilers as a popular farm animal species. Therefore, this study was designed to investigate the possible effects of boldenone on broiler chicks from safety and meat quality aspects as a trial to evaluate its possible use as a growth promoter in the broiler industry.</p>
<p>&nbsp;</p>
<h2 id="sectitle0025" class="u-h3 u-margin-l-top u-margin-xs-bottom">2.&nbsp;Methods</h2>
<hr>
<p>&nbsp;</p>
<section id="sec2.1">
<h3 id="sectitle0030" class="u-h4 u-margin-m-top u-margin-xs-bottom">2.1.&nbsp;Boldenone</h3>
<p id="p0030">Chemically, 17β-boldenone, also called&nbsp;1-dehydrotestosterone, androsta-1,4-diene-17β-ol-3-1, is a&nbsp;steroid&nbsp;with androgenic activity that differs from 17β-testosterone by only one double bond at the 1 position.&nbsp;Esters&nbsp;of 17β-boldenone (e.g.,&nbsp;undecylenate&nbsp;ester) are pharmaceutically produced as anabolic preparations for veterinary use. In the present study, boldenone was obtained as the patent preparation Equigan (Laboratorios Tornel S.A., México) that is an intramuscular therapy for muscle building in equines. This preparation is formulated as 10&nbsp;mL glass vials containing 50&nbsp;mg boldenone undecylenate/mL&nbsp;sesame&nbsp;oil. The drug was administered intramuscularly in the thigh as single doses of 5&nbsp;mg/kg body weight of&nbsp;<a title="Learn more about Broiler from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/broiler">broiler</a>&nbsp;chick.</p>
</section>
<section id="sec2.2">
<h3 id="sectitle0035" class="u-h4 u-margin-m-top u-margin-xs-bottom">2.2.&nbsp;Experimental animals</h3>
<p id="p0035">Twenty-four Ross broiler chicks, aged 2&nbsp;weeks and weighing approximately 600&nbsp;g, were used for the present study. Animals were purchased from a local farm at 1&nbsp;week old and kept in our controlled environment for a further week for acclimatization before use. All animals were maintained on standard growing rations and water&nbsp;<em>ad libitum</em>. Animal care and experimentation were according to guidelines of the European Commission Directive 86/609/EEC for animal experiments and were approved by our local institutional committee.</p>
</section>
<section id="sec2.3">
<h3 id="sectitle0040" class="u-h4 u-margin-m-top u-margin-xs-bottom">2.3.&nbsp;Experimental design</h3>
<p id="p0040">A parallel design is followed in this study, where animals were randomly divided into two groups (<em>n</em>&nbsp;=&nbsp;12 for each) and labeled appropriately. The first group received 0.1&nbsp;mL of&nbsp;sesame oil&nbsp;(solvent of boldenone) intramuscularly in the thigh muscle and kept as the control group. The second group received a single dose of boldenone undecylenate (5&nbsp;mg/kg) as 0.1&nbsp;mL of sesame oil-diluted Equigan injectable solution in the same manner and kept as the treated group. After different treatments, all animals were observed daily for extraordinary symptoms throughout the period of study. Blood samples were collected from the wing and metatarsal veins using syringes with 22-gauge needles 1&nbsp;week, 2&nbsp;weeks, and 3&nbsp;weeks post-injection. The samples were received into centrifuge tubes containing&nbsp;lithium&nbsp;heparin. Each sample was divided into two parts, with the first kept as whole blood for hematological analysis and the second centrifuged for 5&nbsp;min at 12,000<em>g</em>&nbsp;to separate plasma that was used for the clinicochemical study. At the end of experiment, all animals were humanely sacrificed, and the liver and kidneys were removed for histopathological examination. Also, pectoral muscles on the keel bone were picked for meat-quality examination.</p>
</section>
<section id="sec2.4">
<h3 id="sectitle0045" class="u-h4 u-margin-m-top u-margin-xs-bottom">2.4.&nbsp;Hematological assays</h3>
<p id="p0045">To assess the blood-safety profile of boldenone, the following hematological parameters were automatically evaluated by auto-hematology analyzer (Mindray, Model BC-2800Vet, Shenzhen, China). Erythrocytic parameters included red blood cell (RBC) count, hematocrit value (Hct), mean corpuscular volume (MCV),&nbsp;<a title="Learn more about Hemoglobin from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/hemoglobin">hemoglobin</a>&nbsp;concentration (Hgb), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC). Leukocytic parameters included white blood cell (WBC) count, differential leukocyte count (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), platelet (PLT) concentration, and mean platelet volume (MPV). The analyzer adopted the Coulter Principle to count RBC, WBC, and PLT cells and to draw their corresponding histograms. The Hgb concentration was obtained by the&nbsp;<a title="Learn more about Calorimetry from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/calorimetry">colorimetric method</a>&nbsp;and the MCV was calculated electronically. The rest of the indices were mathematically derived.</p>
</section>
<section id="sec2.5">
<h3 id="sectitle0050" class="u-h4 u-margin-m-top u-margin-xs-bottom">2.5.&nbsp;Clinicochemical assays</h3>
<p id="p0050">Estimating plasma clinicochemical parameters and evaluating hepatotoxicity,&nbsp;<a title="Learn more about Nephrotoxicity from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/nephrotoxicity">nephrotoxicity</a>&nbsp;and/or metabotoxicity was carried out spectrophotometrically (Model 6500, Jenway, Germany) using diagnostic kits purchased from Analyticon Biotechnologies AG (Lichtenfels, Germany). The parameters were&nbsp;alkaline phosphatase&nbsp;[17],&nbsp;aspartate aminotransferase&nbsp;[18],&nbsp;alanine aminotransferase&nbsp;[18], total protein&nbsp;[19],&nbsp;creatine kinase&nbsp;[20],&nbsp;albumin&nbsp;[21], urea&nbsp;[22],&nbsp;creatinine&nbsp;[23], glucose&nbsp;[24], and total cholesterol&nbsp;[25]. Plasma&nbsp;triacylglycerol&nbsp;level was estimated using a diagnostic kit purchased from Biolabo SA (Maizy, France) according to Fossati and Prencipe&nbsp;[26].&nbsp;<a title="Learn more about Globulin from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/globulin">Globulin</a>&nbsp;level was calculated by subtracting the value of albumin from the value of total protein according to Doumas and Biggs&nbsp;[27].</p>
</section>
<section id="sec2.6">
<h3 id="sectitle0055" class="u-h4 u-margin-m-top u-margin-xs-bottom">2.6.&nbsp;Histopathological assay</h3>
<p id="p0055">The liver and the two kidneys were taken from sacrificed birds in both groups, preserved in&nbsp;<a title="Learn more about Formaldehyde from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/formaldehyde">formalin</a>&nbsp;solution (10%), and subjected for histopathological examination according to Bancroft and Gamble&nbsp;[28].</p>
</section>
<section id="sec2.7">
<h3 id="sectitle0060" class="u-h4 u-margin-m-top u-margin-xs-bottom">2.7.&nbsp;Determination of pH values of chicken breasts (pectoralis) samples during cold-chilled storage</h3>
<p id="p0060">Chicken breasts&nbsp;(<em>pectoralis</em>) pH values for the boldenone and control groups were determined after 2&nbsp;h, 24&nbsp;h, 48&nbsp;h and 72&nbsp;h&nbsp;<em>post mortem</em>&nbsp;during cold storage at 4°C. The measurement was based on using a fiber-optic pH Meter (Jenway 3505 pH Meter, Barloworld Scientific Ltd., Dunmow, UK) after calibrating using standard buffers at pH 4.0 and pH 7.0 (Merck Millipore, Waltham, MA, USA). The glass electrodes were mechanically inserted into pre-opened&nbsp;<em>pectoralis</em>&nbsp;with a sterile scalpel&nbsp;[29].</p>
</section>
<section id="sec2.8">
<h3 id="sectitle0065" class="u-h4 u-margin-m-top u-margin-xs-bottom">2.8.&nbsp;Microbiological Analysis</h3>
<p id="p0065">Two groups of chicken breasts (<em>pectoralis</em>) from boldenone-treated and control groups were subjected for microbiological analysis after 24-h storage at 4°C. Preparation of samples, decimal dilutions, culturing, and enumeration techniques for bacteria were performed according to the methods described by the American Public Health Association&nbsp;[30],&nbsp;[31]. Briefly, 25&nbsp;g of the sample was removed with sterile scalpels and transferred to a sterile Stomacher bag (Stomacher 400, Seaward Medicals, UK.) under aseptic conditions. The sample was then diluted to a 10:1 dilution with 225&nbsp;mL&nbsp;peptone&nbsp;water (M0216, Park Scientific, Ltd., Northampton, UK) and stomached for 2&nbsp;min using a Seward’s Stomacher 400 Circulator (Stomacher 400, Seaward Medicals). Serial dilutions were then performed using sterile 0.1% peptone water (Park Scientific, Ltd.). Determination of the aerobic plate count (APC) was performed using plate-count agar (Difco Laboratories, Detroit, MI, USA), inoculated with serial dilutions on triplicate agar plates, and incubated at 37°C for 48&nbsp;h. Countable plates were those containing from 25 to 250 colonies.</p>
<p id="p0070">Determination of&nbsp;coliform&nbsp;count was performed using Violet Red Bile Lactose agar (VRBA, Park Scientific, Ltd.). VRBA triplicate agar plates were inoculated using an overlay method and incubated at 37°C for 24&nbsp;h. Purple-red colonies, 0.5&nbsp;mm in diameter or larger, surrounded by a zone of precipitated&nbsp;bile acids&nbsp;were counted.</p>
<p id="p0075">Enumeration of total&nbsp;<em>Staphylococci</em>&nbsp;count was performed using Baird-Parker agar (Park Scientific, Ltd.). The inoculums were surface plated using a sterile bent-glass streaking rod on triplicate agar plates. Plates were inverted and incubated at 37°C for 48&nbsp;h.</p>
</section>
<section id="sec2.9">
<h3 id="sectitle0070" class="u-h4 u-margin-m-top u-margin-xs-bottom">2.9.&nbsp;Statistical analysis</h3>
<p id="p0080">Results are expressed as mean&nbsp;±&nbsp;standard error of the mean for 12 observations (<em>n</em>). A factorial linear statistical model was fitted to the data, and differences between the control and treated group at different time points were tested for significance using a one-way analysis of variance, followed by least-significant difference post-hoc test. A&nbsp;<em>p</em>&nbsp;≤&nbsp;0.05 was considered significant. All statistical analytical procedures were done using SPSS software version 20 (IBM Corp., Armonk, NY, USA).</p>
<p>&nbsp;</p>
</section>
<h2 id="sectitle0075" class="u-h3 u-margin-l-top u-margin-xs-bottom">3.&nbsp;Results</h2>
<hr>
<p id="p0085">The animals post-boldenone administration appeared lively with good appetites and did not show any abnormal signs. No mortalities were recorded throughout the experiment, and no significant increases in body weight gain were recorded.</p>
<section id="sec3.1">
<h3 id="sectitle0080" class="u-h4 u-margin-m-top u-margin-xs-bottom">3.1.&nbsp;Hematological study</h3>
<div bis_skin_checked="1">
<p id="p0090">The administration of&nbsp;boldenone&nbsp;significantly affected both the erythrocyte and leukocyte parameters as compared to the control group (<em>p</em>&nbsp;&gt;&nbsp;0.05). A single dose of boldenone (second group) significantly increased RBC count and Hct and Hgb values in the 2<sup>nd</sup>&nbsp;and 3<sup>rd</sup>&nbsp;weeks. Meanwhile, MCH and MCHC index values decreased. Boldenone significantly decreased total leukocytic count, with changes in differential count, where lymphocytes exhibited significant decreases and granulocytes exhibited significant increases as compared to control (Table 1,&nbsp;Table 2).</p>
</div>
<p><span class="label">Table 1</span>.&nbsp;Effects of single&nbsp;intramuscular injection&nbsp;of&nbsp;boldenone&nbsp;(5&nbsp;mg/kg) on erythrocytic parameters of&nbsp;broilers&nbsp;over a 3-week experimental course (mean&nbsp;±&nbsp;SEM;&nbsp;<em>n</em>&nbsp;=&nbsp;12).</p>
<div class="groups" bis_skin_checked="1">
<table>
<thead>
<tr class="rowsep-1 valign-top">
<th colspan="2" scope="col">Group / Parameter</th>
<th scope="col">RBC (10<sup>12</sup>/L)</th>
<th scope="col">Hct (%)</th>
<th scope="col">Hgb (g/dL)</th>
<th scope="col">MCV (<em>f</em>L)</th>
<th scope="col">MCH (pg)</th>
<th scope="col">MCHC (g/dL)</th>
</tr>
</thead>
<tbody>
<tr class="valign-top">
<td rowspan="2">1<sup>st</sup>&nbsp;w</td>
<td>Control</td>
<td class="align-char">2.20&nbsp;±&nbsp;0.06</td>
<td class="align-char">28.43&nbsp;±&nbsp;0.77</td>
<td class="align-char">13.00&nbsp;±&nbsp;0.06</td>
<td class="align-char">129.23&nbsp;±&nbsp;0.15</td>
<td class="align-char">59.16&nbsp;±&nbsp;1.29</td>
<td class="align-char">45.78&nbsp;±&nbsp;1.03</td>
</tr>
<tr class="valign-top">
<td>Boldenone</td>
<td class="align-char">2.33&nbsp;±&nbsp;0.03</td>
<td class="align-char">30.15&nbsp;±&nbsp;0.44</td>
<td class="align-char">13.32&nbsp;±&nbsp;0.09</td>
<td class="align-char">129.23&nbsp;±&nbsp;0.12</td>
<td class="align-char">57.08&nbsp;±&nbsp;0.42</td>
<td class="align-char">44.17&nbsp;±&nbsp;0.33</td>
</tr>
<tr class="valign-top">
<td rowspan="2">2<sup>nd</sup>&nbsp;w</td>
<td>Control</td>
<td class="align-char">2.40&nbsp;±&nbsp;0.06</td>
<td class="align-char">30.49&nbsp;±&nbsp;0.76</td>
<td class="align-char">13.33&nbsp;±&nbsp;0.12</td>
<td class="align-char">127.03&nbsp;±&nbsp;0.12</td>
<td class="align-char">55.60&nbsp;±&nbsp;0.86</td>
<td class="align-char">43.76&nbsp;±&nbsp;0.71</td>
</tr>
<tr class="valign-top">
<td>Boldenone</td>
<td class="align-char">2.77&nbsp;±&nbsp;0.03*</td>
<td class="align-char">35.02&nbsp;±&nbsp;0.43*</td>
<td class="align-char">13.80&nbsp;±&nbsp;0.06*</td>
<td class="align-char">126.57&nbsp;±&nbsp;0.12</td>
<td class="align-char">49.89&nbsp;±&nbsp;0.44*</td>
<td class="align-char">39.42&nbsp;±&nbsp;0.36*</td>
</tr>
<tr class="valign-top">
<td rowspan="2">3<sup>rd</sup>&nbsp;w</td>
<td>Control</td>
<td class="align-char">2.70&nbsp;±&nbsp;0.06</td>
<td class="align-char">33.83&nbsp;±&nbsp;0.75</td>
<td class="align-char">13.57&nbsp;±&nbsp;0.03</td>
<td class="align-char">125.30&nbsp;±&nbsp;0.17</td>
<td class="align-char">50.29&nbsp;±&nbsp;1.09</td>
<td class="align-char">40.14&nbsp;±&nbsp;0.89</td>
</tr>
<tr class="valign-top">
<td>Boldenone</td>
<td class="align-char">3.40&nbsp;±&nbsp;0.15*</td>
<td class="align-char">42.49&nbsp;±&nbsp;1.91*</td>
<td class="align-char">14.42&nbsp;±&nbsp;0.17*</td>
<td class="align-char">124.97&nbsp;±&nbsp;0.18</td>
<td class="align-char">42.53&nbsp;±&nbsp;1.49*</td>
<td class="align-char">34.04&nbsp;±&nbsp;1.20*</td>
</tr>
</tbody>
</table>
</div>
</section>
<p>&nbsp;</p>
<div id="tbl1" class="tables frame-topbot colsep-0 rowsep-0" bis_skin_checked="1">
<p id="tspara0020">Hct&nbsp;=&nbsp;hematocrit count; Hgb&nbsp;=&nbsp;<a title="Learn more about Hemoglobin from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/hemoglobin">hemoglobin</a>; MCH&nbsp;=&nbsp;mean corpuscular hemoglobin; MCHC&nbsp;=&nbsp;mean corpuscular hemoglobin concentration; MCV&nbsp;=&nbsp;mean corpuscular volume; RBC&nbsp;=&nbsp;red blood cell.</p>
</div>
<div id="tbl2" class="tables frame-topbot colsep-0 rowsep-0" bis_skin_checked="1">
<p id="tspara0025"><span class="label">Table 2</span>.&nbsp;Effects of single&nbsp;<a title="Learn more about Intramuscular Injection from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/intramuscular-injection">intramuscular injection</a>&nbsp;of&nbsp;<a title="Learn more about Boldenone from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/boldenone">boldenone</a>&nbsp;(5&nbsp;mg/kg) on leukocytic parameters of&nbsp;<a title="Learn more about Broiler from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/broiler">broilers</a>&nbsp;over a 3-week experimental course (mean&nbsp;±&nbsp;SEM;&nbsp;<em>n</em>&nbsp;=&nbsp;12).</p>
</div>
<div class="groups" bis_skin_checked="1">
<table>
<thead>
<tr class="rowsep-1 valign-top">
<th colspan="2" scope="col">Group / Parameter</th>
<th scope="col">WBC (10<sup>9</sup>/L)</th>
<th scope="col">Lymph. (10<sup>9</sup>/L)</th>
<th scope="col">Mid. (10<sup>9</sup>/L)</th>
<th scope="col">Gran. (10<sup>9</sup>/L)</th>
<th scope="col">PLT (10<sup>9</sup>/L)</th>
<th scope="col">PCT (%)</th>
<th scope="col">MPV (<em>f</em>L)</th>
</tr>
</thead>
<tbody>
<tr class="valign-top">
<td rowspan="2">1<sup>st</sup>&nbsp;w</td>
<td>Control</td>
<td class="align-char">21.36&nbsp;±&nbsp;0.31</td>
<td class="align-char">8.92&nbsp;±&nbsp;0.34</td>
<td class="align-char">1.00&nbsp;±&nbsp;0.12</td>
<td class="align-char">11.43&nbsp;±&nbsp;0.14</td>
<td class="align-char">0.058&nbsp;±&nbsp;0.01</td>
<td class="align-char">0.033&nbsp;±&nbsp;0.003</td>
<td class="align-char">5.40&nbsp;±&nbsp;0.06</td>
</tr>
<tr class="valign-top">
<td>Boldenone</td>
<td class="align-char">20.53&nbsp;±&nbsp;0.21</td>
<td class="align-char">8.33&nbsp;±&nbsp;0.12</td>
<td class="align-char">0.94&nbsp;±&nbsp;0.08</td>
<td class="align-char">11.26&nbsp;±&nbsp;0.15</td>
<td class="align-char">0.056&nbsp;±&nbsp;.004</td>
<td class="align-char">0.037&nbsp;±&nbsp;.003</td>
<td class="align-char">5.73&nbsp;±&nbsp;0.12</td>
</tr>
<tr class="valign-top">
<td rowspan="2">2<sup>nd</sup>&nbsp;w</td>
<td>Control</td>
<td class="align-char">21.88&nbsp;±&nbsp;0.10</td>
<td class="align-char">10.13&nbsp;±&nbsp;0.30</td>
<td class="align-char">1.183&nbsp;±&nbsp;0.04</td>
<td class="align-char">10.57&nbsp;±&nbsp;0.241</td>
<td class="align-char">0.073&nbsp;±&nbsp;0.003</td>
<td class="align-char">0.043&nbsp;±&nbsp;0.003</td>
<td class="align-char">5.83&nbsp;±&nbsp;0.09</td>
</tr>
<tr class="valign-top">
<td>Boldenone</td>
<td class="align-char">20.30&nbsp;±&nbsp;0.12*</td>
<td class="align-char">7.80&nbsp;±&nbsp;0.17*</td>
<td class="align-char">0.900&nbsp;±&nbsp;0.06*</td>
<td class="align-char">11.60&nbsp;±&nbsp;0.10*</td>
<td class="align-char">0.063&nbsp;±&nbsp;0.003</td>
<td class="align-char">0.033&nbsp;±&nbsp;0.003</td>
<td class="align-char">5.73&nbsp;±&nbsp;0.08</td>
</tr>
<tr class="valign-top">
<td rowspan="2">3<sup>rd</sup>&nbsp;w</td>
<td>Control</td>
<td class="align-char">22.10&nbsp;±&nbsp;0.12</td>
<td class="align-char">13.50&nbsp;±&nbsp;0.44</td>
<td class="align-char">1.257&nbsp;±&nbsp;0.03</td>
<td class="align-char">9.85&nbsp;±&nbsp;0.16</td>
<td class="align-char">0.090&nbsp;±&nbsp;0.006</td>
<td class="align-char">0.050&nbsp;±&nbsp;0.006</td>
<td class="align-char">5.63&nbsp;±&nbsp;0.09</td>
</tr>
<tr class="valign-top">
<td>Boldenone</td>
<td class="align-char">20.47&nbsp;±&nbsp;0.18*</td>
<td class="align-char">8.83&nbsp;±&nbsp;0.07*</td>
<td class="align-char">0.960&nbsp;±&nbsp;0.04*</td>
<td class="align-char">10.57&nbsp;±&nbsp;0.20*</td>
<td class="align-char">0.080&nbsp;±&nbsp;0.006</td>
<td class="align-char">0.047&nbsp;±&nbsp;0.003</td>
<td class="align-char">5.70&nbsp;±&nbsp;0.12</td>
</tr>
</tbody>
</table>
</div>
<p id="tspara0030">* Significantly different from corresponding control (p&nbsp;&lt;&nbsp;0.05).</p>
<p>&nbsp;</p>
<p>Gran&nbsp;=&nbsp;granulocyte; Lymph&nbsp;=&nbsp;lymphocyte; Mid&nbsp;=&nbsp;mid-sized cells; MPV&nbsp;= mean platelet volume&nbsp;; PCT&nbsp;=&nbsp;plateletcrit; PLT&nbsp;=&nbsp;platelet; WBC&nbsp;=&nbsp;white blood cell.</p>
<p>&nbsp;</p>
<h3 id="sectitle0085" class="u-h4 u-margin-m-top u-margin-xs-bottom">3.2.&nbsp;Clinicochemical study</h3>
<div bis_skin_checked="1">
<p id="p0095">All hepatorenal function markers, including ALP, ALT, AST, urea, and&nbsp;<a title="Learn more about Creatinine from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/creatinine">creatinine</a>, showed significant increases as compared to control according to the studied dose level of boldenone. Additionally, cardiac function marker CK showed significant increases after boldenone administration (Table 3).</p>
<div id="tbl3" class="tables frame-topbot colsep-0 rowsep-0" bis_skin_checked="1">
<p id="tspara0040"><span class="label">Table 3</span>.&nbsp;Effects of single&nbsp;intramuscular injection&nbsp;of&nbsp;boldenone&nbsp;(5&nbsp;mg/kg) on liver and renal function parameters of&nbsp;<a title="Learn more about Broiler from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/broiler">broilers</a>&nbsp;over a 3-week experimental course (mean&nbsp;±&nbsp;SEM;&nbsp;<em>n</em>&nbsp;=&nbsp;12).</p>
</div>
<div class="groups" bis_skin_checked="1">
<table>
<thead>
<tr class="rowsep-1 valign-top">
<th colspan="2" scope="col">Group / Parameter</th>
<th scope="col">ALP (IU/L)</th>
<th scope="col">AST (IU/L)</th>
<th scope="col">ALT (IU/L)</th>
<th scope="col">CK (IU/L)</th>
<th scope="col">Urea (mg/dL)</th>
<th scope="col">Creatinine (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr class="valign-top">
<td rowspan="2">1<sup>st</sup>&nbsp;w</td>
<td>Control</td>
<td class="align-char">464.0&nbsp;±&nbsp;7.81</td>
<td class="align-char">149.67&nbsp;±&nbsp;4.33</td>
<td class="align-char">24.90&nbsp;±&nbsp;2.98</td>
<td class="align-char">80.00&nbsp;±&nbsp;5.77</td>
<td class="align-char">15.00&nbsp;±&nbsp;1.15</td>
<td class="align-char">0.32&nbsp;±&nbsp;0.04</td>
</tr>
<tr class="valign-top">
<td>Boldenone</td>
<td class="align-char">501.67&nbsp;±&nbsp;6.01*</td>
<td class="align-char">174.33&nbsp;±&nbsp;2.96*</td>
<td class="align-char">41.25&nbsp;±&nbsp;2.14*</td>
<td class="align-char">105.00&nbsp;±&nbsp;2.89*</td>
<td class="align-char">28.33&nbsp;±&nbsp;2.40*</td>
<td class="align-char">0.63&nbsp;±&nbsp;0.06*</td>
</tr>
<tr class="valign-top">
<td rowspan="2">2<sup>nd</sup>&nbsp;w</td>
<td>Control</td>
<td class="align-char">390.00&nbsp;±&nbsp;5.77</td>
<td class="align-char">162.03&nbsp;±&nbsp;4.36</td>
<td class="align-char">44.33&nbsp;±&nbsp;5.21</td>
<td class="align-char">96.00&nbsp;±&nbsp;3.79</td>
<td class="align-char">17.67&nbsp;±&nbsp;1.45</td>
<td class="align-char">0.39&nbsp;±&nbsp;0.02</td>
</tr>
<tr class="valign-top">
<td>Boldenone</td>
<td class="align-char">468.33&nbsp;±&nbsp;4.41*</td>
<td class="align-char">198.33&nbsp;±&nbsp;6.01*</td>
<td class="align-char">68.33&nbsp;±&nbsp;4.41*</td>
<td class="align-char">114.00&nbsp;±&nbsp;3.06*</td>
<td class="align-char">35.00&nbsp;±&nbsp;2.89*</td>
<td class="align-char">0.74&nbsp;±&nbsp;0.04*</td>
</tr>
<tr class="valign-top">
<td rowspan="2">3<sup>rd</sup>&nbsp;w</td>
<td>Control</td>
<td class="align-char">325.00&nbsp;±&nbsp;7.64</td>
<td class="align-char">174.67&nbsp;±&nbsp;3.48</td>
<td class="align-char">60.33&nbsp;±&nbsp;3.18</td>
<td class="align-char">108.33&nbsp;±&nbsp;4.06</td>
<td class="align-char">22.33&nbsp;±&nbsp;1.76</td>
<td class="align-char">0.39&nbsp;±&nbsp;0.01</td>
</tr>
<tr class="valign-top">
<td>Boldenone</td>
<td class="align-char">416.67&nbsp;±&nbsp;8.82*</td>
<td class="align-char">241.00&nbsp;±&nbsp;6.66*</td>
<td class="align-char">91.00&nbsp;±&nbsp;5.51*</td>
<td class="align-char">130.33&nbsp;±&nbsp;2.60*</td>
<td class="align-char">53.33&nbsp;±&nbsp;4.41*</td>
<td class="align-char">0.72&nbsp;±&nbsp;0.04*</td>
</tr>
</tbody>
</table>
</div>
<p id="tspara0045">* Significantly different from corresponding control (p&nbsp;&lt;&nbsp;0.05).</p>
</div>
<div bis_skin_checked="1">
<div id="tbl3" class="tables frame-topbot colsep-0 rowsep-0" bis_skin_checked="1">
<p id="tspara0050">ALP&nbsp;=&nbsp;alkaline phosphatase; ALT&nbsp;=&nbsp;alanine aminotransferase; AST&nbsp;=&nbsp;aspartate aminotransferase; CK&nbsp;=&nbsp;creatine kinase.</p>
</div>
</div>
<div bis_skin_checked="1">
<p id="p0100">Boldenone also adversely affected metabolic parameters, including significant increases in Tp and Glb concentrations, without significant changes in Alb level as compared to control. Significant increases in Chol, Tag, and Glu were also recorded (Table 4).</p>
<div id="tbl4" class="tables frame-topbot colsep-0 rowsep-0" bis_skin_checked="1">
<p id="tspara0055"><span class="label">Table 4</span>.&nbsp;Effects of single&nbsp;intramuscular injection&nbsp;of&nbsp;boldenone&nbsp;(5&nbsp;mg/kg) on some metabolic parameters of&nbsp;broilers&nbsp;over a 3-week experimental course (mean&nbsp;±&nbsp;SEM;&nbsp;<em>n</em>&nbsp;=&nbsp;12).</p>
</div>
<div class="groups" bis_skin_checked="1">
<table>
<thead>
<tr class="rowsep-1 valign-top">
<th colspan="2" scope="col">Group / Parameter</th>
<th scope="col">Tp (g/dL)</th>
<th scope="col">Alb (g/dL)</th>
<th scope="col">Glb (g/dL)</th>
<th scope="col">Chol (mg/dL)</th>
<th scope="col">Tag (mg/dL)</th>
<th scope="col">Glu (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr class="valign-top">
<td rowspan="2">1<sup>st</sup>&nbsp;w</td>
<td>Control</td>
<td class="align-char">4.23&nbsp;±&nbsp;0.18</td>
<td class="align-char">1.72&nbsp;±&nbsp;0.09</td>
<td class="align-char">2.51&nbsp;±&nbsp;0.09</td>
<td class="align-char">110.33&nbsp;±&nbsp;5.78</td>
<td class="align-char">53.18&nbsp;±&nbsp;3.25</td>
<td class="align-char">197.00&nbsp;±&nbsp;3.79</td>
</tr>
<tr class="valign-top">
<td>Boldenone</td>
<td class="align-char">4.80&nbsp;±&nbsp;0.10*</td>
<td class="align-char">1.80&nbsp;±&nbsp;0.03</td>
<td class="align-char">2.99&nbsp;±&nbsp;0.09*</td>
<td class="align-char">128.33&nbsp;±&nbsp;3.28*</td>
<td class="align-char">65.00&nbsp;±&nbsp;3.21*</td>
<td class="align-char">199.00&nbsp;±&nbsp;4.36</td>
</tr>
<tr class="valign-top">
<td rowspan="2">2<sup>nd</sup>&nbsp;w</td>
<td>Control</td>
<td class="align-char">4.90&nbsp;±&nbsp;0.12</td>
<td class="align-char">2.03&nbsp;±&nbsp;0.06</td>
<td class="align-char">2.87&nbsp;±&nbsp;0.06</td>
<td class="align-char">109.67&nbsp;±&nbsp;2.91</td>
<td class="align-char">53.33&nbsp;±&nbsp;3.76</td>
<td class="align-char">176.00&nbsp;±&nbsp;6.03</td>
</tr>
<tr class="valign-top">
<td>Boldenone</td>
<td class="align-char">5.50&nbsp;±&nbsp;0.12*</td>
<td class="align-char">2.02&nbsp;±&nbsp;0.05</td>
<td class="align-char">3.48&nbsp;±&nbsp;0.07*</td>
<td class="align-char">141.00&nbsp;±&nbsp;3.21*</td>
<td class="align-char">76.00&nbsp;±&nbsp;2.08*</td>
<td class="align-char">193.00&nbsp;±&nbsp;2.31*</td>
</tr>
<tr class="valign-top">
<td rowspan="2">3<sup>rd</sup>&nbsp;w</td>
<td>Control</td>
<td class="align-char">5.40&nbsp;±&nbsp;0.12</td>
<td class="align-char">2.27&nbsp;±&nbsp;0.02</td>
<td class="align-char">3.13&nbsp;±&nbsp;0.10</td>
<td class="align-char">115.67&nbsp;±&nbsp;2.96</td>
<td class="align-char">58.33&nbsp;±&nbsp;4.26</td>
<td class="align-char">175.00&nbsp;±&nbsp;2.08</td>
</tr>
<tr class="valign-top">
<td>Boldenone</td>
<td class="align-char">6.10&nbsp;±&nbsp;0.12*</td>
<td class="align-char">2.16&nbsp;±&nbsp;0.04</td>
<td class="align-char">3.94&nbsp;±&nbsp;0.08*</td>
<td class="align-char">160.33&nbsp;±&nbsp;9.21*</td>
<td class="align-char">87.00&nbsp;±&nbsp;5.29*</td>
<td class="align-char">196.67&nbsp;±&nbsp;3.38*</td>
</tr>
</tbody>
</table>
</div>
<p id="tspara0060">* Significantly different from corresponding control (p&nbsp;&lt;&nbsp;0.05).</p>
<p id="tspara0065">Alb&nbsp;=&nbsp;albumin; Chol&nbsp;=&nbsp;cholesterol; Glb&nbsp;=&nbsp;globulin; Glu&nbsp;=&nbsp;glutamate; Tag&nbsp;=&nbsp;triglyceride; Tp&nbsp;=&nbsp;total protein.</p>
</div>
<h3 id="sectitle0090" class="u-h4 u-margin-m-top u-margin-xs-bottom">3.3.&nbsp;Histopathological study</h3>
<div bis_skin_checked="1">
<p id="p0105">No histopathological alterations and normal histological structure of the central and portal veins and surrounding hepatocytes was recorded. However, the liver of chicks treated with boldenone showed mild dilatation in the portal veins associated with diffuse inflammatory cell infiltration in between the hepatocytes (Figure&nbsp;1).</p>
</div>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://ars.els-cdn.com/content/image/1-s2.0-S1021949816000077-gr1.jpg"><noscript><img src="https://ars.els-cdn.com/content/image/1-s2.0-S1021949816000077-gr1.jpg" /></noscript></p>
<p><span class="label">Figure&nbsp;1</span>.&nbsp;Histological section of liver from a boldenone-treated&nbsp;<a title="Learn more about Broiler from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/broiler">broiler</a>&nbsp;chick showing mild dilatation in the central veins associated with diffuse inflammatory cell infiltration in between the hepatocytes (H&amp;E 40×). H&amp;E&nbsp;=&nbsp;Hematoxylin&nbsp;and&nbsp;eosin.</p>
<p>&nbsp;</p>
<p>Similarly, no histopathological alteration in the kidney of the control chicks and normal histological structure of the glomeruli and tubules at the cortex were recorded. Boldenone caused focal inflammatory cellular infiltration in between the renal tubules and around the congested blood vessels associated with appearance of homogenous eosinophilic casts in the lumen of dilated tubules (<a class="workspace-trigger" href="https://www.sciencedirect.com/science/article/pii/S1021949816000077#fig2" name="bfig2">Figure&nbsp;2</a>).</p>
<p>&nbsp;</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://ars.els-cdn.com/content/image/1-s2.0-S1021949816000077-gr2.jpg"><noscript><img src="https://ars.els-cdn.com/content/image/1-s2.0-S1021949816000077-gr2.jpg" /></noscript></p>
<p>&nbsp;</p>
<h3 id="sectitle0095" class="u-h4 u-margin-m-top u-margin-xs-bottom">3.4.&nbsp;Meat quality study</h3>
<section id="sec3.4.1">
<h4 id="sectitle0100" class="u-margin-m-top u-margin-xs-bottom">3.4.1.&nbsp;pH value</h4>
<p id="p0115">The pH of meat influences its color,&nbsp;water-holding capacity, flavor, tenderness, and shelf-life. Its measurement at different times&nbsp;<em>post mortem</em>&nbsp;provides information about forthcoming quality characteristics&nbsp;[29].</p>
<div bis_skin_checked="1">
<p id="p0120">The pH values of&nbsp;chicken breasts&nbsp;(<em>pectoralis</em>) at 2&nbsp;h, 24&nbsp;h, 48&nbsp;h, and 72&nbsp;h&nbsp;<em>post mortem</em>&nbsp;during cold chilled storage (4°C) of the control group were stable (6.03&nbsp;±&nbsp;0.025, 6.11&nbsp;±&nbsp;0.022, 6.09&nbsp;±&nbsp;0.023, and 6.1&nbsp;±&nbsp;0.027, respectively;&nbsp;<em>n</em>&nbsp;=&nbsp;3,&nbsp;<em>p</em>&nbsp;&lt;&nbsp;0.05). However, pH values of breasts from the boldenone-treated group were significantly raised from 6.043&nbsp;±&nbsp;0.04 to 6.3&nbsp;±&nbsp;0.04 after 24-h chilled storage (<em>n</em>&nbsp;=&nbsp;3,&nbsp;<em>p</em>&nbsp;&lt;&nbsp;0.05;&nbsp;Figure&nbsp;3).</p>
</div>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://ars.els-cdn.com/content/image/1-s2.0-S1021949816000077-gr3.jpg"><noscript><img src="https://ars.els-cdn.com/content/image/1-s2.0-S1021949816000077-gr3.jpg" /></noscript></p>
<p><span class="label">Figure&nbsp;3</span>.&nbsp;Effect of&nbsp;boldenone&nbsp;on pH values of&nbsp;chicken breasts&nbsp;(pectoralis) during cold-chilled storage.</p>
</section>
<h4 id="sectitle0105" class="u-margin-m-top u-margin-xs-bottom">3.4.2.&nbsp;Total bacterial count</h4>
<div bis_skin_checked="1">
<p id="p0125">APC,&nbsp;<em>Staphylococci</em>, and&nbsp;<a title="Learn more about Coliform Bacterium from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/coliform-bacterium">coliform</a>&nbsp;counts were compared between chicken breasts (<em>pectoralis</em>) from the boldenone-treated group and the control group with APC (32&nbsp;×&nbsp;10<sup>5</sup>&nbsp;±&nbsp;12&nbsp;×&nbsp;10<sup>4</sup>&nbsp;vs. 17&nbsp;×&nbsp;10<sup>5</sup>&nbsp;± 53&nbsp;×&nbsp;10<sup>4</sup>&nbsp;cfu/g;&nbsp;<em>n</em>&nbsp;=&nbsp;3,&nbsp;<em>p</em>&nbsp;&lt;&nbsp;0.05),&nbsp;<em>Staphylococci</em>&nbsp;(66&nbsp;×&nbsp;10<sup>3</sup>&nbsp;±&nbsp;76&nbsp;×&nbsp;10<sup>2</sup>&nbsp;vs. 21&nbsp;×&nbsp;10<sup>3</sup>&nbsp;± 38&nbsp;×&nbsp;10<sup>2</sup>&nbsp;cfu/g;&nbsp;<em>n</em>&nbsp;=&nbsp;3,&nbsp;<em>p</em>&nbsp;&lt;&nbsp;0.05), and coliform count (82&nbsp;×&nbsp;10<sup>4</sup>&nbsp;±&nbsp;36&nbsp;×&nbsp;10<sup>3</sup>&nbsp;vs. 71&nbsp;×&nbsp;10<sup>3</sup>&nbsp;± 26&nbsp;×&nbsp;10<sup>3</sup>&nbsp;cfu/g;&nbsp;<em>n</em>&nbsp;=&nbsp;3,&nbsp;<em>p</em>&nbsp;&lt;&nbsp;0.05) shown in&nbsp;Figure&nbsp;4.</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://ars.els-cdn.com/content/image/1-s2.0-S1021949816000077-gr4.jpg"><noscript><img src="https://ars.els-cdn.com/content/image/1-s2.0-S1021949816000077-gr4.jpg" /></noscript></p>
<p><span class="label">Figure&nbsp;4</span>.&nbsp;Effect of&nbsp;boldenone&nbsp;on growth of indicator bacteria in&nbsp;chicken breasts&nbsp;(pectoralis) during cold-chilled storage (24&nbsp;h at 4°C). APC&nbsp;=&nbsp;aerobic plate count.</p>
</div>
<p>&nbsp;</p>
<h2 id="sectitle0110" class="u-h3 u-margin-l-top u-margin-xs-bottom">4.&nbsp;Discussion</h2>
<hr>
<p>&nbsp;</p>
<section id="sec4">
<p id="p0130">Boldenone&nbsp;is an&nbsp;anabolic steroid&nbsp;characterized by high anabolic and low androgenic activities. 17β-Boldenone, also called 1-dehydrotestosterone, androsta-1,4-diene-17β-ol-3-1, is a&nbsp;steroid&nbsp;with androgenic activity that differs from 17β-testosterone by only one double bond at the 1 position. Important steroids closely related to 17β-boldenone and 17β-testosterone are the 17β-boldenone epimer, i.e., 17α-boldenone, androsta-1,4-diene-3,17-dione, and&nbsp;<a title="Learn more about Androstenedione from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/androstenedione">androst-4-ene-3,17-dione</a>. The two latter diketo substances are precursors of 17β-boldenone and 17β-testosterone, respectively, in humans and different animal species. 17β-Boldenone,&nbsp;<a title="Learn more about Ester from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/ester">esters</a>&nbsp;of 17b-boldenone (e.g.,&nbsp;undecylenate&nbsp;ester), and androsta-1,4-diene-3,17-dione are available for open sale as anabolic preparations&nbsp;[8],&nbsp;[9].</p>
<p id="p0135">Boldenone has been used in many countries for improving meat mass in animals and in body building for humans. Anabolic steroids, including boldenone, are thought to exert their actions by several different mechanisms, including modulating&nbsp;androgen receptor&nbsp;expression as a consequence of (1) intracellular metabolism and (2) directly affecting the topology of the androgen receptor and, thus, subsequent interaction with co-activators and transcriptional activity. Other mechanisms include an anticatabolic effect by interfering with&nbsp;glucocorticoid receptor&nbsp;expression and by non-genomic and genomic pathways in the central nervous system resulting in behavioral changes&nbsp;<a class="workspace-trigger" href="https://www.sciencedirect.com/science/article/pii/S1021949816000077#bib32" name="bbib32">[32]</a>.</p>
<p id="p0140">Unsupervised use of boldenone and similar drugs is sometimes associated with adverse effects or any other possible drug-related problems. This study was designed to evaluate the possible use of boldenone as a&nbsp;growth promoter&nbsp;in&nbsp;<a title="Learn more about Broiler from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/broiler">broiler</a>&nbsp;chicks regarding its safety and meat-quality changes.</p>
<p id="p0145">The supranormal levels of RBC parameters (number, Hct and Hgb concentration) calculated by automated cell counter indicated that boldenone administration enhanced erythropoiesis processes. This result may be supported by Donaldson et&nbsp;al.&nbsp;[33], who found that anabolic steroids stimulated erythropoiesis by increasing erythropoietin-stimulating factor. The data are also consistent with Alen&nbsp;<a class="workspace-trigger" href="https://www.sciencedirect.com/science/article/pii/S1021949816000077#bib34" name="bbib34">[34]</a>, who reported increases in these parameters in athletes on anabolic steroids; however, his description regarding MCH and MVHC was different from our findings. Other recent investigations also reported similar results in rabbits&nbsp;[14], calves&nbsp;[12], and lambs&nbsp;[13]. However, horses were reported to exhibit no significant changes in Hgb and Hct values&nbsp;[35]. RBC size is expressed by the MCV in femtoliters (<em>f</em>L) and usually reflects the degree of regeneration from&nbsp;anemia.&nbsp;Macrocytosis&nbsp;(an increase in the MCV) usually correlates with regenerative anemia, i.e., the bone marrow is reactive to repair the occurred decrease in blood parameters. Microcytic RBCs are the hallmark of&nbsp;iron-deficiency anemia&nbsp;<a class="workspace-trigger" href="https://www.sciencedirect.com/science/article/pii/S1021949816000077#bib36" name="bbib36">[36]</a>. Here, MCV was insignificantly changed, indicating no anemia. MCH and MCHC are two indices correlating Hgb concentration to either RBC count or Hct value, respectively. Although the Hgb value was significantly increased by boldenone, these indices were decreased due to the parallel increase in both RBC count and Hct value.</p>
<p id="p0150">Leuckocytic parameters showed significant changes as compared to those of the control. Total leuckocytic count decreased as a result of the decreased number of lymphocytes (lymphopenia), which constituted the major percentage of the differential count. In contrast, the number of granulocytes exhibited significant increases (granulocytosis). Increased numbers of granulocytes are an indicator of inflammation caused by boldenone in the liver and kidney, as indicated by biomarkers, as well as histopathology. Decreased numbers of lymphocytes despite the increased&nbsp;globulin&nbsp;concentration in this study may have indicated that the increment of globulin concentration could be attributed to the increased levels of α- and β-fractions of globulins rather than the γ-fractions. The former are biomarkers of inflammation, while the latter are biomarkers of immunity. Positive&nbsp;acute-phase proteins&nbsp;represent&nbsp;plasma proteins&nbsp;that increase significantly during acute systemic response to inflammation. These include&nbsp;haptoglobin,&nbsp;fibrinogen,&nbsp;C-reactive protein, serum amyloid-A, and α1-acid&nbsp;glycoprotein&nbsp;[37]. Lymphopenia may also be attributed to its redistribution among different body compartments after anabolic steroid administration&nbsp;[38]. The recorded&nbsp;lymphopenia&nbsp;was consistent with the findings of Saleh and Waded&nbsp;[39], who reported decreased immunological parameters in rabbits after boldenone administration in particularly large doses.</p>
<p id="p0155">Estimation of some biomarkers, such as the activities of enzymes in blood, tissues, and body fluids, plays a major role in assessment of drug safety. Here, the biomarkers in the tested group showed significant differences from those of the control group. ALP, ALT, and AST activity values at the tested dose of boldenone were significantly increased as compared to those of the controls. ALT is a cytoplasmic enzyme, and its increased level in plasma is an indication of mild injuries caused by the drug to the liver, while AST is a&nbsp;mitochondrial enzyme&nbsp;whose increased activity in plasma reflects severe hepatic-tissue injury&nbsp;[40]. It should be noted that although ALP is formed mostly in the liver, it is nonspecific to hepatic injury, as it is also formed by other tissues, such as bone, kidney, skeletal muscle, and placenta. Degenerative changes in the liver tissue shown in&nbsp;Figure&nbsp;1&nbsp;may support hepatic injury caused by boldenone administration. Oral administration may be more stressful on the liver relative to injection due to the&nbsp;first-pass effect. It is also worth noting that ALP concentration in juvenile birds is significantly higher than that of adult birds, as it is induced by increased cellular activity and synthesis rather than cell damage. In contrast to mammals, ALP in birds is also found at higher concentrations in duodenum and kidney&nbsp;[41].</p>
<p id="p0160">The observed significant increase in urea and&nbsp;creatinine&nbsp;values after boldenone injection suggested that the drug might cause&nbsp;renal damage. This biochemical result confirms the histopathological alterations recorded in kidney samples taken from the tested group (Figure&nbsp;2). As urea is metabolized only in the liver, its elevation also indicates&nbsp;hepatic dysfunction, as discussed earlier. In normal birds, the pool of&nbsp;creatine&nbsp;from which creatinine is formed depends mainly upon muscle mass, and is mostly excreted before being converted to creatinine. Therefore, the level interval of creatinine in the blood of birds is 0.1–0.4&nbsp;mg/dL, which is much lower than that of mammals&nbsp;[42]. Urea is also found in much lower concentrations in normal birds than that of normal mammalian species.</p>
<p id="p0165">Elevated levels of CK in this study indicated an adverse effect of boldenone on cardiac and/or skeletal muscle. Multiple investigations reported that boldenone abuse was associated with occurrences of serious cardiovascular events in young athletes, including development of&nbsp;cardiomyopathy,&nbsp;atrial fibrillation,&nbsp;infarction, disturbances of&nbsp;hemostatic&nbsp;system, and ventricular&nbsp;thrombosis&nbsp;[43]. In animals, the organ dysfunction data recorded in broilers in this study may be parallel with those recorded in some other species, including rats&nbsp;[44], rabbits&nbsp;[15], and lambs&nbsp;[11].</p>
<p id="p0170">Although&nbsp;hypoproteinemia&nbsp;is an established finding in liver damage&nbsp;[45], given that the liver creates most&nbsp;plasma-protein fractions, here, the total&nbsp;<a title="Learn more about Serum Globulin from ScienceDirect's AI-generated Topic Pages" href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/serum-globulin">plasma protein and globulin</a>&nbsp;concentrations were significantly increased after boldenone administration. These findings could be attributed to the nitrogen-retention capacity of the drug. Additionally, as mentioned earlier, the increment of globulins may be attributed to the increased α- and β-fractions rather than the γ-fractions, including positive acute-phase proteins.&nbsp;Albumin, in contrast, is considered a negative acute-phase protein that is decreased in inflammation, especially hepatic. Although the calculated albumin/globulin ratio was decreased, albumin concentrations showed insignificant changes in the present study.</p>
<p id="p0175">Parallel elevation of Chol, Tag, and Glu is also a result of liver injury, as lipid and carbohydrate products are managed by the liver to maintain their physiological limits. Blood should be routinely cleared from supra-normal levels of Chol and Tag by a healthy liver with the help of&nbsp;lipoproteins&nbsp;and&nbsp;lipases. Chol is utilized in the synthesis of steroidal hormones and Tag is stored in fat cells for energy when needed. Glu should be converted to&nbsp;glycogen&nbsp;by the liver and muscles, as well. A diseased liver, therefore, results in what is called “Metabolic Syndrome”, as indicated by elevated Chol, Tag, and Glu. Metabolic results in broilers recorded in the present study were consistent with this general rule, and with data reported by other investigators&nbsp;[46].</p>
<p id="p0180">Here, pH values of breast meat from the boldenone-treated group were significantly higher as compared to those of the control. Myofibrillar refraction contributed to differences in light scattering between pale, soft, exudative and dark, firm, dry chicken meat, as it does in pork and beef&nbsp;[47]. This phenomenon was evident when comparing the meat quality of&nbsp;chicken breasts&nbsp;(<em>pectoralis</em>) at low pH (5.91&nbsp;±&nbsp;0.12,&nbsp;<em>n</em>&nbsp;=&nbsp;10) with breasts at high pH (6.36&nbsp;±&nbsp;0.25,&nbsp;<em>n</em>&nbsp;=&nbsp;10,&nbsp;<em>p</em>&nbsp;&lt;&nbsp;0.001). Low-pH breasts had the highest reflectance (<em>p</em>&nbsp;&lt;&nbsp;0.001; from 400&nbsp;nm to 700&nbsp;nm). High-pH breasts had the greatest transmittance into their depth and across individual muscle fibers (<em>p</em>&nbsp;&lt;&nbsp;0.001). The differences in refractive index between ordinary and extraordinary rays across individual muscle fibers were greater in low-pH relative to high-pH breasts (<em>p</em>&nbsp;&lt;&nbsp;0.001). Light at low wavelengths had greater reflectance and lower transmittance relative to light at long wavelengths (<em>p</em>&nbsp;&lt;&nbsp;0.001)&nbsp;[47]. In Brown Swiss&nbsp;veal&nbsp;calves, boldenone administration slowed the process of carcass&nbsp;acidification&nbsp;in the first 24&nbsp;h&nbsp;<em>post mortem</em>; however, the ultimate pH value resulted in the custom. Meat cutting&nbsp;at 7&nbsp;days&nbsp;<em>post mortem</em>&nbsp;showed that treatment improved the meat shininess and color&nbsp;[48].</p>
<p id="p0185">The quality and safety of meat is dictated by the nature and number of spoilage and pathogenic species, which form the total flora. The microbiology of meat is, therefore, normally considered according to two criteria: total bacterial counts, also known as aerobic colony count; and APC and total viable count provide an indication of gross levels of contamination. Specific counts of species are related to spoilage or pathogenic bacteria of particular significance, for example,&nbsp;<em>Salmonella</em>&nbsp;spp.,&nbsp;<em>Enterobacteriaceae</em>, and generic&nbsp;<em>Escherichia coli</em>&nbsp;[49]. In the present study, APC,&nbsp;<em>Staphylococci</em>, and&nbsp;coliform&nbsp;counts were much higher in chicken breasts (<em>pectoralis</em>) from the boldenone-treated group as compared to the control group. It is worth noting that there is a significant relationship between meat pH and shelf life, as high ultimate pH increases the vulnerability of meat to growth of spoilage bacteria&nbsp;[49].</p>
<p id="p0190">In conclusion, the results of the this study indicated that boldenone may cause hepatotoxic and nephrotoxic effects, as well as reductions in meat quality in broilers. Therefore, its use as a growth enhancer is discouraged in this species.</p>
</section>
<section id="sec5">
<h2 id="sectitle0115" class="u-h3 u-margin-l-top u-margin-xs-bottom">Conflicts of interest</h2>
<hr>
<p id="p0195">The authors declare that there are no conflicts of interest related to the present study.</p>
</section>
<p>&nbsp;</p>
<h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">References</h2>
<hr>
<p>&nbsp;</p>
<p>[1]<br>
Anonymous<br>
The U.S. National Institute on Drug Abuse<br>
(2005)<br>
Available from:<br>
http://www.nida.nih.gov/ResearchReports/Steroids/anabolicsteroids2.html#what<br>
Google Scholar<br>
[2]<br>
A.T. Kicman, D. Gower<br>
Anabolic steroids in sport: biochemical, clinical and analytical perspectives<br>
Ann Clin Biochem, 40 (4) (2003), pp. 321-356<br>
View Record in ScopusGoogle Scholar<br>
[3]<br>
J.F. Sykes<br>
Hormonal relationships and application in the production of meats, milk, and eggs<br>
National Research Council (U.S.) Committee on Animal Nutrition (1953)<br>
Google Scholar<br>
[4]<br>
A. Raun, R. Preston (Eds.), History of hormonal modifier use. Proc impact of implants on performance and carcass value of beef cattle, Okla Agric Exp Stn, Stillwater (1997), p. 957<br>
Google Scholar<br>
[5]<br>
R.W. Stephany<br>
Hormonal growth promoting agents in food producing animals. Doping in sports: biochemical principles, effects and analysis<br>
Springer (2010), pp. 355-367<br>
View Record in ScopusGoogle Scholar<br>
[6]<br>
F.T. Cannizzo, G. Zancanaro, F. Spada, C. Mulasso, B. Biolatti<br>
Pathology of the testicle and sex accessory glands following the administration of boldenone and boldione as growth promoters in veal calves<br>
J Vet Med Sci, 69 (2007), pp. 1109-1116<br>
CrossRefView Record in ScopusGoogle Scholar<br>
[7]<br>
A. Alm-Eldeen, E. Tousson<br>
Deterioration of glomerular endothelial surface layer and the alteration in the renal function after a growth promoter boldenone injection in rabbits<br>
Hum Exp Toxicol, 31 (2012), pp. 465-472<br>
CrossRefView Record in ScopusGoogle Scholar<br>
[8]<br>
H. De Brabander, S. Poelmans, R. Schilt, R. Stephany, B. Le Bizec, R. Draisci, S.S. Sterk, L.A. van Ginkel, D. Courtheyn, N. Van Hoof, A. Macrì, K. De Wasch<br>
Presence and metabolism of the anabolic steroid boldenone in various animal species: a review<br>
Food Addit Contam, 21 (2004), pp. 515-525<br>
View Record in ScopusGoogle Scholar<br>
[9]<br>
J. Scarth, C. Akre, L. Van Ginkel, B. Le Bizec, H. De Brabander, W. Korth, J. Points, P. Teale, J. Kay<br>
Presence and metabolism of endogenous androgenic–anabolic steroid hormones in meat-producing animals: a review<br>
Food Addit Contam, 26 (2009), pp. 640-671<br>
CrossRefView Record in ScopusGoogle Scholar<br>
[10]<br>
M. Dumasia, E. Houghton, C.V. Bradley, D. Williams<br>
Studies related to the metabolism of anabolic steriods in the horse: the metabolism of 1-dehydrotestosterone and the use of fast atom bombardment mass spectrometry in the identification of steroid conjugates<br>
Biol Mass Spectrom, 10 (1983), pp. 434-440<br>
CrossRefView Record in ScopusGoogle Scholar<br>
[11]<br>
M. van Puymbroeck<br>
Identification of selective metabolites to reveal the abuse of some synthetic anabolic steroids in cattle<br>
Limburgs Universitair Centrum, Diepenbeek: Belgium (2000)<br>
Google Scholar<br>
[12]<br>
A.N. Neamat-Allah<br>
Effect of Boldenone undecylenate on haematological and biochemical parameters in veal calves<br>
Global Veterinaria, 13 (2014), pp. 1092-1096<br>
View Record in ScopusGoogle Scholar<br>
[13]<br>
F. Gabr, T. Abo El-Maaty, M. Amal, A. Aotifa<br>
Effects of growth promoter boldenone undecylenate on weaned male lambs<br>
Nature and Science, 7 (2009), pp. 61-69<br>
View Record in ScopusGoogle Scholar<br>
[14]<br>
E. Tousson, M. El-Moghazy, A. Massoud, E. El-Atrash, O. Sweef, A. Akel<br>
Physiological and biochemical changes after boldenone injection in adult rabbits<br>
Toxicol Ind Health, 32 (2013), pp. 177-182<br>
Google Scholar<br>
[15]<br>
E. Tousson<br>
Histopathological alterations after a growth promoter boldenone injection in rabbits<br>
Toxicol Ind Health, 32 (2013), pp. 299-305<br>
Google Scholar<br>
[16]<br>
F. Galletti, R. Gardi<br>
Metabolism of 1-dehydroand rostanes in man: I. Metabolism of 17β-hydroxyandrosta-1, 4-dien-3-one, 17β-cyclopent-1′-enyloxyandrosta-1, 4-dien-3-one (quinbolone) and androsta-1, 4-diene-3, 17-dione<br>
Steroids, 18 (1971), pp. 39-50<br>
ArticleDownload PDFView Record in ScopusGoogle Scholar<br>
[17]<br>
O.A. Bessey, O.H. Lowry, M.J. Brock<br>
A method for the rapid determination of alkaline phosphates with five cubic millimeters of serum<br>
J. Biol. Chem, 164 (1946), pp. 321-329<br>
ArticleDownload PDFView Record in ScopusGoogle Scholar<br>
[18]<br>
H.U. Bergmeyer, M. Horder, R. Rej<br>
International Federation of Clinical Chemistry (IFCC) Scientific Committee, Analytical Section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 2. IFCC method for aspartate aminotransferase (L-aspartate: 2-oxoglutarate aminotransferase, EC 2.6.1.1)<br>
J Clin Chem Clin Biochem, 24 (1986), pp. 497-510<br>
View Record in ScopusGoogle Scholar<br>
[19]<br>
N.W. Tietz<br>
Clinical guide to laboratory tests<br>
(3rd ed.), Saunders Company, Philadelphia (1995)<br>
Google Scholar<br>
[20]<br>
H.R. Black, H. Quallich, C.B. Gareleck<br>
Racial differences in serum creatine kinase levels<br>
The Am J Med, 81 (1986), pp. 479-487<br>
ArticleDownload PDFView Record in ScopusGoogle Scholar<br>
[21]<br>
W.J. Marshall<br>
Illustrated textbook of clinical chemistry<br>
(3rd ed.), Gower Medical Publishing, London (1989)<br>
Google Scholar<br>
[22]<br>
M. Krieg, K.J. Gunsser, E. Steinhagen-Thiessen, H. Becker<br>
Comparative quantitative clinico-chemical analysis of the characteristics of 24-hour urine and morning urine<br>
J Clin Chem Clin Biochem, 24 (1986), pp. 863-869<br>
View Record in ScopusGoogle Scholar<br>
[23]<br>
H. Bartels<br>
Serum creatinine and creatinine clearance<br>
Med Welt, 23 (1972), pp. 961-963<br>
View Record in ScopusGoogle Scholar<br>
[24]<br>
F.H. Schmidt<br>
Enzymatic determination of glucose and fructose simultaneously<br>
Klin Wochenschr, 39 (1961), pp. 1244-1247<br>
CrossRefView Record in ScopusGoogle Scholar<br>
[25]<br>
C.C. Allain, L.S. Poon, C.S. Chan, W. Richmond, P.C. Fu<br>
Enzymatic determination of total serum cholesterol<br>
Clin Chem, 20 (1974), pp. 470-475<br>
CrossRefView Record in ScopusGoogle Scholar<br>
[26]<br>
P. Fossati, L. Prencipe<br>
Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide<br>
Clin Chem, 28 (1982), pp. 2077-2080<br>
CrossRefView Record in ScopusGoogle Scholar<br>
[27]<br>
B.T. Doumas, H.G. Biggs<br>
Determination of serum globulins<br>
G.R. Cooper (Ed.), Standard methods of clinical chemistry, Academic Press, New York, NY (1972), p. 175<br>
ArticleDownload PDFGoogle Scholar<br>
[28]<br>
J.D. Bancroft, M. Gamble<br>
Theory and practice of histological techniques<br>
Churchill Livingstone, London (2008)<br>
Google Scholar<br>
[29]<br>
K.O. Honikel<br>
Chemical and physical characteristics of meat pH Measurement<br>
W.K. Jensen (Ed.), Encyclopedia of meat sciences, Elsevier, Oxford (2004), pp. 238-242<br>
ArticleDownload PDFView Record in ScopusGoogle Scholar<br>
[30]<br>
R.D. Morton<br>
Aerobic plate count<br>
F.P. Downes, K. Ito (Eds.), Compendium of methods for the microbiological examination of foods (4th ed.), American Public Health Association (2001), pp. 63-67<br>
Google Scholar<br>
[31]<br>
K.M.J. Swanson, R.L. Petran, J.H. Hanlin<br>
Culture methods for enumeration of microorganisms<br>
F.P. Downes, K. Ito (Eds.), Compendium of methods for the microbiological examination of foods, American Public Health Association (2001), pp. 53-62<br>
Google Scholar<br>
[32]<br>
A. Kicman<br>
Pharmacology of anabolic steroids<br>
Br J Pharmacol, 154 (2008), pp. 502-521<br>
CrossRefView Record in ScopusGoogle Scholar<br>
[33]<br>
I. Donaldson, I. Hart, R. Heitzman<br>
Growth hormone, insulin, prolactin, and total thyroxine in the plasma of sheep implanted with the anabolic steroid trenbolone acetate alone or with oestradiol<br>
Res Vet Sci, 30 (1981), pp. 7-13<br>
ArticleDownload PDFView Record in ScopusGoogle Scholar<br>
[34]<br>
M. Alen<br>
Androgenic steroid effects on liver and red cells<br>
Br J Sports Med, 19 (1985), pp. 15-20<br>
CrossRefView Record in ScopusGoogle Scholar<br>
[35]<br>
J. O’Connor, M. Stillions, W. Reynolds, W. Linkenheimer, D. Maplesden<br>
Evaluation of Boldenone undecylenate as an anabolic agent in horses<br>
Can Vet J, 14 (1973), p. 154<br>
View Record in ScopusGoogle Scholar<br>
[36]<br>
M.H. Beers, R. Berkow<br>
The Merck manual of diagnosis and therapy<br>
Merck and Co., Inc. (1999)<br>
Google Scholar<br>
[37]<br>
M.A. Thrall, G. Weiser, R. Allison, T.W. Campbell<br>
Veterinary hematology and clinical chemistry<br>
Wiley, Oxford (2012)<br>
Google Scholar<br>
[38]<br>
A. Saad, M. Torroba, A. Varas, A. Zapata<br>
Testosterone induces lymphopenia in turtles<br>
Vet Immunol Immunopathol, 28 (1991), pp. 173-180<br>
ArticleDownload PDFView Record in ScopusGoogle Scholar<br>
[39]<br>
N. Saleh, E. Waded<br>
Immune response following the administration of the anabolic steroid Boldenone Undecylenate in rabbits<br>
Stem Cell, 5 (2014), pp. 80-87<br>
View Record in ScopusGoogle Scholar<br>
[40]<br>
A.C. Martins<br>
Clinical chemistry and metabolic medicine<br>
(7th ed.), UK Edward Arnold Ltd, London (2006)<br>
Google Scholar<br>
[41]<br>
S.L. Clubb, R.M. Schubot, K. Joyner, J.G. Zinkl, S. Wolf, J. Escobar<br>
Hematologic and serum biochemical reference intervals in juvenile eclectus parrots (Eclectus roratus)<br>
J Avian Med Surg, 4 (1990), pp. 218-225<br>
CrossRefView Record in ScopusGoogle Scholar<br>
[42]<br>
D.J. Bell, B.M. Freeman<br>
Physiology and biochemistry of the domestic fowl<br>
Academic Press, Cambridge, MA (1984)<br>
Google Scholar<br>
[43]<br>
F. Hartgens, H. Kuipers<br>
Effects of androgenic-anabolic steroids in athletes<br>
Sports Med, 34 (2004), pp. 513-554<br>
CrossRefView Record in ScopusGoogle Scholar<br>
[44]<br>
H. Matinhomaee, S.J. Ziaolhagh, M.A. Azarbayjani, M. Piri<br>
Effects of Boldenone consumption and resistance exercise on hepatocyte morphologic damages in male wistar rats<br>
Eur J Exp Biol, 4 (2014), pp. 211-214<br>
View Record in ScopusGoogle Scholar<br>
[45]<br>
D. Larrey (Ed.), Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Seminars in liver Disease, Thieme Medical Publishers, Inc., New York (2002)<br>
Google Scholar<br>
[46]<br>
Y.A. Attia, W.S. El-Tahawy, A.E.-H.E. Abd El-Hamid, A. Nizza, M.A. Al-Harthi, M.I. El-Kelway, F. Bovera<br>
Effect of feed form, pellet diameter and enzymes supplementation on carcass characteristics, meat quality, blood plasma constituents and stress indicators of broilers<br>
Archiv Tierzucht, 57 (2014), pp. 1-14<br>
CrossRefView Record in ScopusGoogle Scholar<br>
[47]<br>
H.J. Swatland<br>
How pH causes paleness or darkness in chicken breast meat<br>
Meat Science, 80 (2008), pp. 396-400<br>
ArticleDownload PDFView Record in ScopusGoogle Scholar<br>
[48]<br>
M. Marcazzani<br>
Effects of an hormonal treatment with Boldenone about productive performances and meat quality of veal calves<br>
Thesis<br>
Università degli Studi di Padova, Italy (2004)<br>
Google Scholar<br>
[49]<br>
D.S. Collins, R.J. Huey<br>
Gracey’s meat hygiene<br>
Wiley, London (2015)<br>
Google Scholar</p>
<h2>Source:</h2>
<p>https://www.sciencedirect.com/science/article/pii/S1021949816000077</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/03/25/evaluation-of-boldenone-as-a-growth-promoter-in-broilers-safety-and-meat-quality-aspects/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/03/25/evaluation-of-boldenone-as-a-growth-promoter-in-broilers-safety-and-meat-quality-aspects/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5174 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>11.03.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/03/11/amoxicillin-clavulanic-acid-for-the-treatment-of-odontogenic-infections-a-randomised-study-comparing-efficacy-and-tolerability-versus-clindamycin-2/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/03/11/amoxicillin-clavulanic-acid-for-the-treatment-of-odontogenic-infections-a-randomised-study-comparing-efficacy-and-tolerability-versus-clindamycin-2/">Amoxicillin/Clavulanic Acid for the Treatment of Odontogenic Infections: A Randomised Study Comparing Efficacy and Tolerability versus Clindamycin</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p><span class="">Archiel Launch Tancawan,<sup>1</sup>&nbsp;</span><span class="">Maria Noemi Pato,<sup>2</sup>&nbsp;</span><span class="">Khamiza Zainol Abidin,<sup>3</sup>&nbsp;</span><span class="">A. S. Mohd Asari,<sup>4</sup>&nbsp;</span><span class="">Tran Xuan Thong,<sup>5</sup>&nbsp;</span><span class=""><b>Puja Kochhar</b>,<sup>6</sup>&nbsp;</span><span class="">Chandra Muganurmath,<sup>7</sup>&nbsp;</span><span class="">Monique Twynholm,<sup>8</sup>&nbsp;and&nbsp;</span><span class="">Keith Barker<sup>9</sup></span></p>
<p>&nbsp;</p>
<h4 id="abstract" class="header">Abstract</h4>
<hr>
<p>&nbsp;</p>
<p><i>Background</i>. Treatment of odontogenic infections includes surgical drainage and adjunctive antibiotics. This study was designed to generate efficacy and safety data to support twice daily dosing of amoxicillin/clavulanic acid compared to clindamycin in odontogenic infections.&nbsp;<i>Methods</i>. This was a phase IV, randomised, observer blind study; 472 subjects were randomised to receive amoxicillin/clavulanic acid (875 mg/125 mg BID,&nbsp;) or clindamycin (150 mg QID,&nbsp;) for 5 or 7 days based on clinical response. The primary endpoint was percentage of subjects achieving clinical success (composite measure of pain, swelling, fever, and additional antimicrobial therapy required) at the end of treatment.&nbsp;<i>Results</i>. The upper limit of two-sided 95% confidence interval for the treatment difference between the study arms (7.7%) was within protocol specified noninferiority margin of 10%, thus demonstrating noninferiority of amoxicillin/clavulanic acid to clindamycin. Secondary efficacy results showed a higher clinical success rate at Day 5 in the amoxicillin/clavulanic acid arm. Most adverse events (raised liver enzymes, diarrhoea, and headache) were similar across both arms and were of mild to moderate intensity.&nbsp;<i>Conclusion</i>. Amoxicillin/clavulanic acid was comparable to clindamycin in achieving clinical success (88.2% versus 89.7%) in acute odontogenic infections and the safety profile was consistent with the known side effects of both drugs.&nbsp;<i>Trial Registration</i>. This trial is registered with Clinicaltrials.gov identifier:&nbsp;NCT02141217.</p>
<p>&nbsp;</p>
<h4 id="introduction">1. Introduction</h4>
<hr>
<p>&nbsp;</p>
<p>Odontogenic infections are one of the most prevalent diseases worldwide and the principal reason for seeking dental care. Dental prescriptions account for nearly 7% to 11% of all common antibiotic prescriptions [<a class="refAnchor">1</a>]. The commonest emergency odontogenic infections are periapical abscess (25%), pericoronitis (11%), and periodontal abscess (7%) [<a class="refAnchor">2</a>].</p>
<p>Odontogenic infections are mostly polymicrobial and frequently encountered odontopathogens are<i>&nbsp;Streptococci</i>&nbsp;spp.,<i>&nbsp;Corynebacterium</i>&nbsp;spp. and<i>&nbsp;Staphylococcus</i>&nbsp;spp.,<i>&nbsp;Prevotella</i>&nbsp;spp.,<i>&nbsp;Porphyromonas</i>&nbsp;spp.,<i>&nbsp;Fusobacterium</i>&nbsp;spp., and<i>&nbsp;Bacteroides</i>&nbsp;spp. [<a class="refAnchor">2</a>,&nbsp;<a class="refAnchor">3</a>]. Therapeutic success in odontogenic infections is determined by the control of infection by surgical debridement and/or antimicrobial therapy which is indicated when there are clear signs of systemic involvement such as pyrexia or lymphadenopathy [<a class="refAnchor">2</a>]. The polymicrobial nature of odontogenic infections necessitates the use of antibiotics active against both aerobic and anaerobic bacteria [<a class="refAnchor">4</a>]. The antibiotics most commonly prescribed for acute dental abscesses are amoxicillin, penicillin, metronidazole, and erythromycin with clindamycin as an alternative in individuals allergic to the beta-lactam antibiotics [<a class="refAnchor">3</a>].</p>
<p>Recently, published evidence suggests that penicillin and amoxicillin are being rendered increasingly less effective because of beta-lactamase producing bacteria. More than half of the Gram-negative anaerobic bacilli (including<i>&nbsp;Prevotella</i>,<i>&nbsp;Porphyromonas</i>,<i>&nbsp;Bacteroides</i>, and<i>&nbsp;Fusobacterium</i>&nbsp;spp.) are capable of producing beta-lactamase leading to treatment failures in dental infections [<a class="refAnchor">5</a>]. Studies have revealed the presence of beta-lactamase producing species in 74–88% of patients with periodontitis [<a class="refAnchor">4</a>]. Addition of a beta-lactamase inhibitor such as clavulanic acid to amoxicillin (Augmentin) confers resistance to beta-lactamases thereby extending the antibiotic spectrum to anaerobes such as<i>&nbsp;Prevotella</i>&nbsp;spp. and<i>&nbsp;Bacteroides</i>&nbsp;spp. anaerobes and to<i>&nbsp;Staphylococcus</i>&nbsp;spp. [<a class="refAnchor">4</a>]. Efficacy of amoxicillin/clavulanic acid in the treatment of acute periapical abscess has been established in several studies [<a class="refAnchor">2</a>,&nbsp;<a class="refAnchor">4</a>].</p>
<p>Clindamycin is a broad-spectrum antibiotic with activity against aerobic, anaerobic bacteria including coverage against beta-lactamase producing pathogens [<a class="refAnchor">6</a>]. Clinical trials have demonstrated the efficacy of clindamycin in treating odontogenic infections [<a class="refAnchor">7</a>–<a class="refAnchor">11</a>]. Use of clindamycin in dental infections is based on careful patient selection in view of reported cases of pseudomembranous colitis (a rare but serious consequence of clindamycin).</p>
<p>Despite published evidence evaluating different oral formulations of amoxicillin/clavulanic acid in dental infections, there is limited published data on the use of twice daily dosing of 875/125 mg in odontogenic infections. Available evidence suggests that twice daily dosing with 875/125 mg amoxicillin/clavulanic acid results in a successful clinical outcome, better patient compliance, and less gastrointestinal upset, due to a reduction in the dose of clavulanic acid [<a class="refAnchor">1</a>]. The aim of the current study was to assess the clinical efficacy and safety of amoxicillin/clavulanic acid 875/125 mg twice daily versus clindamycin 150 mg four times daily, for 5 or 7 days in dental infections.</p>
<p>&nbsp;</p>
<h4 id="methods">2. Methods</h4>
<hr>
<p>&nbsp;</p>
<h5 id="sec2.1">2.1. Study Design</h5>
<p>AUG117044 was a phase IV, randomised, parallel group, comparative, observer blind study to evaluate efficacy, safety, and tolerability of amoxicillin/clavulanic acid (875 mg/125 mg) and clindamycin (150 mg) in the treatment of acute odontogenic infection with or without abscess. The study was conducted in fifteen centres across four countries with four centres each in Malaysia, Philippines, and Vietnam and three in Thailand.</p>
<p>The study protocol, the informed consent, and other information that required preapproval were reviewed and approved by a national, regional, or investigational centre ethics committee or institutional review board, in accordance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) and applicable country-specific requirements. Written informed consent was obtained from each subject prior to the performance of any study-specific procedures. The study was conducted in accordance with ICH GCP and all applicable subject privacy requirements and the ethical principles that are outlined in the Declaration of Helsinki 2008.</p>
<p>A total of 472 subjects were randomised in a 1 : 1 ratio in each of the treatment arms. The study included a one-day screening period followed by a treatment period of five days that could be extended to seven days based on clinical response. Standard surgical intervention for odontogenic infection was permitted only before commencing study treatment. Eligible subjects were randomized on the day of their screening visit or within a day of screening. Efficacy and safety evaluations were performed on Day 2, Day 5, and/or Day 7 (based on treatment duration) (Figure&nbsp;<a href="https://www.hindawi.com/journals/ijd/2015/472470/fig1/" target="_blank" rel="noopener">1</a>). Study treatment included amoxicillin/clavulanic acid (875 mg/125 mg) administered twice daily or clindamycin (150 mg) administered four times daily along with meals for 5 or 7 days. Clinical efficacy (cure (cure was defined as complete resolution of signs and symptoms of infection present at baseline such that no additional antimicrobial therapy was required), improvement (improvement was defined as resolution of fever (if present at baseline) and &gt;70% reduction in swelling and pain and improvement in other signs and symptoms such that no additional antimicrobial therapy was required), and failure (failure was defined as inability to improve the signs and symptoms of infection after seven days of therapy so that additional antimicrobial therapy was required)) of the study treatment was assessed based on the response shown by the subjects on the Visual Analogue Scale (VAS) scores of pain and swelling. Since these clinical efficacy parameters were based on symptomatic relief, an optimal study design would have been a double blind design. However, the different dosage regimens and formulations of the study drugs presented practical challenges for a double blind design. Based on these considerations, the study was designed to be an observer blind study with the investigator remaining blinded throughout the study period. An unblinded study team member was appointed for the study for drug dispensing and drug accountability and was also present during the clinic visits to ensure that the investigators remained blinded to treatment assignment. Adherence to the study design requirements was essential and no protocol waivers or exemptions were allowed during the study. This study did not require an independent data safety monitoring board and no interim analysis was performed.</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://static-01.hindawi.com/articles/ijd/volume-2015/472470/figures/472470.fig.001.svgz"><noscript><img src="https://static-01.hindawi.com/articles/ijd/volume-2015/472470/figures/472470.fig.001.svgz" /></noscript></p>
<div class="floats-partial-caption" bis_skin_checked="1"><span class="caption-text">Figure 1</span><a class="caption-partial-url" title="full view" href="https://www.hindawi.com/journals/ijd/2015/472470/fig1/" target="_blank" rel="noopener" aria-label="full view">&nbsp;</a></div>
<div class="floats-partial-caption-text" bis_skin_checked="1">
<div bis_skin_checked="1">Study schema. Note: the study had a 1-day screening period (Day 1 to Day 0) during which eligibility was assessed and laboratory tests were performed. Randomisation occurred within 24 hours of screening at baseline (Day 0). Further visits (Day 2, Day 5, and Day 7) were calculated from the baseline/randomisation visit (Day 0).</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h5 id="sec2.2">2.2. Study Population</h5>
<p>Inclusion criteria: the study enrolled subjects ≥18 years of age with a diagnosis of acute odontogenic infections (periapical abscess, acute periodontitis, and pericoronitis) that required antibiotic therapy. Radiographic evidence of odontogenic infection and dental pain on mastication were mandatory diagnostic criteria for enrollment. Exclusion criteria: subjects presenting with complicated odontogenic infections (such as osteomyelitis, dentocutaneous and dentoalveolar fistula, and facial-space swelling) or odontogenic infections secondary to traumatic injury or requiring hospitalisation, aggressive intravenous antimicrobial therapy, or local application of antimicrobials for the treatment of odontogenic infection were excluded. Further, patients with other key exclusion criteria such as conditions prone to infective endocarditis and those treated with systemic antibiotics within two weeks before the study of drug administration or injectable long acting antibiotics administered four weeks prior to study of drug administration were also excluded from study.</p>
<h5 id="sec2.3">2.3. Study Variables</h5>
<p>The primary objective of the study was the comparison of clinical efficacy of amoxicillin/clavulanic acid with clindamycin in subjects with acute odontogenic infection with or without abscess. This efficacy endpoint was based on the percentage of subjects achieving clinical success (cure or improvement) at the end of treatment (Day 5 or 7). The secondary endpoints of the study included percentage of subjects achieving clinical success at Day 5 and change in the VAS score for pain and swelling from baseline to Days 2, 5, and 7. Safety assessments included monitoring of adverse events (AEs) and serious adverse events (SAEs) from the start of study treatment until the end of study treatment. The antibiotic susceptibility of bacterial isolates obtained from pus specimens was recorded at baseline.</p>
<h5 id="sec2.4">2.4. Statistical Analysis</h5>
<p>A sample size of 205 evaluable subjects in each of the treatment arms provided 90% power to assess noninferiority for the primary endpoint. This was based on a noninferiority margin of 10%, assuming clinical success response rate in the comparator arm (clindamycin 150 mg) of 90% and a one-sided&nbsp;%. Considering a 15% drop-out rate, a final sample size of 236 subjects in each study group was chosen. Thus total randomised subjects in the study were 472 for a 1 : 1 treatment allocation in each study group to get at least 205 evaluable subjects in each arm.</p>
<p>The per-protocol (PP) population was a subset of Intent-to-Treat (ITT) population that had a postbaseline clinical success response assessment and did not report major protocol deviation(s). However, those subjects who discontinued from the study without any postbaseline assessment and where the reason for discontinuation was documented as “Lack of Efficacy” or “Treatment Failure” were included in the PP population with clinical success outcome treated as “Clinical Failure.” For noninferiority analysis, the PP population using observed case (OC) method was treated as the primary dataset. The assessment of noninferiority for clinical success response was based on two-sided 95% confidence interval (CI); the upper limit of two-sided 95% CI of the difference of proportion between the two treatments of less than 0.10 (10%) was set to conclude the noninferiority between the treatment arms. The analysis of the Intent-to-Treat-Efficacy (ITT-E) population (all randomised subjects with at least one postbaseline assessment of clinical success response) using the OC dataset was provided as a sensitivity analysis for the primary endpoint and was also used to evaluate secondary endpoints. The ITT population (all randomised subjects who received at least one dose of study medication) was the safety dataset for the study.</p>
<p>The investigator’s judgment was considered decisive for the assessment of clinical improvement in a subject. In the event that the main signs and symptoms were cured or improved (complete resolution of fever and &gt;70% reduction in swelling and pain) and there was “no change” or “worsening from baseline” in other signs and symptoms (such as increased leucocyte count/tooth mobility/lymphadenopathy), the investigator’s opinion was sought as to whether additional antimicrobial therapy was required. Subjects that required no additional antimicrobial therapy per the investigators judgment were considered a “success” while those requiring additional antimicrobials were deemed as “failures.” The analysis based on the investigator’s judgment of clinical success or failure was considered as the primary analysis for testing of noninferiority between the treatment groups and the analysis excluding the investigator’s assessment for clinical success was presented as supportive analysis.</p>
<p>For sensitivity analysis, all subjects with an assessment of cure or improvement (complete resolution of fever, &gt;70% reduction in swelling and pain) but with “no change” or “worsening from baseline” in other signs and symptoms (increased leucocyte count/tooth mobility/lymphadenopathy) were considered as “Clinical Failures” irrespective of the clinical judgment of investigator.</p>
<p>Clinical laboratory assessments were summarized on ITT population using OC approach for missing values. Liver function tests (LFTs) values were summarised after values were normalised. Any LFT parameter which was out of reference range for that particular laboratory was considered an adverse event (AE). However, AST, ALT, and alkaline phosphatase values &gt;3 × upper limit of reference range (ULRR) and total bilirubin &gt;1.5 × ULRR were considered to be of potential clinical concern (PCC) as defined by sponsor.</p>
</div>
<p>&nbsp;</p>
<h4 id="results">3. Results</h4>
<hr>
<p>&nbsp;</p>
<h5 id="sec3.1">3.1. Participants</h5>
<p>A total of 510 subjects were screened for a planned enrollment of 472 subjects. Amongst the 472 randomised subjects, 235 (46.1%) subjects were randomised to the amoxicillin/clavulanic acid arm and 237 (46.5%) to the clindamycin arm. However, a total of 236 subjects received amoxicillin/clavulanic acid and 235 subjects received clindamycin (one subject randomised to the amoxicillin/clavulanic acid arm did not receive any study drug and two subjects randomised to the clindamycin arm incorrectly received amoxicillin/clavulanic acid). A similar proportion of enrolled subjects completed the study in both the treatment arms (223 (94.9%) in the amoxicillin/clavulanic acid arm and 229 (96.6%) in the clindamycin arm). A total of 11 (4.7%) subjects in the amoxicillin/clavulanic acid arm and 8 (3.4%) subjects in the clindamycin arm discontinued before study completion and the main reasons for discontinuations were as follows: AEs (one and two in amoxicillin/clavulanic acid and clindamycin arms, resp.), protocol noncompliance (one and four in amoxicillin/clavulanic acid and clindamycin arms, resp.), and meeting the withdrawal criteria (nine and two in amoxicillin/clavulanic acid and clindamycin arms, resp.).</p>
<h5 id="sec3.2">3.2. Baseline Characteristics</h5>
<p>Subjects recruited in the study were South East Asian in origin with similar age and sex distribution across both treatment arms. Periapical abscess was the predominant odontogenic infection across both arms (56.8% and 54.9% subjects in the amoxicillin/clavulanic acid and clindamycin arms, resp.). There was no significant difference in baseline characteristics such as pain, swelling, radiographic evidence of dental infection, and medical history/preexisting conditions between the treatment arms (Table&nbsp;<a href="https://www.hindawi.com/journals/ijd/2015/472470/tab1/" target="_blank" rel="noopener">1</a>).</p>
<p>&nbsp;</p>
<p><img class="alignnone size-medium wp-image-5175" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20640%20863'%3E%3C/svg%3E" alt="" width="640" height="863" data-lazy-srcset="/../../../../wp-content/uploads/2021/01/Capture1-640x863.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2021/01/Capture1-320x431.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2021/01/Capture1.jpg 646w" data-lazy-sizes="(max-width: 640px) 100vw, 640px" data-lazy-src="/../../../../wp-content/uploads/2021/01/Capture1-640x863.jpg"><noscript><img class="alignnone size-medium wp-image-5175" src="/../../../../wp-content/uploads/2021/01/Capture1-640x863.jpg" alt="" width="640" height="863" srcset="/../../../../wp-content/uploads/2021/01/Capture1-640x863.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2021/01/Capture1-320x431.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2021/01/Capture1.jpg 646w" sizes="(max-width: 640px) 100vw, 640px" /></noscript></p>
<p>&nbsp;</p>
<p>Percentage is calculated based on number of subjects in ITT population for each treatment arm and by actual randomised arm. As per randomisation, there were 234 subjects in amoxicillin/clavulanic acid arm and 237 in clindamycin arm but due to wrong randomisation process, two subjects were administered amoxicillin/clavulanic acid instead of clindamycin. Hence as per actual treatment received, there were 236 subjects in amoxicillin/clavulanic acid arm and 235 subjects in clindamycin arm.</p>
<p>&nbsp;</p>
<h5 id="sec3.3">3.3. Primary Efficacy Results</h5>
<p>The primary efficacy analysis using the PP population demonstrated that the clinical efficacy of amoxicillin/clavulanic acid was noninferior to clindamycin, since the upper limit of two-sided 95% CI was within the protocol specified noninferiority margin of 10%.</p>
<p>The percentage of subjects achieving clinical success using the primary analysis population was 88.2% (95% CI: 83.0%, 92.2%) in the amoxicillin/clavulanic acid arm and 89.7% (95% CI: 84.6%, 93.5%) in the clindamycin arm. The treatment difference between the treatment arms was 1.5% (95% CI: −4.7%, 7.7%) using Miettinen and Nurminen method, 1.5% (95% CI: −4.9%, 8.0%) using Farrington and Manning method, and 1.5% (95% CI: −4.5%, 7.6%) using a two-sample proportion test. Since the upper limit of the two-sided 95% CI for between-group percentages differences was less than the prespecified noninferiority margin of 10%, noninferiority of amoxicillin/clavulanic acid to clindamycin with respect to clinical success was demonstrated. This result was also corroborated by sensitivity analysis using the ITT-E population (Table&nbsp;<a href="https://www.hindawi.com/journals/ijd/2015/472470/tab2/" target="_blank" rel="noopener">2</a>).</p>
<h2>Table 2</h2>
<div class="floats-full-page-caption" bis_skin_checked="1">Primary efficacy endpoint: clinical success outcome at the end of the study.</div>
<div class="floats-full-page-content" bis_skin_checked="1">
<table id="tab2" class="table-group">
<tbody>
<tr>
<td>
<table class="table">
<tbody>
<tr>
<td class="thead-hr" colspan="6">
<hr>
</td>
</tr>
<tr class="thead">
<td rowspan="2" align="left">Population</td>
<td rowspan="2" align="center">Clindamycin [% (95% CI)]</td>
<td rowspan="2" align="center">Amoxicillin/clavulanic acid [% (95% CI)]</td>
<td colspan="3" align="center">Treatment difference</td>
</tr>
<tr class="thead">
<td align="center">Miettinen and Nurminen method (primary) [% (95% CI)]</td>
<td align="center">Farrington and Manning method [% (95% CI)]</td>
<td align="center">Two-sample proportion test [% (95% CI)]</td>
</tr>
<tr>
<td class="thead-hr" colspan="6">
<hr>
</td>
</tr>
<tr>
<td align="left">PP</td>
<td align="center">89.7%<br>
(84.6%, 93.5%)</td>
<td align="center">88.2% (83.0%, 92.2%)</td>
<td align="center">1.5% ( 95 CI: −4.7%, 7.7%)</td>
<td align="center">1.5%<br>
(−4.9%, 8.0%)</td>
<td align="center">1.5% (−4.5%, 7.6%)</td>
</tr>
<tr>
<td colspan="6" align="center">
<hr>
</td>
</tr>
<tr>
<td align="left">ITT-E</td>
<td align="center">86.4%<br>
(81.3%, 90.5%)</td>
<td align="center">85.5% (80.3%, 89.8%)</td>
<td align="center">0.9% (−5.5%, 7.3%)</td>
<td align="center">0.9%<br>
(−5.6%, 7.4%)</td>
<td align="center">0.9% (−5.5%, 7.2%)</td>
</tr>
<tr>
<td colspan="6" align="center">
<hr>
</td>
</tr>
<tr>
<td align="left">ITT (randomised treatment arm)</td>
<td align="center">85.7%<br>
(80.5%, 89.9%)</td>
<td align="center">83.3% (77.9%, 87.9%)</td>
<td align="center">2.3% (−4.3%, 9.0%)</td>
<td align="center">2.3%<br>
(−4.4%, 9.0%)</td>
<td align="center">2.3% (−4.2%, 8.9%)<p></p>
<p>&nbsp;</p>
<p>&nbsp;</p></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<h5 id="sec3.4">3.4. Secondary Efficacy Results</h5>
<p>A slightly higher percentage of subjects achieved clinical success in the amoxicillin/clavulanic acid arm by Day 5 [76.8% (95% CI: 70.7%, 82.2%)] than the clindamycin arm [69.1% (95% CI 62.7%, 75.0%)] possibly indicating a faster response in subjects receiving amoxicillin/clavulanic acid arm as compared to subjects who received clindamycin.</p>
<p>The least square mean change in the VAS score for pain (using ITT-E dataset with OC approach) was maximum at Day 7 (6.38 and 6.34 in the amoxicillin/clavulanic acid and clindamycin arms, resp.) compared to Day 5 (5.49 and 5.38 in the treatment arms, resp.) and Day 2 (3.34 and 3.07, resp.) and it was similar between the treatment arms at each time point. Similar results were also noted for swelling (Table&nbsp;<a href="https://www.hindawi.com/journals/ijd/2015/472470/tab3/" target="_blank" rel="noopener">3</a>). A summary of VAS by visit and treatment arms demonstrated that higher mean percentage reduction in pain by Day 2 was achieved in the amoxicillin/clavulanic acid arm (49.5%) compared with (45.6%) the clindamycin arm. Similarly, a higher mean percentage reduction in swelling by Day 2 was achieved in the amoxicillin/clavulanic acid arm (43.6%) compared with the clindamycin arm (39.6%).</p>
<p><img class="alignnone size-medium wp-image-5176" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20640%20447'%3E%3C/svg%3E" alt="" width="640" height="447" data-lazy-srcset="/../../../../wp-content/uploads/2021/01/Capture2-640x447.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2021/01/Capture2-1024x716.jpg 1024w, //ikigaicorporation.com/wp-content/uploads/2021/01/Capture2-320x224.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2021/01/Capture2.jpg 1097w" data-lazy-sizes="(max-width: 640px) 100vw, 640px" data-lazy-src="/../../../../wp-content/uploads/2021/01/Capture2-640x447.jpg"><noscript><img class="alignnone size-medium wp-image-5176" src="/../../../../wp-content/uploads/2021/01/Capture2-640x447.jpg" alt="" width="640" height="447" srcset="/../../../../wp-content/uploads/2021/01/Capture2-640x447.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2021/01/Capture2-1024x716.jpg 1024w, //ikigaicorporation.com/wp-content/uploads/2021/01/Capture2-320x224.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2021/01/Capture2.jpg 1097w" sizes="(max-width: 640px) 100vw, 640px" /></noscript></p>
<h5 id="sec3.5">3.5. Microbiological Results</h5>
<p>Pus specimens were obtained in 58 subjects who consented to microbiological sampling including two who were screen failures (25 in the amoxicillin/clavulanic acid arm and 31 in the clindamycin arm; the 2 screen failures were excluded). A total of 61 isolates were obtained from 56 samples, 26 in the amoxicillin/clavulanic acid arm and 35 in the clindamycin arm. Organisms isolated in both the treatment arms were similar and predominantly viridans streptococci group (() including<i>&nbsp;Streptococcus oralis</i>,<i>&nbsp;Streptococcus mitis</i>, and<i>&nbsp;Streptococcus parasanguinis</i>),<i>&nbsp;Enterobacter</i>&nbsp;spp. (),<i>&nbsp;Klebsiella</i>&nbsp;spp. (),<i>&nbsp;Pseudomonas</i>&nbsp;spp. (), and<i>&nbsp;Staphylococcus</i>&nbsp;spp. (). CLSI breakpoints are not uniformly available for all isolates for both study drugs which posed a challenge in providing meaningful interpretation of susceptibility data.</p>
<h5 id="sec3.6">3.6. Safety Results</h5>
<p>A total of 243 treatment emergent AEs (TEAEs) were reported in 123 subjects in the amoxicillin/clavulanic acid arm and 236 events were reported in 124 subjects in the clindamycin arm. The most frequently observed TEAEs with frequency ≥3% were abdominal discomfort, raised liver enzymes (AST, ALT, and bilirubin), diarrhoea, dizziness, headache, increased appetite, and somnolence (Table&nbsp;<a href="https://www.hindawi.com/journals/ijd/2015/472470/tab4/" target="_blank" rel="noopener">4</a>). Generally the incidence of TEAEs was similar between treatment arms, except for diarrhoea and headache which were reported in slightly more patients in the clindamycin arm. Most AEs were of mild to moderate intensity. The incidence of drug related TEAEs in both the treatment arms was similar (165 AEs reported in 93 (39.4%) subjects and 171 AEs reported in 97 (41.3%) subjects in the amoxicillin/clavulanic acid and clindamycin arms, resp.). The most frequently reported drug related TEAEs were gastrointestinal disorders including abdominal discomfort, diarrhoea, nausea and vomiting, abnormal LFTs, increased appetite, somnolence, dizziness, and headache<i>.</i>&nbsp;Most of the related TEAEs were mild to moderate in intensity except for six events of severe intensity. These were elevated ALT, headache, and vomiting reported in the amoxicillin/clavulanic acid arm and burning sensation, hypertension, and hypersomnia in the clindamycin arm. All events had resolved by the end of the study except hypersomnia. A total of 89 subjects in the amoxicillin/clavulanic acid arm and 76 subjects in the clindamycin arm had AEs that remained ongoing at the end of the study. Increased LFT was the predominant ongoing AE and was present in 46 subjects in the amoxicillin/clavulanic acid arm and 40 subjects in clindamycin arm, respectively. The probable reason for the ongoing AEs could be the short duration of the study (7 to 8 days) and the lack of a planned follow-up visit after study treatment. No subjects in the study showed shift in ALT and AST from normal at baseline (with respect to local laboratory reference range) to PCC range (as defined in statistical analysis section) at end of the study whereas three subjects each in both the study arms showed shift in total bilirubin to PCC range at the end of the study. However, since these subjects only had increased bilirubin with no increase in ALT or AST, these were not of clinical concern. Four subjects in the clindamycin arm with high LFT parameter (one subject each for ALT and AST and two subjects for total bilirubin) at baseline remained in the PCC range at the end of the study (Figure&nbsp;<a href="https://www.hindawi.com/journals/ijd/2015/472470/fig2/" target="_blank" rel="noopener">2</a>). No events of SAE or death were reported in the study.</p>
<p>&nbsp;</p>
<h2>Table 4</h2>
<div class="floats-full-page-caption" bis_skin_checked="1">Summary of commonly observed treatment emergent AEs (≥3% in either of the arms).</div>
<div class="floats-full-page-content" bis_skin_checked="1">
<table id="tab4" class="table-group">
<tbody>
<tr>
<td>
<table class="table">
<tbody>
<tr>
<td class="thead-hr" colspan="3">
<hr>
</td>
</tr>
<tr class="thead">
<td align="left">MedDRA preferred term</td>
<td align="center">Amoxicillin/clavulanic acid<br>
(N=236)</td>
<td align="center">Clindamycin<br>
(N=235)</td>
</tr>
<tr>
<td class="thead-hr" colspan="3">
<hr>
</td>
</tr>
<tr>
<td align="left">Total number of treatment emergent AEs</td>
<td align="center">243</td>
<td align="center">236</td>
</tr>
<tr>
<td align="left">Subjects who experienced at least one AE</td>
<td align="center">123 (52.1%)</td>
<td align="center">124 (52.8%)</td>
</tr>
<tr>
<td align="left">Abdominal discomfort</td>
<td align="center">11 (4.7%)</td>
<td align="center">7 (3.0%)</td>
</tr>
<tr>
<td align="left">Alanine aminotransferase increased</td>
<td align="center">26 (11.0%)</td>
<td align="center">24 (10.2%)</td>
</tr>
<tr>
<td align="left">Aspartate aminotransferase increased</td>
<td align="center">24 (10.2%)</td>
<td align="center">20 (8.5%)</td>
</tr>
<tr>
<td align="left">Blood bilirubin increased</td>
<td align="center">12 (5.1%)</td>
<td align="center">13 (5.5%)</td>
</tr>
<tr>
<td align="left">Diarrhoea</td>
<td align="center">19 (8.1%)</td>
<td align="center">28 (11.9%)</td>
</tr>
<tr>
<td align="left">Dizziness</td>
<td align="center">18 (7.6%)</td>
<td align="center">14 (6.0%)</td>
</tr>
<tr>
<td align="left">Headache</td>
<td align="center">8 (3.4%)</td>
<td align="center">14 (6.0%)</td>
</tr>
<tr>
<td align="left">Increased appetite</td>
<td align="center">20 (8.5%)</td>
<td align="center">15 (6.4%)</td>
</tr>
<tr>
<td align="left">Nausea</td>
<td align="center">7 (3.0%)</td>
<td align="center">4 (1.7%)</td>
</tr>
<tr>
<td align="left">Somnolence</td>
<td align="center">19 (8.1%)</td>
<td align="center">17 (7.2%)</td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<p><img class="alignnone size-medium wp-image-5177" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20640%20557'%3E%3C/svg%3E" alt="" width="640" height="557" data-lazy-srcset="/../../../../wp-content/uploads/2021/01/Capture3-640x557.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2021/01/Capture3-320x279.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2021/01/Capture3.jpg 697w" data-lazy-sizes="(max-width: 640px) 100vw, 640px" data-lazy-src="/../../../../wp-content/uploads/2021/01/Capture3-640x557.jpg"><noscript><img class="alignnone size-medium wp-image-5177" src="/../../../../wp-content/uploads/2021/01/Capture3-640x557.jpg" alt="" width="640" height="557" srcset="/../../../../wp-content/uploads/2021/01/Capture3-640x557.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2021/01/Capture3-320x279.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2021/01/Capture3.jpg 697w" sizes="(max-width: 640px) 100vw, 640px" /></noscript></p>
<p>&nbsp;</p>
<h4 id="discussion">4. Discussion</h4>
<p>The primary treatment in acute odontogenic infections is surgical drainage while antibiotics are an adjunct in patients showing signs of systemic involvement [<a class="refAnchor">12</a>]. The polymicrobial component of odontogenic infection necessitates the use of antibiotics that are active against both aerobic and anaerobic bacteria and therefore are recommended [<a class="refAnchor">4</a>]. The current study was aimed at comparing the clinical efficacy of amoxicillin/clavulanic acid (875 mg/125 mg) to clindamycin (150 mg) in subjects with acute odontogenic infections.</p>
<p>Amoxicillin/clavulanic acid (875 mg/125 mg) was administered twice daily for 5–7 days and was found to be noninferior or “comparable” to clindamycin (150 mg) administered four times daily. The overall clinical success seen with amoxicillin/clavulanic acid in the study (88.2% (95% CI: 83.0%, 92.2%)) was similar to results seen in other published studies. Success rates of 87% with amoxicillin/clavulanic acid 1 g twice daily and 96% with amoxicillin/clavulanic acid 625 mg thrice daily have been previously reported in other studies [<a class="refAnchor">13</a>,&nbsp;<a class="refAnchor">14</a>]. A higher percentage of pain and swelling reduction (49.5% and 43.6%) was achieved in the amoxicillin/clavulanic acid arm compared to the clindamycin arm (45.6% and 39.6%) after two days of treatment. In a similar study aimed at demonstrating possible differences in the severity of symptoms after the use of amoxicillin and amoxicillin/clavulanic acid in dental ailments, pain was found to be less acute with amoxicillin/clavulanic acid [<a class="refAnchor">15</a>]. Thus, these results indicate that amoxicillin/clavulanic acid given twice daily for the treatment of odontogenic infection serves as an appropriate treatment option with the potential advantage of an early clinical response.</p>
<p>Safety of the subjects, assessed throughout the study, showed that the overall incidences of TEAEs were similar across both the treatment arms. These were mainly events such as abdominal discomfort, diarrhoea, and raised liver enzymes. As per the available safety information of amoxicillin/clavulanic acid 875/125 mg, nausea and diarrhoea are commonly reported events [<a class="refAnchor">16</a>]. Diarrhoea was seen in 8.1% of subjects in amoxicillin/clavulanic acid arm (compared to 11.9% in the clindamycin arm) and this is consistent with the known pharmacological effects of the drug and with the global prescribing information. Raised liver enzymes are a known but uncommon side effect (≥1/1,000 to &lt;1/100) of amoxicillin/clavulanic acid. In the current study, a total of 34 subjects (14.4%) in the amoxicillin/clavulanic acid arm had raised liver enzymes posttreatment compared to 33 subjects (14.04%) in the clindamycin arm that were assessed by the investigator as related to the study drug. However, most of these events were of mild to moderate intensity and none of the subjects were considered to have any LFT values that were of clinical concern. Pseudomembranous colitis is a rare but serious side effect of both clindamycin and amoxicillin-clavulanic acid. However, literature evidence suggests that the incidence is particularly low when these antibiotics are given in outpatient care settings (6.7 cases/100,000 antibiotic exposures). In dental infections there is not much difference in the incidence of<i>&nbsp;C. difficile</i>&nbsp;colitis between the two drugs [<a class="refAnchor">6</a>]. In the current study there were no cases of pseudomembranous colitis with either of the study drugs. There were no SAEs or deaths reported in this study.</p>
<p>One of the main limitations of the study was the use of an outcome measure based on a subjective score (VAS score) to assess pain and swelling to derive the composite clinical outcome. However, to overcome the subjectivity of the VAS score and to reflect real world practice, only subjects demonstrating &gt;70% reduction in pain and swelling were considered for calculating clinical success response. Another limitation was not having a planned follow-up visit for the subjects after the end of the study visits. As a result, ongoing AEs typically key laboratory parameters such as liver enzymes could not be followed until resolution; however, most were mild and transient in nature.</p>
<h4 id="conclusions">5. Conclusions</h4>
<p>Amoxicillin/clavulanic acid (875 mg/125 mg) administered twice daily was found to be comparable to clindamycin (150 mg) administered four times daily in achieving clinical success in acute odontogenic infections with or without abscess. It was also found to be well tolerated with a safety profile consistent with the known pharmacologic effects of amoxicillin/clavulanic acid and with that described in the global prescribing information.</p>
<h4 id="conflict-of-interests">Conflict of Interests</h4>
<p>Archiel Launch Tancawan, Maria Noemi Pato, Khamiza Zainol Abidin, A. S. Mohd Asari, and Tran Xuan Thong declare no conflict of interests regarding the publication of this paper. Puja Kochhar, Chandra Muganurmath, Monique Twynholm, and Keith Barker are employees of GlaxoSmithKline and hold stocks/shares in GlaxoSmithKline. Archiel Launch Tancawan, Maria Noemi Pato, Khamiza Zainol Abidin, A. S. Mohd Asari, and Tran Xuan Thong were principal investigators in AUG117044 study.</p>
<h4 id="acknowledgments">Acknowledgments</h4>
<p>Nooraini Bt Osman (Putrajaya Dental Clinic, Malaysia), Christopher Vincent (Selayang Hospital, Malaysia), Haidee Daphnee Digma (Southern Philippines Medical Center, Philippines), Margarita Oasin (Rizal Medical Center, Philippines), Ngo Thi Quynh Lan (University of Medicine and Pharmacy, Vietnam), Huynh Dai Hai (Odonto-Maxillo-Facial Hospital, Vietnam), Dao Thi Dung (Vietnam-Cuba Friendship, Hanoi), Tanakrit Noppakunwijai (Tanarat Fort Hospital, Thailand), Prisana Pripatnanont (Prince of Songkla University, Thailand), and Nipon Chaisrisookumporn (Lampang Regional Hospital, Thailand) were principal investigators. Gandhali Paranjape and Kavitha Rangappa (DiagnoSearch Life Sciences Pvt. Ltd.) were responsible for editorial assistance; Boshi Mohala (GlaxoSmithKline) was responsible for safety review; Jie Ding (GlaxoSmithKline) and Varsha Parulekar (DiagnoSearch Life Sciences Pvt. Ltd.) were responsible for statistical support. Study was funded by GlaxoSmithKline Pharmaceuticals Ltd. and editorial assistance was provided by DiagnoSearch Life Sciences Pvt. Ltd.</p>
<p>&nbsp;</p>
<h4 id="references" class="references">References</h4>
<hr>
<p>&nbsp;</p>
<ol>
<li>N. S. Dar-Odeh, O. Abu-Hammad, M. K. Al-Omiri, A. S. Khraisat, and A. A. Shehabi, “Antibiotic prescribing practices by dentists: a review,” Therapeutics and Clinical Risk Management, vol. 6, pp. 301–306, 2010.<br>
View at: Publisher Site | Google Scholar<br>
R. López-Píriz, L. Aguilar, and M. J. Giménez, “Management of odontogenic infection of pulpal and periodontal origin,” Medicina Oral, Patología Oral y Cirugía Bucal, vol. 12, no. 2, pp. E154–E159, 2007.</li>
<li>D. Robertson and A. J. Smith, “The microbiology of the acute dental abscess,” Journal of Medical Microbiology, vol. 58, no. 2, pp. 155–162, 2009.<br>
View at: Publisher Site | Google Scholar<br>
A. B. Martínez, J. M. A. Urízar, A. B. Fenoll et al., “Consensus statement on antimicrobial treatment of odontogenic bacterial infections,” Medicina Oral, Patologia Oral y Cirugia Bucal, vol. 9, no. 5, pp. 363–376, 2004.</li>
<li>I. Brook, E. H. Frazier, and M. E. Gher, “Aerobic and anaerobic microbiology of periapical abscess,” Oral Microbiology and Immunology, vol. 6, no. 2, pp. 123–125, 1991.<br>
View at: Publisher Site | Google Scholar<br>
I. Brook, M. A. O. Lewis, G. K. B. Sándor, M. Jeffcoat, L. P. Samaranayake, and J. V. Rojas, “Clindamycin in dentistry: more than just effective prophylaxis for endocarditis?” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 100, no. 5, pp. 550–558, 2005.<br>
View at: Publisher Site | Google Scholar<br>
C. Walker and J. Gordon, “The effect of clindamycin on the microbiota associated with refractory periodontitis,” Journal of Periodontology, vol. 61, no. 11, pp. 692–698, 1990.<br>
View at: Publisher Site | Google Scholar<br>
W. C. Gilmore, N. V. Jacobus, S. L. Gorbach, H. C. Doku, and F. P. Tally, “A prospective double-blind evaluation of penicillin versus clindamycin in the treatment of odontogenic infections,” Journal of Oral and Maxillofacial Surgery, vol. 46, no. 12, pp. 1065–1070, 1988.<br>
View at: Publisher Site | Google Scholar<br>
L. Von Konow, P. A. Kondell, C. E. Nord, and A. Heimdahl, “Clindamycin versus phenoxymethylpenicillin in the treatment of acute orofacial infections,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 11, no. 12, pp. 1129–1135, 1992.<br>
View at: Publisher Site | Google Scholar<br>
S. Mangundjaja and K. Hardjawinata, “Clindamycin versus ampicillin in the treatment of odontogenic infections,” Clinical Therapeutics, vol. 12, no. 3, pp. 242–249, 1990.</li>
<li>J. Gordon, C. Walker, C. Hovliaras, and S. Socransky, “Efficacy of clindamycin hydrochloride in refractory periodontitis: 24-month results,” Journal of Periodontology, vol. 61, no. 11, pp. 686–691, 1990.<br>
View at: Publisher Site | Google Scholar<br>
S. J. Ellison, “An outcome audit of three day antimicrobial prescribing for the acute dentoalveolar abscess,” British Dental Journal, vol. 211, no. 12, pp. 591–594, 2011.<br>
View at: Publisher Site | Google Scholar<br>
B. J. Al-Selivany, N. A. Al-Derzi, and S. Y. Agha, “Dental infections: clinical and microbiological evaluation of responsiveness to twice daily amoxicillin-clavulanic acid (amoxiclave),” Jordan Medical Journal, vol. 44, no. 3, pp. 305–312, 2010.</li>
<li>C. F. Adriaenssen, “Comparison of the efficacy, safety and tolerability of azithromycin and co-amoxiclav in the treatment of acute periapical abscesses,” Journal of International Medical Research, vol. 26, no. 5, pp. 257–265, 1998.</li>
<li>N. Sulejmanagić, H. Sulejmanagić, Z. Ljutović, D. Salihagić, and M. Sijercić, “Combined application of amoxicillin and clavulanic acid after oral surgical interventions,” Bosnian Journal of Basic Medical Sciences, vol. 5, no. 1, pp. 61–68, 2005.</li>
<li>AUGMENTIN 875/125MG, “Amoxicillin/clavulanic acid,” Product Information, 2013.</li>
</ol>
<p>&nbsp;</p>
<h2>Source:</h2>
<p>https://www.hindawi.com/journals/ijd/2015/472470/</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/03/11/amoxicillin-clavulanic-acid-for-the-treatment-of-odontogenic-infections-a-randomised-study-comparing-efficacy-and-tolerability-versus-clindamycin-2/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/03/11/amoxicillin-clavulanic-acid-for-the-treatment-of-odontogenic-infections-a-randomised-study-comparing-efficacy-and-tolerability-versus-clindamycin-2/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5165 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>28.02.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/02/28/identical-pattern-of-highly-variable-absorption-of-clavulanic-acid-from-four-different-oral-formulations-of-co-amoxiclav-in-healthy-subjects/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/02/28/identical-pattern-of-highly-variable-absorption-of-clavulanic-acid-from-four-different-oral-formulations-of-co-amoxiclav-in-healthy-subjects/">Identical pattern of highly variable absorption of clavulanic acid from four different oral formulations of co-amoxiclav in healthy subjects</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><div class="wi-authors" bis_skin_checked="1">
<div class="al-authors-list" bis_skin_checked="1"><span class="al-author-name-more js-flyout-wrap"><a class="linked-name js-linked-name-trigger">Tom B. Vree</a><span class="delimiter">,</span></span>&nbsp;<span class="al-author-name-more js-flyout-wrap"><a class="linked-name js-linked-name-trigger">Erik Dammers</a><span class="delimiter">,</span></span>&nbsp;<span class="al-author-name-more js-flyout-wrap"><a class="linked-name js-linked-name-trigger">Peter S. Exler</a></span></div>
</div>
<div class="pub-history-wrap clearfix" bis_skin_checked="1">
<div class="pub-history-row clearfix" bis_skin_checked="1">
<div class="ww-citation-primary" bis_skin_checked="1"><em>Journal of Antimicrobial Chemotherapy</em>, Volume 51, Issue 2, February 2003, Pages 373–378,&nbsp;<a href="https://doi.org/10.1093/jac/dkg082">https://doi.org/10.1093/jac/dkg082</a></div>
</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h2 id="13169816" class="abstract-title">Abstract</h2>
<hr>
</div>
<p>&nbsp;</p>
<section class="abstract">
<p class="chapter-para">The aims of this investigation were to calculate the pharmacokinetic parameters of amoxicillin and clavulanic acid, and to identify parameters that may affect their observed differences in absorption. Data were obtained from plasma concentration–time curves from four different open, randomized, two-treatment, two-period, two-sequence, crossover Phase I bioequivalence studies, with the following co-amoxiclav formulations: tablets 250/125, 500/125 and 875/125 mg, or 10 mL of an oral suspension 250/62.5 mg per 5 mL. Data from 144 subjects and 288 drug administrations were available for evaluation. After a 125 mg clavulanic acid dose (administered as potassium clavulanate) for all four different formulations, the clavulanic acid AUC<sub>t</sub>&nbsp;data ranged from 1.5 to 8 mg·h/L, varying by a factor of 5. The absorption of clavulanic acid was not related to the absorption of amoxicillin, or demographic factors, and we were unable to identify the reasons for the large variability in the absorption of clavulanic acid. We conclude that the absorption of clavulanic acid, after oral administration, is highly variable and may vary over a five-fold range between patients.</p>
</section>
<div class="article-metadata-panel clearfix" bis_skin_checked="1">
<div class="kwd-group" bis_skin_checked="1"><a class="kwd-part kwd-main" data-keyword="&quot;Keywords: amoxicillin-clavulanate, co-amoxiclav, amoxiclav, pharmacokinetics, variable absorption, AUC, amoxicillin/clavulanate ratio&quot;">Keywords: amoxicillin-clavulanate, co-amoxiclav, amoxiclav, pharmacokinetics, variable absorption, AUC, amoxicillin/clavulanate ratio</a></div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">Received 26 October 2001; returned 20 June 2002; revised 30 October 2002; accepted 6 November 2002</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h2 id="13169820" class="section-title">Introduction</h2>
<hr>
</div>
<p>&nbsp;</p>
<p class="chapter-para">Clavulanic acid improves the antibacterial spectrum of amoxicillin by rendering strains that are resistant due to β-lactamase production susceptible to amoxicillin. The binding of β-lactamases to clavulanic acid is a complex physicochemical process. In general, a reversible complex is formed initially, followed by covalent binding, which leads to irreversible inactivation of both the β-lactamase and clavulanic acid. For this interaction, relatively low plasma concentrations of clavulanic acid are required.<span id="jumplink-DKG082C1" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C1">1</a><sup>–</sup><span id="jumplink-DKG082C3" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C3">3</a>&nbsp;As both amoxicillin and clavulanic acid are absorbed after oral administration and possess similar pharmacokinetic properties (similar elimination kinetics with similar half-lives of 1 h), they offer a rational antimicrobial combination.<span id="jumplink-DKG082C4" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C4">4</a><sup>,</sup><span id="jumplink-DKG082C5" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C5">5</a></p>
<p class="chapter-para">The standard dose of co-amoxiclav (amoxicillin/clavulanic acid) for adults with lower respiratory tract infection has, for many years, been 500/125 mg orally three times a day. However, it is generally recognized that patient compliance improves with a reduced dosing frequency, and co-amoxiclav has now been licensed for use at a dose of 875/125 mg orally twice daily. The efficacy of this twice-daily dosage regimen is supported by pharmacokinetic, microbiological and clinical data.<span id="jumplink-DKG082C6" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C6">6</a><sup>–</sup><span id="jumplink-DKG082C10" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C10">10</a></p>
<p class="chapter-para">The dosage ratio of amoxicillin/clavulanic acid in oral co-amoxiclav formulations has changed since the combination has been in use, from 2:1 initially, to 4:1, and more recently to 7:1. The amoxicillin/clavulanic acid ratio was increased in order to reduce the incidence of side effects of clavulanic acid seen with the 2:1 ratio.<span id="jumplink-DKG082C11" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C11">11</a>&nbsp;As the efficacies of all of these combinations appear to be similar, this would suggest that the amount of clavulanic acid necessary to inhibit bacterial β-lactamases may not be that critical.</p>
<p class="chapter-para">The aims of this investigation were to calculate the pharmacokinetic parameters, and to identify parameters that may influence the observed differences in absorption of clavulanic acid and amoxicillin, following administration of four different dosage formulations.</p>
<p>&nbsp;</p>
<h2 id="13169825" class="section-title">Materials and methods</h2>
<hr>
<p>&nbsp;</p>
<h3 id="13169826" class="section-title">Experimental design</h3>
<p class="chapter-para">The evaluation was based on the data from plasma concentration–time curves obtained from four different open, randomized, two-treatment, two-period, two-sequence, crossover Phase I bioequivalence studies, each involving 36 male subjects. Subjects were treated with any of the following co-amoxiclav formulations, given as a single dose: tablets 250/125, 500/125 and 875/125 mg, or 10 mL of an oral suspension 250/62.5 mg per 5 mL, and data from 144 subjects and 288 drug administrations were available for evaluation. Treatments were separated by a 1 week washout period, and each subject participated in one study only.</p>
<p class="chapter-para">The clinical trials were performed by the Gesellschaft für Therapeutische Forschung (GTF, Nürnberg-Heroldsberg, Germany). The study protocols and written volunteer information sheets were granted approval by the Ethics committee of the University of Köln (Köln, Germany) and all volunteers gave written informed consent.</p>
<p class="chapter-para">Subjects were not allowed to consume beverages/food containing methylxanthines, grapefruit products and/or alcohol for 24 h before until 24 h after dosing. Smoking was allowed, except for 2 h before until 4 h after dosing.</p>
<h3 id="13169830" class="section-title">Trial course</h3>
<p class="chapter-para">For each study, the subjects were divided randomly into two groups. Randomization was carried out by following the procedure PLAN of the SAS Institute (Cary, NC, USA).</p>
<p class="chapter-para">Group 1 was assigned to treatment sequence I–II (formulation I followed by formulation II). Group 2 was assigned to sequence II–I. Subjects received each of the following two formulations following an overnight fast.</p>
<p class="chapter-para"><em>Study 1.</em>&nbsp;Formulation A1 = single oral dose of one co-amoxiclav 250/125 mg tablet [Losan Pharma, Neuenburg, Germany (287 mg amoxicillin trihydrate and 148.9 mg potassium salt of clavulanic acid)], and formulation B1 = single oral dose of one Augmentin 375 mg film-coated tablet (Beecham Research, UK). Thirty-six healthy Caucasian male volunteers without any co-medication (age 26 ± 5 years, height 182.1 ± 5.8 cm, body weight 78.6 ± 8.4 kg).</p>
<p class="chapter-para"><em>Study 2.</em>&nbsp;Formulation A2 = single oral dose of one co-amoxiclav 500/125 mg tablet (Losan Pharma; 574 mg amoxicillin trihydrate and 148.9 mg potassium salt of clavulanic acid), and formulation B2 = single oral dose of one Augmentin 625 mg film-coated tablet (Beecham Research). Thirty-six healthy Caucasian male volunteers without any co-medication (age 26 ± 5 years, height 183.3 ± 6.9 cm, body weight 78.9 ± 8.6 kg).</p>
<p class="chapter-para"><em>Study 3.</em>&nbsp;Formulation A3 = one single oral dose of 10 mL co-amoxiclav 250/62.5 mg/5 mL oral suspension, equivalent to 500 mg amoxicillin and 125 mg clavulanic acid (Losan Pharma; 574 mg amoxicillin trihydrate and 148.9 mg potassium salt of clavulanic acid), and formulation B3 = 10 mL suspension of Augmentin 250/62 SF oral suspension (Beecham Research). Thirty-six healthy Caucasian male volunteers without any co-medication (age 28 ± 4 years, height 181.8 ± 7.1 cm, body weight 79.7 ± 8.2 kg).</p>
<p class="chapter-para"><em>Study 4.</em>&nbsp;Formulation A4 = single oral dose of one co-amoxiclav 875/125 mg tablet [Cimex AG Pharmaceutika, Liesberg, Switzerland (1004 mg amoxicillin trihydrate and 148.9 mg potassium salt of clavulanic acid)], and formulation B4 = single oral dose of one Augmentin 1 g tablet (SmithKline Beecham, Austria). Thirty-six healthy Caucasian male volunteers without any co-medication (age 28 ± 4 years, height 181.8 ± 7.1 cm, body weight 79.7 ± 8.2 kg).</p>
<h3 id="13169840" class="section-title">Drug administration</h3>
<p class="chapter-para">Before drug administration, subjects fasted for at least 10 h. Fasting was continued until 4 h after dosing. Subjects were free to drink water, low-fat milk, apple juice, diluted orange juice, coffee and tea after the initial 4 h. All subjects received the same standardized low-fat lunch (6 h) and light snack (9 h) after drug administration.</p>
<h3 id="13169842" class="section-title">Blood sampling</h3>
<p class="chapter-para">On the day of dosing, a physician inserted an indwelling Venflon 2 intravenous cannula in a forearm vein of each subject. The cannula was removed after withdrawal of the 12 h post-dosing sample.</p>
<p class="chapter-para">Blood samples (5 mL) were collected in heparinized glass tubes just before dosing and at 0.25, 0.50, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 5, 6, 8, 10 and 12 h after dosing. The blood samples were centrifuged at 3280<strong>g</strong>&nbsp;for 10 min and plasma was stored at –70°C until analysis.</p>
<h3 id="13169845" class="section-title">Bioanalysis</h3>
<p class="chapter-para">Plasma amoxicillin and clavulanic acid concentrations were determined using validated methods such as LC/MS/MS analysis (GTF).<span id="jumplink-DKG082C12" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C12">12</a><sup>,</sup><span id="jumplink-DKG082C13" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C13">13</a>&nbsp;Lower limit of quantification (LOQ) values were, respectively, 20.0 and 50.0 ng/mL.</p>
<p class="chapter-para">In brief, mass spectrometric positive ion detection (selected reaction monitoring, SRM) was achieved by precursor [M+H]<sup>+</sup>→product ion for amoxicillin&nbsp;<em>m</em>/<em>z</em>&nbsp;366→208, and for the internal standard&nbsp;<em>m</em>/<em>z</em>&nbsp;350→160. For clavulanic acid, the precursor [M+H]<sup>+</sup>→product ions were&nbsp;<em>m</em>/<em>z</em>&nbsp;198→108, and for the internal standard&nbsp;<em>m</em>/<em>z</em>&nbsp;232→140.</p>
<p class="chapter-para">The inter-day precision and accuracy (relative error) of the back-calculated calibration standards of amoxicillin ranged from 1.1% to 6.5% and from –5.6% to 4.4%, respectively. For the spiked quality control standards of amoxicillin, the inter-day precision ranged from 3.6% to 9.2% with an inter-day accuracy (relative error) between –4.3% and 6.7%. The intra-day precision and relative error of the amoxicillin assay ranged from 2.1% to 9.1% and between –6.1% and 5.0%.</p>
<p class="chapter-para">The inter-day precision and accuracy (relative error) of the back-calculated calibration standards of clavulanic acid ranged from 0.7% to 4.6% and from –3.1% to 6.5%, respectively. For the spiked quality control standards of clavulanic acid, the inter-day precision ranged from 2.7% to 5.4%, with an inter-day accuracy (relative error) between –1.3% and 6.2%. The intra-day precision and relative error of the clavulanic acid assay ranged from 0.7% to 2.6% and between –0.5% and 6.8%.</p>
<h3 id="13169850" class="section-title">Pharmacokinetics</h3>
<p class="chapter-para">Based on the plasma amoxicillin and clavulanic acid concentrations of individual subjects, the following pharmacokinetic parameters were determined by non-compartmental analysis using WinNonlin Professional (Version 2.0, Pharsight Corporation, copyright 1994–1998, Palo Alto, CA, USA): maximum plasma drug concentration (<em>C</em><sub>max</sub>, mg/L); time to reach&nbsp;<em>C</em><sub>max</sub>&nbsp;(<em>T</em><sub>max</sub>, h); area under the plasma concentration–time curve until the last measurable concentration (<em>C</em><sub>t</sub>), calculated by the linear trapezoidal method (AUC<sub>t</sub>, mg·h/L); elimination half-life associated with the terminal slope of a semi-logarithmic concentration–time curve (<em>t</em><sub>1/2z</sub>, h), calculated as ln2/λ<sub>z</sub>, where λ is the elimination rate constant; means of the individual AUC<sub>t</sub>&nbsp;data of clavulanic acid were calculated over the intervals of 1 AUC<sub>t</sub>&nbsp;unit (mg·h/L) and correlated for variation in amoxicillin AUC<sub>t</sub>&nbsp;and demographic data.</p>
<h3 id="13169852" class="section-title">Statistical analysis</h3>
<p class="chapter-para">Analysis of variance (ANOVA) was carried out, and significance was defined at&nbsp;<em>P</em>&nbsp;≤ 0.05.</p>
<p>&nbsp;</p>
<h2 id="13169854" class="section-title">Results</h2>
<hr>
<p>&nbsp;</p>
<p class="chapter-para">The mean (±&nbsp;<span class="small-caps">S.D</span>.) plasma concentration–time curves of amoxicillin and clavulanic acid in 36 healthy male subjects after oral administration of 500/125 mg co-amoxiclav tablets (formulation A2) are shown in Figure&nbsp;<span id="jumplink-DKG082F1" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082F1">1</a>. The other dose formulations gave similar-shaped concentration–time curves. The half-life of elimination of amoxicillin was ~1.46 h, and that of clavulanic acid was ~1.08 h for all dosages. Absorption of all formulations was fast, although the&nbsp;<em>T</em><sub>max</sub>&nbsp;of amoxicillin increased with the dose, from 1.14 ± 0.41 h at 250 mg to 2.04 ± 1.01 h (<em>P</em>&nbsp;&lt; 0.0001) at 875 mg (Table&nbsp;<span id="jumplink-DKG082TB1" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082TB1">1</a>). The AUC<sub>t</sub>&nbsp;values of amoxicillin increased proportionally with the dose, from 10 mg·h/L at 250 mg to 33 mg·h/L at 875 mg. Table&nbsp;<span id="jumplink-DKG082TB2" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082TB2">2</a>&nbsp;shows the means (±&nbsp;<span class="small-caps">S.D</span>.) of the pharmacokinetic parameters of clavulanic acid after the four oral dosages with the two formulations; no differences in the pharmacokinetic parameters were seen between the different formulations.</p>
<p class="chapter-para">Figure&nbsp;<span id="jumplink-DKG082F2" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082F2">2</a>&nbsp;shows a plot of AUC<sub>t amoxicillin</sub>&nbsp;against AUC<sub>t clavulanic acid</sub>&nbsp;after oral administration of 500/125 mg co-amoxiclav tablets (formulations A2 and B2). Although there was a five-fold variation in the AUC<sub>t</sub>&nbsp;of clavulanic acid with both formulations, the AUC<sub>t</sub>&nbsp;of amoxicillin only varied by a factor of 1.2. The other formulations gave similar results (data not shown).</p>
<p class="chapter-para">The plots of AUCt amoxicillin versus AUCt clavulanic acid after three oral administrations of 250/125, 500/125 and 875/125 mg co-amoxiclav tablets, and the 500/125 mg co-amoxiclav oral suspension (formulations A+B), are shown in Figure&nbsp;<span id="jumplink-DKG082F3" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082F3">3</a>. For each of the four dosages studied there was relatively little variation in the mean AUCs observed for amoxicillin, yet in excess of a five-fold variation in those of clavulanic acid.</p>
<p>&nbsp;</p>
<h2 id="13169858" class="section-title">Discussion</h2>
<hr>
<p>&nbsp;</p>
<p class="chapter-para">After intravenous administration, the&nbsp;<em>V</em><sub>ss</sub>&nbsp;of amoxicillin has been reported as 0.26 ± 0.06 L/kg, and the&nbsp;<em>V</em><sub>ss</sub>&nbsp;of clavulanic acid as 0.22 ± 0.06 L/kg, giving a ratio for the volume of distribution between clavulanic acid and amoxicillin of 0.85.<span id="jumplink-DKG082C14" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C14">14</a>&nbsp;Consequently, for a co-amoxiclav dose of 500/125, and a&nbsp;<em>V</em><sub>ss</sub>&nbsp;ratio of 0.85, the ratio of amoxicillin to clavulanic acid AUCs should be 3.4. In this study, the lowest AUC<sub>t</sub>&nbsp;amoxicillin/clavulanic acid ratio observed was 2.7 ± 0.50 at the lower doses used, suggesting equivalent absorption of both amoxicillin and clavulanic acid. Higher amoxicillin/clavulanic acid AUC<sub>t</sub>&nbsp;ratios (in the present studies up to 12), as seen with the 875/125 formulation, would suggest that with a similar amoxicillin absorption, clavulanic acid absorption must have been reduced. It has been reported that the absolute bioavailability of clavulanic acid, when co-administered with amoxicillin, ranged from 31.4% to 98.8%.<span id="jumplink-DKG082C15" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C15">15</a>&nbsp;Similar findings have been reported by Witkowski&nbsp;<em>et al</em>.,<span id="jumplink-DKG082C3" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C3">3</a>&nbsp;who found that although the mean AUC<sub>t</sub>&nbsp;of 125 mg clavulanate was not affected by co-administration of 500 mg amoxicillin, the coefficient of variation for the AUC increased from 27.6% for clavulanic acid alone to 45.6% when given with amoxicillin. In contrast, in other studies where clavulanic acid was administered alone, the mean absorption was 97% with little inter-patient variability, suggesting an interaction between the absorption of amoxicillin and clavulanic acid.<span id="jumplink-DKG082C16" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C16">16</a><sup>,</sup><span id="jumplink-DKG082C17" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C17">17</a>&nbsp;This is supported by data from studies where co-amoxiclav has been given as an intravenous infusion. In these studies, a dose ratio of 10:1 (50/5 mg/kg) has been used for intravenous administration, which results in an AUC<sub>t</sub>&nbsp;ratio of 10 and an identical plasma clearance of both amoxicillin and clavulanic acid, with no evidence of a pharmacokinetic interaction between the two agents.<span id="jumplink-DKG082C18" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C18">18</a></p>
<p class="chapter-para">The AUC observed for amoxicillin in this study did not show significant variation either between subjects, based on demographic data, or between formulations, once corrected for the dose. In contrast, high variability was seen between subjects in the AUC of clavulanic acid, with values ranging over a five-fold difference. All subjects in this study were healthy males (with normal renal function), and it is difficult to explain the high variability seen in the clavulanic acid AUC on patient factors. However, similar findings to these have been reported in other studies.<span id="jumplink-DKG082C15" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C15">15</a><sup>,</sup><span id="jumplink-DKG082C18" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C18">18</a><sup>–</sup><span id="jumplink-DKG082C20" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C20">20</a></p>
<p class="chapter-para">With the highest dosage of amoxicillin (875 mg) used in this study, the&nbsp;<em>T</em><sub>max</sub>&nbsp;broadened, which would suggest a rate-limiting step in the absorption process, in line with other studies.<span id="jumplink-DKG082C21" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C21">21</a><sup>,</sup><span id="jumplink-DKG082C22" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C22">22</a>&nbsp;Of interest, in Figure&nbsp;<span id="jumplink-DKG082F3" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082F3">3</a>&nbsp;the AUC<sub>amox</sub>/AUC<sub>clav</sub>&nbsp;regression curve of amoxicillin 875 mg has a negative slope, which may indicate that the saturable absorption seen for amoxicillin is influenced by the presence of clavulanic acid. This effect is reported to be bigger with higher dosages of amoxicillin, of up to 3 g in humans,<span id="jumplink-DKG082C21" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C21">21</a><sup>,</sup><span id="jumplink-DKG082C22" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C22">22</a>&nbsp;or at even higher doses of 25 mg/kg in cats<span id="jumplink-DKG082C23" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C23">23</a>&nbsp;and dogs.<span id="jumplink-DKG082C24" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C24">24</a>&nbsp;In contrast, the slopes of the regression lines of the 250/125 and 500/125 mg dosages were all positive, indicating no influence of clavulanic acid administration on the absorption of amoxicillin at these dosages.</p>
<p class="chapter-para">In this study, we have been able to show that four different co-amoxiclav formulations each gave a five-fold variation in the absorption, or in the AUC<sub>t</sub>&nbsp;value, of clavulanic acid for the same 125 mg dose. This would suggest that in some patients only a 20:1 amoxicillin/clavulanic acid AUC<sub>t</sub>&nbsp;ratio is achieved after the oral dose of 500/125 mg co-amoxiclav, yet they still appear to benefit from the presence of clavulanic acid (as therapy failures are rarely reported). For patients receiving the 875/125 mg dosage, our findings would indicate that the individual AUC<sub>t</sub>&nbsp;ratio may vary up to 35:1. However, as the clinical efficacy of co-amoxiclav has been maintained for &gt;10 years with an apparent excess of clavulanic acid in fixed-dose combination preparations, it is probable that the absolute amount of clavulanic acid administered to patients is more important than maintaining a minimal plasma concentration ratio of the two agents.<span id="jumplink-DKG082C25" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C25">25</a><sup>–</sup><span id="jumplink-DKG082C28" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="DKG082C28">28</a></p>
<p class="chapter-para">In conclusion, the observed variations in the AUC<sub>t</sub>&nbsp;ratio of amoxicillin/clavulanic acid (2–10:1) highlight the variable nature of clavulanic acid absorption. However, clinical data would suggest that such variability does not affect the efficacy of co-amoxiclav and that the current dosage ratio of 4:1 may be considered as conservative.</p>
<p class="chapter-para"><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Figure 1. Mean (± s.d.) plasma concentration–time curves of amoxicillin (Amoxi) and clavulanic acid (Clav) after an oral dose of 500/125 mg co-amoxiclav tablets in 36 healthy volunteers (formulation A2)." data-lazy-src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/2/10.1093/jac/dkg082/2/m_dkg082f1.gif?Expires=1611412425&amp;Signature=uGSGpJkWej70nCDVyG~cIBCk7wMx3vmMHkDj-vUTyn2nZcj8zqnuB-WAOFgORP0UTenGpkh0hIaFGMF8VeQJJmAiPyR~aLLHzP-bZEcJRUpl68NUsKagC8wlycjaL4sancZ~bR~yknP90B99TOnn0HOSFrRg8IJxUcFoZPoiT4gOzAgtP5f6uGadwcktOQC~Ym2GILiO7cwA2WbpRUZYT2gjTYdkew1LJzOujXEgqYK95jne9JPFNcu3PEkWSZ7z2nTdvzf0mYKA3XDB2FcPdAeP3mcc40PXHWGbSIeNNYhoZ665hm-SSGKGdYSw2cirkuH-MRIqqltDo-r7HrviWQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"><noscript><img src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/2/10.1093/jac/dkg082/2/m_dkg082f1.gif?Expires=1611412425&amp;Signature=uGSGpJkWej70nCDVyG~cIBCk7wMx3vmMHkDj-vUTyn2nZcj8zqnuB-WAOFgORP0UTenGpkh0hIaFGMF8VeQJJmAiPyR~aLLHzP-bZEcJRUpl68NUsKagC8wlycjaL4sancZ~bR~yknP90B99TOnn0HOSFrRg8IJxUcFoZPoiT4gOzAgtP5f6uGadwcktOQC~Ym2GILiO7cwA2WbpRUZYT2gjTYdkew1LJzOujXEgqYK95jne9JPFNcu3PEkWSZ7z2nTdvzf0mYKA3XDB2FcPdAeP3mcc40PXHWGbSIeNNYhoZ665hm-SSGKGdYSw2cirkuH-MRIqqltDo-r7HrviWQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Figure 1. Mean (± s.d.) plasma concentration–time curves of amoxicillin (Amoxi) and clavulanic acid (Clav) after an oral dose of 500/125 mg co-amoxiclav tablets in 36 healthy volunteers (formulation A2)." /></noscript></p>
<div class="fig fig-section js-fig-section" data-id="DKG082F1" bis_skin_checked="1">
<div class="caption fig-caption" bis_skin_checked="1">
<p class="chapter-para"><strong>Figure 1.</strong> Mean (±&nbsp;<span class="small-caps">S.D</span>.) plasma concentration–time curves of amoxicillin (Amoxi) and clavulanic acid (Clav) after an oral dose of 500/125 mg co-amoxiclav tablets in 36 healthy volunteers (formulation A2).</p>
</div>
</div>
<div class="fig fig-modal reveal-modal" bis_skin_checked="1">
<div class="graphic-wrap" bis_skin_checked="1">
<p><img class="content-image" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Figure 1. Mean (± s.d.) plasma concentration–time curves of amoxicillin (Amoxi) and clavulanic acid (Clav) after an oral dose of 500/125 mg co-amoxiclav tablets in 36 healthy volunteers (formulation A2)." data-path-from-xml="dkg082f1.gif" data-lazy-src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/2/10.1093/jac/dkg082/2/m_dkg082f1.gif?Expires=1611412425&amp;Signature=uGSGpJkWej70nCDVyG~cIBCk7wMx3vmMHkDj-vUTyn2nZcj8zqnuB-WAOFgORP0UTenGpkh0hIaFGMF8VeQJJmAiPyR~aLLHzP-bZEcJRUpl68NUsKagC8wlycjaL4sancZ~bR~yknP90B99TOnn0HOSFrRg8IJxUcFoZPoiT4gOzAgtP5f6uGadwcktOQC~Ym2GILiO7cwA2WbpRUZYT2gjTYdkew1LJzOujXEgqYK95jne9JPFNcu3PEkWSZ7z2nTdvzf0mYKA3XDB2FcPdAeP3mcc40PXHWGbSIeNNYhoZ665hm-SSGKGdYSw2cirkuH-MRIqqltDo-r7HrviWQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"><noscript><img class="content-image" src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/2/10.1093/jac/dkg082/2/m_dkg082f1.gif?Expires=1611412425&amp;Signature=uGSGpJkWej70nCDVyG~cIBCk7wMx3vmMHkDj-vUTyn2nZcj8zqnuB-WAOFgORP0UTenGpkh0hIaFGMF8VeQJJmAiPyR~aLLHzP-bZEcJRUpl68NUsKagC8wlycjaL4sancZ~bR~yknP90B99TOnn0HOSFrRg8IJxUcFoZPoiT4gOzAgtP5f6uGadwcktOQC~Ym2GILiO7cwA2WbpRUZYT2gjTYdkew1LJzOujXEgqYK95jne9JPFNcu3PEkWSZ7z2nTdvzf0mYKA3XDB2FcPdAeP3mcc40PXHWGbSIeNNYhoZ665hm-SSGKGdYSw2cirkuH-MRIqqltDo-r7HrviWQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Figure 1. Mean (± s.d.) plasma concentration–time curves of amoxicillin (Amoxi) and clavulanic acid (Clav) after an oral dose of 500/125 mg co-amoxiclav tablets in 36 healthy volunteers (formulation A2)." data-path-from-xml="dkg082f1.gif" /></noscript></p>
<div class="fig-orig original-slide" bis_skin_checked="1"></div>
</div>
<div class="caption fig-caption" bis_skin_checked="1">
<div class="fig fig-section js-fig-section" data-id="DKG082F1" bis_skin_checked="1">
<div class="caption fig-caption" bis_skin_checked="1">
<p class="chapter-para"><strong>Figure 1.</strong> Mean (±&nbsp;<span class="small-caps">S.D</span>.) plasma concentration–time curves of amoxicillin (Amoxi) and clavulanic acid (Clav) after an oral dose of 500/125 mg co-amoxiclav tablets in 36 healthy volunteers (formulation A2).</p>
</div>
</div>
<div class="fig fig-modal reveal-modal" bis_skin_checked="1">
<div class="graphic-wrap" bis_skin_checked="1"><img class="content-image" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Figure 1. Mean (± s.d.) plasma concentration–time curves of amoxicillin (Amoxi) and clavulanic acid (Clav) after an oral dose of 500/125 mg co-amoxiclav tablets in 36 healthy volunteers (formulation A2)." data-path-from-xml="dkg082f1.gif" data-lazy-src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/2/10.1093/jac/dkg082/2/m_dkg082f1.gif?Expires=1611412425&amp;Signature=uGSGpJkWej70nCDVyG~cIBCk7wMx3vmMHkDj-vUTyn2nZcj8zqnuB-WAOFgORP0UTenGpkh0hIaFGMF8VeQJJmAiPyR~aLLHzP-bZEcJRUpl68NUsKagC8wlycjaL4sancZ~bR~yknP90B99TOnn0HOSFrRg8IJxUcFoZPoiT4gOzAgtP5f6uGadwcktOQC~Ym2GILiO7cwA2WbpRUZYT2gjTYdkew1LJzOujXEgqYK95jne9JPFNcu3PEkWSZ7z2nTdvzf0mYKA3XDB2FcPdAeP3mcc40PXHWGbSIeNNYhoZ665hm-SSGKGdYSw2cirkuH-MRIqqltDo-r7HrviWQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"><noscript><img class="content-image" src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/2/10.1093/jac/dkg082/2/m_dkg082f1.gif?Expires=1611412425&amp;Signature=uGSGpJkWej70nCDVyG~cIBCk7wMx3vmMHkDj-vUTyn2nZcj8zqnuB-WAOFgORP0UTenGpkh0hIaFGMF8VeQJJmAiPyR~aLLHzP-bZEcJRUpl68NUsKagC8wlycjaL4sancZ~bR~yknP90B99TOnn0HOSFrRg8IJxUcFoZPoiT4gOzAgtP5f6uGadwcktOQC~Ym2GILiO7cwA2WbpRUZYT2gjTYdkew1LJzOujXEgqYK95jne9JPFNcu3PEkWSZ7z2nTdvzf0mYKA3XDB2FcPdAeP3mcc40PXHWGbSIeNNYhoZ665hm-SSGKGdYSw2cirkuH-MRIqqltDo-r7HrviWQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Figure 1. Mean (± s.d.) plasma concentration–time curves of amoxicillin (Amoxi) and clavulanic acid (Clav) after an oral dose of 500/125 mg co-amoxiclav tablets in 36 healthy volunteers (formulation A2)." data-path-from-xml="dkg082f1.gif" /></noscript></div>
</div>
<div class="fig fig-section js-fig-section" data-id="DKG082F2" bis_skin_checked="1"><strong>Figure 1.</strong> Mean (±&nbsp;<span class="small-caps">S.D</span>.) plasma concentration–time curves of amoxicillin (Amoxi) and clavulanic acid (Clav) after an oral dose of 500/125 mg co-amoxiclav tablets in 36 healthy volunteers (formulation A2).</div>
</div>
</div>
<div data-id="DKG082F2" bis_skin_checked="1"></div>
<div data-id="DKG082F2" bis_skin_checked="1"><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Figure 2. Individual AUCts of amoxicillin plotted versus the AUCts of clavulanic acid for both the A2 and B2 formulations (white and black circles, respectively). It can be seen that there is a five-fold variation in the AUCts of clavulanic acid, with little variation in those of amoxicillin. Dotted lines represent the 95% confidence interval." data-lazy-src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/2/10.1093/jac/dkg082/2/m_dkg082f2.gif?Expires=1611412425&amp;Signature=pLrUhwvu2kQs1zc01f-kNLuE6Kz3WFPrXf43bhVbZu-lx8AiCsR15hiwytaJCZ~VECNKk6MOT03cWVjaqiLLnU7rKOpChmms550XonQVgchmxTNVsm3-1b4jTAjwUNAgqsiGFP0Or9akRK77GIygU17gGLqgJKBhkI6NtFmcEez2e-cnMut2yCuPTyrVye5Mo0S0rw7LphrOCIZ5RfpY-nh3L~dc3vCGqqhTNDquVH~ymblAXFJlUgbvKGH9LbHqkRokxDals2bnaFmgriF-AzypqFKpiz0orS9WBJJv3LSlt5ow1O0V8kA80pvjk3CVnwNiyg7Gpiqb9fqesoN8iw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"><noscript><img src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/2/10.1093/jac/dkg082/2/m_dkg082f2.gif?Expires=1611412425&amp;Signature=pLrUhwvu2kQs1zc01f-kNLuE6Kz3WFPrXf43bhVbZu-lx8AiCsR15hiwytaJCZ~VECNKk6MOT03cWVjaqiLLnU7rKOpChmms550XonQVgchmxTNVsm3-1b4jTAjwUNAgqsiGFP0Or9akRK77GIygU17gGLqgJKBhkI6NtFmcEez2e-cnMut2yCuPTyrVye5Mo0S0rw7LphrOCIZ5RfpY-nh3L~dc3vCGqqhTNDquVH~ymblAXFJlUgbvKGH9LbHqkRokxDals2bnaFmgriF-AzypqFKpiz0orS9WBJJv3LSlt5ow1O0V8kA80pvjk3CVnwNiyg7Gpiqb9fqesoN8iw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Figure 2. Individual AUCts of amoxicillin plotted versus the AUCts of clavulanic acid for both the A2 and B2 formulations (white and black circles, respectively). It can be seen that there is a five-fold variation in the AUCts of clavulanic acid, with little variation in those of amoxicillin. Dotted lines represent the 95% confidence interval." /></noscript></div>
<div data-id="DKG082F2" bis_skin_checked="1"></div>
<div data-id="DKG082F2" bis_skin_checked="1"><strong>Figure 2.</strong> Individual AUC<sub>t</sub>s of amoxicillin plotted versus the AUC<sub>t</sub>s of clavulanic acid for both the A2 and B2 formulations (white and black circles, respectively). It can be seen that there is a five-fold variation in the AUC<sub>t</sub>s of clavulanic acid, with little variation in those of amoxicillin. Dotted lines represent the 95% confidence interval.</div>
<div data-id="DKG082F2" bis_skin_checked="1"></div>
<div data-id="DKG082F2" bis_skin_checked="1"><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Figure 3. Mean AUCts of amoxicillin plotted versus the mean AUCts of clavulanic acid for the oral administration (A/B formulations) of co-amoxiclav suspension (black circles), and co-amoxiclav oral tablets 500/125 mg (white circles), oral tablets 875/125 mg (white triangles) and oral tablets 250/125 mg (black triangles). Dotted lines represent the 95% confidence intervals." data-lazy-src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/2/10.1093/jac/dkg082/2/m_dkg082f3.gif?Expires=1611412426&amp;Signature=FAgIG--Y5vDkiIZ0AmCW-ajBT8OqJC-9Zqixx1GSVJ2t7lsTl0ovKVfHuzpPuPz~PMK59wfpVZtveunMwhmrSuvzAgq-jS202q8wZXTsdEZ4j0it8qyZqIBm6C39AI0atoOEO9AAXiVSPMQW3KenYasyaSrvnmlMjvBADp5F~tW8u1mYU~tpFHd4Jg-J4K0ZHaP24ATx059Cens~K8Gp9FvoT~tCjiMcOEMISFmZ49nDN-DhIFs-gERNO0CySaxemYwbZ3Z9p5uakEZ6eE8nsxcDDgCdIwfYItLLRci21B9BL~lY8~lXS1YKULyPSWf2Bi70Gbj-4ufwkooEVHjnew__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"><noscript><img src="https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jac/51/2/10.1093/jac/dkg082/2/m_dkg082f3.gif?Expires=1611412426&amp;Signature=FAgIG--Y5vDkiIZ0AmCW-ajBT8OqJC-9Zqixx1GSVJ2t7lsTl0ovKVfHuzpPuPz~PMK59wfpVZtveunMwhmrSuvzAgq-jS202q8wZXTsdEZ4j0it8qyZqIBm6C39AI0atoOEO9AAXiVSPMQW3KenYasyaSrvnmlMjvBADp5F~tW8u1mYU~tpFHd4Jg-J4K0ZHaP24ATx059Cens~K8Gp9FvoT~tCjiMcOEMISFmZ49nDN-DhIFs-gERNO0CySaxemYwbZ3Z9p5uakEZ6eE8nsxcDDgCdIwfYItLLRci21B9BL~lY8~lXS1YKULyPSWf2Bi70Gbj-4ufwkooEVHjnew__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Figure 3. Mean AUCts of amoxicillin plotted versus the mean AUCts of clavulanic acid for the oral administration (A/B formulations) of co-amoxiclav suspension (black circles), and co-amoxiclav oral tablets 500/125 mg (white circles), oral tablets 875/125 mg (white triangles) and oral tablets 250/125 mg (black triangles). Dotted lines represent the 95% confidence intervals." /></noscript></div>
<div data-id="DKG082F2" bis_skin_checked="1"></div>
<div data-id="DKG082F2" bis_skin_checked="1"><strong>Figure 3.</strong> Mean AUC<sub>t</sub>s of amoxicillin plotted versus the mean AUC<sub>t</sub>s of clavulanic acid for the oral administration (A/B formulations) of co-amoxiclav suspension (black circles), and co-amoxiclav oral tablets 500/125 mg (white circles), oral tablets 875/125 mg (white triangles) and oral tablets 250/125 mg (black triangles). Dotted lines represent the 95% confidence intervals.</div>
<div data-id="DKG082F2" bis_skin_checked="1"></div>
<div data-id="DKG082F2" bis_skin_checked="1">
<div id="DKG082TB1" class="table-wrap-title" data-id="DKG082TB1" bis_skin_checked="1">
<p><span class="label"><strong>Table 1.</strong></span></p>
<div class="caption" bis_skin_checked="1">
<p class="chapter-para"> Pharmacokinetic parameters of amoxicillin (mean ±&nbsp;<span class="small-caps">S.D.</span>)</p>
</div>
</div>
<div class="table-overflow" bis_skin_checked="1">
<table>
<tbody>
<tr>
<td>Formulation</td>
<td>Dose (mg)</td>
<td><em>t</em><sub>1/2</sub>&nbsp;(h)</td>
<td><em>T</em><sub>max</sub>&nbsp;(h)</td>
<td><em>C</em><sub>max</sub>&nbsp;(mg/L)</td>
<td>AUC (mg·h/L)</td>
<td>AUC (range)</td>
</tr>
<tr>
<td>A1</td>
<td>250</td>
<td>1.43 ± 0.18</td>
<td>1.14 ± 0.41</td>
<td>4.33 ± 1.07</td>
<td>10.1 ± 1.59</td>
<td>7.26–14.3</td>
</tr>
<tr>
<td>A2</td>
<td>500</td>
<td>1.46 ± 0.16</td>
<td>1.46 ± 0.46</td>
<td>6.81 ± 1.94</td>
<td>18.3 ± 3.55</td>
<td>8.63–24.1</td>
</tr>
<tr>
<td>A3</td>
<td>500</td>
<td>1.54 ± 0.17</td>
<td>1.14 ± 0.37</td>
<td>7.59 ± 1.45</td>
<td>19.2 ± 3.29</td>
<td>10.9–25.4</td>
</tr>
<tr>
<td>A4</td>
<td>875</td>
<td>1.76 ± 0.36</td>
<td>2.02 ± 0.96</td>
<td>9.93 ± 3.14</td>
<td>32.8 ± 7.05</td>
<td>19.4–48.7</td>
</tr>
<tr>
<td>B1</td>
<td>250</td>
<td>1.40 ± 0.18</td>
<td>1.39 ± 0.60</td>
<td>3.88 ± 1.15</td>
<td>9.87 ± 1.68</td>
<td>6.31–13.7</td>
</tr>
<tr>
<td>B2</td>
<td>500</td>
<td>1.48 ± 0.23</td>
<td>1.70 ± 0.70</td>
<td>6.34 ± 1.63</td>
<td>18.3 ± 3.43</td>
<td>5.15–22.9</td>
</tr>
<tr>
<td>B3</td>
<td>500</td>
<td>1.51 ± 0.17</td>
<td>1.14 ± 0.31</td>
<td>7.19 ± 1.29</td>
<td>18.9 ± 2.83</td>
<td>10.9–24.1</td>
</tr>
<tr>
<td>B4</td>
<td>875</td>
<td>1.71 ± 0.34</td>
<td>2.04 ± 1.01</td>
<td>9.77 ± 3.17</td>
<td>32.9 ± 8.15</td>
<td>14.3–47.8<p></p>
<p>&nbsp;</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<p>&nbsp;</p>
<div id="DKG082TB2" class="table-wrap-title" data-id="DKG082TB2" bis_skin_checked="1">
<p><span class="label"><strong>Table 2.</strong></span></p>
<div class="caption" bis_skin_checked="1">
<p class="chapter-para"> Pharmacokinetic parameters of clavulanic acid (mean ±&nbsp;<span class="small-caps">S.D</span>.)</p>
</div>
</div>
<div class="table-overflow" bis_skin_checked="1">
<table>
<tbody>
<tr>
<td>Formulation</td>
<td>Dose (mg)</td>
<td><em>t</em><sub>1/2</sub>&nbsp;(h)</td>
<td><em>T</em><sub>max</sub>&nbsp;(h)</td>
<td><em>C</em><sub>max</sub>&nbsp;(mg/L)</td>
<td>AUC (mg·h/L)</td>
<td>AUC (range)</td>
</tr>
<tr>
<td>A1</td>
<td>125</td>
<td>1.00 ± 0.16</td>
<td>1.24 ± 0.48</td>
<td>2.63 ± 0.90</td>
<td>5.49 ± 1.48</td>
<td>2.32–8.25</td>
</tr>
<tr>
<td>A2</td>
<td>125</td>
<td>1.08 ± 0.16</td>
<td>1.17 ± 0.22</td>
<td>2.32 ± 0.83</td>
<td>5.13 ± 1.80</td>
<td>1.24–8.32</td>
</tr>
<tr>
<td>A3</td>
<td>125</td>
<td>1.19 ± 0.29</td>
<td>1.10 ± 0.40</td>
<td>2.99 ± 0.74</td>
<td>6.74 ± 1.43</td>
<td>3.68–9.74</td>
</tr>
<tr>
<td>A4</td>
<td>125</td>
<td>0.98 ± 0.11</td>
<td>1.18 ± 0.30</td>
<td>2.68 ± 0.96</td>
<td>5.85 ± 2.15</td>
<td>1.88–9.93</td>
</tr>
<tr>
<td>B1</td>
<td>125</td>
<td>1.01 ± 0.14</td>
<td>1.29 ± 0.59</td>
<td>2.31 ± 1.09</td>
<td>4.79 ± 1.83</td>
<td>1.62–8.79</td>
</tr>
<tr>
<td>B2</td>
<td>125</td>
<td>1.09 ± 0.17</td>
<td>1.24 ± 0.31</td>
<td>2.03 ± 0.88</td>
<td>4.28 ± 1.76</td>
<td>1.32–7.90</td>
</tr>
<tr>
<td>B3</td>
<td>125</td>
<td>1.15 ± 0.18</td>
<td>1.09 ± 0.37</td>
<td>2.80 ± 0.67</td>
<td>6.28 ± 1.26</td>
<td>2.79–8.69</td>
</tr>
<tr>
<td>B4</td>
<td>125</td>
<td>0.97 ± 0.08</td>
<td>1.20 ± 0.44</td>
<td>2.67 ± 1.12</td>
<td>5.81 ± 2.25</td>
<td>0.84–9.16</td>
</tr>
</tbody>
</table>
</div>
<p>&nbsp;</p>
<h2 id="13169871" class="backreferences-title">References</h2>
<hr>
<p>&nbsp;</p>
<p>1. Fisher, J., Charnas, R. L. &amp; Knowles, J. R. (1978). Kinetic studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid. Biochemistry 17, 2180–4.<br>
2. Reading, C. &amp; Cole, M. (1977). Clavulanic acid: a beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus. Antimicrobial Agents and Chemotherapy 11, 852–7.<br>
3. Witkowski, G., Lode, H., Höffken, G. &amp; Koeppe, P. (1982). Pharmacokinetic studies of amoxicillin, potassium clavulanate and their combination. European Journal of Clinical Microbiology 1, 233–7.<br>
4. Staniforth, D. H., Jackson, D., Horton, R. &amp; Davies, B. (1984). Parenteral augmentin: pharmacokinetics. International Journal of Clinical Pharmacology Therapy and Toxicology 22, 430–4.<br>
5. Todd, P. A. &amp; Benfield, P. (1990). Amoxicillin/clavulanic acid—an update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 39, 264–307.<br>
6. Balgos, A. A., Rodriguez-Gomez, G., Nasnas, A. A., Mahashur, B. P., Margono, J. C., Tinoco-Favila, R. H. et al. (1998). A double-blind, randomized, parallel group study comparing the efficacy and safety of amoxicillin/clavulanate 875/125 mg p.o. b.i.d. versus 500/125 mg p.o. b.i.d. in the treatment of bacterial lower respiratory tract infection. In Programs and Abstracts of the Thirty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 1998. Abstract L-110, p. 581. American Society for Microbiology, Washington, DC, USA.<br>
7. Calver, A. D., Walsh, N. S., Quinn, P. F., Baran, C., Lonergan, V., Singh, K. P. et al. (1997). Dosing of amoxicillin/clavulanate given every 12 h is as effective as dosing every 8 h for treatment of lower respiratory tract infection. Clinical Infectious Diseases 24, 570–4.<br>
8. Cooper, C. E., Slocombe, B. &amp; White, A. R. (1990). Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against beta-lactamase producing Branhamella catarrhalis and Haemophilus influenzae. Journal of Antimicrobial Chemotherapy 26, 371–80.<br>
9. Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S. &amp; Craig, W. A. (1988). Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. Journal of Infectious Diseases 158, 831–47.<br>
10. Reed, M. D. (1998). The clinical pharmacology of amoxicillin and clavulanic acid. Pediatric Infectious Disease Journal 17, 957–62.<br>
11. Reed, M. D. (1996). Clinical pharmacokinetics of amoxicillin and clavulanate. Pediatric Infectious Disease Journal 15, 949–54.<br>
12. Straub, R. F. &amp; Voyksner, R. D. (1993). Determination of penicillin G, ampicillin, amoxicillin, cloxacillin and cephapirin by high-performance liquid chromatography–electrospray mass spectrometry. Journal of Chromatography 647, 167–81.<br>
13. Suwanrumpha, S., Flory, D. A., Freas, R. B. &amp; Vestal, M. B. (1988). Tandem mass spectrometric studies of the fragmentation of penicillins and their metabolites. Biomedical Mass Spectrometry 16, 381–6.<br>
14. Horber, F. F., Frey, F. J., Descoeurders, C., Murray, A. T. &amp; Reubi, F. C. (1986). Differential effect of impaired renal function on the kinetics of clavulanic acid and amoxicillin. Antimicrobial Agents and Chemotherapy 29, 614–9.<br>
15. Nilsson-Ehle, I., Fellner, H., Hedström, S. A., Nilsson-Ehle, P. &amp; Sjövall, J. (1985). Pharmacokinetics of clavulanic acid, given in combination with amoxicillin, in volunteers. Journal of Antimicrobial Chemotherapy 16, 491–8.<br>
16. Allen, G. D., Coates, P. E. &amp; Davies, B. E. (1988). On the absorption of clavulanic acid. Biopharmaceutics and Drug Disposition 9, 127–36.<br>
17. Bolton, G. C., Allen, G. D., Davies, B. E., Filer, C. W. &amp; Jeffery, D. J. (1986). The disposition of clavulanic acid in man. Xenobiotica 16, 853–63.<br>
18. Elias Jones, A., Barnes, N. D., Tasker, T. C. G. &amp; Horton, R. (1990). Pharmacokinetics of intravenous amoxycillin and potassium clavulanate in seriously ill children. Journal of Antimicrobial Chemotherapy 25, 269–74.<br>
19. Neu, H. C. (1984). Beta-lactamases: a perspective on the contribution of these enzymes to bacterial resistance. Postgraduate Medicine 76, Suppl., 7–21.<br>
20. Neu, H. C. &amp; Fu, K. P. (1984). Clavulanic acid, a novel inhibitor of β-lactamases. Antimicrobial Agents and Chemotherapy 14, 650–5.<br>
21. Chulavatnatol, S. &amp; Charles, B. G. (1994). Determination of dose-dependent absorption of amoxycillin from urinary excretion data in healthy subjects. British Journal of Clinical Pharmacology 38, 274–7.<br>
22. Sjövall, J., Alván, G. &amp; Westerlund, D. (1985). Dose-dependent absorption of amoxycillin and bacampicillin. Clinical Pharmacology and Therapeutics 38, 241–50.<br>
23. Vree, T. B., Dammers, E. &amp; van Duuren, E. (2002). Variable absorption of clavulanic acid after an oral dose of 25 mg/kg of clavubactin and synulox in healthy cats. Scientific World Journal 2, 1369–78.<br>
24. Vree, T. B., Dammers, E. &amp; van Duuren, E. (2002). Variable absorption of clavulanic acid after an oral dose of 25 mg/kg of Clavubactin and Synulox in healthy dogs. Journal of Veterinary Pharmacology and Therapeutics, in press.<br>
25. Ball, A. P., Geddes, A. &amp; Rolinson, G. (1997). Amoxycillin clavulanate: an assessment after 15 years of clinical application. Journal of Chemotherapy 9, 167–98.<br>
26. Hoberman, A., Paradise, J. L., Burch, D. J., Valinski, W. A., Hedrick, J. A., Aronovitz, G. H. et al. (1997). Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Pediatric Infectious Disease Journal 16, 463–70.<br>
27. Martin, C., Mallet, M., Sastre, B., Viviand, X., Martin, A., deMicco, P. et al. (1995). Comparison of concentrations of two doses of clavulanic acid (200 and 400 mg) administered with amoxicillin (2000 mg) in tissues of patients undergoing colorectal surgery. Antimicrobial Agents and Chemotherapy 39, 94–8.<br>
28. Natsch, S. &amp; van der Meer, J. W. (1998). Dosing of amoxicillin/clavulanate for treatment of lower respiratory tract infection. Clinical Infectious Diseases 26, 529–30.</p>
<p>&nbsp;</p>
<h2>Source:</h2>
<p>https://academic.oup.com/jac/article/51/2/373/748831</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/02/28/identical-pattern-of-highly-variable-absorption-of-clavulanic-acid-from-four-different-oral-formulations-of-co-amoxiclav-in-healthy-subjects/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/02/28/identical-pattern-of-highly-variable-absorption-of-clavulanic-acid-from-four-different-oral-formulations-of-co-amoxiclav-in-healthy-subjects/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5162 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>20.02.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/02/20/azithromycin-for-cystic-fibrosis/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/02/20/azithromycin-for-cystic-fibrosis/">Azithromycin for cystic fibrosis</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><div class="highwire-cite-authors" bis_skin_checked="1"><span class="highwire-citation-authors"><span class="highwire-citation-author first has-tooltip hasTooltip author-popup-hover" data-delta="0" data-hasqtip="0" aria-describedby="qtip-0"><span class="nlm-given-names">K.W.</span>&nbsp;<span class="nlm-surname">Southern</span></span>,&nbsp;<span class="highwire-citation-author" data-delta="1"><span class="nlm-given-names">P.M.</span>&nbsp;<span class="nlm-surname">Barker</span></span></span></div>
<div class="highwire-cite-metadata" bis_skin_checked="1"><span class="highwire-cite-metadata-journal highwire-cite-metadata">European Respiratory Journal&nbsp;</span><span class="highwire-cite-metadata-date highwire-cite-metadata">2004&nbsp;</span><span class="highwire-cite-metadata-volume highwire-cite-metadata">24:&nbsp;</span><span class="highwire-cite-metadata-pages highwire-cite-metadata">834-838;&nbsp;</span><span class="highwire-cite-metadata-doi highwire-cite-metadata"><span class="label">DOI:</span>&nbsp;10.1183/09031936.04.00084304</span></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h2>Abstract</h2>
<hr>
</div>
<p>&nbsp;</p>
<p id="p-1">During what is a relatively barren time for new therapies for cystic fibrosis (CF), azithromycin has received a lot of attention as a potential treatment for CF lung disease. Laboratory studies suggest that azithromycin may have indirect actions, including anti-inflammatory, in addition to the standard antibacterial properties. The unique pharmacokinetics of azithromycin sets it aside from other macrolide antibiotics, but may result in increased resistance patterns.</p>
<p id="p-2">Three well-designed randomised controlled trials have demonstrated a small but significant improvement in respiratory function (forced expiratory volume in one second) with azithromycin compared with placebo. These trial results are confirmed by a recent meta-analysis. Mild adverse events (wheeze, diarrhoea and nausea) were significantly increased in one trial. There is no clear consensus regarding the correct dose and length of treatment with azithromycin.</p>
<p id="p-3">The present review discusses the role of azithromycin in the management of cystic fibrosis and the need for close monitoring of patients started on this drug. In addition, clinics should liaise closely with their microbiology departments and monitor resistance patterns.</p>
<div id="notes-1" class="section notes" bis_skin_checked="1">
<p id="p-4">P.M. Barker has been co-investigator on a study examining clarithromycin for cystic fibrosis, which received grant support from Abbott Laboratories.</p>
</div>
<div id="sec-1" class="section" bis_skin_checked="1">
<p id="p-5">Active treatment of lung infection is a cornerstone of cystic fibrosis (CF) management&nbsp;1. Together with attention to nutritional well-being, this strategy has led to considerable improvement in median survival for people with CF over the past 50 yrs&nbsp;2. However, over the past decade, little in the way of therapeutic advance has been available for the CF team. Recombinant DNAse, and purer formulations of tobramycin have improved the range of aerosolised therapies available&nbsp;3,&nbsp;4, but there have been no new anti-pseudomonal antibiotics, and more fundamental therapies, such as ion transport modulation or gene replacement, are yet to prove themselves at clinical trial&nbsp;5,&nbsp;6. In this climate, azithromycin has been enthusiastically embraced by many centres across the world as a potentially important and relatively inexpensive treatment for CF lung disease. The present study will critically review evidence from randomised controlled trials (RCTs) and reflect on the role of azithromycin in the management of CF lung disease. Meta-analysis in the current review is from a recent update of a systematic review published on the Cochrane database&nbsp;7,&nbsp;8. Investigators gave original data to the present review and are acknowledged for their contribution.</p>
</div>
<p>&nbsp;</p>
<h2>Background</h2>
<hr>
<p>&nbsp;</p>
<p>Azithromycin is an azalide antibiotic, which is a subclass ofthe macrolide family&nbsp;9. It has no direct killing effect against the Gram-negative bacteria,&nbsp;<em>Pseudomonas aeruginosa</em>, but it is active against other Gram-negative bacteria, such as&nbsp;<em>Haemophilus influenzae</em>&nbsp;and&nbsp;<em>Moraxella catarrhalis</em>. It has a similar, though less potent, spectrum of activity as erythromycin against Gram-positive bacteria, such as&nbsp;<em>Streptococci</em>&nbsp;and&nbsp;<em>Staphylococcus aureus</em>. The structure of azithromycin results in a distinct pharmacokinetic profile to other macrolides, such as erythromycin and clarithromycin. Although plasma concentrations are low, azithromycin has good tissue penetration and high concentrations in airway secretions can be achieved. Consequently, a short course of once a day treatment has been advocated for soft tissue and respiratory tract infection. These advantages may be offset by development of resistance in target pathogens because of the widespread use and long tissue half-life of azithromycin&nbsp;10. A recent report described high nasal carriage rates of&nbsp;<em>S. aureus</em>&nbsp;from students in the USA; a quarter of these isolates were resistant to azithromycin&nbsp;11. Similar to other macrolides, azithromycin also has a role in treating atypical infections such as&nbsp;<em>Mycoplasma pneumoniae</em>, Lyme disease and&nbsp;<em>Chlamydia pneumoniae</em>.</p>
<p>&nbsp;</p>
<h2>Early reports of macrolides for cystic fibrosis</h2>
<hr>
<p>&nbsp;</p>
<p id="p-7">In 1994, Hoiby&nbsp;<a id="xref-ref-12-1" class="xref-bibr" href="https://erj.ersjournals.com/content/24/5/834#ref-12">12</a>&nbsp;highlighted similarities between CF and diffuse panbronchiolitis, a condition associated with chronic&nbsp;<em>P. aeruginosa</em>&nbsp;lung infection, found principally in the East Asian population. He commented on the improvement that many of these patients had experienced in their respiratory condition following treatment with the macrolide antibiotic, erythromycin, and suggested that macrolide antibiotics might have a role in CF through indirect anti-pseudomonal properties.</p>
<p id="p-8">The variety of nonantibiotic effects attributed to azithromycin has been extensively reviewed by Bush and Rubin&nbsp;13. There is good evidence that macrolides modulate inflammatory pathways by suppressing pro-inflammatory cytokines&nbsp;14. In addition, macrolides may have more wide ranging effects on the innate immune system, modulating neutrophil function, reducing the presentation of adhesion molecules and altering expression of nitric oxide synthases&nbsp;15–17. Finally, macrolides may have more mechanistic effects, reducing airway mucus production and altering the biofilm phenotype of&nbsp;<em>P. aeruginosa</em>&nbsp;18,&nbsp;19.</p>
<p>&nbsp;</p>
<h2>Does azithromycin work in cystic fibrosis?</h2>
<hr>
<p>&nbsp;</p>
<p>Three well-designed RCTs have examined azithromycin&nbsp;<em>versus</em>&nbsp;placebo for CF lung disease&nbsp;20–22. All employed appropriate treatment allocation and concealment. In total, 286 adults and children (&gt;8 yrs) with CF were included in these trials (table 1<a id="xref-table-wrap-1-1" class="xref-down-link" href="https://erj.ersjournals.com/content/24/5/834#T1">⇓</a>). Change in forced expiratory volume in one second (FEV<sub>1</sub>) over the course of the study period was the primary outcome measure in each trial, though different methods were used to analyse these data (table 1<a id="xref-table-wrap-1-2" class="xref-down-link" href="https://erj.ersjournals.com/content/24/5/834#T1">⇓</a>). Although the three trials examined different time points, and a trial by Equi&nbsp;<em>et al</em>.&nbsp;20&nbsp;employed a cross-over design, meta-analysis of relative change in FEV<sub>1</sub>&nbsp;was possible with data at five time points (data from the first arm of the cross-over study were included as the two groups had similar baseline characteristics). Relative change in FEV<sub>1</sub>&nbsp;is calculated as follows:</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Embedded Image" data-lazy-src="https://erj.ersjournals.com/sites/default/files/highwire/erj/24/5/834/embed/graphic-1.gif"><noscript><img src="https://erj.ersjournals.com/sites/default/files/highwire/erj/24/5/834/embed/graphic-1.gif" alt="Embedded Image" /></noscript></p>
<p>At both 1 and 6 months, the weighted mean difference in relative change of FEV<sub>1</sub>&nbsp;is significantly in favour of azithromycin (table 2⇓; fig. 1⇓). At 6 months, this value was 5.8% (95% confidence interval: 2.4–9.2%). This meta-analysis is consistent with the reported improvements in FEV<sub>1</sub>&nbsp;in each of the trials and provides reassurance of a small but true improvement in FEV<sub>1</sub>&nbsp;with azithromycin. Similar improvements are seen with forced vital capacity (significant at time points 2 months and 6 months). These data suggest a consistent, but small improvement in respiratory function following treatment with azithromycin for a period of 6 months.</p>
<p>&nbsp;</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Fig. 1.—" data-lazy-src="https://erj.ersjournals.com/content/erj/24/5/834/F1.medium.gif"><noscript><img src="https://erj.ersjournals.com/content/erj/24/5/834/F1.medium.gif" alt="Fig. 1.—" /></noscript></p>
<p>&nbsp;</p>
<p>Fig. 1.—</p>
<p>A “forest” plot demonstrating the combined data for relative change in forced expiratory volume in one second from the three randomised controlled trials included in the Cochrane review, “macrolide antibiotics for cystic fibrosis”&nbsp;<a id="xref-ref-8-4" class="xref-bibr" href="https://erj.ersjournals.com/content/24/5/834#ref-8">8</a>,&nbsp;<a id="xref-ref-20-9" class="xref-bibr" href="https://erj.ersjournals.com/content/24/5/834#ref-20">20</a>–<a id="xref-ref-22-14" class="xref-bibr" href="https://erj.ersjournals.com/content/24/5/834#ref-22">22</a>. Data are available for five times points (1, 2, 3, 4 and 6 months). The plots show results from individual trials: mean (<span class="highwire-responsive-lazyload"><img class="highwire-embed lazyloaded" src="https://erj.ersjournals.com/sites/default/files/highwire/erj/24/5/834/F1/embed/inline-graphic-1.gif" alt="Embedded Image" data-src="https://erj.ersjournals.com/sites/default/files/highwire/erj/24/5/834/F1/embed/inline-graphic-1.gif"></span>) and 95% confidence interval (95% CI; –––) and combined data (♦). The weighted mean difference consistently favours treatment with azithromycin and is statistically significant at 1 and 6 months. Refer to table 2<a id="xref-table-wrap-2-2" class="xref-down-link" href="https://erj.ersjournals.com/content/24/5/834#T2">⇓</a>&nbsp;for specific data in relation to this figure.</p>
<p>&nbsp;</p>
<p>Table 1—</p>
<p>Details of three randomised controlled trials included in the Cochrane review&nbsp;<a id="xref-ref-8-5" class="xref-bibr article-ref-popup hasTooltip" href="https://erj.ersjournals.com/content/24/5/834#ref-8" data-hasqtip="2">8</a></p>
<table id="table-1">
<tbody id="tbody-1" class="">
<tr id="tr-1" class="">
<td id="td-1" class="table-left table-vtop table-bborder" colspan="1" rowspan="1" align="left" valign="top">Study [Ref]</td>
<td id="td-2" class="table-center table-vtop table-bborder" colspan="1" rowspan="1" align="center" valign="top">Study design</td>
<td id="td-3" class="table-center table-vtop table-bborder" colspan="1" rowspan="1" align="center" valign="top">Subjects n</td>
<td id="td-4" class="table-center table-vtop table-bborder" colspan="1" rowspan="1" align="center" valign="top">Age range yrs</td>
<td id="td-5" class="table-center table-vtop table-bborder" colspan="1" rowspan="1" align="center" valign="top">Concerns</td>
<td id="td-6" class="table-center table-vtop table-bborder" colspan="1" rowspan="1" align="center" valign="top">Primary outcome measure</td>
<td id="td-7" class="table-center table-vtop table-bborder" colspan="1" rowspan="1" align="center" valign="top">Adverse events</td>
</tr>
<tr id="tr-2" class="">
<td id="td-8" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Wolter&nbsp;<em>et al</em>. 2002 19</td>
<td id="td-9" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">RPCT, 250 mg OD for 3 months</td>
<td id="td-10" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">60</td>
<td id="td-11" class="table-center table-vtop" colspan="1" rowspan="1" align="center" valign="top">18–44</td>
<td id="td-12" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">More males overall and improved respiratory function in the placebo group</td>
<td id="td-13" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Change in FEV<sub>1</sub>&nbsp;% pred<sup>#</sup>, mean±<span class="sc">se</span>&nbsp;excess effect of AZM was 3.62±1.78%</td>
<td id="td-14" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">One urticarial reaction, likely related to AZM</td>
</tr>
<tr id="tr-3" class="">
<td id="td-15" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Equi&nbsp;<em>et al</em>. 2002 20</td>
<td id="td-16" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">RPCT cross-over, 250 mg OD for 6 months<sup>¶</sup>, 500 mg if weight &gt;40 kg</td>
<td id="td-17" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">41</td>
<td id="td-18" class="table-center table-vtop" colspan="1" rowspan="1" align="center" valign="top">8–18</td>
<td id="td-19" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Potential for hangover effect into the second arm of the study. A significant number of participants did not grow&nbsp;<em>P. aeruginosa</em></td>
<td id="td-20" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Relative change in FEV<sub>1</sub>&nbsp;between AZM and placebo treatment periods, taking the average of months 4 and 6 and dividing by the baseline FEV<sub>1</sub>&nbsp;and multiplying by 100. Median relative difference was 5.4% in favour of AZM (95% CI: 0.8–10.5)</td>
<td id="td-21" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Transient rise in liver enzymes in one participant</td>
</tr>
<tr id="tr-4" class="">
<td id="td-22" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Saiman&nbsp;<em>et al.</em>&nbsp;2003 21</td>
<td id="td-23" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">RPCT, multi-centre, 500 mg (250 if &lt;40 kg) three times a week for 6 months</td>
<td id="td-24" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">185</td>
<td id="td-25" class="table-center table-vtop" colspan="1" rowspan="1" align="center" valign="top">6–adult age (19 subjects aged &lt;13 yrs)</td>
<td id="td-26" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Randomisation stratified to prevent centre bias</td>
<td id="td-27" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Relative change in FEV<sub>1</sub>. Mean±<span class="sc">sd</span>&nbsp;increase in the AZM group was 0.097±0.26 L compared with 0.003±0.23 L in the placebo group. Mean difference between groups 6.2% (95% CI: 2.6–9.8)</td>
<td id="td-28" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Significant increased reporting of nausea, diarrhoea and wheezing with AZM</td>
</tr>
</tbody>
</table>
<div class="table-foot" bis_skin_checked="1">
<ul class="table-footnotes">
<li id="fn-1" class="fn">
<p id="p-24">RPCT: randomised placebo-controlled trial; OD: once a day;&nbsp;<em>P. aeruginosa</em>:&nbsp;<em>Pseudomonas aeruginosa</em>; FEV<sub>1</sub>&nbsp;% pred: forced expiratory volume in one second expressed as percentage predicted; AZM: azithromycin; 95% CI: 95% confidence interval.&nbsp;<sup>#</sup>: combining data at each time point;&nbsp;<sup>¶</sup>: each arm</p>
</li>
</ul>
</div>
<p>&nbsp;</p>
<div class="table-caption" bis_skin_checked="1">
<p><span class="table-label">Table 2—</span></p>
<p id="p-25">Data at five time points for the relative changes in forced expiratory volume in one second (FEV<sub>1</sub>) from the three randomised controlled trials included in the Cochrane review 8, 20–22</p>
<div class="sb-div caption-clear" bis_skin_checked="1"></div>
</div>
<table id="table-2">
<tbody id="tbody-2" class="">
<tr id="tr-5" class="">
<td id="td-29" class="table-left table-vtop table-bborder" colspan="1" rowspan="1" align="left" valign="top">Study or sub-category</td>
<td id="td-30" class="table-center table-vtop table-bborder" colspan="1" rowspan="1" align="center" valign="top">Subjects n</td>
<td id="td-31" class="table-center table-vtop table-bborder" colspan="1" rowspan="1" align="center" valign="top">Azithromycin mean±<span class="sc">sd</span></td>
<td id="td-32" class="table-center table-vtop table-bborder" colspan="1" rowspan="1" align="center" valign="top">Subjects n</td>
<td id="td-33" class="table-center table-vtop table-bborder" colspan="1" rowspan="1" align="center" valign="top">Placebo mean±<span class="sc">sd</span></td>
<td id="td-34" class="table-center table-vtop table-bborder" colspan="1" rowspan="1" align="center" valign="top">Weight %</td>
<td id="td-35" class="table-center table-vtop table-bborder" colspan="1" rowspan="1" align="center" valign="top">WMD fixed (95% CI)</td>
</tr>
<tr id="tr-6" class="">
<td id="td-36" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">At 1 month</td>
<td id="td-37" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-38" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-39" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-40" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-41" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-42" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-7" class="">
<td id="td-43" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"> Wolter&nbsp;<em>et al</em>. 20</td>
<td id="td-44" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">22</td>
<td id="td-45" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">2.92±7.72</td>
<td id="td-46" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">23</td>
<td id="td-47" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">−1.32±5.51</td>
<td id="td-48" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">41.05</td>
<td id="td-49" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">4.24 (0.31–8.17)</td>
</tr>
<tr id="tr-8" class="">
<td id="td-50" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"> Saiman&nbsp;<em>et al</em>. 22</td>
<td id="td-51" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">87</td>
<td id="td-52" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">4.01±13.03</td>
<td id="td-53" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">97</td>
<td id="td-54" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">0.20±9.10</td>
<td id="td-55" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">58.95</td>
<td id="td-56" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">3.81 (0.53–7.09)</td>
</tr>
<tr id="tr-9" class="">
<td id="td-57" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Subtotal 95% CI</td>
<td id="td-58" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">109</td>
<td id="td-59" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-60" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">120</td>
<td id="td-61" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-62" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">100.00</td>
<td id="td-63" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">3.99 (1.47–6.51)</td>
</tr>
<tr id="tr-10" class="">
<td id="td-64" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Test for heterogeneity: Chi<sup>2</sup>=0.03, df=1 (p=0.87), I<sup>2</sup>=0%</td>
<td id="td-65" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-66" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-67" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-68" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-69" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-70" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-11" class="">
<td id="td-71" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Test for overall effect: Z=3.10 (p=0.002)</td>
<td id="td-72" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-73" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-74" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-75" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-76" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-77" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-12" class="">
<td id="td-78" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">At 2 months</td>
<td id="td-79" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-80" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-81" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-82" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-83" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-84" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-13" class="">
<td id="td-85" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"> Equi&nbsp;<em>et al</em>. 21</td>
<td id="td-86" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">20</td>
<td id="td-87" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">5.29±9.69</td>
<td id="td-88" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">21</td>
<td id="td-89" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">3.25±13.86</td>
<td id="td-90" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">27.57</td>
<td id="td-91" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">2.04 (−5.25–9.33)</td>
</tr>
<tr id="tr-14" class="">
<td id="td-92" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"> Wolter&nbsp;<em>et al</em>. 20</td>
<td id="td-93" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">24</td>
<td id="td-94" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">1.51±8.84</td>
<td id="td-95" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">17</td>
<td id="td-96" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">−1.17±5.85</td>
<td id="td-97" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">72.43</td>
<td id="td-98" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">2.68 (−1.82–7.18)</td>
</tr>
<tr id="tr-15" class="">
<td id="td-99" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Subtotal 95% CI</td>
<td id="td-100" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">44</td>
<td id="td-101" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-102" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">38</td>
<td id="td-103" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-104" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">100.00</td>
<td id="td-105" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">2.50 (−1.33–6.33)</td>
</tr>
<tr id="tr-16" class="">
<td id="td-106" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Test for heterogeneity: Chi<sup>2</sup>=0.02, df=1 (p=0.88), I<sup>2</sup>=0%</td>
<td id="td-107" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-108" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-109" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-110" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-111" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-112" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-17" class="">
<td id="td-113" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Test for overall effect: Z=1.28 (p=0.20)</td>
<td id="td-114" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-115" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-116" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-117" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-118" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-119" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-18" class="">
<td id="td-120" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">At 3 months</td>
<td id="td-121" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-122" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-123" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-124" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-125" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-126" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-19" class="">
<td id="td-127" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"> Wolter&nbsp;<em>et al</em>. 20</td>
<td id="td-128" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">22</td>
<td id="td-129" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">2.95±9.22</td>
<td id="td-130" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">21</td>
<td id="td-131" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">−0.91±5.99</td>
<td id="td-132" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">37.20</td>
<td id="td-133" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">3.86 (−0.77–8.49)</td>
</tr>
<tr id="tr-20" class="">
<td id="td-134" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"> Saiman&nbsp;<em>et al</em>. 22</td>
<td id="td-135" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">87</td>
<td id="td-136" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">2.33±12.47</td>
<td id="td-137" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">95</td>
<td id="td-138" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">0.32±11.99</td>
<td id="td-139" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">62.80</td>
<td id="td-140" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">2.01 (−1.55–5.57)</td>
</tr>
<tr id="tr-21" class="">
<td id="td-141" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Subtotal 95% CI</td>
<td id="td-142" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">109</td>
<td id="td-143" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-144" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">116</td>
<td id="td-145" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-146" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">100.00</td>
<td id="td-147" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">2.70 (−0.12–5.52)</td>
</tr>
<tr id="tr-22" class="">
<td id="td-148" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Test for heterogeneity: Chi<sup>2</sup>=0.39, df=1 (p=0.53), I<sup>2</sup>=0%</td>
<td id="td-149" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-150" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-151" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-152" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-153" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-154" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-23" class="">
<td id="td-155" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Test for overall effect: Z=1.87 (p=0.06)</td>
<td id="td-156" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-157" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-158" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-159" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-160" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-161" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-24" class="">
<td id="td-162" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">At 4 months</td>
<td id="td-163" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-164" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-165" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-166" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-167" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-168" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-25" class="">
<td id="td-169" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"> Equi&nbsp;<em>et al</em>. 21</td>
<td id="td-170" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">20</td>
<td id="td-171" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">8.07±14.58</td>
<td id="td-172" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">21</td>
<td id="td-173" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">2.73±15.37</td>
<td id="td-174" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">100.00</td>
<td id="td-175" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">5.34 (−3.83–14.51)</td>
</tr>
<tr id="tr-26" class="">
<td id="td-176" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Subtotal 95% CI</td>
<td id="td-177" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">20</td>
<td id="td-178" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-179" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">21</td>
<td id="td-180" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-181" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">100.00</td>
<td id="td-182" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">5.34 (−3.83–14.51)</td>
</tr>
<tr id="tr-27" class="">
<td id="td-183" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Test for heterogeneity:&nbsp;<span class="sc">na</span></td>
<td id="td-184" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-185" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-186" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-187" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-188" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-189" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-28" class="">
<td id="td-190" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Test for overall effect: Z=1.14 (p=0.25)</td>
<td id="td-191" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-192" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-193" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-194" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-195" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-196" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-29" class="">
<td id="td-197" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">At 6 months</td>
<td id="td-198" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-199" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-200" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-201" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-202" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-203" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-30" class="">
<td id="td-204" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"> Equi&nbsp;<em>et al</em>. 21</td>
<td id="td-205" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">20</td>
<td id="td-206" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">6.74±13.74</td>
<td id="td-207" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">21</td>
<td id="td-208" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">3.45±16.56</td>
<td id="td-209" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">13.21</td>
<td id="td-210" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">3.29 (−6.01–12.59)</td>
</tr>
<tr id="tr-31" class="">
<td id="td-211" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"> Saiman&nbsp;<em>et al</em>. 22</td>
<td id="td-212" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">84</td>
<td id="td-213" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">4.44±13.60</td>
<td id="td-214" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">93</td>
<td id="td-215" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">−1.77±10.66</td>
<td id="td-216" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">86.79</td>
<td id="td-217" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">6.21 (2.58–9.84)</td>
</tr>
<tr id="tr-32" class="">
<td id="td-218" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Subtotal 95% CI</td>
<td id="td-219" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">104</td>
<td id="td-220" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-221" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">114</td>
<td id="td-222" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-223" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">100.00</td>
<td id="td-224" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">5.82 (2.45–9.20)</td>
</tr>
<tr id="tr-33" class="">
<td id="td-225" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Test for heterogeneity: Chi<sup>2</sup>=0.33, df=1 (p=0.57), I<sup>2</sup>=0%</td>
<td id="td-226" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-227" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-228" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-229" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-230" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-231" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-34" class="">
<td id="td-232" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Test for overall effect: Z=3.38 (p=0.0007)</td>
<td id="td-233" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-234" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-235" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-236" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-237" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-238" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
</tbody>
</table>
<div class="table-foot" bis_skin_checked="1">
<ul class="table-footnotes">
<li id="fn-2" class="fn">
<p id="p-26">The relative change in FEV<sub>1</sub>&nbsp;is presented for each trial at each available time point. Combined data are available at four time points (1, 2, 3 and 6months). The weighted mean difference (WMD) is presented for individual and combined trial data (positive value (fig. 1) favours treatment withazithromycin). Chi<sup>2</sup>: Chi-squared test is a test for heterogeneity; I<sup>2</sup>: a measure of inconsistency across studies due to heterogeneity rather thanchance; df: degrees of freedom (although these values suggest consistency, the number of studies is too small for this to be a valid assumption); Zvalue: this isa test for overall effect of the combined data (significant at 1 and 6 months); 95% CI: 95% confidence interval;&nbsp;<span class="sc">na</span>: not applicable</p>
</li>
</ul>
</div>
<p>&nbsp;</p>
<p id="p-10">Regarding secondary outcomes that are more relevant to patients, Wolter&nbsp;<em>et al</em>.&nbsp;20&nbsp;demonstrated a significant reduction in hospital inpatient days and number of additional courses of&nbsp;<em>i.v.</em>&nbsp;antibiotics in the azithromycin group. These findings were not reproduced in the studies by Equi&nbsp;<em>et al</em>.&nbsp;21&nbsp;or Saiman&nbsp;<em>et al</em>.&nbsp;22. However, Saiman&nbsp;<em>et al</em>.&nbsp;22&nbsp;did demonstrate a significant reduction in the number of patients admitted in the azithromycin group (14 out of 97&nbsp;<em>versus</em>&nbsp;29 out of 98; p=0.05).</p>
<p id="p-11">Wolter&nbsp;<em>et al</em>.&nbsp;20&nbsp;and Saiman&nbsp;<em>et al</em>.&nbsp;22&nbsp;employed validated “Quality of Life” (QoL) questionnaires to monitor for improvement over the trial period. Wolter&nbsp;<em>et al</em>.&nbsp;20&nbsp;demonstrated improvement in both groups (RCTs improve your QoL!), although more pronounced in the azithromycin group. Saiman&nbsp;<em>et al</em>.&nbsp;22&nbsp;demonstrated a significant improvement in the “physical functioning” component of their questionnaire in the azithromycin group. Equi&nbsp;<em>et al</em>.&nbsp;21&nbsp;demonstrated no difference with a visual analogue score (appropriate for children). Overall, the changes in these secondary outcomes were not impressive, and inconsistencies between the studies were found.</p>
<p>&nbsp;</p>
<h2>Why does it work?</h2>
<hr>
<p>&nbsp;</p>
<p id="p-12">Having noted the significant improvement in respiratory function, it is useful to reflect on the mechanism of action. Does it relate to an indirect anti-pseudomonal or anti-inflammatory effect, or is it simply the result of standard antibiotic properties of azithromycin? Wolter&nbsp;<em>et al</em>.&nbsp;20&nbsp;reported a significant effect on the “time trend” of C-reactive protein over the course of the study with a fall in the azithromycin group. However, this systemic measure of inflammation is not a valid predictor of the local inflammatory process in the airways&nbsp;23. Saiman&nbsp;<em>et al</em>.&nbsp;22&nbsp;measured interleukin-8 and neutrophil elastase (both markers of inflammation in CF) in sputum and demonstrated no clinically significant difference between the groups at the end of the study period.</p>
<p id="p-13">There was no evidence of decreased acquisition of&nbsp;<em>P. aeruginosa</em>&nbsp;in patients treated with azithromycin. In the study by Saiman&nbsp;<em>et al</em>.&nbsp;22, eight patients had a new acquisition of&nbsp;<em>P. aeruginosa</em>&nbsp;(five in placebo group). There was no significant change in pathogens isolated from respiratory culture in the studies by either Wolter&nbsp;<em>et al</em>.&nbsp;20&nbsp;or Equi&nbsp;<em>et al</em>.&nbsp;21. However, in the study by Saiman&nbsp;<em>et al</em>.&nbsp;22, 12 patients in the placebo group had recently detected&nbsp;<em>S. aureus</em>&nbsp;compared to two in the azithromycin group (p=0.01). All the trials had relatively high levels of&nbsp;<em>S. aureus</em>&nbsp;isolated in the patients involved. Even if the mechanism of action for azithromycin isanti-pseudomonal, a significant reduction in positive respiratory cultures may not occur, particularly if the action is indirect. However, these data, overall, are not supportive of an anti-inflammatory hypothesis, and data from the study by Saiman&nbsp;<em>et al</em>.&nbsp;22&nbsp;suggest that the improvement in respiratory function may relate to the anti-staphylococcal properties of azithromycin.</p>
<p id="p-14">Azithromycin has received the most attention for CF, although other macrolide antibiotics have been examined in clinical trials. A total of four underpowered trials have examined clarithromycin and have not reported a difference in outcomes (data presented at conferences but not published)&nbsp;8.</p>
<p>&nbsp;</p>
<h2>Is azithromycin safe?</h2>
<hr>
<p>&nbsp;</p>
<p id="p-15">There have been no reports of serious adverse events related to azithromycin in any of the trials reported to date; however, the RCT is not the ideal tool for detecting serious, but uncommon, adverse events, and the longest duration of treatment was 6 months. The study by Saiman&nbsp;<em>et al</em>.&nbsp;22&nbsp;reported a significant increase in mild adverse effects (wheeze, diarrhoea and nausea) in patients receiving azithromycin. Whilst diarrhoea and nausea are recognised sequelae of macrolide therapy, it is more difficult to explain the increased relative risk (RR) of wheeze in these patients (RR=4.2; 95% confidence interval: 1.46–12.25))&nbsp;<a id="xref-ref-8-3" class="xref-bibr" href="https://erj.ersjournals.com/content/24/5/834#ref-8">8</a>. There are no data from the trial by Saiman&nbsp;<em>et al</em>.&nbsp;22&nbsp;to suggest an increased incidence of allergic bronchopulmonary aspergillosis, but some attention to this finding is required in future studies. These adverse events are mild and may be self-limiting. However, this increased RR may result in reduced concordance with azithromycin treatment.</p>
<p id="p-16">Given the unique pharmacology of azithromycin, it is important that careful monitoring and reporting of adverse events is undertaken on patients started on the drug. In a small randomised study assessing different doses of azithromycin, a significant rise in liver enzymes occurred in one patient on 1,000 mg of azithromycin, once a day for 5 days (and smaller rises in two other patients)&nbsp;2<a id="xref-ref-24-1" class="xref-bibr" href="https://erj.ersjournals.com/content/24/5/834#ref-24">4</a>. All returned to normal levels, and ultrasound scans were normal 2 weeks after the dosing period. An isolated rise in liver enzymes in one patient was reported by Equi&nbsp;<em>et al</em>.&nbsp;21.</p>
<p>&nbsp;</p>
<h2>What is the correct dose?</h2>
<hr>
<p>&nbsp;</p>
<p>There are limited data available as to the correct dosage of azithromycin in CF. The largest of the three RCTs employed a dose of 500 mg given once on a Monday, Wednesday and Friday (dose reduced to 250 mg in patients weighing &lt;40 kg). The studies by Wolter&nbsp;<em>et al</em>.&nbsp;20&nbsp;and Equi&nbsp;<em>et al</em>.&nbsp;21&nbsp;employed daily dosage regimes with no obvious improvement in outcome compared to the study by Saiman&nbsp;<em>et al</em>.&nbsp;22. The pharmacokinetic study by Cipolli&nbsp;<em>et al</em>.&nbsp;<a id="xref-ref-24-2" class="xref-bibr" href="https://erj.ersjournals.com/content/24/5/834#ref-24">24</a>&nbsp;demonstrated high levels of azithromycin in bronchial secretions 6 days after a 5-day course (either 500 or 1,000 mg), supporting the Saiman&nbsp;<em>et al</em>.&nbsp;22&nbsp;study regime of intermittent dosing and raising the possibility that even less frequent administration (<em>i.e.</em>&nbsp;weekly) may be a possible strategy.</p>
<p>&nbsp;</p>
<h2>When should we prescribe azithromycin for cystic fibrosis?</h2>
<hr>
<p>&nbsp;</p>
<p id="p-18">There is consistent evidence from three well-designed placebo-controlled RCTs of a significant, although small, improvement in respiratory function in CF patients receiving azithromycin for periods of 3–6 months. Should the CF team now prescribe azithromycin for all their patients? The current authors suggest that there are still questions to be answered before adopting this policy, not least regarding dosage. Thereis probably a good argument for reserving azithromycin for patients with chronic&nbsp;<em>P.</em>&nbsp;<em>aeruginosa</em>&nbsp;infection, in whommaintaining respiratory condition has been difficult. Ofconcern in this cohort of patients (many of whom will be on DNAse) is the reported inhibitory effect of macrolides on DNAse activity&nbsp;25. DNA hydrolysis was significantly reduced&nbsp;<em>in vitro</em>&nbsp;by all macrolides, but most noticeably by azithromycin. The subgroup analysis in the trial by Equi&nbsp;<em>et al</em>.&nbsp;21&nbsp;demonstrated an apparent lack of efficacy when participants were on DNAse. The possibility of azithromycin inhibiting DNAse&nbsp;<em>in vivo</em>&nbsp;requires further investigation.</p>
<p id="p-19">Some participants in the three RCTs (table 1⇑) were not infected with&nbsp;<em>P. aeruginosa</em>. However, at present, it is not clear whether azithromycin improves respiratory condition in suchcases. A further study is planned in the USA examining the question of the use of azithromycin for children with CF without chronic&nbsp;<em>P. aeruginosa</em>&nbsp;infection (personal communication, L. Saiman, Columbia University, New York, NY, USA). In CF centres that advocate anti-staphylococcal prophylaxis (generally in Europe), azithromycin may replace the standard regime (often flucloxacillin or cefradine), as well as offering potential anti-pseudomonal effects. The role of azithromycin as a prophylactic agent in newly diagnosed infants, for example those identified through newborn screening programmes, requires a rigorous multi-centre RCT with clearly defined and relevant outcomes. There is an urgent need for such a study, which must assess increasing resistance patterns to azithromycin, as well as efficacy outcomes.</p>
<p id="p-20">All patients prescribed azithromycin for medium to long-term periods need to be monitored carefully for adverseeffects. In view of the transient derangement in liver function experienced in the study by Cipolli&nbsp;<em>et al</em>.&nbsp;24, it would appear prudent to monitor this with an annual liverultrasound scan and twice yearly analysis of serum enzymes. Any adverse effects noted should be reported to the national drug monitoring agency and to the national CF database.</p>
<p id="p-21">In a barren time for new therapies, azithromycin increases the cystic fibrosis physician’s armamentarium and offers a potentially useful therapy to arrest respiratory decline. However, questions remain as to its precise role in the clinic and continued vigilance is required for adverse outcomes.</p>
<p>&nbsp;</p>
<h2>Acknowledgments</h2>
<hr>
<p>&nbsp;</p>
<div id="ack-1" class="section ack" bis_skin_checked="1">
<p id="p-27">The authors would like to thank investigators for sharing their original data and for their support with the systematic review, in particular S. Bell, L. Saiman, P. Campbell III and M. Rosenthal. The authors would also like to acknowledge the invaluable support of the Cochrane Cystic Fibrosis and Genetics Disorders Group.</p>
</div>
<ul class="history-list">
<li class="received"><span class="received-label">Received&nbsp;</span>July 14, 2004.</li>
<li class="accepted"><span class="accepted-label">Accepted&nbsp;</span>July 23, 2004.</li>
</ul>
<ul class="copyright-statement">
<li id="copyright-statement-1" class="fn">© ERS Journals Ltd</li>
</ul>
<p>&nbsp;</p>
<h2>References</h2>
<hr>
<p>&nbsp;</p>
<p>1. ↵ Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361:681–689.CrossRefPubMedWeb of Science<br>
2. ↵ Lewis PA, Epidemiology. In: Hodson ME, Geddes D, eds. Cystic fibrosis. Arnold, New York, 2000; pp. 13–25.<br>
3. ↵ Jones AP, Wallis CE. Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev 2003;3:CD001127.<br>
4. ↵ Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003;3:CD001021.<br>
5. ↵ Brennan AL, Geddes DM. Bringing new treatments to the bedside in cystic fibrosis. Pediatr Pulmonol 2004;37:87–98.CrossRefPubMedWeb of Science<br>
6. ↵ Jaffe A, Bush A. Cystic fibrosis: review of the decade. Monaldi Arch Chest Dis 2001;56:240–247.PubMedGoogle Scholar<br>
7. ↵ www.cochrane.org. Date last updated: February 17 2004. Date last accessed: September 6 2004.<br>
8. ↵ Southern KW, Barker PM, Solis A, Macrolide antibiotics for cystic fibrosis (Cochrane Rev). In: The Cochrane Library, issue no. 3. Chichester, John Wiley and Sons Ltd, 2004.<br>
9. ↵ Kucers A, Crowe S, Grayson ML, Hoy J, Azithromycin. In: Kucers A, Crowe S, Grayson ML, Hoy J, eds. The use ofantibiotics. Butterworth-Heinemann, Oxford, 1997; pp. 653–662.<br>
10. ↵ Lukehart SA, Godornes C, Molini BJ, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med 2004;351:154–158.CrossRefPubMedWeb of Science<br>
11. ↵ Bischoff WE, Wallis ML, Tucker KB, Reboussin BA, Sherertz RJ. Staphylococcus aureus nasal carriage in a student community: prevalence, clonal relationships, and risk factors. Infect Control Hosp Epidemiol 2004;25:485–491.CrossRefPubMedWeb of Science<br>
12. ↵ Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994;49:531–532.FREE Full Text<br>
13. ↵ Bush A, Rubin BK. Macrolides as biological response modifiers in cystic fibrosis and bronchiectasis. Semin Resp Crit Care Med 2003;24:737–747.CrossRef<br>
14. ↵ Garey KW, Alwani A, Danziger LH, Rubinstein I. Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases. Chest 2003;123:261–265.CrossRefPubMedWeb of Science<br>
15. ↵ Inamura K, Ohta N, Fukase S, Kasajima N, Aoyagi M. The effects of erythromycin on human peripheral neutrophil apoptosis. Rhinology 2000;38:124–129.PubMedWeb of Science<br>
16. Matsuoka N, Eguchi K, Kawakami A, et al. Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clin Exp Immunol 1996;104:501–508.CrossRefPubMedWeb of Science<br>
17. ↵ Kohri K, Tamaoki J, Kondo M, Aoshiba K, Tagaya E, Nagai A. Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. Eur Respir J 2000;15:62–67.Abstract/FREE Full Text<br>
18. ↵ Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997;155:2018–2023.PubMedWeb of Science<br>
19. ↵ Ichimiya T, Takeoka K, Hiramatsu K, Hirai K, Yamasaki T, Nasu M. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 1996;42:186–191.PubMedWeb of Science<br>
20. ↵ Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212–216.Abstract/FREE Full Text<br>
21. ↵ Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978–984.CrossRefPubMedWeb of Science<br>
22. ↵ Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749–1756.CrossRefPubMedWeb of Science<br>
23. ↵ Jones AM, Martin L, Bright-Thomas RJ, et al. Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa. Eur Respir J 2003;22:503–506.Abstract/FREE Full Text<br>
24. ↵ Cipolli M, Cazzola G, Novelli A, Cassetta MI, Falllani S, Mazzei T. Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis. Clin Drug Invest 2001;21:353–360.CrossRef<br>
25. ↵ Ripoll L, Reinert P, Pepin LF, Lagrange PH. Interaction of macrolides with alpha dornase during DNA hydrolysis. J Antimicrob Chemother 1996;37:987–991.Abstract/FREE Full Text</p>
<p>&nbsp;</p>
<h2>Source:</h2>
<p><a href="https://erj.ersjournals.com/content/24/5/834">https://erj.ersjournals.com/content/24/5/834</a></p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/02/20/azithromycin-for-cystic-fibrosis/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/02/20/azithromycin-for-cystic-fibrosis/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5158 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>14.02.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/02/14/azithromycin-for-episodes-with-asthma-like-symptoms-in-young-children-aged-1-3-years-a-randomised-double-blind-placebo-controlled-trial/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/02/14/azithromycin-for-episodes-with-asthma-like-symptoms-in-young-children-aged-1-3-years-a-randomised-double-blind-placebo-controlled-trial/">Azithromycin for episodes with asthma-like symptoms in young children aged 1–3 years: a randomised, double-blind, placebo-controlled trial</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><div class="article-header__wrapper" bis_skin_checked="1">
<div class="article-header__middle" bis_skin_checked="1">
<ul class="rlist loa inline-bullet-list " data-number-of-author="6">
<li class="loa__item author">
<div class="dropBlock article-header__info" bis_skin_checked="1">Jakob Stokholm, PhD, Bo L Chawes, PhD, Nadja H Vissing, PhD, Elín Bjarnadóttir, MD, Tine M Pedersen, MD, Rebecca K Vinding, MD, Ann-Marie M Schoos, PhD, Helene M Wolsk, MD, Sunna Thorsteinsdóttir, MD, Henrik W Hallas, MD, Lambang Arianto, MD, Susanne Schjørring, PhD, Prof Karen A Krogfelt, PhD, Prof Thea K Fischer, DMSc, Christian B Pipper, PhD, Klaus Bønnelykke, PhD, Prof Hans Bisgaard, DMSc</div>
</li>
</ul>
<div class="inline-it" bis_skin_checked="1"><span class="article-header__publish-date bulleted"><span class="article-header__publish-date__label">Published:</span><span class="article-header__publish-date__value">December 15, 2015 </span></span></div>
<div class="inline-it" bis_skin_checked="1"><span class="article-header__doi bulleted"><span class="article-header__doi__label">DOI:</span><a class="article-header__doi__value" href="https://doi.org/10.1016/S2213-2600(15)00500-7">https://doi.org/10.1016/S2213-2600(15)00500-7</a></span></div>
</div>
</div>
<div class="col-md-6 static-md" bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h2 id="seccestitle10" class="top" tabindex="0" data-left-hand-nav="Summary"><span class="top__text">Summary</span></h2>
<hr>
</div>
<div class="content-navigation__btn__wrapper--prev" bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h3>Background</h3>
<div class="section-paragraph" bis_skin_checked="1">Bacteria and viruses are equally associated with the risk of acute episodes of asthma-like symptoms in young children, suggesting antibiotics as a potential treatment for such episodes. We aimed to assess the effect of azithromycin on the duration of respiratory episodes in young children with recurrent asthma-like symptoms, hypothesising that it reduces the duration of the symptomatic period.</div>
<h3>Methods</h3>
<div class="section-paragraph" bis_skin_checked="1">In this randomised, double-blind, placebo-controlled trial, we recruited children aged 1–3 years, who were diagnosed with recurrent asthma-like symptoms from the Copenhagen Prospective Studies on Asthma in Childhood 2010 cohort; a birth cohort consisting of the general Danish population of Zealand, including Copenhagen. Exclusion criteria were macrolide allergy, heart, liver, neurological, and kidney disease, and, before each treatment, one or more clinical signs of pneumonia (respiratory frequency of ≥50 breaths per min; fever of ≥39°C; C-reactive protein concentration of ≥476·20 nmol/L [≥50 mg/L]). Each episode of asthma-like symptoms lasting at least 3 days was randomly allocated to a 3-day course of azithromycin oral solution of 10 mg/kg per day or placebo after thorough examination by a study physician at the Copenhagen Prospective Studies on Asthma research unit. Each episode was randomly allocated independently of previous treatment from a computer-generated list of random numbers in blocks of ten (generated at the Pharmacy of Glostrup). Investigators and children were masked until the youngest child turned 3 years of age and throughout the data validation and analysis phases. The primary outcome was duration of the respiratory episode after treatment, verified by prospective daily diaries and analysed with Poisson regression. Analyses were per protocol (excluding those without a primary outcome measure or who did not receive treatment). This trial is registered with&nbsp;<a href="https://clinicaltrials.gov/" target="_blank" rel="noopener">ClinicalTrials.gov</a>, number&nbsp;<a href="https://clinicaltrials.gov/show/NCT01233297" target="_blank" rel="noopener">NCT01233297</a>.</div>
<h3>Findings</h3>
<div class="section-paragraph" bis_skin_checked="1">Between Nov 17, 2010, and Jan 28, 2014, we randomly allocated 158 asthma-like episodes in 72 children (79 [50%] to azithromycin and 79 [50%] to placebo). The mean duration of the episode after treatment was 3·4 days for children receiving azithromycin compared with 7·7 days for children receiving placebo. Azithromycin caused a significant shortening of the episode of 63·3% (95% CI 56·0–69·3; p&lt;0·0001). The effect size increased with early initiation of treatment, showing a reduction in episode duration of 83% if treatment was initiated before day 6 of the episode compared with 36% if initiated on or after day 6 (p&lt;0·0001). We noted no differences in clinical adverse events between the azithromycin (18 [23%] of 78 episodes included in final analysis) and placebo (24 [30%] of 79) groups (p=0·30), but we did not investigate bacterial resistance patterns after treatment.</div>
<h3>Interpretation</h3>
<div class="section-paragraph" bis_skin_checked="1">Azithromycin reduced the duration of episodes of asthma-like symptoms in young children, suggesting that this drug could have a role in acute management of exacerbations. Further research is needed to disentangle the inflammatory versus antimicrobial aspects of this relation.</div>
<h3>Funding</h3>
<div class="section-paragraph" bis_skin_checked="1">Lundbeck Foundation, Danish Ministry of Health, Danish Council for Strategic Research, Capital Region Research Foundation.</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h2 id="seccestitle70" class="top" tabindex="0" data-left-hand-nav="Introduction"><span class="top__text">Introduction</span></h2>
<hr>
</div>
<p>&nbsp;</p>
<p>Childhood asthma is often preceded by recurrent episodes of troublesome lung symptoms in relation to airway infections in the first years of life.1, 2 Treatment of such episodes represents a major unmet clinical need; they are the most common cause of admission to hospital in young children, are a reason for stress and anxiety for families, and cause a major draw on health-care resources.3, 4, 5<br>
We discovered in our birth cohort, the Copenhagen Prospective Studies on Asthma in Childhood 2000 (COPSAC2000; a previous birth cohort of children born to mothers with asthma), that airway bacteria (Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis) and respiratory viruses (at least one of picornavirus, respiratory syncytial virus, coronavirus, parainfluenzavirus, influenza virus, human metapneumovirus, adenovirus, or bocavirus) are equally closely associated with episodes of asthma-like symptoms in the first 3 years of life.6 Bacteria and viruses occurred together in most cases, challenging the previous hypothesis that episodes with asthma-like symptoms in this age group are largely virally induced.7, 8, 9 This finding suggested that bacteria might play an equal part in the pathogenesis of such episodes and that treatment with antibiotics might ameliorate symptoms. At present, guidelines do not recommend antibiotics for treatment of early asthma-like episodes,10 yet they are widely used.4 We did a randomised controlled trial (RCT) of azithromycin for treatment of episodes of troublesome lung symptoms in young children who were followed up prospectively in our new unselected Copenhagen Prospective Studies on Asthma in Childhood 2010 (COPSAC2010) birth cohort.11</p>
<p>&nbsp;</p>
<p><b>Research in context</b></p>
<div class="section-paragraph" bis_skin_checked="1"><strong>Evidence before this study</strong></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<div class="section-paragraph" bis_skin_checked="1">Findings from a publication from the Copenhagen Prospective Studies on Asthma in Childhood showed that both bacteria and viruses are equally associated with the risk of acute episodes of asthma-like symptoms in young children, suggesting that antibiotics such as azithromycin could help in management of such episodes. We searched PubMed up to Oct 15, 2010, with no language limits, for various combinations of the search terms “RCT”, “childhood”, “asthma”, “wheeze”, and “antibiotics”. We identified all previous randomised controlled trials of treatment with antibiotics for asthma and wheezy exacerbations, but focused mainly on childhood asthma. The search led us to new articles, but also identified other relevant old publications for background material. Investigators of two randomised trials concluded no beneficial effect of β-lactam treatment for acute exacerbations, which has led to present guidelines not recommending antibiotic treatment for episodes of acute asthma-like symptoms.</div>
<div class="section-paragraph" bis_skin_checked="1"><strong>Added value of this study</strong></div>
<div class="section-paragraph" bis_skin_checked="1">This study is, to our knowledge, the first randomised controlled trial of azithromycin treatment of acute episodes of asthma-like symptoms in children aged 1–3 years with a history of recurrent episodes and its findings show a clinically significant shortening of symptom duration by 63% after intervention.</div>
<div class="section-paragraph" bis_skin_checked="1"><strong>Implications of all the available evidence</strong></div>
<div class="section-paragraph" bis_skin_checked="1">Present guidelines do not recommend antibiotics for treatment of episodes of asthma-like symptoms in young children, yet antibiotics remain among the most commonly prescribed drugs in these episodes. Our findings suggest that azithromycin might be beneficial after medical assessment of an acute asthma-like episode in young children with a known history of such symptoms and without clinical signs of pneumonia. How the effect of azithromycin is compared with narrow-spectrum antibiotics and whether long-term effects are associated with recurrent use of azithromycin need to be investigated.</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h2 id="seccestitle80" class="top" tabindex="0" data-left-hand-nav="Methods"><span class="top__text">Methods</span></h2>
<hr>
</div>
<p>&nbsp;</p>
<section id="cesec30" tabindex="0" data-locator="cesec30">
<h3 class="sectionTitle"><span class="top__text">Study design and participants</span></h3>
<div class="section-paragraph" bis_skin_checked="1">
<p>In this randomised, double-blind, placebo-controlled trial, we recruited children from the COPSAC<sub>2010</sub>&nbsp;cohort, which is a single-centre, population-based birth cohort of 700 children recruited from the general Danish population of Zealand, including Copenhagen, at 1 week of age and followed up prospectively at the Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) research unit (Copenhagen and Naestved, Denmark) with deep clinical phenotyping.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>11</sup></div>
<p>Children aged 1–3 years diagnosed with recurrent asthma-like symptoms (troublesome lung symptoms) as defined in the Procedures section were eligible each time they had an episode of troublesome lung symptoms lasting at least 3 days. Exclusion criteria were macrolide allergy, heart, liver, neurological, and kidney disease, and, before each treatment, one or more clinical signs of pneumonia (respiratory frequency of 50 breaths per min or higher, fever of 39°C or higher, or C-reactive protein [CRP] concentration of 476·20 nmol/L [50 mg/L] or higher). Most mothers from the COPSAC<sub>2010</sub>&nbsp;cohort also participated in other medical trials while pregnant and may have received dietary supplements or an influenza vaccination (<a href="https://clinicaltrials.gov/show/NCT00856947" target="_blank" rel="noopener">NCT00856947</a>,&nbsp;<a href="https://clinicaltrials.gov/show/NCT00798226" target="_blank" rel="noopener">NCT00798226</a>, and&nbsp;<a href="https://clinicaltrials.gov/show/NCT01012557" target="_blank" rel="noopener">NCT01012557</a>).</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>11</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>12</sup></div>
<p>Additional details of baseline characteristics of the cohort are outlined in the COPSAC<sub>2010</sub>&nbsp;cohort design report.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>11</sup></div>
</div>
<div class="section-paragraph" bis_skin_checked="1">This trial was approved by the ethics committee for Copenhagen (H-3-2010-065), Danish Data Protection Agency (2010-41-5023), and Danish Health and Medicines Authority (2612-4329). Parents of children gave written and oral informed consent before enrolment of participants. The complete biobank is publicly available at the Danish National&nbsp;<a href="https://www.biobankdenmark.dk/" target="_blank" rel="noopener">Biobank</a>. The entire COPSAC dataset, including the RCT-specific data, are currently being transferred to a publicly available database (the Danish Data&nbsp;<a href="https://www.sa.dk/" target="_blank" rel="noopener">Archive</a>).</div>
</section>
<section id="cesec40" tabindex="0" data-locator="cesec40">
<h3 class="sectionTitle"><span class="top__sub">&nbsp;</span><span class="top__text">Randomisation and masking</span></h3>
<div class="section-paragraph" bis_skin_checked="1">Each episode of troublesome lung symptoms that occurred up to the age of 3 years or up to a maximum of seven treatments per child was randomised individually to either azithromycin or placebo. Treatments were randomly allocated at the Pharmacy of Glostrup (Copenhagen, Denmark) with a computer-generated list of random numbers in blocks of ten. Copies of the randomisation code were kept in sealed envelopes at the research site and the pharmacy. Investigators and participating families were masked to treatment assignment until the youngest child turned 3 years of age and throughout the data validation and analysis phases. Those assessing the primary outcome were masked; those doing subanalyses were not.</div>
</section>
<section id="cesec50" tabindex="0" data-locator="cesec50">
<h3 class="sectionTitle"><span class="top__sub">&nbsp;</span><span class="top__text">Procedures</span></h3>
<div class="section-paragraph" bis_skin_checked="1">
<p>Troublesome lung symptoms, consisting of cough, wheeze, or dyspnoea, severely affecting the wellbeing of the child, were monitored using daily diary cards filled out by the parents from birth.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>11</sup></div>
<p>We defined an episode as at least 3 consecutive days of troublesome lung symptoms, at which point we requested that the parents brought the child to the COPSAC research unit for an acute visit. We used the composite score of troublesome lung symptoms to describe asthma-like symptoms in the children, a score previously validated</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>13</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>14</sup></div>
<p>and used in our clinical observational cohort studies of young children</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>13</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>15</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>16</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>17</sup></div>
<p>and a randomised controlled trial.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>19</sup></div>
</div>
<div class="section-paragraph" bis_skin_checked="1">
<p>At each acute visit, the diary cards were reviewed with the family by trained COPSAC paediatricians to validate symptom definitions and severity. Additionally, the research paediatrician did a thorough physical examination, consisting of assessment of fever, tachypnoea, chest recessions, wheezing, and lung and heart auscultation, and examination of the skin, ears, nose, and throat. Furthermore, we measured CRP concentration (detection limit of 76·19–1523·84 nmol/L [8–160 mg/L]) in the peripheral blood with the QuickRead 101 instrument (Orion Diagnostica, Espoo, Finland). We collected a hypopharyngeal aspirate using a soft suction catheter passed through the nose into the hypopharynx, as previously described.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>18</sup></div>
<p>We cultured the samples and isolated the airway bacterial pathogens&nbsp;<em>H influenzae, S pneumoniae</em>, and&nbsp;<em>M catarrhalis</em>. We obtained a nasopharyngeal aspirate for viral identification with PCR. The viral airway pathogens analysed were rhinoviruses, respiratory syncytial virus (RSV), and enteroviruses.</p>
</div>
<div class="section-paragraph" bis_skin_checked="1">We treated episodes of troublesome lung symptoms with the β2 agonist salbutamol (Airomir; Teva, Kongens Lyngby, Denmark) inhaled from a pressurised metered dose inhaler delivered via a spacer (AeroChamber; Trudell Medical International, London, ON, Canada) as needed. We added 4 mg of montelukast in the evening for 2 weeks in children who had previously benefited from this treatment. We added prednisolone 1–2 mg/kg per day for 3 days for severe episodes at the discretion of the attending paediatricians in the COPSAC research unit.</div>
<div class="section-paragraph" bis_skin_checked="1">
<p>Recurrent troublesome lung symptoms were diagnosed if a child had: daily diary recordings of five episodes of troublesome lung symptoms within 6 months; 4 weeks of continuous symptoms; or a severe acute episode needing oral prednisolone or hospital admission. This diagnosis algorithm had previously been validated in our at-risk COPSAC<sub>2000</sub>&nbsp;birth cohort.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>19</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>20</sup></div>
<p>At diagnosis of recurrent troublesome lung symptoms, we gave children a 3-month course of 2 × 50 μg fluticasone (Flixotide; GlaxoSmithKline, UK) inhaled from a pressurised metered dose inhaler delivered via a spacer twice daily. If a second relapse of troublesome lung symptoms occurred after cessation of inhaled corticosteroids, we initiated a 6-month course of inhaled corticosteroids.</p>
</div>
<div class="section-paragraph" bis_skin_checked="1">Children diagnosed with recurrent troublesome lung symptoms and participating in this trial were prescribed azithromycin or placebo at the COPSAC research unit when subsequent acute episodes of troublesome lung symptoms occurred after diagnosis. We gave azithromycin as an oral solution of 10 mg/kg per day in closed bottles (Teva) for 3 consecutive days or a matching placebo of similar look and taste (Pharmacy of Glostrup).</div>
</section>
<section id="cesec60" tabindex="0" data-locator="cesec60">
<h3 class="sectionTitle"><span class="top__sub">&nbsp;</span><span class="top__text">Outcomes</span></h3>
<div class="section-paragraph" bis_skin_checked="1">The primary outcome was diary-verified duration of episodes of troublesome lung symptoms after initiation of treatment. Secondary outcomes were the time from treatment to the next episode of troublesome lung symptoms, the number of episodes that turned into severe exacerbations (need for oral steroids or admission to hospital), and the duration of β2 agonist use after treatment. Serious adverse events, any adverse events, gastrointestinal symptoms, or other infections were documented with daily diary cards and hospital records.</div>
</section>
<section id="cesec70" tabindex="0" data-locator="cesec70">
<h3 class="sectionTitle"><span class="top__sub">&nbsp;</span><span class="top__text">Statistical analysis</span></h3>
<div class="section-paragraph" bis_skin_checked="1">
<p>We based our power calculations on the duration of episodes of troublesome lung symptoms at age 1–3 years in the children of the previous COPSAC<sub>2000</sub>&nbsp;cohort.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>18</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>19</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>21</sup></div>
<p>86 independent episodes were needed to detect a difference of 1 day duration of episodes with a power of 90%, a p value of 0·05, and an SD of the duration of an episode of 1·4 days.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>18</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>19</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>21</sup></div>
</div>
<div class="section-paragraph" bis_skin_checked="1">We analysed the duration of an episode of troublesome lung symptoms and β2 agonist use after treatment with Poisson regression with a log link. This type of regression is ideal for modelling counts because it captures both skewness and variance heterogeneity and provides an easy-to-interpret quantification of effects as relative change in mean counts. The model includes fixed effects of the categorical variable episode number and an effect of treatment. We included a random effect of child to account for heterogeneity between children. We analysed factors potentially modifying the treatment effect with robust Poisson regression to account for within-child correlation. We obtained inference by means of the generalised estimating equations procedure with a working independence assumption.</div>
<div class="section-paragraph" bis_skin_checked="1">We analysed gap times between episodes with Cox regression, including γ-distributed frailties shared by gap times within each child to account for between-child heterogeneity. We included fixed effects of treatment at the preceding episode in the model and stratified baseline hazards by episode number. We obtained estimates with maximum likelihood estimation with Wald 95% CIs and a 0·05 p value cutoff. We did analyses using R version 3.2.2 and the add-on package lme4.</div>
<div class="section-paragraph" bis_skin_checked="1">Primary analyses were per protocol (excluding those without a primary outcome measure or who did not receive treatment). Safety analyses included those without a primary outcome measure but who did receive the study treatment.</div>
<div class="section-paragraph" bis_skin_checked="1">This trial was monitored by the Good Clinical Practice unit at Copenhagen University Hospital (Copenhagen, Denmark). This trial is registered with&nbsp;<a href="https://clinicaltrials.gov/" target="_blank" rel="noopener">ClinicalTrials.gov</a>, number&nbsp;<a href="https://clinicaltrials.gov/show/NCT01233297" target="_blank" rel="noopener">NCT01233297</a>.</div>
</section>
<section id="cesec80" tabindex="0" data-locator="cesec80">
<h3 class="sectionTitle"><span class="top__text">Role of the funding source</span></h3>
<div class="section-paragraph" bis_skin_checked="1">The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. JS, CBP, and HB had access to the raw data. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.</div>
</section>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h2 id="seccestitle150" class="top" tabindex="0" data-left-hand-nav="Results"><span class="top__text">Results</span></h2>
<hr>
</div>
<p>&nbsp;</p>
<p>207 (30%) of the 700 children enrolled in the main cohort were diagnosed with recurrent troublesome lung symptoms during the first 3 years of life; between Nov 17, 2010, and Jan 28, 2014, we randomly allocated 158 episodes for trial treatment (79 [50%] to azithromycin and 79 [50%] to placebo;&nbsp;<a id="back-gr1" class="figure-link scroll-into-link" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext#fig1" data-link="modal" data-target="#image-S2213-2600(15)00500-7gr1" data-locator="fig1">figure 1</a>) from 72 (35%) of these children. Before analyses, we excluded ten (6%) episodes from the analysis (five [6%] in each group), nine (6%) because of missing diary information (azithromycin four [5%]; placebo five [6%]) and one (1%; in azithromycin group) because the treatment was never given to the child.</p>
<div class="floatDisplay" bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Figure thumbnail gr1" data-lazy-src="https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1d601971-a528-4fd7-8314-36846737b2ae/gr1.gif"><noscript><img src="https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1d601971-a528-4fd7-8314-36846737b2ae/gr1.gif" alt="Figure thumbnail gr1" /></noscript></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<div class="section-paragraph" bis_skin_checked="1">Mean age at randomisation was 2·0 years (SD 0·6). The mean number of randomisations for each child was 2·2 treatments (SD 1·5). In 121 (82%) of the 148 episodes analysed (62 [84%] in the azithromycin-treated episodes and 59 [80%] in the placebo-treated episodes), the child received concurrent treatment with inhaled corticosteroids. In 89 (60%) episodes, the child received concurrent treatment with montelukast (47 [64%] in the azithromycin-treated episodes and 42 [57%] in the placebo-treated episodes). Treatment was complied with in 154 (97%) of 158 episodes: one (1%) azithromycin treatment was never given and three (2%) treatments were discontinued after initiation; one (1%) in the azithromycin group and two (1%) in the placebo group. 71 (99%) of 72 children had complete clinical follow-up from inclusion in the study until age 3 years.</div>
<div class="section-paragraph" bis_skin_checked="1">Baseline characteristics did not differ significantly between participants in the trial and other children diagnosed with recurrent troublesome lung symptoms from the COPSAC<sub>2010</sub>&nbsp;cohort who did not participate in the trial, except for a higher proportion of mothers of RCT participants being asthmatic (31 [44%] of 71) than of mothers of non-participants (38 [28%] of 135; p=0·03;&nbsp;<a class="scroll-into-link" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext#tbl1">table 1</a>). The mean total duration of respiratory episodes was 13·7 days. The episode duration after randomisation was unrelated to sex, mother’s smoking status, allergic sensitisation to inhalant or food allergens at 6 months or 18 months, atopic dermatitis, or 17q21 genetic risk variant (<a class="scroll-into-link" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext#sec1">appendix</a>).</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<div class="inline-table__head" bis_skin_checked="1"><span class="inline-table__label">Table 1</span><span class="inline-table__title">Baseline characteristics</span></div>
<div class="table-with-References" bis_skin_checked="1">
<table class="scrollable bordered" border="0" width="100%" cellspacing="0" cellpadding="0">
<thead>
<tr>
<th class="rowsep"></th>
<th class="rowsep"></th>
<th class="rowsep"><strong>RCT participants (n=72)</strong></th>
<th class="rowsep"><strong>Non-RCT participants (n=135)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4"><strong>Child</strong></td>
</tr>
<tr>
<td colspan="2">Male sex</td>
<td>47 (65%)</td>
<td>74 (55%)</td>
</tr>
<tr>
<td colspan="2">White</td>
<td>70 (97%)</td>
<td>130 (96%)</td>
</tr>
<tr>
<td colspan="2">Older children in the home at birth</td>
<td>39 (54%)</td>
<td>70 (52%)</td>
</tr>
<tr>
<td colspan="2">Sensitisation (SPT or specific IgE)</td>
<td>8 (11%)</td>
<td>20 (15%)<p></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><a id="back-tbl1fn1" class="reference-citations__ctrl scroll-into-link" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext#" data-db-target-for="tbl1fn1-d3836012e106" aria-expanded="false" aria-controls="tbl1fn1"><sup>*</sup></a></div>
</td>
</tr>
<tr>
<td colspan="2">Atopic dermatitis</td>
<td>21 (30%)<p></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><a id="back-tbl1fn1" class="reference-citations__ctrl scroll-into-link" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext#" data-db-target-for="tbl1fn1-d3836012e114" aria-expanded="false" aria-controls="tbl1fn1"><sup>*</sup></a></div>
</td>
<td>39 (30%)<p></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><a id="back-tbl1fn2" class="reference-citations__ctrl scroll-into-link" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext#" data-db-target-for="tbl1fn2-d3836012e119" aria-expanded="false" aria-controls="tbl1fn2"><sup>†</sup></a></div>
</td>
</tr>
<tr>
<td colspan="2">17q21 risk variant (RS2305480)</td>
<td>26 (41%)<p></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><a id="back-tbl1fn3" class="reference-citations__ctrl scroll-into-link" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext#" data-db-target-for="tbl1fn3-d3836012e127" aria-expanded="false" aria-controls="tbl1fn3"><sup>‡</sup></a></div>
</td>
<td>46 (39%)<p></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><a id="back-tbl1fn4" class="reference-citations__ctrl scroll-into-link" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext#" data-db-target-for="tbl1fn4-d3836012e132" aria-expanded="false" aria-controls="tbl1fn4"><sup>§</sup></a></div>
</td>
</tr>
<tr>
<td colspan="2">Smoking in pregnancy</td>
<td>9 (13%)</td>
<td>16 (12%)</td>
</tr>
<tr>
<td colspan="2">Cat or dog at birth</td>
<td>26 (36%)</td>
<td>48 (36%)</td>
</tr>
<tr>
<td colspan="2">Antibiotics in pregnancy</td>
<td>31 (43%)</td>
<td>50 (37%)</td>
</tr>
<tr>
<td colspan="2">Term birth &gt;37 weeks</td>
<td>67 (93%)</td>
<td>127 (94%)</td>
</tr>
<tr>
<td colspan="2">Caesarean section</td>
<td>18 (25%)</td>
<td>31 (23%)</td>
</tr>
<tr>
<td colspan="2">Season of birth</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Winter</td>
<td>25 (35%)</td>
<td>38 (28%)</td>
</tr>
<tr>
<td></td>
<td>Spring</td>
<td>17 (24%)</td>
<td>37 (27%)</td>
</tr>
<tr>
<td></td>
<td>Summer</td>
<td>12 (17%)</td>
<td>29 (21%)</td>
</tr>
<tr>
<td></td>
<td>Autumn</td>
<td>18 (25%)</td>
<td>31 (23%)</td>
</tr>
<tr>
<td colspan="4"><strong>Mother</strong></td>
</tr>
<tr>
<td colspan="2">Maternal age at birth (years)</td>
<td>31·9 (4·7)</td>
<td>32·2 (4·5)</td>
</tr>
<tr>
<td colspan="2">Maternal asthma<p></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><a id="back-tbl1fn5" class="reference-citations__ctrl scroll-into-link" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext#" data-db-target-for="tbl1fn5-d3836012e222" aria-expanded="false" aria-controls="tbl1fn5"><sup>¶</sup></a></div>
</td>
<td>31 (44%)<p></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><a id="back-tbl1fn1" class="reference-citations__ctrl scroll-into-link" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext#" data-db-target-for="tbl1fn1-d3836012e227" aria-expanded="false" aria-controls="tbl1fn1"><sup>*</sup></a></div>
</td>
<td>38 (28%)</td>
</tr>
<tr>
<td colspan="2">Maternal educational level</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Low<p></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><a id="back-tbl1fn6" class="reference-citations__ctrl scroll-into-link" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext#" data-db-target-for="tbl1fn6-d3836012e241" aria-expanded="false" aria-controls="tbl1fn6"><sup>‖</sup></a></div>
</td>
<td>9 (13%)</td>
<td>15 (11%)</td>
</tr>
<tr>
<td></td>
<td>Medium<p></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><a id="back-tbl1fn7" class="reference-citations__ctrl scroll-into-link" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext#" data-db-target-for="tbl1fn7-d3836012e253" aria-expanded="false" aria-controls="tbl1fn7"><sup>**</sup></a></div>
</td>
<td>53 (74%)</td>
<td>83 (61%)</td>
</tr>
<tr>
<td></td>
<td>High<p></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"></div>
</td>
<td>10 (14%)</td>
<td>37 (27%)</td>
</tr>
<tr>
<td colspan="2">Household annual income</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Low<p></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"></div>
</td>
<td>4 (6%)</td>
<td>17 (13%)</td>
</tr>
<tr>
<td></td>
<td>Medium<p></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"></div>
</td>
<td>45 (63%)</td>
<td>73 (54%)</td>
</tr>
<tr>
<td></td>
<td>High<p></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"></div>
</td>
<td>23 (32%)</td>
<td>45 (33%)</td>
</tr>
</tbody>
</table>
</div>
<div class="inline-table__tail" bis_skin_checked="1">
<div class="section-paragraph" bis_skin_checked="1">Data are n (%) or mean (SD). RCT=randomised controlled trial. SPT=skin prick test.</div>
<div class="inline-table__footnote" bis_skin_checked="1">*&nbsp;One child has missing information.</div>
<div class="inline-table__footnote" bis_skin_checked="1">†&nbsp;Seven children have data missing.</div>
<div class="inline-table__footnote" bis_skin_checked="1">‡&nbsp;Nine children have missing information.</div>
<div class="inline-table__footnote" bis_skin_checked="1">§&nbsp;17 children have data missing.</div>
<div class="inline-table__footnote" bis_skin_checked="1">¶&nbsp;History of doctor-diagnosed asthma.</div>
<div class="inline-table__footnote" bis_skin_checked="1">‖&nbsp;Primary school, secondary school, or college graduate.</div>
<div class="inline-table__footnote" bis_skin_checked="1">**&nbsp;Tradesman or Bachelor degree.</div>
<div class="inline-table__footnote" bis_skin_checked="1">††&nbsp;Masters degree.</div>
<div class="inline-table__footnote" bis_skin_checked="1">‡‡&nbsp;Less than €50 000.</div>
<div class="inline-table__footnote" bis_skin_checked="1">§§&nbsp;€50 000–110 000.</div>
<div class="inline-table__footnote" bis_skin_checked="1">¶¶&nbsp;More than €110 000.</div>
</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">Figure 2&nbsp;shows the proportion of symptomatic children day-by-day during the 30 days after treatment, showing a shortening of the symptomatic period after treatment with azithromycin. The average number of symptom days after azithromycin treatment was 3·4 days versus 7·7 days after placebo, corresponding to a calculated reduction in episode length of 63·3% (95% CI 56·0–69·3; p&lt;0·0001) within a child due to azithromycin treatment (table 2). Restriction of the analysis to the first randomised treatment in each child substantiated a significant reduction of symptom duration by 44·4% (30·9–55·2; p&lt;0·0001) after treatment with azithromycin, corresponding to a mean duration of 4·0 days after azithromycin versus 7·1 days after placebo.</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Figure thumbnail gr2" data-lazy-src="https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/95fa46ee-6000-414f-b728-ea676fdaa4bf/gr2.jpg"><noscript><img src="https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/95fa46ee-6000-414f-b728-ea676fdaa4bf/gr2.jpg" alt="Figure thumbnail gr2" /></noscript></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"><span class="label figure__label" data-fv-label="Fig. 2">Figure 2. </span><span class="figure__title__text">Duration of episodes of troublesome lung symptoms after treatment</span></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"><span class="inline-table__label">Table 2. </span><span class="inline-table__title">Duration of episodes of troublesome lung symptoms after intervention and effect modification from paraclinical measures</span></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<table class="scrollable bordered" border="0" width="100%" cellspacing="0" cellpadding="0">
<thead>
<tr>
<th class="rowsep"></th>
<th class="rowsep"></th>
<th class="rowsep"><strong>n (%)</strong></th>
<th class="rowsep"><strong>Mean azithromycin episode duration (days)</strong></th>
<th class="rowsep"><strong>Mean placebo episode duration (days)</strong></th>
<th class="rowsep"><strong>% reduction (95% CI)</strong></th>
<th class="rowsep"><strong>p value</strong></th>
<th class="rowsep"><strong>Modification p value</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">All</td>
<td>148</td>
<td>3·4</td>
<td>7·7</td>
<td>63·3%(56·0 to 69·3)</td>
<td>&lt;0·0001</td>
<td></td>
</tr>
<tr>
<td colspan="3">Clinical measures</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td colspan="2">C-reactive protein concentration (nmol/L)</td>
<td>133 (100%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0·6350</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥76·19 nmol/L (≥8 mg/L)</td>
<td>23 (17%)</td>
<td>3·6</td>
<td>6·3</td>
<td>45·6% (−53·9 to 80·8)</td>
<td>0·2510</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt;76·19 nmol/L (&lt;8 mg/L; lowest detection)</td>
<td>110 (83%)</td>
<td>3·5</td>
<td>8·4</td>
<td>59·4%(15·6 to 80·5)</td>
<td>0·0158</td>
<td></td>
</tr>
<tr>
<td></td>
<td colspan="2">Fever (°C)</td>
<td>136 (100%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0·4809</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥38</td>
<td>23 (17%)</td>
<td>3·8</td>
<td>4·9</td>
<td>21·4% (−61·6 to 61·8)</td>
<td>0·5122</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt;38</td>
<td>113 (83%)</td>
<td>3·6</td>
<td>7·2</td>
<td>47·3%(2·9 to 71·4)</td>
<td>0·0401</td>
<td></td>
</tr>
<tr>
<td></td>
<td colspan="2">Objective wheeze</td>
<td>144 (100%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0·8140</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yes</td>
<td>26 (18%)</td>
<td>3·4</td>
<td>8·8</td>
<td>55·0%(6·3 to 78·4)</td>
<td>0·0330</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>No</td>
<td>118 (82%)</td>
<td>3·6</td>
<td>13·0</td>
<td>60·1%(18·3 to 80·5)</td>
<td>0·0120</td>
<td></td>
</tr>
<tr>
<td colspan="3">Bacterial infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td colspan="2">Any pathogenic bacteria</td>
<td>135 (100%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0·2864</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Present</td>
<td>90 (67%)</td>
<td>4·2</td>
<td>7·9</td>
<td>41·6% (−8·3 to 68·5)</td>
<td>0·0881</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not present</td>
<td>45 (33%)</td>
<td>2·0</td>
<td>5·5</td>
<td>64·7%(35·6 to 80·7)</td>
<td>0·0007</td>
<td></td>
</tr>
<tr>
<td></td>
<td colspan="2"><em>Haemophilus influenzae</em></td>
<td>135 (100%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0·0323</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Present</td>
<td>32 (24%)</td>
<td>2·7</td>
<td>12·1</td>
<td>77·0%(58·0 to 87·4)</td>
<td>&lt;0·0001</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not present</td>
<td>103 (76%)</td>
<td>3·8</td>
<td>5·9</td>
<td>33·4% (−28·7 to 65·6)</td>
<td>0·2264</td>
<td></td>
</tr>
<tr>
<td></td>
<td colspan="2"><em>Moraxella catarrhalis</em></td>
<td>135 (100%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0·9062</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Present</td>
<td>64 (47%)</td>
<td>4·4</td>
<td>8·7</td>
<td>40·5% (−64·3 to 78·5)</td>
<td>0·3163</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not present</td>
<td>71 (53%)</td>
<td>2·8</td>
<td>5·2</td>
<td>45·0%(1·7 to 69·3)</td>
<td>0·0436</td>
<td></td>
</tr>
<tr>
<td></td>
<td colspan="2"><em>Streptococcus pneumoniae</em></td>
<td>135 (100%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0·8576</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Present</td>
<td>43 (32%)</td>
<td>3·3</td>
<td>6·2</td>
<td>44·4% (−22·1 to 74·7)</td>
<td>0·1436</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not present</td>
<td>92 (68%)</td>
<td>3·6</td>
<td>7·5</td>
<td>49·6%(3·8 to 73·5)</td>
<td>0·0377</td>
<td></td>
</tr>
<tr>
<td colspan="3">Viral infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td colspan="2">Any pathogenic virus</td>
<td>135 (100%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0·7999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Present</td>
<td>58 (43%)</td>
<td>3·8</td>
<td>6·8</td>
<td>44·0% (−32·4 to 76·4)</td>
<td>0·1866</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not present</td>
<td>77 (57%)</td>
<td>2·7</td>
<td>7·4</td>
<td>50·7%(27·3 to 66·6)</td>
<td>0·0004</td>
<td></td>
</tr>
<tr>
<td></td>
<td colspan="2">Rhinovirus</td>
<td>135 (100%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0·5125</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Present</td>
<td>26 (19%)</td>
<td>4·6</td>
<td>6·9</td>
<td>26·7% (−172·6 to 80·3)</td>
<td>0·6430</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not present</td>
<td>109 (81%)</td>
<td>3·1</td>
<td>7·1</td>
<td>54·1% (34·3 to 67·9)</td>
<td>&lt;0·0001</td>
<td></td>
</tr>
<tr>
<td></td>
<td colspan="2">RSV</td>
<td>135 (100%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0·8886</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Present</td>
<td>22 (16%)</td>
<td>3·3</td>
<td>5·9</td>
<td>42·1% (−71·7 to 80·5)</td>
<td>0·3242</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not present</td>
<td>113 (84%)</td>
<td>3·6</td>
<td>7·2</td>
<td>46·9%(6·3 to 69·9)</td>
<td>0·0289</td>
<td></td>
</tr>
<tr>
<td></td>
<td colspan="2">Enteroviruses</td>
<td>135 (100%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0·1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Present</td>
<td>27 (20%)</td>
<td>2·1</td>
<td>6·8</td>
<td>66·3%(31·5 to 83·4)</td>
<td>0·0026</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Not present</td>
<td>108 (80%)</td>
<td>4·0</td>
<td>7·1</td>
<td>41·1% (−2·7 to 66·2)</td>
<td>0·0619</td>
<td></td>
</tr>
</tbody>
</table>
<div class="inline-table__tail" bis_skin_checked="1">
<div class="section-paragraph" bis_skin_checked="1">p values correspond to associations and test for effect modification by covariants. RSV=respiratory syncytial virus.</div>
</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">The effect of azithromycin was increased when the duration of symptoms before treatment was shorter, showing a reduction in episode duration of 83% if treatment was initiated before day 6 of the episode compared with 36% if initiated on or after day 6 (p&lt;0·0001).&nbsp;<a id="back-gr3" class="figure-link scroll-into-link" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext#fig3" data-link="modal" data-target="#image-S2213-2600(15)00500-7gr3" data-locator="fig3">Figure 3</a>&nbsp;shows the reduction of episode duration after azithromycin treatment as a function of episode duration before treatment (less than or more than the median value of 6 days). We noted no differential effect for episodes presenting with fever of ≥38°C or with increased CRP concentration of ≥76·19 nmol/L (≥8 mg/L), and treatment was equally effective in episodes with and without objective wheeze during examination in the research clinic (table 2).</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Figure thumbnail gr3" data-lazy-src="https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/fd2224b9-c58b-45b4-b940-d056ff13a501/gr3.jpg"><noscript><img src="https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/fd2224b9-c58b-45b4-b940-d056ff13a501/gr3.jpg" alt="Figure thumbnail gr3" /></noscript></div>
<div bis_skin_checked="1"><span class="label figure__label" data-fv-label="Fig. 3">Figure 3</span><span class="figure__title__text">Reduction of duration of episodes of troublesome lung symptoms after azithromycin treatment as a function of episode duration before treatment</span></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<div class="section-paragraph" bis_skin_checked="1">Presence of any pathogenic bacteria did not significantly modify the treatment effect compared with episodes without detection of bacteria, but azithromycin was more effective in episodes positive for&nbsp;<em>H influenzae</em>&nbsp;(table 2). Presence of any virus did not modify the treatment effect of azithromycin. None of the detected viruses significantly modified treatment effects (<a class="scroll-into-link" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext#tbl2">table 2</a>). Concurrent treatment with inhaled steroids (p value for interaction=0·57) or montelukast (p value for interaction=0·69) did not significantly modify the treatment effect, and responses were equal (appendix).</div>
<div class="section-paragraph" bis_skin_checked="1">Treatment with azithromycin did not significantly affect the time to next episode of troublesome lung symptoms in individual children (hazard ratio 0·95 [95% CI 0·65–1·40]; p=0·82). Treatment with azithromycin significantly reduced the duration of treatment with β2 agonists after intervention. The mean number of β2 agonist days after azithromycin treatment was 8·9 days versus 10·1 days after placebo, corresponding to a calculated reduction in duration of β2 agonist treatment of 22·0% (95% CI 7·0–34·6; p=0·006). Too few episodes requiring oral steroids or admission to hospital occurred for this secondary outcome to be analysed statistically (azithromycin three [4%] episodes; placebo two [3%] episodes).</div>
<div class="section-paragraph" bis_skin_checked="1">We noted no differences between treatment groups during the 30 days after treatment with respect to serious or any adverse events, gastrointestinal symptoms, or other infections, as documented by daily diary cards and hospital records (appendix).</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h2 id="seccestitle160" class="top" tabindex="0" data-left-hand-nav="Discussion"><span class="top__text">Discussion</span></h2>
<hr>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<section id="cesec100" tabindex="0" data-locator="cesec100">
<div class="section-paragraph" bis_skin_checked="1">Azithromycin significantly reduced the duration of physician-verified episodes of asthma-like symptoms in children aged 1–3 years with a history of recurrent asthma-like symptoms. The duration was decreased by about 63% after azithromycin treatment, with more improvement if treatment was started early in the episode. Azithromycin had no long-term effect on risk of subsequent episodes.</div>
<div class="section-paragraph" bis_skin_checked="1">
<p>This study is substantially strengthened by the prospective, longitudinal, daily diary recordings of lung symptoms before development of attacks, validated by study paediatricians at 6-monthly and acute visits. COPSAC served as the primary health-care centre for the birth cohort, ensuring a standardised approach to diagnosis and treatment, which improves reliability of diagnoses compared with reporting from community doctors and retrospective information from parents.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>18</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>19</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>20</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>22</sup></div>
<p>Diagnosis was based on an algorithm of symptom quantity, which has been analysed and validated in detail</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>13</sup></div>
<p>and applied in our previous RCT</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>19</sup></div>
<p>of inhaled corticosteroids in young children in the at-risk COPSAC<sub>2000</sub>&nbsp;birth cohort. Such strict diagnostic procedure is paramount to clinical assessments, diagnoses, and treatments, which are otherwise poorly standardised in the community and more difficult in young children than later in life.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>13</sup></div>
<p>The in-depth clinical assessment of each respiratory episode by the study paediatrician before randomisation, including a thorough objective examination and CRP concentration measurement in the research clinic, ensured validity and homogeneity of the primary outcome and exclusion of children with clinical signs of pneumonia. This assessment minimised the possibility of the azithromycin effect being driven by treatment of bacterial pneumonia misclassified as an episode of asthma-like symptoms.</p>
</div>
<div class="section-paragraph" bis_skin_checked="1">Another strength is the centralised longitudinal clinical follow-up of the cohort by a research team with a well established routine of doing clinical cohort studies. This routine ensured a high follow-up of the cohort, with 99% of the randomised children completing full follow-up until 3 years of age and only 6% of randomised treatments being unavailable. We obtained airway samples before treatment in 91% of episodes, with only 13 episodes missed. Our results are generalisable to a similar group of children with a known history of recurrent asthma-like symptoms, with or without concomitant treatment with inhaled steroids and with an episode duration of at least 3 days. An important limitation is that our data pertain to children with a detailed clinical history and acute worsening judged by the study clinician. They cannot be generalised to a more liberal setting, such as initiation at home by parents or children with mild disease.</div>
<div class="section-paragraph" bis_skin_checked="1">
<p>This study is the first, to our knowledge, to investigate and show an effect of azithromycin for treatment of acute respiratory episodes in young children with a history of recurrent asthma-like symptoms, in a cohort designed and powered to explore such effects. A third of all children will experience an episode of asthma-like symptoms in relation to airway infections before 3 years of age.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>23</sup></div>
<p>Shortening of such episodes by 63% is therefore clinically significant to the child, families, health-care user, and society. We noted that azithromycin had a marked effect in relation to any given type of episode independently of the trigger, clinical presentation, or symptom duration before the intervention, which suggests a broad application. The sensitivity analysis restricting episodes to the first randomisation validated the primary finding.</p>
</div>
<div class="section-paragraph" bis_skin_checked="1">
<p>Asthma-like episodes in young children probably represent a heterogeneous clinical syndrome. Importantly, we excluded typical pneumonia based on predefined clinical criteria. Furthermore, most children (more than 80%) had undetectable concentrations of CRP and no fever at randomisation, and the treatment effect was similar in these children, strongly suggesting that the effect of azithromycin is not due to misclassification of pneumonia. Azithromycin treatment was particularly effective in children who were treated shortly after symptom debut. This finding makes us speculate that azithromycin is mainly acting on the acute inflammatory</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>24</sup></div>
<p>or infectious</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>6</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>25</sup></div>
<p>processes related to exacerbations, rather than a persistent underlying inflammation. This hypothesis is supported by the absence of effect on time to next episode. Alternatively, azithromycin acts by clearing bacterial pathogens indirectly responsible for the respiratory episode through subsequent co-infection by a viral trigger, and therefore the treatment was more effective when initiated early in the episode than when initiated late.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>26</sup></div>
</div>
<div class="section-paragraph" bis_skin_checked="1">
<p>This study is based on our previous birth cohort study</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>6</sup></div>
<p>in which we discovered that pathogenic airway bacteria and respiratory viruses are equally closely associated with acute episodes of asthma-like symptoms in young children and mostly occur together. Our finding in this study that the treatment effect was strong, even in episodes for which no bacterial pathogen was detected, suggests that the effect of azithromycin is not only antibacterial. Macrolide antibiotics are active against both common airway pathogenic bacteria and atypical bacteria,</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>27</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>28</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>29</sup></div>
<p>but also have anti-inflammatory activity</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>24</sup></div>
<p>and, possibly, antiviral effects.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>30</sup></div>
<p>Studies of macrolides in adults with severe asthma episodes are ambiguous,</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>31</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>32</sup></div>
<p>and macrolides reportedly reduce exacerbations in adults with an asthma type characterised by chronic neutrophilic inflammation.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>33</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>34</sup></div>
<p>Indeed, recurrent asthma-like symptoms in young children are also characterised by neutrophilic inflammation,</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>25</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>35</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup><a id="back-bib36" class="reference-citations__ctrl" href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext#" data-db-target-for="bib36-d3836012e1614" aria-expanded="false" aria-controls="bib36">36</a></sup></div>
<p>which, in particular, might be present for episodes triggered by&nbsp;<em>H influenzae</em>.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>34</sup></div>
<p>This corresponds with our finding of a stronger azithromycin effect in episodes triggered by&nbsp;<em>H influenzae</em>. Viral infection in general did not predict an altered effect of azithromycin treatment. Low numbers in some viral species groups limit the conclusions drawn about effect modification by specific viruses. Thus, the antibacterial, anti-inflammatory, and antiviral pathways of azithromycin could have contributed to the shortening of episode length observed in this study. We cannot rule out that the effects noted are mainly anti-inflammatory because episodes triggered by&nbsp;<em>H influenzae</em>&nbsp;induce neutrophilic inflammation</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>34</sup></div>
<p>and azithromycin also reduced episode duration in children without any evidence of bacterial infection. An RCT</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>37</sup></div>
<p>of treatment with azithromycin in RSV-positive children showed a reduction of the neutrophilic marker interleukin 8 at day 14 after azithromycin treatment. This finding could point towards an anti-inflammatory effect as the primary mediator of our findings and also explain why findings from previous RCTs</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>38</sup></div>
<p><sup>,&nbsp;</sup></p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>39</sup></div>
<p>have failed to show treatment effects of non-anti-inflammatory antibiotics in acute exacerbations of childhood asthma.</p>
</div>
<div class="section-paragraph" bis_skin_checked="1">
<p>Present guidelines do not recommend antibiotics for treatment of episodes of asthma-like symptoms in young children</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>10</sup></div>
<p>and yet they are among the most commonly prescribed drugs for such episodes in both the USA and Europe.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>4</sup></div>
<p>Our data suggest an effect of azithromycin on acute asthma-like episodes and thereby identify a potential future treatment, but do not provide sufficient evidence to recommend this treatment in clinical practice. How the effect of azithromycin compares with narrow-spectrum antibiotics and whether any long-term effects are associated with recurrent use need to be investigated. We are keenly aware of the potential ecological issues relating to use of antibiotics in terms of bacterial ecology and resistance. Macrolide resistance in organisms causing respiratory illness in children is already an issue.</p>
<div class="dropBlock reference-citations" bis_skin_checked="1"><sup>40</sup></div>
<p>Future research should establish the choice of antimicrobial treatment and criteria for treatment, taking societal aspects into consideration. We did not identify strong effect modifiers from the objective clinical measures, concomitant treatments, or the microbiological profile other than the presence of&nbsp;<em>H influenzae</em>. Our data suggest that the effect increases by starting early in the episode. Future studies might help to identify specific disease phenotypes or biomarkers directing the treatment to specific groups of young children.</p>
</div>
<div class="section-paragraph" bis_skin_checked="1">The results of this study identify a potential treatment for a common childhood disease for which better treatment options are needed than are currently available. Better treatments might help to alleviate a substantial disease burden for children, families, and society.</div>
</section>
<div class="section-paragraph" bis_skin_checked="1"><strong>Contributors</strong></div>
<div class="section-paragraph" bis_skin_checked="1">HB conceived, designed, and carried out the study, acquired, analysed, and interpreted data, and wrote the report. JS, BLC, and KB contributed to design of the study. JS acquired, analysed, and interpreted data and drafted the report. CBP did the statistical analyses. SS and KAK cultured and identified the bacteria. TKF identified the viruses. BLC, NHV, EB, TMP, RKV, A-MMS, HMW, ST, HWH, LA, and KB collected and interpreted data and wrote the report. All coauthors have contributed substantially to the analyses or interpretation of the data and have provided important intellectual input and approval of the final version of the manuscript.</div>
<div class="section-paragraph" bis_skin_checked="1"><strong>Declaration of interests</strong></div>
<div class="section-paragraph" bis_skin_checked="1">HB has received funds for research and for members of research staff and been paid as a consultant for Chiesi. All other authors declare no competing interests.</div>
<section>
<div class="section-paragraph" bis_skin_checked="1"><strong>Acknowledgments</strong></div>
<div class="section-paragraph" bis_skin_checked="1">Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) is funded by private and public research funds all listed on&nbsp;<a href="http://www.copsac.com/" target="_blank" rel="noopener">www.copsac.com</a>. The Lundbeck Foundation, Danish Ministry of Health, Danish Council for Strategic Research, and Capital Region Research Foundation have provided core support for COPSAC. We express our gratitude to the children and families of the COPSAC<sub>2010</sub>&nbsp;cohort for all their support and commitment. We likewise acknowledge and appreciate the unique efforts and teamwork of the COPSAC research team. Steffen Lynge Jørgensen is thanked for microbiological technical assistance.</div>
</section>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h2 id="seccestitle180" class="top" tabindex="0" data-left-hand-nav="References"><span class="top__text">References</span></h2>
<hr>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">1.Masoli M Fabian D Holt S Beasley R<br>
The global burden of asthma: executive summary of the GINA Dissemination Committee report.<br>
Allergy. 2004; 59: 469-478<br>
2.Papadopoulos NG Christodoulou I Rohde G et al.<br>
Viruses and bacteria in acute asthma exacerbations—a GA2 LEN-DARE systematic review.<br>
Allergy. 2011; 66: 458-468<br>
3.Kocevar VS Bisgaard H Jönsson L et al.<br>
Variations in pediatric asthma hospitalization rates and costs between and within Nordic countries.<br>
Chest. 2004; 125: 1680-1684<br>
4.Bisgaard H Szefler S<br>
Prevalence of asthma-like symptoms in young children.<br>
Pediatr Pulmonol. 2007; 42: 723-728<br>
5.Bush A<br>
Practice imperfect—treatment for wheezing in preschoolers.<br>
N Engl J Med. 2009; 360: 409-410<br>
6.Bisgaard H Hermansen MN Bønnelykke K et al.<br>
Association of bacteria and viruses with wheezy episodes in young children: prospective birth cohort study.<br>
BMJ. 2010; 341: c4978<br>
7.Minor TE Dick EC DeMeo AN Ouellette JJ Cohen M Reed CE<br>
Viruses as precipitants of asthmatic attacks in children.<br>
JAMA. 1974; 227: 292-298<br>
8.Kusel MM de Klerk NH Holt PG Kebadze T Johnston SL Sly PD<br>
Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life.<br>
Pediatr Infect Dis J. 2006; 25: 680-686<br>
9.Khetsuriani N Kazerouni NN Erdman DD et al.<br>
Prevalence of viral respiratory tract infections in children with asthma.<br>
J Allergy Clin Immunol. 2007; 119: 314-321<br>
10.Reddel HK Bateman ED Becker A et al.<br>
A summary of the new GINA strategy: a roadmap to asthma control.<br>
Eur Respir J. 2015; 46: 622-639<br>
11.Bisgaard H Vissing NH Carson CG et al.<br>
Deep phenotyping of the unselected COPSAC2010 birth cohort study.<br>
Clin Exp Allergy. 2013; 43: 1384-1394<br>
12.Bischoff AL Følsgaard NV Carson CG et al.<br>
Altered response to A(H1N1)pnd09 vaccination in pregnant women: a single blinded randomized controlled trial.<br>
PLoS One. 2013; 8: e56700<br>
13.Bisgaard H Pipper CB Bønnelykke K<br>
Endotyping early childhood asthma by quantitative symptom assessment.<br>
J Allergy Clin Immunol. 2011; 127 (64.e2): 1155<br>
14.Skytt N Bønnelykke K Bisgaard H<br>
‘To wheeze or not to wheeze’: that is not the question.<br>
J Allergy Clin Immunol. 2012; 130 (07.e5): 403<br>
15.Chawes BL Stokholm J Bønnelykke K Brix S Bisgaard H<br>
Neonates with reduced neonatal lung function have systemic low-grade inflammation.<br>
J Allergy Clin Immunol. 2015; 135 (56.e1): 1450<br>
16.Vissing NH Chawes BL Bisgaard H<br>
Increased risk of pneumonia and bronchiolitis after bacterial colonization of the airways as neonates.<br>
Am J Respir Crit Care Med. 2013; 188: 1246-1252<br>
17.Kreiner-Møller E Chawes BL Vissing NH et al.<br>
VEGFA variants are associated with pre-school lung function, but not neonatal lung function.<br>
Clin Exp Allergy. 2013; 43: 1236-1245<br>
18.Bisgaard H Hermansen MN Buchvald F et al.<br>
Childhood asthma after bacterial colonization of the airway in neonates.<br>
N Engl J Med. 2007; 357: 1487-1495<br>
19.Bisgaard H Hermansen MN Loland L Halkjaer LB Buchvald F<br>
Intermittent inhaled corticosteroids in infants with episodic wheezing.<br>
N Engl J Med. 2006; 354: 1998-2005<br>
20.Bisgaard H Bønnelykke K Sleiman PM et al.<br>
Chromosome 17q21 gene variants are associated with asthma and exacerbations but not atopy in early childhood.<br>
Am J Respir Crit Care Med. 2009; 179: 179-185<br>
21.Bisgaard H<br>
The Copenhagen Prospective Study on Asthma in Childhood (COPSAC): design, rationale, and baseline data from a longitudinal birth cohort study.<br>
Ann Allergy Asthma Immunol. 2004; 93: 381-389<br>
22.Chawes BL Buchvald F Bischoff AL et al.<br>
Elevated exhaled nitric oxide in high-risk neonates precedes transient early but not persistent wheeze.<br>
Am J Respir Crit Care Med. 2010; 182: 138-142<br>
23.Martinez FD Wright AL Taussig LM Holberg CJ Halonen M Morgan WJ<br>
Asthma and wheezing in the first six years of life. The Group Health Medical Associates.<br>
N Engl J Med. 1995; 332: 133-138<br>
24.Fonseca-Aten M Okada PJ Bowlware KL et al.<br>
Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial.<br>
Ann Allergy Asthma Immunol. 2006; 97: 457-463<br>
25.Schwerk N Brinkmann F Soudah B Kabesch M Hansen G<br>
Wheeze in preschool age is associated with pulmonary bacterial infection and resolves after antibiotic therapy.<br>
PLoS One. 2011; 6: e27913<br>
26.Jartti T Kuneinen S Lehtinen P et al.<br>
Nasopharyngeal bacterial colonization during the first wheezing episode is associated with longer duration of hospitalization and higher risk of relapse in young children.<br>
Eur J Clin Microbiol Infect Dis. 2011; 30: 233-241<br>
27.Freymuth F Vabret A Brouard J et al.<br>
Detection of viral, Chlamydia pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma in children.<br>
J Clin Virol. 1999; 13: 131-139<br>
28.Biscardi S Lorrot M Marc E et al.<br>
Mycoplasma pneumoniae and asthma in children.<br>
Clin Infect Dis. 2004; 38: 1341-1346<br>
29.Esposito S Blasi F Arosio C et al.<br>
Importance of acute Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with wheezing.<br>
Eur Respir J. 2000; 16: 1142-1146<br>
30.Gielen V Johnston SL Edwards MR<br>
Azithromycin induces anti-viral responses in bronchial epithelial cells.<br>
Eur Respir J. 2010; 36: 646-654<br>
31.Koutsoubari I Papaevangelou V Konstantinou GN et al.<br>
Effect of clarithromycin on acute asthma exacerbations in children: an open randomized study.<br>
Pediatr Allergy Immunol. 2012; 23: 385-390<br>
32.Johnston SL Blasi F Black PN Martin RJ Farrell DJ Nieman RB<br>
The effect of telithromycin in acute exacerbations of asthma.<br>
N Engl J Med. 2006; 354: 1589-1600<br>
33.Brusselle GG Vanderstichele C Jordens P et al.<br>
Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial.<br>
Thorax. 2013; 68: 322-329<br>
34.Brusselle GG Joos G<br>
Is there a role for macrolides in severe asthma?.<br>
Curr Opin Pulm Med. 2014; 20: 95-102<br>
35.Le Bourgeois M Goncalves M Le Clainche L et al.<br>
Bronchoalveolar cells in children &lt;3 years old with severe recurrent wheezing.<br>
Chest. 2002; 122: 791-797<br>
36.Saglani S Malmström K Pelkonen AS et al.<br>
Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction.<br>
Am J Respir Crit Care Med. 2005; 171: 722-727<br>
37.Beigelman A Isaacson-Schmid M Sajol G et al.<br>
Randomized trial to evaluate azithromycin’s effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis.<br>
J Allergy Clin Immunol. 2015; 135: 1171-1178.e1<br>
38.Shapiro GG Eggleston PA Pierson WE Ray CG Bierman CW<br>
Double-blind study of the effectiveness of a broad spectrum antibiotic in status asthmaticus.<br>
Pediatrics. 1974; 53: 867-872<br>
39.Graham VA Milton AF Knowles GK Davies RJ<br>
Routine antibiotics in hospital management of acute asthma.<br>
Lancet. 1982; 1: 418-420<br>
40.Spreading US macrolide resistance.JAMA. 2015; 314: 1218</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<h2>Source:</h2>
<p>https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00500-7/fulltext</p>
<div bis_skin_checked="1"></div>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/02/14/azithromycin-for-episodes-with-asthma-like-symptoms-in-young-children-aged-1-3-years-a-randomised-double-blind-placebo-controlled-trial/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/02/14/azithromycin-for-episodes-with-asthma-like-symptoms-in-young-children-aged-1-3-years-a-randomised-double-blind-placebo-controlled-trial/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5156 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>02.02.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/02/02/effect-of-clindamycin-and-a-live-biotherapeutic-on-the-reproductive-outcomes-of-ivf-patients-with-abnormal-vaginal-microbiota-protocol-for-a-double-blind-placebo-controlled-multicentre-trial/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/02/02/effect-of-clindamycin-and-a-live-biotherapeutic-on-the-reproductive-outcomes-of-ivf-patients-with-abnormal-vaginal-microbiota-protocol-for-a-double-blind-placebo-controlled-multicentre-trial/">Effect of clindamycin and a live biotherapeutic on the reproductive outcomes of IVF patients with abnormal vaginal microbiota: protocol for a double-blind, placebo-controlled multicentre trial</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p><span class="name">Thor Haahr</span><a id="xref-aff-1-1" class="xref-aff" href="https://bmjopen.bmj.com/content/10/10/e035866#aff-1">1</a><span class="xref-sep">,</span><a id="xref-aff-2-1" class="xref-aff" href="https://bmjopen.bmj.com/content/10/10/e035866#aff-2">2</a>,&nbsp;<span class="name">Nina La Cour Freiesleben</span><a id="xref-aff-3-1" class="xref-aff" href="https://bmjopen.bmj.com/content/10/10/e035866#aff-3">3</a>,&nbsp;<span class="name">Anja Pinborg</span><a id="xref-aff-4-1" class="xref-aff" href="https://bmjopen.bmj.com/content/10/10/e035866#aff-4">4</a>,&nbsp;<span class="name">Henriette Svarre Nielsen</span><a id="xref-aff-3-2" class="xref-aff" href="https://bmjopen.bmj.com/content/10/10/e035866#aff-3">3</a>,&nbsp;<span class="name">Vibeke Hartvig</span><a id="xref-aff-5-1" class="xref-aff" href="https://bmjopen.bmj.com/content/10/10/e035866#aff-5">5</a>,&nbsp;<span class="name">Anne-Lis Mikkelsen</span><a id="xref-aff-6-1" class="xref-aff" href="https://bmjopen.bmj.com/content/10/10/e035866#aff-6">6</a>,&nbsp;<span class="name">Thomas Parks</span><a id="xref-aff-7-1" class="xref-aff" href="https://bmjopen.bmj.com/content/10/10/e035866#aff-7">7</a>,&nbsp;<span class="name">Niels Uldbjerg</span><a id="xref-aff-1-2" class="xref-aff" href="https://bmjopen.bmj.com/content/10/10/e035866#aff-1">1</a><span class="xref-sep">,</span><a id="xref-aff-8-1" class="xref-aff" href="https://bmjopen.bmj.com/content/10/10/e035866#aff-8">8</a>,&nbsp;<a class="bmjj-markup-orcid-logo" href="https://orcid.org/0000-0002-7464-7435" target="_blank" rel="noopener">http://orcid.org/0000-0002-7464-7435</a><span class="name">Jørgen Skov Jensen</span><a id="xref-aff-9-1" class="xref-aff" href="https://bmjopen.bmj.com/content/10/10/e035866#aff-9">9</a>,&nbsp;<a class="bmjj-markup-orcid-logo" href="https://orcid.org/0000-0001-6884-5366" target="_blank" rel="noopener">http://orcid.org/0000-0001-6884-5366</a><span class="name">Peter Humaidan</span><a id="xref-aff-1-3" class="xref-aff" href="https://bmjopen.bmj.com/content/10/10/e035866#aff-1">1</a><span class="xref-sep">,</span><a id="xref-aff-2-2" class="xref-aff" href="https://bmjopen.bmj.com/content/10/10/e035866#aff-2">2</a></p>
<p>Department of Clinical Medicine, Aarhus Universitet, Aarhus, Denmark<br>
The Fertility Clinic, Skive Regional Hospital, Skive, Denmark<br>
The Fertility Clinic, Hvidovre University Hospital, Copenhagen, Denmark<br>
The Fertility Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark<br>
Stork Fertility Clinic, Copenhagen, Denmark<br>
The Fertility Clinic, Sjællands Universitetshospital Køge, Koge, Sjaelland, Denmark<br>
Osel Inc, Mountain View, California, USA<br>
Department of Obstetrics and Gynecology, Aarhus Universitetshospital, Aarhus, Denmark<br>
Department of Reproductive Microbiology, Statens Serum Institute, Copenhagen, Denmark</p>
<h2>Abstract</h2>
<hr>
<p>&nbsp;</p>
<div id="sec-1" class="subsection" bis_skin_checked="1">
<p id="p-2"><strong>Introduction</strong>&nbsp;Recent studies in in vitro fertilisation (IVF) patients have associated abnormal vaginal microbiota (AVM) with poor clinical pregnancy rates of 6%–9% per embryo transfer. The biological plausibility for this finding is hypothesised to be ascending infection to the endometrium which in turn hampers embryo implantation. New molecular based diagnosis may offer advantages compared to microscopical diagnosis of AVM which has huge inter-study variability ranging from 4 to 38%; however, the important question is whether screening and treatment of AVM would improve reproductive outcomes in IVF patients. Herein, we describe a protocol for an ongoing double-blind, placebo-controlled multicentre trial of IVF patients diagnosed with AVM and randomised in three parallel groups 1:1:1.</p>
</div>
<div id="sec-2" class="subsection" bis_skin_checked="1">
<p id="p-3"><strong>Methods and analysis</strong>&nbsp;This is a drug intervention study where IVF patients will be screened for AVM, using a qPCR assay targeting&nbsp;<em>Atopobium vaginae</em>&nbsp;and&nbsp;<em>Gardnerella vaginalis</em>. If positive, patients will be randomised to one of the three study arms. The first arm consists of clindamycin 300 mg ×2 daily for 7 days followed by vaginal&nbsp;<em>Lactobacillus crispatus</em>&nbsp;CTV-05 until clinical pregnancy scan week 7–9. The second arm consists of clindamycin and placebo&nbsp;<em>L. crispatus</em>&nbsp;CTV-05, whereas patients in the third arm will be treated with placebo/placebo. We used a superiority design to estimate that active treatment in both arms will increase the primary outcome, clinical pregnancy rate per embryo transfer, from 20% to 40%. A potential difference between the two active arms was considered exploratory. With a power of 80% and an alpha at 5%, the sample size is estimated to be 333 patients randomised. A pre-planned interim analysis is scheduled at 167 patients randomised.</p>
</div>
<div id="sec-3" class="subsection" bis_skin_checked="1">
<p id="p-4"><strong>Ethics and dissemination</strong>&nbsp;All patients have to give informed consent. Dissemination of results is ensured in clinical trial agreements whether they be positive or not. Ethics committee, Central Denmark Region approved this protocol.</p>
</div>
<div id="sec-4" class="subsection" bis_skin_checked="1">
<p id="p-5"><strong>Trial registration number</strong>&nbsp;ICH-GCP monitored trial, EudraCT 2016-002385-31; Pre-results.</p>
</div>
<p><span class="ali-license-ref"><a href="https://creativecommons.org/licenses/by-nc/4.0/" rel="license">http://creativecommons.org/licenses/by-nc/4.0/</a></span></p>
<p id="p-1">This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:&nbsp;<a href="https://creativecommons.org/licenses/by-nc/4.0/" rel="license">http://creativecommons.org/licenses/by-nc/4.0/</a>.</p>
<p>&nbsp;</p>
<h3>Strengths and limitations of this study</h3>
<ul id="list-1" class="list-unord ">
<li id="list-item-1">
<p id="p-6">Molecular-based diagnosis of abnormal vaginal microbiota was validated in pilot studies.</p>
</li>
<li id="list-item-2">
<p id="p-7">The first randomised controlled trial in IVF patients diagnosed with abnormal vaginal microbiota investigating treatment effect on reproductive outcome of clindamycin and live&nbsp;<em>Lactobacillus</em>&nbsp;treatment.</p>
</li>
<li id="list-item-3">
<p id="p-8">The&nbsp;<em>Lactobacillus crispatus</em>&nbsp;CTV-05 treatment is an investigational live biotherapeutic product regulated by the US FDA.</p>
</li>
<li id="list-item-4">
<p id="p-9">ICH-GCP monitored trial.</p>
</li>
<li id="list-item-5">
<p id="p-10">Inclusion criteria are relatively broad.</p>
</li>
</ul>
<p>&nbsp;</p>
<h2 class="">Introduction</h2>
<hr>
<p>&nbsp;</p>
<p id="p-11">Bacterial vaginosis (BV) is a common vaginal dysbiosis in women of reproductive age with a prevalence of 29% (95% CI 27% to 31%) as reported in a US population–based survey, n=3739.<a id="xref-ref-1-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-1">1</a>&nbsp;It is well known that there is a higher BV rate among African Americans compared with Caucasian women.<a id="xref-ref-1-2" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-1">1</a>&nbsp;However, this finding could be affected by the fact that asymptomatic African Americans seem to have a more diverse physiological vaginal microbiota as compared with Caucasians.<a id="xref-ref-2-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-2">2 3</a>&nbsp;Other risk factors include vaginal douching and number of lifetime sex partners.<a id="xref-ref-1-3" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-1">1</a>&nbsp;In the in vitro fertilisation (IVF) population, a recent meta-analysis (n=2980) reported that the prevalence of BV exhibited huge interstudy heterogeneity ranging from 4% to 38%.<a id="xref-ref-4-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-4">4</a>&nbsp;In this study, BV was clearly associated with tubal factor infertility, but not endometriosis. The most recent studies using a molecular-based analysis to determine an abnormal vaginal microbiota observed a prevalence of 17% and 28%, respectively.<a id="xref-ref-5-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-5">5 6</a>&nbsp;It is known that despite diagnosed with BV by the gold standard Nugent method,<a id="xref-ref-7-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-7">7</a>&nbsp;more than 80% of BV positives remain asymptomatic.<a id="xref-ref-1-4" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-1">1</a>&nbsp;Hence, the important question is whether the many asymptomatic BV cases should be screened and treated. Clinical guidelines recommend screening and treatment for BV in patients undergoing gynaecological surgery or invasive diagnostic procedures with vaginal access to minimise infection.<a id="xref-ref-8-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-8">8</a>&nbsp;However, most clinical guidelines do not support screening and treatment for asymptomatic BV to optimise reproductive outcome—a topic which has been thoroughly investigated in obstetric populations for preterm birth prevention.<a id="xref-ref-9-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-9">9 10</a>&nbsp;Today, a new frontier is emerging with optimised molecular-based diagnosis of bacterial dysbiosis and new treatment possibilities including well-studied and well-characterised probiotics that have been designated ‘live biotherapeutic products’ by FDA.<a id="xref-ref-11-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-11">11 12</a></p>
<p id="p-12">Haahr&nbsp;<em>et al</em>&nbsp;reported the advantages of a molecular-based diagnosis of vaginal dysbiosis in IVF patients.<a id="xref-ref-5-2" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-5">5</a>&nbsp;The main advantages were (1) a more objective diagnosis as microscopists had significant inter-rater variability with the prior gold standard, Nugent score; (2) dichotomisation of the Nugent intermediate group which was difficult to interpret clinically; and (3) the establishment of quantitative thresholds using key vaginal bacteria to detect IVF patients at risk of a poor reproductive outcome. Hence, a new terminology termed abnormal vaginal microbiota (AVM) was proposed for IVF patients.<a id="xref-ref-5-3" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-5">5 13</a>&nbsp;AVM was significantly associated with poor clinical pregnancy rates as compared with normal vaginal microbiota patients, 9% (2/22) versus 44% (27/62).<a id="xref-ref-5-4" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-5">5</a>&nbsp;Later, these findings were corroborated by Koedooder&nbsp;<em>et al</em><a id="xref-ref-6-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-6">6</a>&nbsp;who found clinical pregnancy rates of 6% (2/34) versus 41% (65/158) in patients with unfavourable and favourable vaginal microbiota, respectively.</p>
<p id="p-13">In the field of reproductive medicine, there have been two different approaches to investigate the potential influence of the genital tract microbiota on IVF outcomes: either (1) to directly investigate the endometrial microbiota by transcervical swabs/suctions<a id="xref-ref-14-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-14">14–16</a>&nbsp;or (2) to investigate the vaginal microbiota as a proxy for the endometrial microbiota.<a id="xref-ref-5-5" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-5">5 6 17</a>&nbsp;The bacterial load in the uterus as compared with the vagina is very low,<a id="xref-ref-18-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-18">18</a>&nbsp;and for this reason the studies on endometrial microbiota have been criticised for reporting contamination from the transcervical sampling approach—and not a genuine endometrial microbiota.<a id="xref-ref-19-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-19">19</a>&nbsp;Nevertheless, endometrial samples from women undergoing hysterectomy provide evidence for a genuine endometrial microbiota<a id="xref-ref-18-2" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-18">18 20</a>&nbsp;that seems to be highly influenced by the vaginal microbiota,<a id="xref-ref-20-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-20">20</a>&nbsp;especially in the case of BV where the odds of having endometrial colonisation, including&nbsp;<em>Gardnerella vaginalis</em>&nbsp;biofilm infection, was significant as compared to normal vaginal microbiota patients: OR 5.7 (95% CI 1.8 to 18.3, p=0.002).<a id="xref-ref-21-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-21">21</a>&nbsp;Several groups are developing or further optimising molecular-based approaches to diagnose IVF women at risk of poor reproductive outcomes caused by genital tract dysbiosis. However, only one study validated a molecular diagnostic approach in IVF women against the gold standard for vaginal dysbiosis—Nugent score of Gram-stained vaginal smears.<a id="xref-ref-5-6" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-5">5</a>&nbsp;Two other studies applied arbitrary cut-offs for&nbsp;<em>Lactobacillus</em>&nbsp;dominance in the vaginal microbiota.<a id="xref-ref-6-2" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-6">6 17</a>&nbsp;Subsequently, these studies were criticised for insufficient methods,<a id="xref-ref-22-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-22">22 23</a>&nbsp;including the application of arbitrary thresholds based on relative abundances which does not sufficiently take into account differences in the total abundance.<a id="xref-ref-22-2" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-22">22–24</a></p>
<p id="p-14">The recommended first-line treatments for BV are antibiotic therapy with either metronidazole or clindamycin as reported by the 2015 CDC (Center for Disease Prevention and Control) Sexually Transmitted Disease Guideline and the 2018 European IUSTI/WHO (International Union against Sexually Transmitted Infections) guideline. Clindamycin was reported to effectively eradicate BV-related bacteria in the endometrium of patients with endometritis,<a id="xref-ref-25-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-25">25</a>&nbsp;while it was also proven to enter the endometrial tissue in high concentrations if administered orally.<a id="xref-ref-26-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-26">26</a>&nbsp;In contrast, metronidazole was less effective against&nbsp;<em>Gardnerella vaginalis</em>&nbsp;both in vivo<a id="xref-ref-27-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-27">27</a>&nbsp;and in vitro.<a id="xref-ref-25-2" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-25">25</a></p>
<p id="p-15">Finally, a recent systematic review and meta-analysis reported that the use of additional probiotic treatment alongside standard treatment of BV could improve BV cure rates, risk ratio (RR)  1.28 (95% CI 1.05 to 1.56).<a id="xref-ref-28-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-28">28</a>&nbsp;However, due to primarily poor study quality,<a id="xref-ref-29-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-29">29</a>&nbsp;there is currently no consensus on which vaginal&nbsp;<em>Lactobacillus</em>&nbsp;product, if any, should be recommended.<a id="xref-ref-30-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-30">30</a></p>
<p id="p-16">The pioneering work by Ravel and colleagues established that the vaginal microbiota consisted of four&nbsp;<em>Lactobacillus</em>-dominated community state types (CSTs) using taxonomic stratification at the species level, with each CST dominated by a different vaginal&nbsp;<em>Lactobacillus</em>&nbsp;species or a diverse CST not dominated by&nbsp;<em>Lactobacillus.</em><a id="xref-ref-2-2" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-2">2</a>&nbsp;Although such stratification was based on hierarchical clustering and relative abundance, in contrast to absolute abundance, these CSTs have been adopted by the majority of researchers in the vaginal microbiome field. Consistently, publications have reported the&nbsp;<em>Lactobacillus crispatus</em>&nbsp;CST to be associated with optimal genital health and reproductive outcomes.<a id="xref-ref-13-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-13">13 17 31–33</a>&nbsp;Moreover, abundant in vitro evidence point towards a beneficial production of both D and L lactic acid isomers by&nbsp;<em>L. crispatus</em>&nbsp;that not all other common vaginal lactobacilli produce.<a id="xref-ref-34-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-34">34 35</a>&nbsp;At the time of planning the present study, only one&nbsp;<em>L. crispatus</em>&nbsp;product, LACTIN-V, existed as an investigational live biotherapeutic product regulated by FDA—at that time in phase II development.<a id="xref-ref-11-2" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-11">11</a>&nbsp;Recently, adjuvant LACTIN-V after vaginal metronidazole was reported to lower BV recurrence rates in a phase IIb trial, RR 0.66 (95% CI 0.44 to 0.87; P=0.01).<a id="xref-ref-36-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-36">36</a></p>
<p id="p-17">Taking into consideration the aforementioned evidence, the research question of the present study is: does antibiotic alone or in combination with live biotherapeutic treatment of an abnormal vaginal microbiota improve the reproductive outcomes of IVF patients? The intervention is clindamycin either alone or in combination with LACTIN-V, a live biotherapeutic product containing&nbsp;<em>L. crispatus</em>&nbsp;CTV-05.<a id="xref-ref-11-3" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-11">11</a>&nbsp;The study is designed as a double-blind, placebo-controlled multicentre trial of three parallel groups randomised 1:1:1. Randomisation is by computer-generated code and allocation concealment is performed by the pharmacy who will send out medication to the participating clinics with identical appearance and randomisation numbers. The randomisation code is with the pharmacy and can only be opened in case of emergency by the principal investigators or as planned by the sponsor-investigator. The benefit of the intervention would potentially lead to increased pregnancy rates and, for those suffering from symptomatic BV, also relief of BV symptoms. In contrast, the expected adverse reactions of concern are especially gastrointestinal symptoms caused by clindamycin, whereas LACTIN-V might cause increased vaginal discharge but is otherwise not expected to cause adverse reactions as based on prior studies.<a id="xref-ref-11-4" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-11">11 37</a></p>
<p>&nbsp;</p>
<h2 class="">Methods and analysis</h2>
<h3>Setting and eligibility criteria</h3>
<p id="p-18">The present trial will be conducted at four University-affiliated clinics and one private fertility clinic in Denmark. The list of study sites is available with EudraCT clinical trial identifier: 2016-002385-31, first registration day 2016-07-11. The current version of the protocol is 9, 2020-02-07. Patients are enrolled in a cohort study (ClinicalTrials.gov&nbsp;<a class="external-ref external-ref-type-clintrialgov" href="https://bmjopen.bmj.com/lookup/external-ref?link_type=CLINTRIALGOV&amp;access_num=NCT03420859&amp;atom=%2Fbmjopen%2F10%2F10%2Fe035866.atom">NCT03420859</a>) from which we will recruit patients for the randomised trial (EudraCT: 2016-002385-31). Eligibility criteria are described in&nbsp;<a id="xref-table-wrap-1-1" class="xref-table" href="https://bmjopen.bmj.com/content/10/10/e035866.full#T1">table 1</a>.</p>
<p>&nbsp;</p>
<div class="table-caption" bis_skin_checked="1">
<p><span class="table-label">Table 1</span></p>
<p id="p-19">Inclusion and exclusion criteria</p>
<div class="sb-div caption-clear" bis_skin_checked="1"></div>
</div>
<table id="table-1" frame="hsides" rules="groups">
<thead id="thead-1">
<tr id="tr-1">
<td id="td-1" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Inclusion criteria</td>
<td id="td-2" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Exclusion criteria</td>
</tr>
</thead>
<tbody id="tbody-1">
<tr id="tr-2">
<td id="td-3" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Abnormal vaginal microbiota as described previously. The screening swab should be repeated if more than 3 months old at randomisation day</td>
<td id="td-4" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">HIV, hepatitis B or C positivity</td>
</tr>
<tr id="tr-3">
<td id="td-5" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">First, second or third IVF stimulation cycle or embryo transfer therefrom</td>
<td id="td-6" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">HPV CIN 2 or higher</td>
</tr>
<tr id="tr-4">
<td id="td-7" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">BMI &lt;35</td>
<td id="td-8" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Known or suspected hypersensitivity to clindamycin</td>
</tr>
<tr id="tr-5">
<td id="td-9" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Informed consent</td>
<td id="td-10" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Former or current inflammatory bowel disease</td>
</tr>
<tr id="tr-6">
<td id="td-11" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">18–42 years old</td>
<td id="td-12" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Severe concomitant disease, including diabetes</td>
</tr>
<tr id="tr-7">
<td id="td-13" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">A maximum of 2 embryos to be transferred</td>
<td id="td-14" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Artificial heart valve</td>
</tr>
<tr id="tr-8">
<td id="td-15" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-16" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Intrauterine malformations with operation indication as determined by treating physician (polyps, septum, fibroma)</td>
</tr>
</tbody>
</table>
<div class="table-foot" bis_skin_checked="1">
<ul class="table-footnotes">
<li id="fn-1" class="fn">
<p id="p-20">BMI, body mass index; CIN, Cervical Intraepithelial Neoplasia; HIV, Human Immunodeficiency Virus; HPV, Human Papilloma Virus.</p>
</li>
</ul>
<p>In brief, IVF patients attending their first, second or third IVF stimulation cycle or embryo transfer therefrom will be approached for informed consent by the study nurse or treating physician. Patients are told about the project in a private room with the right to have an assessor, allowing time to reflect whether they will participate. They are handed out written information material with a link to the study website with full information about the project (<a href="https://www.hospitalsenhedmidt.dk/afdelinger-og-centre/kvindesygdomme-og-foedsler/fertilitetsklinikken-skive/reproflor">www.reproflor.dk</a>). The vaginal swab can be taken by the treating physician or the patient herself after careful instruction. In this case, patients are instructed to place the swab at least 8 cm into the vaginal cavity for 10 s and rotate. This is to ensure that the vaginal bacteria in the fornix or in its close proximity will be caught by the flocked swab. Subsequently, the vaginal swab will be sent to a central laboratory at Statens Serum Institut, Copenhagen to be analysed for AVM within 7 days as previously reported.<a id="xref-ref-5-7" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-5">5</a>&nbsp;If AVM positive, patients are asked to provide informed consent that they are willing to participate in the randomised controlled trial. Patients should ideally be randomised on the first day of ovarian stimulation with exogenous gonadotropins, allowing a minimum of 12 days of study medication to be acceptable for inclusion in the study. If elective frozen embryo transfer (FET) is planned, patients should be randomised during the first days of the FET cycle allowing for at least 12 days of study medication. If patients enter the trial and have less than 12 days of study medication despite the aforementioned inclusion criteria (eg, when hormonal stimulation is shortened due to an unexpected ovarian response), it is considered a protocol violation and they will be excluded from the per-protocol analysis, not from intention-to-treat (ITT) analysis.</p>
</div>
<h2>Interventions</h2>
<hr>
<p>&nbsp;</p>
<div id="sec-9" class="subsection" bis_skin_checked="1">
<h4>Active treatment 1</h4>
<p id="p-22">Oral clindamycin 300 mg two times per day for 7 days followed by LACTIN-V (Osel) until completion of the clinical pregnancy scan at week 7–9. LACTIN-V containing&nbsp;<em>L. crispatus</em>&nbsp;CTV-05 (2×10<sup>9</sup> CFU/dose, 200 mg, delivered with pre-filled, single-use vaginal applicators) regimen is once daily from the clindamycin stop day and for 7 consecutive days, thereafter twice weekly as explained in&nbsp;<a id="xref-table-wrap-2-1" class="xref-table" href="https://bmjopen.bmj.com/content/10/10/e035866.full#T2">table 2</a>.</p>
</div>
<div id="sec-10" class="subsection" bis_skin_checked="1">
<h4>Active treatment 2</h4>
<p id="p-23">Oral clindamycin 300 mg two times per day for 7 days followed by LACTIN-V placebo (Osel) until completion of the clinical pregnancy scan at week 7–9. The LACTIN-V placebo regimen is once daily from the clindamycin stop day and for 7 consecutive days, thereafter twice weekly as explained in&nbsp;<a id="xref-table-wrap-2-2" class="xref-table" href="https://bmjopen.bmj.com/content/10/10/e035866.full#T2">table 2</a>.</p>
</div>
<div id="sec-11" class="subsection" bis_skin_checked="1">
<h4>Inactive treatment (placebo)</h4>
<p id="p-24">Matching clindamycin placebo two times per day for 7 days followed by LACTIN-V placebo (Osel) until completion of the clinical pregnancy scan at week 7–9. LACTIN-V placebo regimen is once daily from clindamycin stop day and for 7 consecutive days, thereafter twice weekly as explained in&nbsp;<a id="xref-table-wrap-2-3" class="xref-table" href="https://bmjopen.bmj.com/content/10/10/e035866.full#T2">table 2</a>.</p>
<p id="p-25">If there are embryos to transfer (approximately 90% of patients), then LACTIN-V/placebo treatment is continued twice weekly until clinical pregnancy scan, however, with a maximum of 21 applicators per patient. If the patient has no embryos to transfer or is confirmed not pregnant (negative hCG test), then LACTIN-V treatment can be stopped by the patient, although at least 7 days of LACTIN-V administration need to be administered. An overview of the study medication and allocation can be seen in&nbsp;<a id="xref-table-wrap-2-4" class="xref-table" href="https://bmjopen.bmj.com/content/10/10/e035866.full#T2">table 2</a>. Patients are not allowed to take other antibiotics (unless medically indicated), probiotics, neuromuscular blocking drugs, immunosuppressive medication or investigational drug preparations other than the study product. Placebo clindamycin consists of encapsulated mannitolum. The placebo LACTIN-V formulation contains the same inactive ingredients as LACTIN-V, without&nbsp;<em>Lactobacillus crispatus</em>&nbsp;CTV-05.</p>
<div class="table-caption" bis_skin_checked="1">
<p><span class="table-label">Table 2</span></p>
<p id="p-26">Study medication scheme</p>
<div class="sb-div caption-clear" bis_skin_checked="1"></div>
</div>
<table id="table-2" frame="hsides" rules="groups">
<thead id="thead-2">
<tr id="tr-9">
<td id="td-17" class="table-left table-vbottom" colspan="1" rowspan="1" align="left" valign="bottom"></td>
<td id="td-18" class="table-left table-vbottom" colspan="1" rowspan="1" align="left" valign="bottom">Clindamycin ‘Alternova’</td>
<td id="td-19" class="table-left table-vbottom" colspan="1" rowspan="1" align="left" valign="bottom">LACTIN-V</td>
</tr>
</thead>
<tbody id="tbody-2">
<tr id="tr-10">
<td id="td-20" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Dose</td>
<td id="td-21" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">300 mg</td>
<td id="td-22" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">200 mg/2×10<sup>9</sup> CFU/applicator</td>
</tr>
<tr id="tr-11">
<td id="td-23" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Dose schedule</td>
<td id="td-24" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Two times per day minimum 6 hours interval. Maximum 14 tablets</td>
<td id="td-25" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Before sleeping<br>
Maximum 21 applicators</td>
</tr>
<tr id="tr-12">
<td id="td-26" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Allocation</td>
<td id="td-27" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Patients start medication at least 12 days prior to embryo transfer in a fresh or a frozen cycle</td>
<td id="td-28" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Patients start medication at least 12 days prior to embryo transfer in a fresh or a frozen cycle</td>
</tr>
<tr id="tr-13">
<td id="td-29" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Route of administration</td>
<td id="td-30" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Oral</td>
<td id="td-31" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Vaginal/topical</td>
</tr>
<tr id="tr-14">
<td id="td-32" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Treatment period</td>
<td id="td-33" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">7 days</td>
<td id="td-34" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Once per day in 7 days followed by administration twice weekly until clinical pregnancy scan or confirmed not pregnant. In the event of negative hCG test (not pregnant), patients are, however, allowed to continue LACTIN-V treatment until all applicators have been used*</td>
</tr>
<tr id="tr-15">
<td id="td-35" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Follow-up period in the present RCT</td>
<td id="td-36" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Clinical pregnancy scan 7–9 weeks later</td>
<td id="td-37" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Clinical pregnancy scan 7–9 weeks later</td>
</tr>
<tr id="tr-16">
<td id="td-38" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Medication permitted</td>
<td id="td-39" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">All other than the below mentioned</td>
<td id="td-40" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">All other than the below mentioned</td>
</tr>
<tr id="tr-17">
<td id="td-41" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Medication not permitted</td>
<td id="td-42" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Other antibiotics (unless medically indicated), probiotics, neuromuscular blocking drugs, immunosuppressive medication. Investigational drug preparations other than the study product</td>
<td id="td-43" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Antibiotics (unless medically indicated), other probiotics and investigational drug preparations other than the study product</td>
</tr>
</tbody>
</table>
<div class="table-foot" bis_skin_checked="1">
<ul class="table-footnotes">
<li id="fn-2" class="fn">
<p id="p-27">*Patients not pregnant are informed to contact the department in case of any LACTIN-V–related side effect.</p>
</li>
<li id="fn-3" class="fn">
<p id="p-28">CFU, colony-forming unit; RCT, randomised controlled trial.</p>
</li>
</ul>
</div>
<p>&nbsp;</p>
<h2>Labelling and packaging</h2>
<hr>
</div>
<p>&nbsp;</p>
<p id="p-29">Labelling and packaging of the medication are performed by Glostrup Pharmacy, Denmark in accordance with ICH-GCP guideline and EU GMP Annex 13. Patients are informed that it is important not to have penile-vaginal intercourse within 12 hours after LACTIN-V application. Patient compliance will be measured by tablet counting of the medication packs (clindamycin). Patients who are not pregnant (negative hCG test) and who decided to continue LACTIN-V treatment are informed to contact the respective clinics in case of adverse events and these will be captured in the electronic case report form (eCRF). If patients decide to end study product treatment, they are informed to contact the clinics and to deliver the unused LACTIN-V to the clinic at which point they would be asked about any adverse events. Study personnel will verify in the eCRF what patients decided to do with remaining LACTIN-V applicators after a negative hCG test or no embryos for transfer.</p>
<p id="p-30">Patients can withdraw their informed consent at any given time and without any reason according to Danish law. If available, the reason for discontinuation has to be stated in the eCRF. Moreover, in case of protocol deviations, this also has to be stated in the eCRF and the principal investigator should decide whether trial medication can continue or not. Furthermore, trial medication is stopped should the patient develop hypersensitivity, allergy or severe diarrhoea that a primary investigator suspects may be trial medication related. Vaginal swabs will be taken alongside treatment to monitor the vaginal microbiota and its response to treatment (see&nbsp;<a id="xref-table-wrap-3-1" class="xref-table" href="https://bmjopen.bmj.com/content/10/10/e035866.full#T3">table 3</a>&nbsp;and&nbsp;<a id="xref-supplementary-material-1-1" class="xref-supplementary-material" href="https://bmjopen.bmj.com/content/10/10/e035866.full#DC1">online supplemental appendix 1</a>). Specifically, vaginal swabs will be taken on the day of randomisation immediately before study medication, after clindamycin treatment, on the day of embryo transfer and again on the day of clinical pregnancy scan. In a substudy, a total of 20 patients will be asked to deliver vaginal samples for each day they take medication and the swab should be taken immediately before the medication on that specific day.</p>
<h3 class="">Supplemental material</h3>
<div bis_skin_checked="1"><span class="inline-linked-media-wrapper"><span id="DC1" class="inline-linked-media"><a class="" href="https://bmjopen.bmj.com/content/bmjopen/10/10/e035866/DC1/embed/inline-supplementary-material-1.pdf?download=true" data-icon-position="" data-hide-link-title="0"><i class="icon-download-alt"></i>[bmjopen-2019-035866supp001.pdf]</a></span></span></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<div class="table-caption" bis_skin_checked="1">
<p><span class="table-label">Table 3</span></p>
<p id="p-32">Study timeline</p>
<div class="sb-div caption-clear" bis_skin_checked="1"></div>
</div>
<table id="table-3" frame="hsides" rules="groups">
<thead id="thead-3">
<tr id="tr-18">
<td id="td-44" class="table-left table-vbottom" colspan="1" rowspan="2" align="left" valign="bottom">Timepoint</td>
<td id="td-45" class="table-left table-vbottom" colspan="1" rowspan="1" align="left" valign="bottom">Enrolment</td>
<td id="td-46" class="table-left table-vbottom" colspan="1" rowspan="1" align="left" valign="bottom">Allocation</td>
<td id="td-47" class="table-left table-vbottom" colspan="4" rowspan="1" align="left" valign="bottom"></td>
</tr>
<tr id="tr-19">
<td id="td-48" class="table-left table-vbottom" colspan="1" rowspan="1" align="left" valign="bottom">Maximum 3 months prior to allocation day</td>
<td id="td-49" class="table-left table-vbottom" colspan="1" rowspan="1" align="left" valign="bottom">Minimum 12 days prior to embryo transfer</td>
<td id="td-50" class="table-left table-vbottom" colspan="1" rowspan="1" align="left" valign="bottom">After 7 days clindamycin/placebo treatment</td>
<td id="td-51" class="table-left table-vbottom" colspan="1" rowspan="1" align="left" valign="bottom">Embryo transfer</td>
<td id="td-52" class="table-left table-vbottom" colspan="1" rowspan="1" align="left" valign="bottom">Pregnancy scan week 7-9</td>
<td id="td-53" class="table-left table-vbottom" colspan="1" rowspan="1" align="left" valign="bottom">Gestational weeks 22, 37 and after birth</td>
</tr>
</thead>
<tbody id="tbody-3">
<tr id="tr-20">
<td id="td-54" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Enrolment for screening</td>
<td id="td-55" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">X</td>
<td id="td-56" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-57" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-58" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-59" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-60" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-21">
<td id="td-61" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Eligibility screen</td>
<td id="td-62" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">X</td>
<td id="td-63" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-64" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-65" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-66" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-67" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-22">
<td id="td-68" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Informed consent</td>
<td id="td-69" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">X</td>
<td id="td-70" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-71" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-72" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-73" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-74" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-23">
<td id="td-75" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"><em>Vaginal swab</em></td>
<td id="td-76" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">X</td>
<td id="td-77" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">X</td>
<td id="td-78" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">X</td>
<td id="td-79" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">X</td>
<td id="td-80" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">X</td>
<td id="td-81" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">X</td>
</tr>
<tr id="tr-24">
<td id="td-82" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Enrolment for RCT, Intervention allocation</td>
<td id="td-83" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-84" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">X</td>
<td id="td-85" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-86" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-87" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-88" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-25">
<td id="td-89" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"><em>Clindamycin/placebo intervention</em></td>
<td id="td-90" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-91" class="table-left table-vtop" colspan="2" rowspan="1" align="left" valign="top"><span class="highwire-responsive-lazyload"><img class="highwire-embed lazyloaded" src="https://bmjopen.bmj.com/sites/default/files/highwire/bmjopen/10/10/e035866/T3/embed/inline-graphic-1.gif" alt="Embedded Image" data-src="https://bmjopen.bmj.com/sites/default/files/highwire/bmjopen/10/10/e035866/T3/embed/inline-graphic-1.gif"></span></td>
<td id="td-92" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-93" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-94" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-26">
<td id="td-95" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"><em>LACTIN-V/placebo intervention</em></td>
<td id="td-96" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-97" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-98" class="table-left table-vtop" colspan="3" rowspan="1" align="left" valign="top"><span class="highwire-responsive-lazyload"><img class="highwire-embed lazyloaded" src="https://bmjopen.bmj.com/sites/default/files/highwire/bmjopen/10/10/e035866/T3/embed/inline-graphic-2.gif" alt="Embedded Image" data-src="https://bmjopen.bmj.com/sites/default/files/highwire/bmjopen/10/10/e035866/T3/embed/inline-graphic-2.gif"></span></td>
<td id="td-99" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-27">
<td id="td-100" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"><em>IVF treatment</em></td>
<td id="td-101" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-102" class="table-left table-vtop" colspan="4" rowspan="1" align="left" valign="top"><span class="highwire-responsive-lazyload"><img class="highwire-embed lazyloaded" src="https://bmjopen.bmj.com/sites/default/files/highwire/bmjopen/10/10/e035866/T3/embed/inline-graphic-3.gif" alt="Embedded Image" data-src="https://bmjopen.bmj.com/sites/default/files/highwire/bmjopen/10/10/e035866/T3/embed/inline-graphic-3.gif"></span></td>
<td id="td-103" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
<tr id="tr-28">
<td id="td-104" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">Adverse event questionnaire*</td>
<td id="td-105" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-106" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-107" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
<td id="td-108" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">X</td>
<td id="td-109" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top">X</td>
<td id="td-110" class="table-left table-vtop" colspan="1" rowspan="1" align="left" valign="top"></td>
</tr>
</tbody>
</table>
<div class="table-foot" bis_skin_checked="1">
<ul class="table-footnotes">
<li id="fn-4" class="fn">
<p id="p-33">*In case of no embryos to transfer or deferred embryo transfer, we sought the questionnaire from patients at oocyte pick-up or when we knew there was no embryo to transfer.</p>
</li>
<li id="fn-5" class="fn">
<p id="p-34">IVF, in vitro fertilisation; RCT, randomised controlled trial.</p>
</li>
</ul>
</div>
</div>
<p>&nbsp;</p>
<div id="sec-13" class="subsection" bis_skin_checked="1">
<h3>Outcomes</h3>
<p id="p-35">The primary outcome is the clinical pregnancy rate per first embryo transfer defined as ultrasound proven fetal heartbeat in gestational weeks 7–9. The secondary outcomes are the live birth rate per embryo transfer, biochemical pregnancy rate (hCG positive at 9–11 days after embryo transfer according to local laboratory standards), implantation rate, early miscarriage, late miscarriage, preterm birth rates, birth weight and adverse effects of the medication through a safety analysis. The effect of treatment on the vaginal microbiota of the mother throughout study participation and potential pregnancy will be determined using quantitative PCR (qPCR) and next-generation sequencing methods. The colonisation of the&nbsp;<em>L. crispatus</em>&nbsp;CTV-05 strain will also be investigated using qPCR. It is pre-planned that reproductive outcome analysis will lead to a first publication by itself, whereas the more laborious sequencing results will arrive in a later publication. Later, we plan to investigate cumulative live birth results of subsequent transfer of spare frozen-thawed embryos of patients attending the study in a fresh cycle.</p>
</div>
<div id="sec-14" class="subsection" bis_skin_checked="1">
<h3>Sample size</h3>
<p id="p-36">In 2014, the average clinical pregnancy rate per embryo transfer in our fertility clinic was approximately 40% for an IVF cycle. In our pilot study,<a id="xref-ref-5-8" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-5">5</a>&nbsp;the adjusted OR between the AVM group and the normal group was 0.06 (95% CI 0.01 to 0.47) for clinical pregnancy per embryo transfer. Taken together, we estimated a superiority design where women in each AVM arm and treated with active medication will have at least a 40% chance for clinical pregnancy per embryo transfer as compared with the placebo arm which was estimated to have a maximum of 20% chance of clinical pregnancy/transfer. By two-sample proportion test with a power of 80% and an alpha at 5%, the aim was to randomise 92 patients in each group. A potential difference between the two active arms was considered exploratory and consequently this was not part of the power calculation, but we decided to include the same number of patients in the active/active arm to investigate a potential added benefit of live biotherapeutic treatment.</p>
<p id="p-37">An interim analysis will be performed, and to adjust for this, we add 10% to the 92 randomised patients as suggested in Wittes .<a id="xref-ref-38-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-38">38</a>&nbsp;Approximately 10% of couples will have no embryos for transfer; we adjusted for this by adding another 10% to each randomised group, that is, 19+92=111 (see&nbsp;<a id="xref-fig-1-1" class="xref-fig" href="https://bmjopen.bmj.com/content/10/10/e035866.full#F1">figure 1</a>). Considering an estimated 20% AVM rate, a total of 1850 IVF patients will be screened to randomise 333 patients (three arms). It was estimated that inclusion will be distributed according to the size of the centres. Furthermore, we make the following assumptions: (1) very limited loss to follow-up, (2) near full compliance to study medication and (3) homogeneity in the treatment effect.</p>
</div>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Figure 1" data-lazy-src="https://bmjopen.bmj.com/content/bmjopen/10/10/e035866/F1.medium.gif"><noscript><img src="https://bmjopen.bmj.com/content/bmjopen/10/10/e035866/F1.medium.gif" alt="Figure 1" /></noscript></p>
<p>&nbsp;</p>
<p><span class="fig-label">Figure 1</span></p>
<p id="p-38" class="first-child">Study flowchart. We add 20% more patients to the powered sample size of 92 randomised patients to adjust for couples who have no embryos for transfer and to adjust for the interim analysis, that is, 19+92=111. Considering an estimated 20% abnormal vaginal microbiota rate, a total of 1850 in vitro fertilisation patients will be screened to randomise 333 patients (three arms).</p>
<p>&nbsp;</p>
<h2>Allocation</h2>
<hr>
<p>&nbsp;</p>
<div id="sec-15" class="subsection" bis_skin_checked="1">
<p id="p-39">Randomisation is performed by Glostrup pharmacy by a computer-generated code (<a href="http://www.randomization.com/">www.randomization.com</a>). The medication packs labelled with the randomisation number are received at the IVF centres from the pharmacy in blocks of 15, five of each of the three treatments, to secure equal distribution of treatment arms at the centres. The medication has identical appearance and only the randomisation number differ, hence both patients and study personnel are blinded for the intervention. A block of 15 medication packs will be sent from the pharmacy from start of study and new blocks can be requested when five medication packs are left. The 15 medication packs are mixed and appear identical to both personnel and patients. The randomisation number is continuous and unique for each patient, starting from 1 to 333 and the number is prelabelled from the pharmacy before distribution to the clinics. The last three medication packs from 331 to 333 is also one block.</p>
<p id="p-40">The randomisation list is secured by the pharmacy throughout the trial, and only the sponsor has the authority to unblind the trial. However, in case of medical emergency, the principal investigator can call the pharmacy to unblind. Each participant’s medication package is labelled with a randomisation number that is linked to their study ID number in the eCRF. Although both patients and clinicians will be blinded to allocation, they may suspect active medication in case of ‘signature’ side effects. This small risk of bias seems to be unavoidable. However, to investigate such an effect, patients are asked if they believed that they received active or inactive medication.</p>
</div>
<div id="sec-16" class="subsection" bis_skin_checked="1">
<h3>Data collection methods</h3>
<hr>
<p>&nbsp;</p>
<p id="p-41">Study data are collected and managed using REDCap (Research Electronic Data Capture) electronic data capture tools hosted at Aarhus University, Denmark.<a id="xref-ref-39-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-39">39 40</a>&nbsp;REDCap is a secure, web-based software platform designed to support data capture for research studies, providing (1) an intuitive interface for validated data capture, (2) audit trails for tracking data manipulation and export procedures, (3) automated export procedures for seamless data downloads to common statistical packages, and (4) procedures for data integration and interoperability with external sources. All data collectors of the study have to be trained in good clinical practice (GCP) procedures and as minimum to have passed the course provided by the Danish GCP institution. All inclusion and exclusion criteria as well as outcome data will be monitored by external GCP monitors to ensure optimal data quality. Data collection forms and other data entry–related information can be requested from the corresponding author.</p>
<p id="p-42">Protocol deviations have to be stated in the eCRF. Loss to follow-up is unlikely for patients in IVF treatment who will be highly motivated to come to the clinic. The eCRF instruments have range checks and other data rules that have to be passed to ensure optimal data input. In case of missing outcome data, we plan to use the framework proposed by White&nbsp;<em>et al</em>.<a id="xref-ref-41-1" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-41">41</a></p>
</div>
<div id="sec-17" class="subsection" bis_skin_checked="1">
<h3>Statistical methods</h3>
<hr>
<p>&nbsp;</p>
<p id="p-43">The total significance level of the study was set to be 5%. Based on the O’Brien-Fleming method, the total significance was split into 0.1% for the interim and 4.9% for the final analysis.<a id="xref-ref-38-2" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-38">38</a>&nbsp;Therefore, a p value with 99.9% CI is calculated in the interim analysis to test the possible effect of one or both active treatment arms (combined or separately) on clinical pregnancy rate per embryo transfer (primary outcome) compared with placebo. A Wald χ<sup>2</sup>&nbsp;test for possible effect will be conducted comparing all three arms. Moreover, four analyses: (1) active/active versus active/placebo, (2) active/placebo versus placebo/placebo, (3) active/active versus placebo/placebo, and (4) average effect of active/active AND active/placebo versus placebo/placebo will be done as first a crude estimate and then secondly adjustment with confounders for double embryo transfer, quality of the embryo (cleavage/blastocyst), female age (continuous variable) and centre effect (public/private). If the trial is discontinued according to the criteria stated under the section ‘Interim analysis’, a full statistical analysis will be made as described next. First, a Wald χ<sup>2</sup>&nbsp;test for possible effect of active treatment on clinical pregnancy rate (primary outcome) will be made across all three groups. Moreover, pairwise comparisons for the aforementioned four tests will be made with ORs and RRs and 94.9% CIs calculated from logistic and linear regressions models, taking the aforementioned confounding factors into account. Analyses will be conducted at modified (m)ITT level defined as all randomised patients who have an embryo transfer following study treatment cycle, including also deferred/frozen embryo transfers due to for example, risk of ovarian hyperstimulation syndrome (OHSS). Patients are excluded from mITT analysis if they do not have embryos for transfer or in case embryo transfer is deferred to a later stage than actual study treatment. Per-protocol analysis will also be considered, that is, an analysis for patients having an embryo transfer as described previously and not violating the protocol as described herein. Sensitivity analyses will also be conducted including strict ITT analysis per randomised patient. The mITT analysis is considered the primary analysis under the assumption that study treatment is not affecting the probability of patients having an embryo transfer.</p>
</div>
<div id="sec-18" class="subsection" bis_skin_checked="1">
<h3>Interim analysis</h3>
<hr>
<p>&nbsp;</p>
<p id="p-44">An interim analysis as described earlier will be performed to evaluate the clinical pregnancy rate per embryo transfer when 167 patients have been randomised and completed the study for primary outcome evaluation. If study medication is affecting the clinical pregnancy rate statistically significant in either of the analyses, the trial will discontinue. Furthermore, the drop-out rate will be evaluated considering both the number of positive AVM declining to participate and the number of patients who drop out after randomisation. A drop-out rate above 20% will lead to discontinuation. External statisticians from Aarhus University, Denmark will conduct the interim analysis. Only a small study board, including sponsor and principal investigators, will know the result of the interim analysis. Sponsor-investigator makes the decision to continue or discontinue the trial. The study will continue in case there is no statistical difference in either of the tests, drop-out rate is acceptable, and the logistical requirements to finish the study can be met within reasonable time considering, for example, expiry of study medication and time to recruit all patients. The time to undertake the interim analysis and the decision to continue or discontinue is approximately 3 weeks.</p>
</div>
<div id="sec-19" class="subsection" bis_skin_checked="1">
<h3>Data monitoring</h3>
<hr>
<p>&nbsp;</p>
<p id="p-45">Investigator(s)/institution(s) will permit direct access to source data/documents for trial-related monitoring, audits, institutional review board/independent ethics committee (IRB/IEC) review and regulatory inspection(s). Primary investigators only have access to patients from their own centre in the eCRF. This study will be monitored by the Danish GCP units, primarily the GCP unit at Aarhus University and the GCP unit at Copenhagen University Hospital. Furthermore, this trial is open for audit and quality assurance by the Danish Medicines Agency as specified by Danish law.</p>
</div>
<div id="sec-20" class="subsection" bis_skin_checked="1">
<h3>Adverse events and reactions</h3>
<hr>
<p>&nbsp;</p>
<p id="p-46">Adverse events and adverse reactions will be registered in a questionnaire handed out by study personnel to the patient on the day of embryo transfer and on the day of the clinical pregnancy scan. In case there are no embryos for transfer, patients will be approached to answer the questionnaire either by email or at oocyte retrieval day. Patients who undergo segmentation (‘freeze-all’) will use the same questionnaire on the oocyte retrieval day of the cycle where they have started study medication, corresponding to approximately 14 days of study medication. In the questionnaire, patients will also be asked to answer questions regarding gastrointestinal symptoms that might be related to the treatment with antibiotic clindamycin. Patients will be asked the same questionnaire concerning potential late occurring LACTIN-V–related side effects on the day of the clinical pregnancy scan. Moreover, patients are asked if they have symptoms at all study visits and if these symptoms are considered adverse reactions they are recorded in the eCRF, including an adverse reaction judgement from the treating physician.</p>
</div>
<div id="sec-21" class="subsection" bis_skin_checked="1">
<h3>Serious adverse events (SAEs)</h3>
<hr>
<p>&nbsp;</p>
<p id="p-47">At each centre, primary investigators will report SAEs to sponsor within 24 hours by email or phone. Sponsor ensures that all suspected unexpected serious adverse reactions (SUSARs) that are fatal or life-threatening are recorded and reported to the Danish Medicines Agency and the scientific Ethics Committee as soon as possible and no later than 7 days after the sponsor became aware of such possible side effect. Within 8 days after a SUSAR has been reported, the sponsor must notify the Danish Medicines Agency and the Ethics Committee with all relevant information on the follow-up of any SUSAR that may occur. All other unexpected serious or suspected serious adverse reactions will be reported to the Danish Medicines Agency and the scientific Ethics Committee within 15 days after the sponsor become aware of these. An annual safety report regarding the trial participants will be performed, consisting of serious adverse event suspected to be related to the investigational drug will be submitted to Danish Medicines Agency and the Ethics Committee. At end of study, all adverse events and SAEs will be reported according to regulations in Denmark.</p>
</div>
<div id="sec-22" class="subsection" bis_skin_checked="1">
<h3>Ethics</h3>
<hr>
<p>&nbsp;</p>
<p id="p-48">Approvals from the Regional Scientific Ethical Committee, Central Denmark Region (M-2017-157-17), the Danish Data Protection Agency<a id="xref-ref-1-5" class="xref-bibr" href="https://bmjopen.bmj.com/content/10/10/e035866.full#ref-1">1–16</a>&nbsp;and Danish Medicines Agency (2016-002385-31) were obtained prior to trial initiation 7 December 2017. Danish law will be complied with regarding the handling of personal information. Protocol amendments will be provided to the relevant parties, including the Regional Scientific Ethical Committees and Danish Medicines Agency. All protocol amendments have to be approved by the Danish Medicines Agency and the scientific ethical committee before taken into use. Logging of trial amendments is secured at both these institutions, the sponsor-investigator as well as updated at EudraCT. Patient confidentiality is ensured by data capture in REDCap. All patients are covered by a public insurance in Denmark.</p>
</div>
<div id="sec-23" class="subsection" bis_skin_checked="1">
<h3>Access to data</h3>
<hr>
<p>&nbsp;</p>
<p id="p-49">Only the sponsor-investigator has full access to the dataset. The interim analysis will be performed by external statisticians at the local university according to the pre-set plan explained previously. Principal investigators and statisticians may have access to data at the discretion of the sponsor-investigator. External parties can only gain access to trial data following establishment of a data handling agreement.</p>
</div>
<div id="sec-24" class="subsection" bis_skin_checked="1">
<h3>Dissemination</h3>
<hr>
<p>&nbsp;</p>
<p id="p-50">Positive, negative as well as inconclusive results will be published, aiming for high-impact journals with full data transparency. Dissemination of results is ensured in clinical trial agreements between the participating institutions and the sponsor’s institution, Aarhus University, Denmark. The Vancouver guidelines for authorship will be followed.</p>
</div>
<div id="sec-25" class="subsection" bis_skin_checked="1">
<h3>Trial status</h3>
<hr>
<p>&nbsp;</p>
<p id="p-51">The first patient was screened 7 December 2017. By 7 September 2019, we had screened 533 patients and randomised 119 patients. Interim analysis is expected by March 2020. End of trial is expected to be summer 2021.</p>
</div>
<div id="sec-26" class="subsection" bis_skin_checked="1">
<h3>Patients and public involvement</h3>
<hr>
<p>&nbsp;</p>
<p id="p-52">Neither patients nor the public were directly involved in the planning of this trial.</p>
</div>
<h2>Acknowledgments</h2>
<hr>
<p>&nbsp;</p>
<p id="p-53">The authors wish to thank all contributing patients, clinicians, nurses, laboratory technicians etc. involved with this study. Specifically, we thank the personnel at the reproductive microbiology laboratory at Statens Serum Institut, Copenhagen and the Fertility Clinics in Skive, Hvidovre, Rigshospitalet and Stork. Moreover, we wish to thank Aparna Udupi from Aarhus University, Denmark for statistical advice concerning this trial. Finally, we wish to thank Kristian Nielsen and Glostrup Pharmacy, Denmark for their contribution concerning medication allocation to the clinics.</p>
<p>&nbsp;</p>
<h2 class="">References</h2>
<hr>
<p>&nbsp;</p>
<p>1. ↵Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007;34:864–9.doi:10.1097/OLQ.0b013e318074e565pmid:17621244CrossRefPubMedWeb of ScienceGoogle Scholar<br>
2. ↵Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A 2011;108 Suppl 1:4680–7.doi:10.1073/pnas.1002611107pmid:http://www.ncbi.nlm.nih.gov/pubmed/20534435CrossRefPubMedGoogle Scholar<br>
3. ↵Serrano MG, Parikh HI, Brooks JP, et al. Racioethnic diversity in the dynamics of the vaginal microbiome during pregnancy. Nat Med 2019;25:1001–11.doi:10.1038/s41591-019-0465-8pmid:http://www.ncbi.nlm.nih.gov/pubmed/31142850CrossRefPubMedGoogle Scholar<br>
4. ↵Haahr T, Zacho J, Bräuner M, et al. Reproductive outcome of patients undergoing in vitro fertilisation treatment and diagnosed with bacterial vaginosis or abnormal vaginal microbiota: a systematic PRISMA review and meta-analysis. BJOG 2019;126:200–7.doi:10.1111/1471-0528.15178pmid:http://www.ncbi.nlm.nih.gov/pubmed/29469992CrossRefPubMedGoogle Scholar<br>
5. ↵Haahr T, Jensen JS, Thomsen L, et al. Abnormal vaginal microbiota may be associated with poor reproductive outcomes: a prospective study in IVF patients. Hum Reprod 2016;31:795–803.doi:10.1093/humrep/dew026pmid:http://www.ncbi.nlm.nih.gov/pubmed/26911864CrossRefPubMedGoogle Scholar<br>
6. ↵Koedooder R, Singer M, Schoenmakers S, et al. The vaginal microbiome as a predictor for outcome of in vitro fertilization with or without intracytoplasmic sperm injection: a prospective study. Hum Reprod 2019;34:1042–54.doi:10.1093/humrep/dez065pmid:http://www.ncbi.nlm.nih.gov/pubmed/31119299CrossRefPubMedGoogle Scholar<br>
7. ↵Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991;29:297–301.doi:10.1128/JCM.29.2.297-301.1991pmid:http://www.ncbi.nlm.nih.gov/pubmed/1706728Abstract/FREE Full TextGoogle Scholar<br>
8. ↵Sherrard J, Wilson J, Donders G, et al. 2018 European (IUSTI/WHO) International Union against Sexually Transmitted Infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS 2018;29:1258–72.doi:10.1177/0956462418785451pmid:http://www.ncbi.nlm.nih.gov/pubmed/30049258CrossRefPubMedGoogle Scholar<br>
9. ↵Subtil D, Brabant G, Tilloy E, et al. Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. Lancet 2018;392:2171–9.doi:10.1016/S0140-6736(18)31617-9pmid:http://www.ncbi.nlm.nih.gov/pubmed/30322724PubMedGoogle Scholar<br>
10. ↵Haahr T, Ersbøll AS, Karlsen MA, et al. Treatment of bacterial vaginosis in pregnancy in order to reduce the risk of spontaneous preterm delivery – a clinical recommendation. Acta Obstet Gynecol Scand 2016;95:850–60.doi:10.1111/aogs.12933pmid:27258798PubMedGoogle Scholar<br>
11. ↵Hemmerling A, Harrison W, Schroeder A, et al. Phase 2A study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm Dis 2010;37:745–50.doi:10.1097/OLQ.0b013e3181e50026pmid:http://www.ncbi.nlm.nih.gov/pubmed/20644497CrossRefPubMedWeb of ScienceGoogle Scholar<br>
12. ↵U.S. Department of Health and Human Services. Early clinical trials with live biotherapeutic products: chemistry, manufacturing, and control information; guidance for industry, 2012.Google Scholar<br>
13. ↵Haahr T, Humaidan P, Elbaek HO, et al. Vaginal microbiota and in vitro fertilization outcomes: development of a simple diagnostic tool to predict patients at risk of a poor reproductive outcome. J Infect Dis 2019;219:1809–17.doi:10.1093/infdis/jiy744pmid:http://www.ncbi.nlm.nih.gov/pubmed/30597027PubMedGoogle Scholar<br>
14. ↵Moreno I, Codoñer FM, Vilella F, et al. Evidence that the endometrial microbiota has an effect on implantation success or failure. Am J Obstet Gynecol 2016;215:684–703.doi:10.1016/j.ajog.2016.09.075pmid:http://www.ncbi.nlm.nih.gov/pubmed/27717732CrossRefPubMedGoogle Scholar<br>
15. ↵Kyono K, Hashimoto T, Kikuchi S, et al. A pilot study and case reports on endometrial microbiota and pregnancy outcome: an analysis using 16S rRNA gene sequencing among IVF patients, and trial therapeutic intervention for dysbiotic endometrium. Reprod Med Biol 2019;18:72–82.doi:10.1002/rmb2.12250pmid:http://www.ncbi.nlm.nih.gov/pubmed/30655724PubMedGoogle Scholar<br>
16. ↵Liu Y, Ko EY-L, Wong KK-W, et al. Endometrial microbiota in infertile women with and without chronic endometritis as diagnosed using a quantitative and reference range-based method. Fertil Steril 2019;112:707–17.doi:10.1016/j.fertnstert.2019.05.015pmid:http://www.ncbi.nlm.nih.gov/pubmed/31327470PubMedGoogle Scholar<br>
17. ↵Vergaro P, Tiscornia G, Barragán M, et al. Vaginal microbiota profile at the time of embryo transfer does not affect live birth rate in IVF cycles with donated oocytes. Reprod Biomed Online 2019;38:883–91.doi:10.1016/j.rbmo.2018.12.019pmid:http://www.ncbi.nlm.nih.gov/pubmed/30879910PubMedGoogle Scholar<br>
18. ↵Winters AD, Romero R, Gervasi MT, et al. Does the endometrial cavity have a molecular microbial signature? Sci Rep 2019;9:9905. doi:10.1038/s41598-019-46173-0pmid:http://www.ncbi.nlm.nih.gov/pubmed/31289304CrossRefPubMedGoogle Scholar<br>
19. ↵Haahr T, Jensen JS, Altmäe S, et al. Low biomass microbiota in the upper genital tract of reproductive age women: fact or fiction? Ann Clin Microbiol Antimicrob 2020;19:41.Google Scholar<br>
20. ↵Mitchell CM, Haick A, Nkwopara E, et al. Colonization of the upper genital tract by vaginal bacterial species in nonpregnant women. Am J Obstet Gynecol 2015;212:611.e1–611.e9.doi:10.1016/j.ajog.2014.11.043pmid:http://www.ncbi.nlm.nih.gov/pubmed/25524398CrossRefPubMedGoogle Scholar<br>
21. ↵Swidsinski A, Verstraelen H, Loening-Baucke V, et al. Presence of a polymicrobial endometrial biofilm in patients with bacterial vaginosis. PLoS One 2013;8:e53997. doi:10.1371/journal.pone.0053997pmid:http://www.ncbi.nlm.nih.gov/pubmed/23320114CrossRefPubMedGoogle Scholar<br>
22. ↵Haahr T, Jensen JS, Humaidan P. Vaginal microbiota and IVF outcomes: poor diagnosis results in flawed conclusions. Reprod Biomed Online 2019;39:178:1809–17. doi:10.1016/j.rbmo.2019.04.006pmid:http://www.ncbi.nlm.nih.gov/pubmed/31053402PubMedGoogle Scholar<br>
23. ↵Haahr T, Humaidan P, Jensen JS. Non-transparent and insufficient descriptions of non-validated microbiome methods and related reproductive outcome results should be interpreted with caution. Hum Reprod 2019;34:2083–4.doi:10.1093/humrep/dez167pmid:http://www.ncbi.nlm.nih.gov/pubmed/31577029PubMedGoogle Scholar<br>
24. ↵Vandeputte D, Kathagen G, D’hoe K, et al. Quantitative microbiome profiling links gut community variation to microbial load. Nature 2017;551:507–11.doi:10.1038/nature24460pmid:http://www.ncbi.nlm.nih.gov/pubmed/29143816CrossRefPubMedGoogle Scholar<br>
25. ↵Petrina MAB, Cosentino LA, Wiesenfeld HC, et al. Susceptibility of endometrial isolates recovered from women with clinical pelvic inflammatory disease or histological endometritis to antimicrobial agents. Anaerobe 2019;56:61–5.doi:10.1016/j.anaerobe.2019.02.005pmid:http://www.ncbi.nlm.nih.gov/pubmed/30753898PubMedGoogle Scholar<br>
26. ↵Elder MG, Bywater MJ, Reeves DS. Pelvic tissue and serum concentrations of various antibiotics given as pre-operative medication. Br J Obstet Gynaecol 1977;84:887–93.doi:10.1111/j.1471-0528.1977.tb12516.xpmid:http://www.ncbi.nlm.nih.gov/pubmed/588499PubMedGoogle Scholar<br>
27. ↵Mayer BT, Srinivasan S, Fiedler TL, et al. Rapid and profound shifts in the vaginal microbiota following antibiotic treatment for bacterial vaginosis. J Infect Dis 2015;212:793–802.doi:10.1093/infdis/jiv079pmid:http://www.ncbi.nlm.nih.gov/pubmed/25676470CrossRefPubMedGoogle Scholar<br>
28. ↵Li C, Wang T, Li Y, et al. Probiotics for the treatment of women with bacterial vaginosis: a systematic review and meta-analysis of randomized clinical trials. Eur J Pharmacol 2019;864:172660. doi:10.1016/j.ejphar.2019.172660pmid:http://www.ncbi.nlm.nih.gov/pubmed/31562865PubMedGoogle Scholar<br>
29. ↵van de Wijgert J, Verwijs MC. Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs. BJOG 2020;127:287–99.doi:10.1111/1471-0528.15870pmid:http://www.ncbi.nlm.nih.gov/pubmed/31299136PubMedGoogle Scholar<br>
30. ↵Hillier SL. The need for better evidence to support probiotics for vaginitis. BJOG 2020;127:300.doi:10.1111/1471-0528.15910pmid:http://www.ncbi.nlm.nih.gov/pubmed/31446672PubMedGoogle Scholar<br>
31. ↵Kindinger L, MacIntyre D, Lees Y, et al. The impact of progesterone on the vaginal microbiome in high-risk pregnancy with a short cervix. BJOG Int J Obstet Gynaecol 2016;123:72.Google Scholar<br>
32. ↵Tabatabaei N, Eren AM, Barreiro LB, et al. Vaginal microbiome in early pregnancy and subsequent risk of spontaneous preterm birth: a case–control study. BJOG 2019;126:349–58.doi:10.1111/1471-0528.15299pmid:29791775PubMedGoogle Scholar<br>
33. ↵Norenhag J, Du J, Olovsson M, et al. The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta-analysis. BJOG 2020;127:171–80.doi:10.1111/1471-0528.15854pmid:http://www.ncbi.nlm.nih.gov/pubmed/31237400CrossRefPubMedGoogle Scholar<br>
34. ↵Witkin SS, Mendes-Soares H, Linhares IM, et al. Influence of vaginal bacteria and D- and L-lactic acid isomers on vaginal extracellular matrix metalloproteinase inducer: implications for protection against upper genital tract infections. mBio 2013;4. doi:doi:10.1128/mBio.00460-13. [Epub ahead of print: 06 Aug 2013].pmid:http://www.ncbi.nlm.nih.gov/pubmed/23919998Google Scholar<br>
35. ↵Edwards VL, Smith SB, McComb EJ, et al. The cervicovaginal microbiota-host interaction modulates Chlamydia trachomatis infection. mBio 2019;10. doi:doi:10.1128/mBio.01548-19. [Epub ahead of print: 13 Aug 2019].pmid:31409678Google Scholar<br>
36. ↵Cohen CR, Wierzbicki MR, French AL, et al. Randomized trial of Lactin-V to prevent recurrence of bacterial vaginosis. N Engl J Med 2020;382:1906–15.doi:10.1056/NEJMoa1915254pmid:http://www.ncbi.nlm.nih.gov/pubmed/32402161PubMedGoogle Scholar<br>
37. ↵Stapleton AE, Au-Yeung M, Hooton TM, et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis 2011;52:1212–7.doi:10.1093/cid/cir183pmid:http://www.ncbi.nlm.nih.gov/pubmed/21498386CrossRefPubMedGoogle Scholar<br>
38. ↵Wittes J. Sample size calculations for randomized controlled trials. Epidemiol Rev 2002;24:39–53.doi:10.1093/epirev/24.1.39pmid:http://www.ncbi.nlm.nih.gov/pubmed/12119854CrossRefPubMedWeb of ScienceGoogle Scholar<br>
39. ↵Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.doi:10.1016/j.jbi.2008.08.010pmid:18929686CrossRefPubMedWeb of ScienceGoogle Scholar<br>
40. ↵Harris PA, Taylor R, Minor BL, et al. The REDCap Consortium: building an international community of software platform partners. J Biomed Inform 2019;95:103208. doi:10.1016/j.jbi.2019.103208pmid:http://www.ncbi.nlm.nih.gov/pubmed/31078660CrossRefPubMedGoogle Scholar<br>
41. ↵White IR, Horton NJ, Carpenter J, et al. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ 2011;342:d40. doi:10.1136/bmj.d40pmid:http://www.ncbi.nlm.nih.gov/pubmed/21300711FREE Full TextGoogle Scholar</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<h2>Source</h2>
<hr>
<p>&nbsp;</p>
<p><a href="https://bmjopen.bmj.com/content/10/10/e035866.full">https://bmjopen.bmj.com/content/10/10/e035866.full</a></p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/02/02/effect-of-clindamycin-and-a-live-biotherapeutic-on-the-reproductive-outcomes-of-ivf-patients-with-abnormal-vaginal-microbiota-protocol-for-a-double-blind-placebo-controlled-multicentre-trial/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/02/02/effect-of-clindamycin-and-a-live-biotherapeutic-on-the-reproductive-outcomes-of-ivf-patients-with-abnormal-vaginal-microbiota-protocol-for-a-double-blind-placebo-controlled-multicentre-trial/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5153 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>27.01.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/01/27/clindamycin-promotes-phagocytosis-and-intracellular-killing-of-periodontopathogenic-bacteria-by-crevicular-granulocytes-an-in-vitro-study/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/01/27/clindamycin-promotes-phagocytosis-and-intracellular-killing-of-periodontopathogenic-bacteria-by-crevicular-granulocytes-an-in-vitro-study/">Clindamycin promotes phagocytosis and intracellular killing of periodontopathogenic bacteria by crevicular granulocytes: an in vitro study</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><div class="wi-authors" bis_skin_checked="1">
<div class="al-authors-list" bis_skin_checked="1"><span class="al-author-name-more js-flyout-wrap"><a class="linked-name js-linked-name-trigger">S. Eick</a><span class="delimiter">,</span></span>&nbsp;<span class="al-author-name-more js-flyout-wrap"><a class="linked-name js-linked-name-trigger">W. Pfister</a><span class="delimiter">,</span></span>&nbsp;<span class="al-author-name-more js-flyout-wrap"><a class="linked-name js-linked-name-trigger">D. Fiedler</a><span class="delimiter">,</span></span>&nbsp;<span class="al-author-name-more js-flyout-wrap"><a class="linked-name js-linked-name-trigger">E. Straube</a></span></div>
</div>
<div class="pub-history-wrap clearfix" bis_skin_checked="1">
<div class="pub-history-row clearfix" bis_skin_checked="1">
<div class="ww-citation-primary" bis_skin_checked="1"><em>Journal of Antimicrobial Chemotherapy</em>, Volume 46, Issue 4, October 2000, Pages 583–588,&nbsp;<a href="https://doi.org/10.1093/jac/46.4.583">https://doi.org/10.1093/jac/46.4.583</a></div>
</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h2 id="13022530" class="abstract-title">Abstract</h2>
<hr>
</div>
<p>&nbsp;</p>
<p>Phagocytosis of periodontopathogenic bacteria by crevicular polymorphonuclear neutrophil granulocytes (PMNs) plays a key role in the aetiology of periodontitis. Antimicrobials such as clindamycin have been proven to be effective in treating progressive forms of this disease. Therefore, the purpose of this study was to determine the effect of clindamycin on the phagocytosing properties of gingival crevicular PMNs obtained from 16 patients with rapidly progressive periodontitis (RPP), eight with localized juvenile periodontitis (LJP), 12 with adult periodontitis (AP) and 13 periodontally healthy controls. The phagocytosis assay was performed with the two strains&nbsp;<em>Porphyromonas gingivalis</em>&nbsp;ATCC 33277 and&nbsp;<em>Actinobacillus actinomycetemcomitans</em>&nbsp;Tanner FDC 44 on a slide<em>.</em>&nbsp;Phagocytosis and intracellular killing were assessed by fluorescence microscopy after staining with acridine orange. The addition of clindamycin elevated the percentage of phagocytosing PMNs in periodontitis patients and controls regardless of whether&nbsp;<em>P. gingivalis</em>&nbsp;or&nbsp;<em>A. actinomycetemcomitans</em>&nbsp;was used as test strain. In granulocytes of healthy controls an enhancement of the intracellular killing of both strains was observed if clindamycin was added. Besides the antimicrobial effect, the enhancement of the phagocytosis might be an additional indication for treatment of periodontitis patients with clindamycin.</p>
<div class="related-topic-tags" bis_skin_checked="1"></div>
<div class="article-metadata-tocSections" bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h2 id="13022531" class="section-title">Introduction</h2>
<hr>
</div>
<p>&nbsp;</p>
<p class="chapter-para"><em>Porphyromonas gingivalis</em>&nbsp;and&nbsp;<em>Actinobacillus actinomycetemcomitans</em>&nbsp;are the most important species in subgingival plaque samples obtained from patients with progressive forms of periodontitis. Rapidly progressive periodontitis is associated with&nbsp;<em>P. gingivalis</em>, which produces connective tissue destructive enzymes.<span id="jumplink-R1" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R1"><sup>1</sup></a><em>A. actinomycetemcomitans</em>&nbsp;is often seen in localized juvenile periodontitis. In cases of periodontitis it usually produces a leucotoxin which is able to impair polymorphonuclear granulocytes.<span id="jumplink-R2" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R2"><sup>2</sup></a>&nbsp;Polymorphonuclear neutrophil granulocytes (PMNs) play a key role in defence against bacterial infections. The ability of specific bacterial pathogens to initiate periodontal diseases depends on their evasion of PMN defences or the presence of host neutrophils that are dysfunctional.<span id="jumplink-R3" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R3"><sup>3</sup></a><sup>–</sup><span id="jumplink-R5" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R5"><sup>5</sup></a></p>
<p class="chapter-para">In dentistry, antimicrobial chemotherapy, e.g. metronidazole, doxycycline and clindamycin, is an effective adjunct in the treatment of patients with progressive periodontal disease.<span id="jumplink-R6" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R6"><sup>6</sup></a>&nbsp;Besides their bacteriostatic or bactericidal effects antibiotics can interact directly with cells of the immune system.<span id="jumplink-R7" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R7"><sup>7</sup></a>&nbsp;Clindamycin has very low MICs for obligate anaerobes such as&nbsp;<em>P. gingivalis</em>,&nbsp;<em>Prevotella intermedia</em>&nbsp;and&nbsp;<em>Fusobacterium nucleatum</em>. In contrast, the capnophilic species&nbsp;<em>A. actinomycetemcomitans</em>&nbsp;exhibits resistance to this drug.<span id="jumplink-R8" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R8"><sup>8</sup></a><sup>,</sup><span id="jumplink-R9" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R9"><sup>9</sup></a>&nbsp;In general clindamycin has a positive immunomodulating effect.<span id="jumplink-R7" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R7"><sup>7</sup></a>&nbsp;Moreover, an enhancement of phagocytosis has been reported.<span id="jumplink-R10" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R10"><sup>10</sup></a><sup>,</sup><span id="jumplink-R11" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R11"><sup>11</sup></a>&nbsp;However, there have not been studies concerning the influence of clindamycin on phagocytosis by gingival crevicular PMNs in cases of periodontitis, in which the function of the granulocytes often seems to be altered.</p>
<p class="chapter-para">In this study the&nbsp;<em>in vitro</em>&nbsp;effect of subinhibitory concentrations of clindamycin on the phagocytosis and intracellular killing of&nbsp;<em>P. gingivalis</em>&nbsp;and&nbsp;<em>A. actinomycetemcomitans</em> by granulocytes obtained from the gingival sulci has been assessed.</p>
<p>&nbsp;</p>
<h2 id="13022535" class="section-title">Material and methods</h2>
<hr>
<p>&nbsp;</p>
<h3 id="13022536" class="section-title">Patients</h3>
<p class="chapter-para">Twenty-four patients with progressive forms of periodontitis [16 with rapidly progressive periodontitis (RPP), eight with localized juvenile periodontitis (LJP) and 12 with non-progressive adult periodontitis (AP)] participated in the trial. Thirteen periodontally healthy subjects served as controls. All subjects selected for the study were systemically healthy. None of them had received antibiotics in the previous 6 months. The diseased sites were characterized by assessment of clinical and radiographic parameters. In addition this diagnosis was confirmed by micro-biological cultivation of subgingival plaque samples.</p>
<h3 id="13022538" class="section-title">Preparation of crevicular granulocytes</h3>
<p class="chapter-para">Leucocytes of the sulcus were obtained from the periodontal pockets or gingival sulci through 15-fold washing with phosphate-buffered saline (PBS) using a 0.005 mL Eppendorf pipette, as described previously.<span id="jumplink-R3" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R3"><sup>3</sup></a>&nbsp;In each patient two periodontal pockets with a probing depth of 6–9 mm were selected in each quadrant. The 0.075 mL cell preparation was centrifuged at 150<strong>g</strong>&nbsp;for 10 min, washed twice and resuspended in 0.2 mL PBS. Finally the pellet was divided into two parts. One part was resuspended in 0.1 mL PBS, and the other one in 0.1 mL PBS containing 0.1 mg/L clindamycin. The viability of the granulocytes was determined by the trypan blue exclusion test.</p>
<h3 id="13022540" class="section-title">Bacterial strains</h3>
<p class="chapter-para">The species&nbsp;<em>P. gingivalis</em>&nbsp;ATCC 33277 and&nbsp;<em>A. actinomycetemcomitans</em>&nbsp;Tanner FDC 44 (known to be a leucotoxin producing strain) were used in the phagocytosis assay. The minimal inhibitory concentration (MIC) of clindamycin (Upjohn, Heppenheim, Germany) had been determined by agar dilution technique as 0.15 mg/L for the&nbsp;<em>P. gingivalis</em>&nbsp;strain and &gt;16 mg/L for&nbsp;<em>A. actinomycetemcomitans</em>&nbsp;FDC 44<em>.</em>&nbsp;The strains were subcultured to log phase on Schaedler agar in the appropriate anaerobic or CO<sub>2</sub>&nbsp;atmosphere 24 h before the assay.</p>
<p class="chapter-para">The bacterial suspensions were adjusted photometrically with PBS to 10<sup>9</sup>&nbsp;bacteria per mL. Each 0.2 mL of suspension was mixed with 0.2 mL anti-AB serum for opsonization for 30 min. These mixtures were centrifuged at 1000<strong>g</strong>&nbsp;for 10 min and then the pellets were washed and resuspended in 1 mL PBS. Finally 0.2 mL of fetal bovine serum was added.</p>
<h3 id="13022543" class="section-title">In vitro phagocytosis assay</h3>
<p class="chapter-para"><em>In vitro</em>&nbsp;phagocytosis was performed on a glass slide according to Smith &amp; Rommel<span id="jumplink-R12" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R12"><sup>12</sup></a>&nbsp;and Pantazis &amp; Kniker.<span id="jumplink-R13" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R13"><sup>13</sup></a>&nbsp;After addition of a 0.05 mL cell suspension the cells were allowed to adhere in a CO<sub>2</sub>&nbsp;incubator at 37°C for 30 min. Subsequently, 0.01 mL of a bacterial suspension was transferred to a slide and the phagocytosis assay was incubated in 5% CO<sub>2</sub>&nbsp;at a temperature of 37°C for 30 min. The slides were stained with acridine orange (2.5 mg/7.5 mL PBS) and a total of 100 PMNs were immediately examined by fluorescence microscopy. Viable and killed bacteria in granulocytes were distinguished by their uptake of acridine orange, viable bacteria appeared green and dead bacteria were red. The number of PMNs containing bacteria was counted. These phagocytosing cells were separated into two groups by the following criteria: cells with less than 10 ingested bacteria and cells with more than 10 ingested bacteria. Additionally, the number of granulocytes containing viable bacteria (granulocytes with viable bacteria/phagocytosing granulocytes) was documented.</p>
<h3 id="13022545" class="section-title">Statistical analysis</h3>
<p class="chapter-para">The Wilcoxon test was used to assess the significance of the results between paired samples. Differences between the periodontitis groups were analysed by the Mann– Whitney&nbsp;<em>U</em>&nbsp;test.</p>
<p>&nbsp;</p>
<h2 id="13022547" class="section-title">Results</h2>
<hr>
<p>&nbsp;</p>
<h3 id="13022548" class="section-title">General findings</h3>
<p class="chapter-para"><em>P. gingivalis</em>&nbsp;was found at higher percentages in subgingival plaque samples of patients with the two progressive forms of periodontitis (RPP, 10.0% ± 7.3%; LJP, 16.7% ± 13.6%) than in controls (0%, both&nbsp;<em>P</em>&nbsp;&lt; 0.05) or AP patients (3.2% ± 2.4%). In patients belonging to the LJP group subgingival plaque contained a high number of&nbsp;<em>A. actinomycemcomitans</em>&nbsp;(LJP, 17.9% ± 12.3%; controls, 0%; RPP, 1.0% ± 1.0%; AP, 0.22% ± 0.36%).</p>
<p class="chapter-para">The granulocytes obtained from the gingival sulci showed sufficient viability with at least 80% viable in each case.</p>
<h3 id="13022551" class="section-title">Phagocytosis of P. gingivalis</h3>
<p class="chapter-para">In all groups more than 90% of the crevicular PMNs were found to contain&nbsp;<em>P. gingivalis.</em>&nbsp;A higher percentage of phagocytosing granulocytes was found in RPP patients (95.0% ± 2.0%) compared with healthy subjects (90.2% ± 3.8%,&nbsp;<em>P</em>&nbsp;&lt; 0.05). This result was due to the number of granulocytes with less than 10 ingested bacteria (RPP, 34.9% ± 15.7%; controls, 29.6 ± 13.3%;&nbsp;<em>P</em>&nbsp;&lt; 0.05). Comparing the cells with viable bacteria/phagocytosing PMNs, there were no significant differences between the two groups without the addition of the antibiotic.</p>
<p class="chapter-para">Treatment of neutrophils with clindamycin resulted in a statistically significant increase in the number of phagocytosing PMNs in each group (Figure 1<span id="jumplink-F1" class="xrefLink"></span>). Moreover, clindamycin elevated the percentage of the granulocytes with more than 10 internalized bacteria (Figure 2<span id="jumplink-F2" class="xrefLink"></span>). These differences were significant in AP patients (<em>P</em>&nbsp;&lt; 0.01) and controls (<em>P</em>&nbsp;&lt; 0.05). The PMNs with less than 10&nbsp;<em>P. gingivalis</em>&nbsp;were reduced, the result was statistically confirmed in the AP group (<em>P</em>&nbsp;&lt; 0.05, Figure 3<span id="jumplink-F3" class="xrefLink"></span>). In control subjects clindamycin significantly promoted intracellular killing (PMNs with viable&nbsp;<em>P. gingivalis</em>: without clindamycin, 20.7% ± 6.9%; with clindamycin, 14.0% ± 6.1%;&nbsp;<em>P</em>&nbsp;&lt; 0.01). The reduced number of granulocytes with viable bacteria in the LJP group was not statistically significant (Figure 4<span id="jumplink-F4" class="xrefLink"></span>).</p>
<h3 id="13022556" class="section-title">Phagocytosis of A. actinomycetemcomitans</h3>
<p class="chapter-para">The observations were similar when using&nbsp;<em>A. actinomycetemcomitans</em>&nbsp;as test strain. Without addition of an antibiotic more phagocytosing PMNs were seen in RPP patients (94.3% ± 4.7%) than in control subjects (91.8% ± 6.8%,&nbsp;<em>P</em>&nbsp;&lt; 0.05). Also there was a significant difference (<em>P</em>&nbsp;&lt; 0.05) in PMNs with less than 10 phagocytosed&nbsp;<em>A. actinomycetemcomitans</em>&nbsp;if comparing RPP group (39.3% ± 16.1%) and controls (30.0% ± 10.1%).</p>
<p class="chapter-para">By treating the PMNs with clindamycin significant increases both in the percentage of phagocytosing PMNs (Figure 1<span id="jumplink-F1" class="xrefLink"></span>) and the percentage of PMNs with more than 10 ingested&nbsp;<em>A. actinomycetemcomitans</em>&nbsp;(Figure 2<span id="jumplink-F2" class="xrefLink"></span>) were observed in each periodontitis and control group.</p>
<p class="chapter-para">In contrast to the result mentioned above, the number of cells with less than 10 phagocytosed bacteria was significantly reduced in all groups (Figure 3<span id="jumplink-F3" class="xrefLink"></span>). Also, the addition of clindamycin significantly depressed the percentage of viable bacteria/phagocytosing PMNs only in controls (<em>P</em>&nbsp;&lt; 0.05), while the difference in LJP patients was not significant (Figure 4<span id="jumplink-F4" class="xrefLink"></span>).</p>
<p>&nbsp;</p>
<h2 id="13022564" class="section-title">Discussion</h2>
<hr>
<p>&nbsp;</p>
<p class="chapter-para">Patients selected for the study suffered from different forms of periodontitis. The microbiological results showed that&nbsp;<em>P. gingivalis</em>&nbsp;comprised a high percentage of cfu in subgingival plaque samples collected from patients with both progressive forms of periodontitis (RPP and LJP), while&nbsp;<em>A. actinomycetemcomitans</em>&nbsp;was detected in a high number only in LJP patients. These microbiological findings confirm that relevant species were used for the phagocytosis assay.</p>
<p class="chapter-para">The fluorochrome PMN phagocytosis and killing assay described by Smith &amp; Rommel<span id="jumplink-R12" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R12"><sup>12</sup></a>&nbsp;and Pantazis &amp; Kniker<span id="jumplink-R13" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R13"><sup>13</sup></a>) was used to determine the effect of a subinhibitory concentration of clindamycin on the phagocytosing and killing properties of granulocytes obtained from the gingival sulci. The endpoint concentration of clindamycin in the cell suspension chosen in our test system was near the MIC for&nbsp;<em>P. gingivalis</em>&nbsp;and much lower than the MIC for the&nbsp;<em>A. actinomycetemcomitans</em>&nbsp;strain tested. The bactericidal effect of the antibiotic can be excluded as the time of exposure to bacteria was only 30 min and, in the periodontitis group, the number of granulocytes with viable&nbsp;<em>P. gingivalis</em>&nbsp;after addition of clindamycin was not significantly reduced.</p>
<p class="chapter-para">Comparisons between each periodontitis group and the controls showed an increased phagocytosis in RPP patients as response to the inflammation. This result was due to the higher number of phagocytes containing&nbsp;<em>P. gingivalis</em>&nbsp;and&nbsp;<em>A. actinomycetemcomitans</em>. However, significant differences between the controls and the periodontitis groups were observed when comparing the granulocytes with a high phagocytosing and intracellular killing capacity.</p>
<p class="chapter-para">Observations clearly confirmed a positive immunomodulating effect of clindamycin on phagocytosis by crevicular PMNs collected from both patients with periodontitis and periodontally healthy subjects. Treatment of neutrophils with clindamycin resulted in an increased number of phagocytosing cells in both periodontitis and control groups, regardless of whether&nbsp;<em>P. gingivalis</em>&nbsp;or&nbsp;<em>A. actinomycetemcomitans</em>&nbsp;was the test strain. Moreover, the percentage of granulocytes with more than 10 ingested bacteria (both for&nbsp;<em>P. gingivalis</em>&nbsp;and&nbsp;<em>A. actinomycetemcomitans</em>) was enhanced in all groups studied.</p>
<p class="chapter-para">Nevertheless, differences were observed between the periodontitis patients and periodontally healthy controls. An enhancement of the intracellular killing of&nbsp;<em>P. gingivalis</em>&nbsp;or&nbsp;<em>A. actinomycetemcomitans</em>&nbsp;after the addition of clindamycin was found only in controls. The lack of any enhancement in bactericidal activity of crevicular PMNs from periodontitis patients suggests that these cells have an intrinsic deficiency.</p>
<p class="chapter-para">The enhancement of opsonophagocytosis by clindamycin is known.<span id="jumplink-R10" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R10"><sup>10</sup></a>&nbsp;Incubation of granulocytes with clindamycin caused an increase in the proportion of granulocytes bearing Fc receptors,<span id="jumplink-R14" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R14"><sup>14</sup></a>&nbsp;but the adhesion of non-opsonized&nbsp;<em>Staphylococcus aureus</em>&nbsp;was decreased after addition of this antibiotic.<span id="jumplink-R15" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R15"><sup>15</sup></a>&nbsp;Clindamycin is highly concentrated in the cytoplasm of the granulocytes.<span id="jumplink-R16" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R16"><sup>16</sup></a>&nbsp;This high concentration in PMNs may promote the bactericidal effect on susceptible species in the cells even if the serum concentration is subinhibitory. Differing effects on intracellular killing have been described. Some authors<span id="jumplink-R17" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R17"><sup>17</sup></a><sup>,</sup><span id="jumplink-R18" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R18"><sup>18</sup></a>&nbsp;found an enhancement of intracellular killing, also of resistant species, while other studies have reported that there was no influence<span id="jumplink-R19" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R19"><sup>19</sup></a>&nbsp;or an inhibition of the respiratory burst.<span id="jumplink-R20" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R20"><sup>20</sup></a></p>
<p class="chapter-para">Clindamycin therapy is an effective means of treating periodontal disease due to obligate anaerobic bacilli such as&nbsp;<em>P. gingivalis</em>&nbsp;and&nbsp;<em>P. intermedia.</em>&nbsp;These species are sufficiently susceptible to this antibiotic.<span id="jumplink-R8" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R8"><sup>8</sup></a><sup>,</sup><span id="jumplink-R9" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R9"><sup>9</sup></a>&nbsp;The use of locally applied clindamycin gel inserted into periodontal pockets was beneficial in the treatment of advanced periodontitis by eliminating and preventing early recolonization of periodontopathogenic species and might avoid known side effects of systemic administration, such as antibioticassociated pseudomembranous enterocolitis.<span id="jumplink-R21" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R21"><sup>21</sup></a><sup>,</sup><span id="jumplink-R22" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R22"><sup>22</sup></a>&nbsp;The enhancement of phagocytosis against periodontopathogenic species is a useful side effect in periodontitis patients, although a promoting effect on intracellular killing was found only in healthy subjects. Other positive effects of clindamycin are the ability to penetrate into bone and the negative influence on the formation of biofilms.<span id="jumplink-R23" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R23"><sup>23</sup></a>&nbsp;However,&nbsp;<em>A. actinomycetemcomitans</em>&nbsp;is also an important species in periodontitis, especially in LJP and exhibits resistance to clindamycin.<span id="jumplink-R9" class="xrefLink"></span><a class="link link-ref link-reveal xref-default" data-open="R9"><sup>9</sup></a>&nbsp;Further&nbsp;<em>in vivo</em>&nbsp;studies are therefore necessary to find out if the improvement in phagocytosis alone justifies the use of clindamycin in such cases.</p>
<p>&nbsp;</p>
<p><strong>Figure 1.</strong></p>
<p>&nbsp;</p>
<p>Crevicular PMNs phagocytosing&nbsp;<em>Porphyromonas gingivalis</em>&nbsp;or&nbsp;<em>Actinobacillus actinomycetemcomitans</em>&nbsp;in different forms of periodontitis with and without the addition of 1 mg/L clindamycin (mean and standard deviation).&nbsp;<em>P. gingivalis</em>:▪ , without clindamycin;▪, with clindamycin;&nbsp;<em>A. actinomycetemcomitans</em>:▪, without clindamycin;▪, with clindamycin; ○,&nbsp;<em>P</em>&nbsp;&lt; 0.05; *,&nbsp;<em>P</em>&nbsp;&lt; 0.01.</p>
<p><strong>Figure 2.</strong></p>
<p>&nbsp;</p>
<p>Crevicular PMNs phagocytosing more than 10&nbsp;<em>Porphyromonas gingivalis</em>&nbsp;or&nbsp;<em>Actinobacillus actinomycetemcomitans</em>&nbsp;in different forms of periodontitis with and without the addition of 1 mg/L clindamycin (mean and standard deviation).&nbsp;<em>P. gingivalis</em>:▪, without clindamycin; , with clindamycin;▪<em>A. actinomycetemcomitans</em>:▪, without clindamycin;▪, with clindamycin; ○,&nbsp;<em>P</em>&nbsp;&lt; 0.05; *,&nbsp;<em>P</em>&nbsp;&lt; 0.01.</p>
<p><strong>Figure 3.</strong></p>
<p>&nbsp;</p>
<p>Crevicular PMNs phagocytosing less than 10&nbsp;<em>Porphyromonas gingivalis</em>&nbsp;or&nbsp;<em>Actinobacillus actinomycetemcomitans</em>&nbsp;in different forms of periodontitis with and without the addition of 1 mg/L clindamycin (mean and standard deviation).&nbsp;<em>P. gingivalis</em>:▪, without clindamycin;▪, with clindamycin;▪<em>A. actinomycetemcomitans</em>:▪, without clindamycin;▪, with clindamycin; ○,&nbsp;<em>P</em>&nbsp;&lt; 0.05; *,&nbsp;<em>P</em>&nbsp;&lt; 0.01.</p>
<p>&nbsp;</p>
<p><strong>Figure 4.</strong></p>
<p>&nbsp;</p>
<p>Crevicular PMNs containing viable&nbsp;<em>Porphyromonas gingivalis</em>&nbsp;or&nbsp;<em>Actinobacillus actinomycetemcomitans</em>/phagocytosing PMNs in different forms of periodontitis with and without the addition of 1 mg/L clindamycin (mean and standard deviation).&nbsp;<em>P. gingivalis</em>:▪, without clindamycin;▪, with clindamycin;&nbsp;<em>A. actinomycetemcomitans</em>:▪, without clindamycin;▪, with clindamycin; ○,&nbsp;<em>P</em>&nbsp;&lt; 0.05; *,&nbsp;<em>P</em>&nbsp;&lt; 0.01.</p>
<p>&nbsp;</p>
<h2 id="13022611" class="backreferences-title">References</h2>
<hr>
<p>&nbsp;</p>
<p>1 Cutler, C. W., Kalmar, J. R. &amp; Genco, C. A. (1995). Pathogenic strategies of the oral anaerobe, Porphyromonas gingivalis. Trends in Microbiology 3, 45–51.<br>
2 Ashkenazi, M., White, R. R. &amp; Dennison, D. K. (1992). Neutrophil modulation by Actinobacillus actinomycetemcomitans II. Phagocytosis and development of respiratory burst. Journal of Periodontal Research 27, 457–65.<br>
3 Sigusch, B., Klinger, G., Holtz, H. &amp; Suss, J. (1992). In vitro phagocytosis by crevicular phagocytes in various forms of periodontitis. Journal of Periodontology 63, 496–501.<br>
4 Offenbacher, S., Collins, J. G. &amp; Arnold, R. R. (1993). New clinical diagnostic strategies based on pathogenesis of disease. Journal of Periodontal Research 28, 523–35.<br>
5 Hart, T. C., Shapira L. &amp; Van Dyke, T. E. (1994). Neutrophil defects as risk factors for periodontal diseases. Journal of Periodontology 65, 521–9.<br>
6 Gordon, J. M. &amp; Walker, C. B. (1993). Current status of systemic antibiotic usage in destructive periodontal disease. Journal of Periodontology 64, Suppl., 760–71.<br>
7 Van Vlem, B., Vanholder, R., De Paepe, P., Vogelsaers, D. &amp; Ringoir, S. (1996). Immunomodulating effects of antibiotics: literature review. Infection 24, 275–91.<br>
8 Miyake, Y., Tsuruda, K., Okuda, K., Widowati, Iwamoto, Y. &amp; Suginaka, H. (1995). In vitro activity of tetracyclines, macrolides, quinolones, clindamycin and metronidazole against periodontopathic bacteria. Journal of Periodontal Research 30, 290–3.<br>
9 Eick, S., Pfister, W. &amp; Straube, E. (1999). Antimicrobial susceptibility of anaerobic and capnophilic bacteria isolated from odontogenic abscesses and rapidly progressive periodontitis. International Journal of Antimicrobial Agents 12, 41–6.<br>
10 Veringa, E. M., Lambe, D. W., Ferguson, D. A. &amp; Verhoef, J. (1989). Enhancement of opsonophagocytosis of Bacteroides spp. by clindamycin in subinhibitory concentrations. Journal of Antimicrobial Chemotherapy 23, 577–87.<br>
11 Mascellino, M. T., De Vito, M. L., Maclean-Feeney, E., Iegri, F. &amp; Catania, S. (1989). Phagocytosis and killing of A-protein positive Staphylococcus aureus in the presence of low doses of antibiotics. Drugs under Experimental and Clinical Research 15, 63–9.<br>
12 Smith, D. L. &amp; Rommel, F. (1977). A rapid micro method for the simultaneous determination of phagocytic-microbiocidal activity of human peripheral blood leukocytes in vitro. Journal of Immunological Methods 17, 241–7.<br>
13 Pantazis, C. G. &amp; Kniker, W. T. (1979). Assessment of blood leukocyte microbial killing by using a new fluorochrome microassay. Journal of the Reticuloendothelial Society 26, 155–70.<br>
14 Noess, A., Hauge, B. &amp; Solberg, C. O. (1989). Effects of clindamycin and cefuroxime on leukocyte membrane receptors and function. Chemotherapy 35, 193–9.<br>
15 Kohada, A., Miyake, Y., Sugai, M., Tsuru, H. &amp; Suginaka, H. (1991). Effects of antibiotics on nonopsonized adherence of Staphylococcus aureus to human polymorphonuclear leukocytes. Chemotherapy 37, 50–6.<br>
16 Hand, W. L. &amp; King-Thompson, N. L. (1990). Uptake of antibiotics by human polymorphonuclear leukocyte cytoplasts. Antimicrobial Agents and Chemotherapy 34, 1189–93.<br>
17 Bassaris, H. P., Lianou, P. E., Skoutelis, A. T. &amp; Papavassiliou, J. T. (1987). In-vivo effects of clindamycin on polymorphonuclear leucocyte phagocytosis and killing of Gram-negative organisms. Journal of Antimicrobial Chemotherapy 19, 467–73.<br>
18 Faden, H., Hong, J. J. &amp; Ogra, P. L. (1985). In-vivo effects of clindamycin on neutrophil function. Journal of Antimicrobial Chemotherapy 16, 649–57.<br>
19 Easmon, C. S. &amp; Crane, J. P. (1984). Cellular uptake of clindamycin and lincomycin. British Journal of Experimental Pathology 65, 725–30.<br>
20 Hand, W. L., Hand, D. L. &amp; King-Thompson, N. L. (1990). Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrobial Agents and Chemotherapy 34, 863–70.<br>
21 Sigusch, B., Eick, S., Klinger, G. &amp; Straube, E. (1994). Study of topical antibiotic therapy in patients with rapidly progressive periodontitis. Journal de Parodontologie &amp; d’Implantologie Orale, Abstracts Europerio 1, Abstract 76, p. 83.<br>
22 Sauvetre, E., Glupczynsky, Y., Labbe, M., Yourassowsky, E. &amp; Pourtois, M. (1993). The effect of clindamycin gel insert in periodontal pockets, as observed on smears and cultures. Infection 21, 245–51.<br>
23 Ichimiya, T., Yamasaki, T. &amp; Nasu, M. (1994). In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. Journal of Antimicrobial Chemotherapy 34, 331–41.<br>
© 2000 The British Society for Antimicrobial Chemotherapy</p>
<p>&nbsp;</p>
<h2>Source</h2>
<hr>
<p>&nbsp;</p>
<p><a href="https://academic.oup.com/jac/article/46/4/583/739785">https://academic.oup.com/jac/article/46/4/583/739785</a></p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/01/27/clindamycin-promotes-phagocytosis-and-intracellular-killing-of-periodontopathogenic-bacteria-by-crevicular-granulocytes-an-in-vitro-study/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/01/27/clindamycin-promotes-phagocytosis-and-intracellular-killing-of-periodontopathogenic-bacteria-by-crevicular-granulocytes-an-in-vitro-study/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5151 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>20.01.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/01/20/ciprofloxacin-for-post-exposure-prophylaxis-of-anthrax/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/01/20/ciprofloxacin-for-post-exposure-prophylaxis-of-anthrax/">Ciprofloxacin for Post-Exposure Prophylaxis of Anthrax</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><h2>Emergency Use Instructions for Healthcare Providers</h2>
<hr>
<p>&nbsp;</p>
<p>This fact sheet provides instructions for the use of ciprofloxacin for post-exposure prophylaxis (PEP) during an emergency involving anthrax (referred to as Emergency Use Instructions (EUI) fact sheet). Ciprofloxacin is FDA-approved for PEP of inhalation anthrax – to reduce the incidence or progression of disease following exposure to aerosolized&nbsp;<em>Bacillus anthracis (B. anthracis)</em>.<sup>1</sup>&nbsp;The Food and Drug Administration (FDA) has also issued an order permitting the emergency dispensing of oral formulations of ciprofloxacin without a prescription during an anthrax emergency to individuals who may have been exposed to&nbsp;<em>B. anthracis.</em><sup>2</sup></p>
<p>&nbsp;</p>
<h3>What is inhalation anthrax?</h3>
<p>Anthrax is a serious disease caused by the spore-forming bacterium&nbsp;<em>B. anthracis</em>. Inhalation anthrax is the most deadly form of the disease, with a historical mortality rate of approximately 90% for untreated cases. Inhalation anthrax occurs when an individual inhales aerosolized spores. It is not spread from person to person. Early symptoms include fever, chills, fatigue, cough or headache. Later symptoms include shortness of breath, chest pain, confusion or nausea. Symptoms usually occur within 7 days of inhaling anthrax spores, but can occur as soon as 24 hours after exposure or may take up to 6 to 7 weeks to appear (animal data show symptoms can occur more than 50 days after exposure).</p>
<p>&nbsp;</p>
<h3>Who should&nbsp;<strong>NOT</strong>&nbsp;take ciprofloxacin?</h3>
<hr>
<p>&nbsp;</p>
<p>Do not give ciprofloxacin to anyone who is allergic to a quinolone antibiotic (including ciprofloxacin) or has a history of myasthenia gravis.&nbsp;<strong>Avoid</strong>&nbsp;concomitant administration of ciprofloxacin and Zanaflex (tizanidine) since ciprofloxacin can increase effects of tizanidine (e.g., bradycardia, hypotension); consider switching either ciprofloxacin or tizanidine to an alternative drug.</p>
<p>&nbsp;</p>
<h3>What is the usual dose of ciprofloxacin for PEP of anthrax?</h3>
<p>The full PEP regimen is 60 days. During an anthrax emergency, recipients may receive an initial 10-day supply to begin ciprofloxacin therapy; public health officials will announce whether recipients need more ciprofloxacin and how to get additional quantities of the drug.</p>
<ul>
<li><strong>Children weighing 67 lbs (31 kg) or more and Adults (≥ 18 years)</strong>: Take one tablet (500 mg) by mouth every 12 hours (one tablet in the morning and one tablet in the evening) each day with a full glass of water (with or without food). For those who cannot swallow tablets, consider an oral suspension/liquid form (of ciprofloxacin or alternative drug) or a drug that can be mixed with food or liquid (such as doxycycline).</li>
<li><strong>Children weighing less than 67 lbs (31 kg)</strong>: Weight-based dosing of ciprofloxacin oral suspension every 12 hours (one dose in the morning and one dose in the evening) each day. For convenience, the table below provides dosing by weight-range based on 15 mg/kg derived calculation.<sup>3</sup>&nbsp;Ciprofloxacin oral suspension comes in two concentrations&nbsp;<strong>[<a href="https://www.cdc.gov/anthrax/public-health/cipro-eui-hcp.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fanthrax%2Fmedical-care%2Fcipro-eui-hcp.html#c250">5% (250 mg/5 mL)</a>&nbsp;and&nbsp;<a href="https://www.cdc.gov/anthrax/public-health/cipro-eui-hcp.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fanthrax%2Fmedical-care%2Fcipro-eui-hcp.html#c500">10% (500 mg/5 mL)</a>]</strong>&nbsp;and is supplied as ciprofloxacin microcapsules with diluent.
<ul>
<li>Follow the instructions provided with the oral suspension to mix the microcapsules in the diluent before dispensing the drug to the recipient. Write the dose on the bottle and mark the dose with a line on the graduated teaspoon or oral syringe.</li>
<li>Tell the recipient to shake the oral suspension very well (15 seconds) before each use.</li>
</ul>
</li>
</ul>
<p>&nbsp;</p>
<h4>Ciprofloxacin Oral Suspension: 250 mg/5 mL Concentration</h4>
<table class="table table-bordered table-sm table-striped bg-gray-l3 opt-in show-more-div-29">
<thead class="bg-primary">
<tr>
<th scope="col">Weight in pounds (kilograms)</th>
<th scope="col">Dose* in mL (mg)</th>
<th scope="col">Number of 100-mL bottles needed for 10-day supply for one child</th>
</tr>
</thead>
<tbody>
<tr class="expanded">
<td>≤ 7 lbs (≤ 3 kg)</td>
<td>1 mL (50 mg)</td>
<td>ONE (1) Bottle</td>
</tr>
<tr class="expanded">
<td>8–14 lbs (4–6 kg)</td>
<td>2 mL (100 mg)</td>
<td>ONE (1) Bottle</td>
</tr>
<tr class="expanded">
<td>15–22 lbs (7–10 kg)</td>
<td>3 mL (150 mg)</td>
<td>ONE (1) Bottle</td>
</tr>
<tr class="expanded">
<td>23–29 lbs (11–13 kg)</td>
<td>4 mL (200 mg)</td>
<td>ONE (1) Bottle</td>
</tr>
<tr class="expanded faded">
<td>30–36 lbs (14–16 kg)</td>
<td>5 mL (250 mg)</td>
<td>ONE (1) Bottle</td>
</tr>
<tr>
<td>37–44 lbs (17–20 kg)</td>
<td>6 mL (300 mg)</td>
<td>TWO (2) Bottles</td>
</tr>
<tr>
<td>45–51 lbs (21–23 kg)</td>
<td>7 mL (350 mg)</td>
<td>TWO (2) Bottles</td>
</tr>
<tr>
<td>52–58 lbs (24–26 kg)</td>
<td>8 mL (400 mg)</td>
<td>TWO (2) Bottles</td>
</tr>
<tr>
<td>59–66 lbs (27–30 kg)</td>
<td>9 mL (450 mg)</td>
<td>TWO (2) Bottles</td>
</tr>
<tr>
<td>&gt; 67 lbs (&gt; 31 kg)</td>
<td>10 mL (500 mg)</td>
<td>TWO (2) Bottles</td>
</tr>
</tbody>
</table>
<div id="show-more-div-29" bis_skin_checked="1"></div>
<p>*Dosage adjustment is needed for individuals with severe renal impairment (see package insert).<sup>1</sup></p>
<hr>
<h4><a id="c500"></a>Ciprofloxacin Oral Suspension: 500 mg/5 mL Concentration</h4>
<table class="table table-bordered table-sm table-striped bg-gray-l3 opt-in show-more-div-206">
<caption class="sr-only">Weight-based dosing of ciprofloxacin oral suspension every 12 hours (one dose in the morning and one dose in the evening) each day.</caption>
<thead class="bg-primary">
<tr>
<th scope="col">Weight in pounds (kilograms)</th>
<th scope="col">Dose* in mL (mg)</th>
<th scope="col">Number of 100-mL bottles needed for 10-day supply for one child</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 7 lbs (≤ 3 kg)</td>
<td>0.5 mL (50 mg)</td>
<td>ONE (1) Bottle</td>
</tr>
<tr>
<td>8–14 lbs (4–6 kg)</td>
<td>1 mL (100 mg)</td>
<td>ONE (1) Bottle</td>
</tr>
<tr>
<td>15–22 lbs (7–10 kg)</td>
<td>1.5 mL (150 mg)</td>
<td>ONE (1) Bottle</td>
</tr>
<tr>
<td>23–29 lbs (11–13 kg)</td>
<td>2 mL (200 mg)</td>
<td>ONE (1) Bottle</td>
</tr>
<tr>
<td>30–36 lbs (14–16 kg)</td>
<td>2.5 mL (250 mg)</td>
<td>ONE (1) Bottle</td>
</tr>
<tr>
<td>37–44 lbs (17–20 kg)</td>
<td>3 mL (300 mg)</td>
<td>ONE (1) Bottle</td>
</tr>
<tr>
<td>45–51 lbs (21–23 kg)</td>
<td>3.5 mL (350 mg)</td>
<td>ONE (1) Bottle</td>
</tr>
<tr>
<td>52–58 lbs (24–26 kg)</td>
<td>4 mL (400 mg)</td>
<td>ONE (1) Bottle</td>
</tr>
<tr>
<td>59–66 lbs (27–30 kg)</td>
<td>4.5 mL (450 mg)</td>
<td>ONE (1) Bottle</td>
</tr>
<tr>
<td>&gt; 67 lbs (&gt; 31 kg)</td>
<td>5 mL (500 mg)</td>
<td>ONE (1) Bottle</td>
</tr>
</tbody>
</table>
<div id="show-more-div-206" bis_skin_checked="1"></div>
<p>*Dosage adjustment is needed for individuals with severe renal impairment (see package insert).<sup>1</sup></p>
<p>&nbsp;</p>
<h3>What are common side effects of ciprofloxacin?</h3>
<p>Inform recipients that mild gastrointestinal side effects such as nausea, vomiting, and/or diarrhea, a mild sunburn or a<br>
vaginal yeast infection may be experienced but to continue taking ciprofloxacin. If these side effects become severe,<br>
over-the-counter or prescription drugs can help to relieve the symptoms.</p>
<h3>What are possible side effects of ciprofloxacin?</h3>
<p>Tell recipients to&nbsp;<strong>STOP</strong>&nbsp;the ciprofloxacin and get medical help immediately if they develop any of the following:</p>
<ul>
<li>Tendon rupture, tendinitis or joint problems</li>
<li>Serious allergic/hypersensitivity reactions (anaphylactic and/or severe rashes)</li>
<li>Liver problems (anorexia, jaundice, dark brown or tea-colored urine, pruritus or tender abdomen)</li>
<li>Central nervous system effects (seizures, tremors, paranoia, anxiety)</li>
<li>Serious heart rhythm changes (QT prolongation and torsade de pointes)</li>
<li>Severe stomach cramps with high fever or bloody diarrhea (antibiotic-associated diarrhea and pseudomembranous colitis)</li>
<li>Changes in sensation and possible nerve damage (peripheral neuropathy)</li>
</ul>
<h3>What should recipients avoid while taking ciprofloxacin?</h3>
<ul>
<li>If a recipient is taking Carafate (sucralfate), Videx (didanosine), phosphate binders or multivitamins, supplements or antacids containing magnesium, calcium, aluminum, iron or zinc, instruct the recipient to take ciprofloxacin at least 2 hours before or 6 hours after taking any of these products.</li>
<li>Ciprofloxacin can interact with certain drugs such as blood thinners (increased blood thinning), oral antidiabetic drugs (increased glucose-lowering effect), phenytoin (loss of seizure control), theophylline (increased theophylline concentration), or clozapine (irregular heartbeat). If a recipient is on these or other drugs with known interaction with ciprofloxacin, consider changing the dose of these drugs or recommending alternative drugs. For more information on ciprofloxacin drug interactions, please see package insert.</li>
</ul>
<h3>What additional information should be provided to recipients taking ciprofloxacin?</h3>
<ul>
<li>Ciprofloxacin can exacerbate myasthenia gravis symptoms. It can also greatly potentiate effects of Zanaflex (tizanidine) (e.g., bradycardia, hypotension). Instruct those with a history of myasthenia gravis or taking tizanidine to avoid taking ciprofloxacin.</li>
<li>Instruct recipients not to take ciprofloxacin with dairy products (like milk or yogurt) or calcium-fortified juices.</li>
<li>Ciprofloxacin can cause sun sensitivity. Instruct recipients to use sunscreen and cover exposed skin.</li>
<li>Ciprofloxacin, while not generally recommended for use in pregnancy, is recommended as antimicrobial PEP for anthrax during pregnancy and while breastfeeding due to the risks of anthrax. The very limited data available on ciprofloxacin use in pregnancy suggest the benefits of ciprofloxacin outweigh the risks.</li>
<li>Recipients may wish to cut back on their caffeine intake, as the caffeine half-life may be prolonged.</li>
<li>Instruct recipients to keep ciprofloxacin tablets dry and to store tablets and reconstituted oral suspension at room temperature (68–77°F or 20–25°C). Reconstituted oral suspension may be stored at room temperature up to 14 days.</li>
<li>If you have been asked to dispense ciprofloxacin with an expired date on the container, please note that FDA is allowing for the use of certain lots of ciprofloxacin beyond the labeled expiration date during an anthrax emergency based on scientific review. For more information, go to the FDA website at&nbsp;<a class="tp-link-policy" href="http://www.fda.gov/" data-domain-ext="gov">www.fda.gov<span class="sr-only">external icon</span></a>&nbsp;(search for “ciprofloxacin expiration”).</li>
<li>The Countermeasures Injury Compensation Program (CICP) is a federal program created to help pay for related costs of medical care and other specific expenses for eligible people seriously injured by the administration or use of certain medical countermeasures. Medical countermeasures may include vaccines, medications, devices or other items used to prevent, diagnose or treat the public during a public health emergency or security threat. For more information about CICP, visit&nbsp;<a class="tp-link-policy" href="https://www.hrsa.gov/cicp" data-domain-ext="gov">www.hrsa.gov/cicp<span class="sr-only">external icon</span></a>&nbsp;or call: 1-855-266-2427.</li>
</ul>
<p>&nbsp;</p>
<h3>Risk‐Benefit Statement</h3>
<p>Although ciprofloxacin has some potential and serious adverse events, the expected benefit of ciprofloxacin to help prevent disease and death associated with anthrax exposure outweigh these risks.</p>
<h3>Available Alternatives</h3>
<p>During an anthrax emergency, you will be informed of any alternative antibiotics that are available, such as doxycycline, levofloxacin or amoxicillin. The risks and benefits of available alternative antibiotics will be explained in their own fact sheets.</p>
<h3>Reporting Adverse Event or Medication Errors</h3>
<p>Report adverse events or medication errors to&nbsp;<a class="tp-link-policy" href="https://www.fda.gov/Safety/MedWatch/default.htm" data-domain-ext="gov">MedWatch<span class="sr-only">external icon</span></a>&nbsp;by completing a MedWatch Form 3500 or by calling 1‐800‐FDA‐1088.</p>
<h2>Source</h2>
<hr>
<p>&nbsp;</p>
<p><a href="https://www.cdc.gov/anthrax/public-health/cipro-eui-hcp.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fanthrax%2Fmedical-care%2Fcipro-eui-hcp.html">https://www.cdc.gov/anthrax/public-health/cipro-eui-hcp.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fanthrax%2Fmedical-care%2Fcipro-eui-hcp.html</a></p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/01/20/ciprofloxacin-for-post-exposure-prophylaxis-of-anthrax/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/01/20/ciprofloxacin-for-post-exposure-prophylaxis-of-anthrax/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5147 post type-post status-publish format-standard hentry category-articles"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>14.01.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/01/14/mutual-potentiation-drives-synergy-between-trimethoprim-and-sulfamethoxazole/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/01/14/mutual-potentiation-drives-synergy-between-trimethoprim-and-sulfamethoxazole/">Mutual potentiation drives synergy between trimethoprim and sulfamethoxazole</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><ul class="c-author-list js-etal-collapsed js-no-scroll" data-etal="25" data-etal-small="3" data-test="authors-list" data-component-authors-activator="authors-list">
<li class="c-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Yusuke-Minato" data-corresp-id="c1" aria-pressed="false" aria-expanded="false">Yusuke Minato</a>,&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Surendra-Dawadi" aria-pressed="false" aria-expanded="false">Surendra Dawadi</a>,&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Shannon_L_-Kordus" aria-pressed="false" aria-expanded="false">Shannon L. Kordus</a>,&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Abiram-Sivanandam" aria-pressed="false" aria-expanded="false">Abiram Sivanandam</a>,&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Courtney_C_-Aldrich" aria-pressed="false" aria-expanded="false">Courtney C. Aldrich</a>&nbsp;&amp;&nbsp;<a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-author-popup="auth-Anthony_D_-Baughn" data-corresp-id="c2" aria-pressed="false" aria-expanded="false">Anthony D. Baughn</a></li>
</ul>
<h2 id="Abs1" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Abstract</h2>
<hr>
<p>&nbsp;</p>
<p>Trimethoprim (TMP)-sulfamethoxazole (SMX) is a widely used synergistic antimicrobial combination to treat a variety of bacterial and certain fungal infections. These drugs act by targeting sequential steps in the biosynthetic pathway for tetrahydrofolate (THF), where SMX inhibits production of the THF precursor dihydropteroate, and TMP inhibits conversion of dihydrofolate (DHF) to THF. Consequently, SMX potentiates TMP by limiting de novo DHF production and this mono-potentiation mechanism is the current explanation for their synergistic action. Here, we demonstrate that this model is insufficient to explain the potent synergy of TMP-SMX. Using genetic and biochemical approaches, we characterize a metabolic feedback loop in which THF is critical for production of the folate precursor dihydropterin pyrophosphate (DHPPP). We reveal that TMP potentiates SMX activity through inhibition of DHPPP synthesis. Our study demonstrates that the TMP-SMX synergy is driven by mutual potentiation of the action of each drug on the other.</p>
<p>&nbsp;</p>
<h2 id="Sec1" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Introduction</h2>
<hr>
<p>&nbsp;</p>
<p>Some antimicrobial drug combinations show strongly synergistic effects, where the combined inhibitory activity is far greater than the sum of individual activities<sup>1</sup>. However, in most cases, it is not clear why combinations may act synergistically. A mixture of trimethoprim (TMP) and sulfamethoxazole (SMX), also known as Co-trimoxazole, is a widely used synergistic antimicrobial combination to treat a variety of bacterial infections<sup>2</sup>. TMP-SMX is also effective against certain fungal infections and is the major treatment choice for pneumocystis pneumonia, which is one of the most common opportunistic infections in people with HIV-AIDS<sup>3</sup>. In bacteria, SMX inhibits dihydropteroate (DHPte) production from the two folate precursors,&nbsp;<i>p</i>-aminobenzoic acid (PABA) and 6-hydroxymethyl-7,8-dihydropterin pyrophosphate (DHPPP) (Fig.&nbsp;1a)<sup>4</sup>. TMP inhibits the reduction of dihydrofolate (DHF) to tetrahydrofolate (THF)<sup>5</sup>. Although no conclusive evidence has been provided, it is generally accepted that the potent synergy between these drugs derives simply from the sequential inhibition of adjacent steps in microbial THF biosynthesis<sup>6</sup>. Mathematical modeling of this pathway suggests that this model is sufficient to explain how SMX action results in potentiation of TMP action, yet is inadequate to explain how TMP action potentiates SMX action<sup>7</sup>.</p>
<p>&nbsp;</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="figure1" data-lazy-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-018-03447-x/MediaObjects/41467_2018_3447_Fig1_HTML.jpg"><noscript><img src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-018-03447-x/MediaObjects/41467_2018_3447_Fig1_HTML.jpg" alt="figure1" /></noscript></p>
<p>&nbsp;</p>
<p>Synergistic activity of anti-folate combinations against&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;and&nbsp;<i>S</i>.&nbsp;<i>aureus</i>.&nbsp;<b>a</b>&nbsp;Targets of anti-folate compounds.&nbsp;<b>b</b>–<b>d</b>&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;BW25113 strain was grown overnight in LB medium. Cultures were washed twice and resuspended in M9-glucose, then inoculated into a 96-well round-bottom plate (Corning) containing the same medium with a range of concentrations of SMX, TMP, MAC173979, or combination of two compounds. Concentration ranges were as follows: SMX (0.024–25 µg ml<sup>−1</sup>), TMP (0.0078–1 µg ml<sup>−1</sup>), and MAC173979 (0.05–25 µg ml<sup>−1</sup>). MICs were determined by visible growth after 24 h incubation at 37 °C. Synergy was assessed by calculating FICI. FICI<sub>m</sub>, minimum value of FICI in the tested combinations is shown. Synergy (FICI<sub>m</sub> ≤ 0.5). No interaction (FICI<sub>m</sub> &gt; 0.5).&nbsp;<b>b</b>–<b>d</b>&nbsp;Graphical representations of&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;BW25113 checkerboard assays are shown. Representative data from at least three independent experiments are shown.&nbsp;<b>b</b>&nbsp;SMX and MAC173979.&nbsp;<b>c</b>&nbsp;TMP and MAC173979.&nbsp;<b>d</b>&nbsp;SMX and TMP</p>
<p>In this study, we take a systematic genetic approach, using&nbsp;<i>Escherichia coli</i>&nbsp;single-gene deletion mutants<sup>8</sup>, and discover that inhibition of DHPPP biosynthesis increases SMX activity. We also identify a functional metabolic feedback loop in the folate biosynthesis pathway by which TMP can also limit DHPPP biosynthesis. Collectively, our study indicates that TMP also potentiates SMX activity, and that the strong synergy between SMX and TMP is mediated by mutual potentiation. Our findings reveal a novel mechanism of drug synergism underlying the therapeutic efficacy of a widely established combination antimicrobial treatment and suggest that other metabolic pathways with functional feedback loops might be similarly susceptible to synergistic inhibitors.</p>
<p>&nbsp;</p>
<h2 id="Sec2" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Results</h2>
<hr>
<p>&nbsp;</p>
<h3 id="Sec3" class="c-article__sub-heading">Inhibition of sequential steps in THF synthesis is not always synergistic</h3>
<p>To test whether inhibition of other sequential steps in the THF pathway can produce synergistic activity we targeted synthesis of PABA, an essential precursor for DHPte, with the antimicrobial compound 3,3-dichloro-1-(3-nitrophenyl) prop-2-en-1-one (MAC173979), which has been shown to inhibit PABA synthesis in&nbsp;<i>E. coli</i><sup>9</sup>&nbsp;(Fig.&nbsp;<a href="https://www.nature.com/articles/s41467-018-03447-x#Fig1" data-track="click" data-track-label="link" data-track-action="figure anchor">1a</a>). As this biosynthetic module is located upstream of the SMX target, MAC173979 is expected to be synergistic with both SMX and TMP. We performed checkerboard assays to determine fractional inhibitory concentration indexes (FICIs) as a measure of interaction between antimicrobial agents<sup>10</sup>. We found that the combination of MAC173979 and SMX was only mildly synergistic (Fig.&nbsp;1b&nbsp;and Supplementary Fig.&nbsp;1a) and the combination of MAC173979 and TMP was merely additive and not synergistic (Fig.&nbsp;1c&nbsp;and Supplementary Fig.&nbsp;1b), while consistent with there being an unexplained aspect of synergy between TMP and SMX (Fig.&nbsp;1d&nbsp;and Supplementary Fig.&nbsp;1c). Further, although MAC173979 could potentiate susceptibility to SMX and, to a lesser degree, TMP, SMX and TMP did not potentiate susceptibility to MAC173979 (Fig.&nbsp;<a href="https://www.nature.com/articles/s41467-018-03447-x#Fig1" data-track="click" data-track-label="link" data-track-action="figure anchor">1b,c</a>). Thus, the interaction of the PABA biosynthesis inhibitor with both SMX and TMP is one of mono-potentiation. These FICI profiles show a stark contrast with the strong mutual potentiation observed between SMX and TMP (Fig.&nbsp;1d&nbsp;and Supplementary Fig.&nbsp;1c). Similar FICI profiles were observed for a clinical isolate of&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;(strain B11)<sup>11</sup>&nbsp;and methicillin-resistant&nbsp;<i>Staphylococcus aureus</i>&nbsp;(strain USA300)<sup>12</sup>, demonstrating that MAC173979 and TMP were not synergistic, whereas SMX and TMP were synergistic against these strains (Table&nbsp;<a href="https://www.nature.com/articles/s41467-018-03447-x#Tab1" data-track="click" data-track-label="link" data-track-action="table anchor">1</a>). These results confirmed that a model based on sequential inhibition within the bacterial THF biosynthesis pathway is not adequate to explain the potent synergy between SMX and TMP.</p>
<h3 id="Sec4" class="c-article__sub-heading">Folate precursors affect susceptibility to SMX and TMP</h3>
<p>To further evaluate synergy through targeting of sequential steps in THF synthesis, we assessed the impact of genetic impairment of steps upstream of DHPte synthesis on potency of SMX and TMP (Fig.&nbsp;<a href="https://www.nature.com/articles/s41467-018-03447-x#Fig2" data-track="click" data-track-label="link" data-track-action="figure anchor">2a</a>). It was previously suggested<sup><a id="ref-link-section-d19872e848" title="Brown, G. M. The biosynthesis of folic acid. II. Inhibition by sulfonamides. J. Biol. Chem. 237, 536–540 (1962)." href="https://www.nature.com/articles/s41467-018-03447-x#ref-CR13" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13">13</a></sup>&nbsp;and recently demonstrated that SMX acts by competing with PABA for ligation with DHPPP<sup>14</sup>. As a result, SMX forms dead-end complexes with DHPPP (dihydropterin-SMX)<sup>15</sup>&nbsp;and inhibits DHPte production through metabolic wasting<sup>13,&nbsp;16</sup>. Based on this model of metabolic wasting, we expected SMX activity would be influenced by the intracellular abundance of both PABA and DHPPP (Fig.&nbsp;2a). We previously found that genetic disruption of the PABA biosynthesis pathway potentiates SMX activity against&nbsp;<i>Mycobacterium tuberculosis</i><sup>17</sup>. Similar to&nbsp;<i>M</i>.&nbsp;<i>tuberculosis</i>, an&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;mutant strain deleted for&nbsp;<i>pabC</i>, encoding the aminodeoxychorismate lyase involved in PABA biosynthesis, showed 4-fold enhanced susceptibility to SMX (Fig.&nbsp;2b). In contrast, the&nbsp;<i>E</i>.&nbsp;<i>coli pabC</i>&nbsp;deletion mutant strain was only twofold more susceptible to TMP (Fig.&nbsp;2c). This observation is consistent with the finding that the combination of MAC173979 and SMX is mildly synergistic (Fig.&nbsp;1b&nbsp;and Supplementary Fig.&nbsp;1a), whereas the combination of MAC173979 and TMP is merely additive (Fig.&nbsp;1c&nbsp;and Supplementary Fig.&nbsp;1b). To determine the impact of DHPPP levels on SMX and TMP susceptibility, we utilized an&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;mutant strain deleted for&nbsp;<i>nudB</i>, which encodes dihydroneopterin triphosphate pyrophosphohydrolase<sup>18</sup>. Interestingly, this strain showed over 300-fold enhanced susceptibility to SMX and 60-fold enhanced susceptibility to TMP (Fig.&nbsp;2b, c), demonstrating that DHPPP levels are far more impactful than PABA levels on SMX and TMP susceptibility. Of note, the Δ<i>nudB</i>&nbsp;strain showed the same susceptibility to ceftazidime and ciprofloxacin as the parent strain, indicating that the enhanced drug susceptibility phenotype of the Δ<i>nudB</i>&nbsp;strain was specific to anti-folate drugs (Supplementary Table&nbsp;1).</p>
<p>&nbsp;</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="figure2" data-lazy-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-018-03447-x/MediaObjects/41467_2018_3447_Fig2_HTML.jpg"><noscript><img src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-018-03447-x/MediaObjects/41467_2018_3447_Fig2_HTML.jpg" alt="figure2" /></noscript></p>
<p>Folate deficiency potentiates SMX activity.&nbsp;<b>a</b>&nbsp;Schematic of&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;folate metabolism. Green characters indicate metabolites and enzymes that affect SMX susceptibility. Blue characters indicate enzymes that affect both SMX and TMP susceptibility.&nbsp;<b>b</b>&nbsp;MICs of SMX and TMP for&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;folate pathway mutants were determined after 24 h of incubation at 37 °C in M9-glucose medium. The selected&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;single-gene deletion mutants and their parental strain BW25113 (WT) from the Keio collection<sup>8</sup>&nbsp;were used.&nbsp;<b>c</b>&nbsp;Effects of inosine (Ino) and methionine (Met) on SMX MIC against&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;BW25113. Ino and Met were added to the medium at 10 µg ml<sup>−1</sup>. MICs of SMX were determined after 24 h incubation at 37 °C in M9-glucose medium. Representative data from at least three independent experiments are shown</p>
<p>&nbsp;</p>
<h3 id="Sec5" class="c-article__sub-heading">Folate-dependent metabolites affect susceptibility to SMX but not TMP</h3>
<p>As DHPPP is ultimately derived from the folate-dependent purine nucleotide guanosine-5’-triphosphate (GTP), we were curious to explore whether alterations in folate inter-conversion could impact on the susceptibility of&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;to TMP and SMX. The genes&nbsp;<i>glyA</i>&nbsp;and&nbsp;<i>gcvPHT</i>&nbsp;code for serine hydroxymethyltransferase and the glycine cleavage system, respectively. These two independent steps yield the 10-formyl-THF precursor 5,10-methylene-THF from THF (Fig.&nbsp;2a) and were previously associated with susceptibility to anti-folate drugs in a high throughput conditional gene essentiality study<sup>19,&nbsp;20</sup>. We observed that the&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;single-gene deletion mutants in these two steps had enhanced susceptibility to SMX (Fig.&nbsp;<a href="https://www.nature.com/articles/s41467-018-03447-x#Fig2" data-track="click" data-track-label="link" data-track-action="figure anchor">2b</a>) and complementation of individual mutants completely restored SMX susceptibility to the level of the parental strain (Supplementary Table&nbsp;<a href="https://www.nature.com/articles/s41467-018-03447-x#MOESM1" data-track="click" data-track-label="link" data-track-action="supplementary material anchor">2</a>). Interestingly, the&nbsp;<i>glyA</i>&nbsp;and&nbsp;<i>gcv</i>&nbsp;deletion mutant strains showed a level of TMP susceptibility that was comparable to that of the parental strain (Fig.&nbsp;<a href="https://www.nature.com/articles/s41467-018-03447-x#Fig2" data-track="click" data-track-label="link" data-track-action="figure anchor">2c</a>). These observations demonstrate that interference with 10-formyl-THF production mediates enhanced susceptibility to SMX and suggests that disruption of folate-dependent metabolism is the likely basis for potentiation of SMX activity by TMP.</p>
<p>We next investigated how disruption of 10-formyl-THF synthesis impacts SMX susceptibility. It has long been known that the combination of two THF-dependent metabolites, inosine and methionine, antagonizes SMX activity by an, as yet, uncharacterized mechanism (Fig.&nbsp;<a href="https://www.nature.com/articles/s41467-018-03447-x#Fig2" data-track="click" data-track-label="link" data-track-action="figure anchor">2b</a>)<sup><a id="ref-link-section-d19872e1063" title="Henry, R. J. The mode of action of sulfonamides. Bacteriol. Rev. 7, 175–262 (1943)." href="https://www.nature.com/articles/s41467-018-03447-x#ref-CR21" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21">21</a></sup>. We found that these metabolites also antagonized SMX susceptibility in the&nbsp;<i>E</i>.&nbsp;<i>coli glyA</i>&nbsp;and&nbsp;<i>gcv</i>&nbsp;deletion mutant strains. Since these deletion mutants showed the same level of SMX susceptibility as the parental strain in the presence of inosine and methionine, they are able to overcome the limited availability of 10-formyl-THF by supplementation with these two THF-dependent metabolites. Of note, inosine and methionine had no effect on TMP susceptibility in&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;(Supplementary Fig.&nbsp;2). Given that 10-formyl-THF is the essential cofactor for the de novo purine biosynthesis pathway and biosynthesis of the folate precursor DHPPP starts from GTP<sup>4</sup>, we hypothesized that limitation of 10-formyl-THF ultimately potentiates SMX susceptibility by impairing the DHPPP biosynthesis pathway. Consistent with this hypothesis, we observed that inosine and methionine did not antagonize SMX activity in the Δ<i>nudB</i>&nbsp;strain, indicating that these metabolites interfere with SMX action by increasing metabolic flux towards DHPPP biosynthesis (Fig.&nbsp;2b). Taken together, our findings suggest the existence of a previously unrecognized functional metabolic connection between downstream and upstream components of the bacterial folate biosynthetic pathway that dramatically impacts on SMX susceptibility.</p>
<h3 id="Sec6" class="c-article__sub-heading">TMP inhibits DHPPP biosynthesis</h3>
<p>As decreased DHPPP biosynthesis enhances SMX susceptibility, it is likely to be that TMP potentiates SMX activity by negatively impacting the DHPPP biosynthesis pathway (Fig.&nbsp;3a). To test this hypothesis, we developed liquid chromatography-tandem mass spectrometry (LC-MS/MS) analytical methods using authentic standards to quantify two of the DHPPP precursors, 7,8-dihydroneopterin (DHN) and 6-hydroxymethyl-7,8-dihydropterin (DHPt). We verified that when treated with TMP,&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;BW25113 strain showed significantly lower intracellular levels of both DHN and DHPt, relative to untreated controls (Fig.&nbsp;3b, c). TMP treatment did not affect intracellular level of PABA, suggesting that the TMP treatment only affected intracellular levels of a specific set of metabolites (Fig.&nbsp;3d). TMP treatment also negatively affected DHPt levels in&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;B11 and&nbsp;<i>S</i>.&nbsp;<i>aureus</i>&nbsp;USA300 strains (Fig.&nbsp;3e,f). Therefore, inhibition of THF biosynthesis by TMP directly impairs DHPPP biosynthesis.</p>
<p>&nbsp;</p>
<p><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3</b></p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="figure3" data-lazy-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-018-03447-x/MediaObjects/41467_2018_3447_Fig3_HTML.jpg"><noscript><img src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-018-03447-x/MediaObjects/41467_2018_3447_Fig3_HTML.jpg" alt="figure3" /></noscript></p>
<p>TMP inhibits DHPPP biosynthesis pathway. The impact of TMP on intracellular levels of&nbsp;<b>a</b>&nbsp;7,8-dihydroneopterin (DHN) and&nbsp;<b>b</b>,&nbsp;<b>e</b>,&nbsp;<b>f</b>&nbsp;6-hydroxymethyl-7,8-dihydropterin (DHPt),&nbsp;<b>c</b>&nbsp;PABA were determined by using LC-MS/MS. The results represent the mean and standard deviation of three biological replicates. **<i>p</i> &lt; 0.05. NS indicates no significant difference (<i>p</i> &gt; 0.05).&nbsp;<i>p</i>-values of pairwise comparisons were calculated by using the Student’s&nbsp;<i>t</i>-test.&nbsp;<b>d</b>&nbsp;Effects of TMP on DHPPP biosynthesis pathway. Red characters are metabolites that decrease intracellular amount in response to TMP treatment (THF<sup>23</sup>, GTP<sup>29</sup>, and ATP<sup>29</sup>&nbsp;were reported previously)</p>
<p>&nbsp;</p>
<p>If impairment of DHPPP synthesis is the mechanistic basis for TMP-mediated potentiation of SMX activity, it follows that TMP-SMX synergy should be abolished in the&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;Δ<i>nudB</i>&nbsp;strain. To evaluate TMP-SMX synergy we performed growth assays with wild-type&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;BW25113 and the Δ<i>nudB</i>&nbsp;strain in the presence of each drug at a concentration that by itself led to mild growth impairment (Fig.&nbsp;4a, b). As anticipated when TMP-SMX were combined, their synergistic action resulted in full growth inhibition of the wild-type strain (Fig.&nbsp;4a). In striking contrast, the combination of TMP-SMX showed an additive inhibitory effect on growth of the&nbsp;<i>E</i>.&nbsp;<i>coli</i>&nbsp;Δ<i>nudB</i>&nbsp;strain (Fig.&nbsp;4b). Furthermore, through the use of checkerboard assays we found that TMP-SMX showed additive effects against the Δ<i>nudB</i>&nbsp;strain (Fig.&nbsp;4c). Thus, synergy between TMP and SMX is contingent upon the ability of TMP to disrupt synthesis of DHPPP (Fig.&nbsp;4d).</p>
<p>&nbsp;</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="figure4" data-lazy-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-018-03447-x/MediaObjects/41467_2018_3447_Fig4_HTML.jpg"><noscript><img src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-018-03447-x/MediaObjects/41467_2018_3447_Fig4_HTML.jpg" alt="figure4" /></noscript></p>
<p>A metabolic feedback loop amplifies SMX-TMP activity.&nbsp;<b>a</b>,&nbsp;<b>b</b>&nbsp;SMX-TMP synergy was assessed by growth kinetics in the presence of a sub-inhibitory concentration of each drug and in combination. The results represent the mean and SD of three biological replicates.&nbsp;<b>a</b>&nbsp;Wild type (<i>E</i>.&nbsp;<i>coli</i>&nbsp;BW25113 strain) was grown in the presence of SMX (0.06 µg ml<sup>−1</sup>), TMP (0.125 µg ml<sup>−1</sup>), or a combination of SMX (0.06 µg ml<sup>−1</sup>) and TMP (0.125 µg ml<sup>−1</sup>).&nbsp;<b>b</b>&nbsp;Δ<i>nudB</i>&nbsp;(<i>E</i>.&nbsp;<i>coli</i>&nbsp;BW25113 Δ<i>nudB</i>) was grown in the presence of SMX (0.003 µg ml<sup>−1</sup>), TMP (0.0125 µg ml<sup>−1</sup>), or a combination of SMX (0.003 µg ml<sup>−1</sup>) and TMP (0.0125 µg ml<sup>−1</sup>).&nbsp;<b>c</b>&nbsp;SMX-TMP synergy against Δ<i>nudB</i>&nbsp;(<i>E</i>.&nbsp;<i>coli</i>&nbsp;BW25113 Δ<i>nudB</i>) was assessed by FICI. FICI<sub>m</sub>, minimum value of FICI for the tested combinations is shown. Representative data from at least three independent experiments are shown.&nbsp;<b>d</b>&nbsp;Relative metabolite abundance and metabolic flux are shown. No drug treatment (i), sub-inhibitory concentrations of each drug (ii), and combination of sub-inhibitory concentrations of each drug (iii). SMX treatment inhibits the accumulation of DHF by TMP that results in potentiation of TMP activity, and TMP treatment decreases DHPPP that potentiates SMX activity. Cyclic mutual potentiation results in amplified depletion of the essential cofactor THF</p>
<p>&nbsp;</p>
<h2 id="Sec7" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Discussion</h2>
<hr>
<p>&nbsp;</p>
<p>Over the past 50 years, the mechanistic basis for the potently synergistic action between TMP and SMX has been explained by an overly simplistic model. Hitchings first proposed that sulfa drugs such as SMX potentiate the action of TMP through inhibition of DHF accumulation, which enhances the interaction of TMP with its target DHF reductase<sup>22</sup>. Several studies have confirmed key elements of this model<sup>23,&nbsp;24</sup>. However, this model does not account for the ability of TMP to enhance microbial susceptibility to SMX. Our findings reveal that TMP potentiates SMX activity through the disruption of a previously unrecognized metabolic feedback loop and the cyclic mutual potentiation of these disruptions results in amplified depletion of the essential cofactor THF (Fig.&nbsp;4d). These findings highlight the importance of metabolic pathway structure in understanding antimicrobial drug interaction and will enable the identification of additional pathways that can be explored for potently synergistic antimicrobial based targeting.</p>
<p>&nbsp;</p>
<h2 id="Sec8" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">Methods</h2>
<hr>
<p>&nbsp;</p>
<h3 id="Sec9" class="c-article__sub-heading">Bacterial strains and growth conditions</h3>
<p>Bacterial strains and plasmids used in this study are listed in Supplementary Table&nbsp;3. Bacterial strains were grown in Lysogeny Broth (LB, Difco) or M9 minimal medium supplemented with 0.2% (vol:vol) glucose (M9-glucose) at 37 °C. 0.5% Casamino acids, pantothenate (f.c. 2 µg ml<sup>−1</sup>), nicotinamide (f.c. 2 µg ml<sup>−1</sup>), thiamin (f.c. 2 µg ml<sup>−1</sup>), and biotin (f.c. 100 ng ml<sup>−1</sup>) were supplemented to M9-glucose for growing&nbsp;<i>S</i>.&nbsp;<i>aureus</i>&nbsp;USA300 strain. When required, media were amended with penicillin G (Sigma-Aldrich) 150 µg ml<sup>−1</sup>&nbsp;or kanamycin (Teknova) 50 µg ml<sup>−1</sup>.</p>
<h3 id="Sec10" class="c-article__sub-heading c-article__sub-heading--divider">Strains construction</h3>
<p>For the complementation analyses, we cloned the&nbsp;<i>nudB</i>,&nbsp;<i>gcvP</i>,&nbsp;<i>gcvH</i>, and&nbsp;<i>gcvT</i>&nbsp;genes as follows. The DNA fragment, which contained the respective open reading frame, was amplified by PCR using chromosomal DNA of&nbsp;<i>E</i>.<i>&nbsp;coli</i>&nbsp;BW25113 as a template. Primers used for these constructs included&nbsp;<i>Sac</i>I and&nbsp;<i>Bam</i>HI restriction sites, respectively, and are listed in Supplementary Table&nbsp;4. The obtained PCR products were digested with&nbsp;<i>Sac</i>I and&nbsp;<i>Bam</i>HI, gel-purified and then ligated into&nbsp;<i>Sac</i>I–<i>Bam</i>HI digested pUC19. The resultant plasmid constructs were verified by DNA sequencing.</p>
<h3 id="Sec11" class="c-article__sub-heading c-article__sub-heading--divider">Antimicrobial agent susceptibility testing</h3>
<p>SMX and TMP were purchased from Sigma-Aldrich. MAC173979 was synthesized as previously described<sup>17</sup>. The minimum inhibitory concentrations (MICs) of SMX, TMP, and MAC173979 were determined by using the microdilution method.</p>
<p>Twofold dilution series of each antimicrobial agent in M9-glucose was prepared in 96-well round-bottom plates (Corning). Bacterial strains were grown overnight in LB medium, sub-cultured into fresh LB medium, and grown to mid-log phase. The cultures were washed twice and resuspended in M9-glucose, then inoculated into each well containing M9-glucose to OD<sub>600</sub>&nbsp;0.001. MICs were determined by visible growth after 24 h incubation at 37 °C. For Supplementary Figure&nbsp;<a href="https://www.nature.com/articles/s41467-018-03447-x#MOESM1" data-track="click" data-track-label="link" data-track-action="supplementary material anchor">1</a>, the same drug susceptibility testing was performed in 96 well flat bottom plate (Corning) and MICs were read spectrophotometrically (OD<sub>600</sub>) to determine the minimum amount of antimicrobial agent required to inhibit at least 50% of growth relative to a no drug control after 24 h incubation at 37 °C. Interaction between antimicrobial agents was assessed by using a checkerboard assay format to determine FICI of each agent in the presence of sub-inhibitory concentrations of another. FICI of antimicrobial agent combinations were calculated using the following equation, FICI = ([MIC drug A in presence of Drug B] [MIC of drug A]<sup>−1</sup>) + ([MIC of drug B in the presence of drug A] [MIC of drug B]<sup>−1</sup>). Minimum FICI (FICI<sub>m</sub>) represents the lowest fractional combination of antimicrobial agent pairs to achieve growth inhibition. FICI<sub>m</sub> ≤ 0.5 is regarded as synergistic.</p>
<h3 id="Sec12" class="c-article__sub-heading c-article__sub-heading--divider">Growth assays</h3>
<p>Bacterial strains were grown overnight in LB medium. The cultures were washed twice and resuspended in M9-glucose then inoculated into each well of a 96-well flat-bottom plate (Corning) containing M9-glucose containing different concentrations of SMX, TMP, or combination of SMX and TMP. Growth was monitored in a Synergy H1 Hybrid Multi-Mode Microplate Reader (BioTek) with the following settings (temperature 37 °C, continuous orbital shaking at 282 cpm (3 mm), read every hour at OD<sub>600</sub>).</p>
<h3 id="Sec13" class="c-article__sub-heading c-article__sub-heading--divider">Synthesis of DHPt</h3>
<p>Synthesis of DHPt was accomplished as shown in Supplementary Fig.&nbsp;3. The synthesis started with the degradation of commercially available folic acid. A solution of folic acid in 40% aqueous hydrogen bromide and excess bromine was heated using a previously described method to obtain 6-formylpterin in 52% yield<sup>25</sup>. Sodium borohydride-mediated reduction of 6-formylpterin in 0.1 N NaOH solution provided 6-hydroxymethylpterin in 95% yield. A well-established method for the selective reduction of 7,8 double bond of folate species was employed for the conversion of 6-hydroxymethylpterin to DHPt. This transformation was accomplished by using sodium dithionite as a reducing agent in the presence of ascorbic acid at pH 6.5<sup>26</sup>. Synthesized DHPt was fully characterized using&nbsp;<sup>1</sup>H,&nbsp;<sup>13</sup>C NMR and high-resolution mass spectrometry.</p>
<h3 id="Sec14" class="c-article__sub-heading c-article__sub-heading--divider">Liquid chromatography-tandem mass spectrometry</h3>
<h4 id="Sec15" class="c-article__sub-heading c-article__sub-heading--small">Sample preparation</h4>
<p>bacterial strains were grown until early log growth phase (OD<sub>600</sub>&nbsp;0.2–0.3). The cells were then diluted to OD<sub>600</sub>&nbsp;0.2 and were treated with 4 µg ml<sup>−1</sup>&nbsp;TMP. After 30 min, and 60 min with or without TMP treatment, 40 ml of each culture was collected by centrifugation. Metabolites were extracted by using 500 µl of acetonitrile:methanol:water (40:40:20) extraction buffer as previously described<sup><a id="ref-link-section-d19872e1524" title="Rabinowitz, J. D. &amp; Kimball, E. Acidic acetonitrile for cellular metabolome extraction from Escherichia coli. Anal. Chem. 79, 6167–6173 (2007)." href="https://www.nature.com/articles/s41467-018-03447-x#ref-CR27" data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27">27</a></sup>. One hundred and fifty microliters of each sample was evaporated using a SpeedVac Concentrator (Savant SC210A, Thermo Scientific) and reconstituted with 50 µL of 10 mM ammonium acetate (95:5 H<sub>2</sub>O:MeCN, pH 9.0) solution containing 200 nM internal standard (hydroxypteroic acid) for DHPt and DHN quantification. Similarly, for PABA quantification, 150 µL of each sample was evaporated and reconstituted with 50 µL of 10 mM aqueous ammonium acetate (pH 4.0) solution containing 100 nM internal standard (d<sub>4</sub>-PABA).</p>
<h4 id="Sec16" class="c-article__sub-heading c-article__sub-heading--small">DHPt and DHN quantification</h4>
<p>LC-MS/MS experiments were performed with Shimadzu UFLC-XR (LC) and AB Sciex QTRAP 5500 (MS) instruments. Synthetic DHPt and DHN (Santa Cruz Biotechnology) were used as authentic standards. Hydroxypteroic acid was used as an internal standard. Reverse-phase LC was performed on an Eclipse XDB-C8 column (4.6 × 150 mm, 5 µm particle size; Agilent, Santa Clara, CA). Mobile phase A was 10 mM ammonium acetate in H<sub>2</sub>O (pH 9.0), whereas mobile phase B was 10 mM ammonium acetate in 5:95 H<sub>2</sub>O:MeCN (pH 9.0). Initial conditions were 5% B from 0 to 1.0 min, after which the %B was increased to 70% from 1.0 to 5.3 min, then %B was increased to 90% from 5.3 to 5.7 min. The column was washed with 90% B from 5.7 to 6.5 min, returned to 5% B at 7.0 min, and allowed to re-equilibrate for 4 min in 5% B, to provide a total run time of 11 min. The flow rate was 0.5 mL min<sup>−1</sup>&nbsp;and the column oven was maintained at 35 °C. The injection volume was 10 µL. All analytes were analyzed by MS in positive ionization mode by Multiple Reaction Monitoring (MRM). To determine the optimum MRM settings (Supplementary Table&nbsp;<a href="https://www.nature.com/articles/s41467-018-03447-x#MOESM1" data-track="click" data-track-label="link" data-track-action="supplementary material anchor">3</a>), each analyte was infused at a concentration of 10 µM in 50:50 H<sub>2</sub>O:MeCN containing 10 mM ammonium acetate at pH 9.0 onto the MS by a syringe pump at a flow of 10 µL min<sup>−1</sup>. During direct infusion, we also observed the presence of oxidized forms of both the analytes, i.e., the presence of neopterin and 6-hydroxymethylpterin. Such auto air oxidation of reduced form of pterin species has been known; thus, we decided to measure both the oxidized and reduced forms of these species (Supplementary Table&nbsp;3). Peak areas of both species were combined for the analytes before converting to the concentration. Analyte and internal standard peak areas were calculated (MultiQuant, version 2.0.2). Analyte peak areas were normalized to internal standard peak areas and the concentrations of DHN and DHPt were determined using appropriate standard curves.</p>
<h4 id="Sec17" class="c-article__sub-heading c-article__sub-heading--small">PABA quantification</h4>
<p>PABA was quantified using a previously developed LC-MS/MS method<sup>28</sup>. d<sub>4</sub>-PABA was used as an internal standard. Reverse-phase LC was performed on a Kinetix C18 column (50 × 2.1 mm, 2.6 μm particle size; Phenomenex, Torrance, CA). Mobile phase A was 10 mM ammonium acetate in H<sub>2</sub>O (pH 4.0), whereas mobile phase B was 0.1% formic acid in 5:95 H<sub>2</sub>O:MeOH. Initial conditions were 5% B, after which the proportion of B was increased to 10% in 1.0 min, 15% in 4.0 min, 55% in 4.5 min, 92% in 4.75 min, returned to initial composition of eluent (5% B) in 5.0 min, and then held for 3.0 min in order to re-equilibrate the column, which provided a total run time of 8 min. The flow rate was 0.5 mL min<sup>−1</sup>&nbsp;and the column oven was maintained at 35 °C. The injection volume was 10 µL. Both analyte and internal standard were analyzed by electrospray ionization MS in positive ionization mode by MRM. The transformations&nbsp;<i>m/z</i>&nbsp;138.05 → 94.07 for PABA and 142.08 → 98.09 for d<sub>4</sub>-PABA were used for MRM (Supplementary Table&nbsp;5).</p>
<h3 id="Sec18" class="c-article__sub-heading c-article__sub-heading--divider">Data availability</h3>
<p>All relevant data are available in this article and its Supplementary Information files, or from the corresponding authors upon request.</p>
<p>&nbsp;</p>
<h2 id="Bib1" class="c-article-section__title js-section-title js-c-reading-companion-sections-item">References</h2>
<hr>
<p>&nbsp;</p>
<ol class="c-article-references">
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR1" class="c-article-references__text">Yeh, P., Tschumi, A. I. &amp; Kishony, R. Functional classification of drugs by properties of their pairwise interactions.&nbsp;<i>Nat. Genet</i>&nbsp;<b>38</b>, 489–494 (2006).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR2" class="c-article-references__text">Smilack, J. D. Trimethoprim-sulfamethoxazole.&nbsp;<i>Mayo Clin. Proc.</i>&nbsp;<b>74</b>, 730–734 (1999).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR3" class="c-article-references__text">Morris, A. et al. Current epidemiology of Pneumocystis pneumonia.&nbsp;<i>Emerg. Infect. Dis.</i>&nbsp;<b>10</b>, 1713–1720 (2004).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR4" class="c-article-references__text">Green, J. M. &amp; Matthews, R. G. Folate biosynthesis, reduction, and polyglutamylation and the interconversion of folate derivatives.&nbsp;<i>EcoSal Plus</i>&nbsp;<b>2,</b>doi:10.1128/ecosalplus.3.6.3.6&nbsp;(2007).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR5" class="c-article-references__text">Poe, M., Breeze, A. S., Wu, J. K., Short, C. R. &amp; Hoogsteen, K. Dihydrofolate reductase from trimethoprim-resistant&nbsp;<i>Escherichia coli</i>&nbsp;MB 3746 and MB 3747. Purification, amino acid composition, and some kinetic properties.&nbsp;<i>J. Biol. Chem.</i>&nbsp;<b>254</b>, 1799–1805 (1979).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR6" class="c-article-references__text">Bushby, S. R. Synergy of trimethoprim-sulfamethoxazole.&nbsp;<i>Can. Med Assoc. J.</i>&nbsp;<b>112</b>, 63–66 (1975).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR7" class="c-article-references__text">Harvey, R. J. Interaction of two inhibitors which act on different enzymes of a metabolic pathway.&nbsp;<i>J. Theor. Biol.</i>&nbsp;<b>74</b>, 411–437 (1978).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR8" class="c-article-references__text">Baba, T. et al. Construction of&nbsp;<i>Escherichia coli</i>&nbsp;K-12 in-frame, single-gene knockout mutants: the Keio collection.&nbsp;<i>Mol. Syst. Biol.</i>&nbsp;<b>2</b>, 2006.0008 (2006).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR9" class="c-article-references__text">Zlitni, S., Ferruccio, L. F. &amp; Brown, E. D. Metabolic suppression identifies new antibacterial inhibitors under nutrient limitation.&nbsp;<i>Nat. Chem. Biol.</i>&nbsp;<b>9</b>, 796–804 (2013).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR10" class="c-article-references__text">Odds, F. C. Synergy, antagonism, and what the chequerboard puts between them.&nbsp;<i>J. Antimicrob. Chemother.</i>&nbsp;<b>52</b>, 1 (2003).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR11" class="c-article-references__text">Hirsch, E. B. et al. Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates.&nbsp;<i>Int J. Antimicrob. Agents</i>&nbsp;<b>46</b>, 642–647 (2015).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR12" class="c-article-references__text">Kennedy, A. D. et al. Epidemic community-associated methicillin-resistant&nbsp;<i>Staphylococcus aureus</i>: recent clonal expansion and diversification.&nbsp;<i>Proc. Natl Acad. Sci. USA</i>&nbsp;<b>105</b>, 1327–1332 (2008).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR13" class="c-article-references__text">Brown, G. M. The biosynthesis of folic acid. II. Inhibition by sulfonamides.&nbsp;<i>J. Biol. Chem.</i>&nbsp;<b>237</b>, 536–540 (1962).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR14" class="c-article-references__text">Yun, M. K. et al. Catalysis and sulfa drug resistance in dihydropteroate synthase.&nbsp;<i>Science</i>&nbsp;<b>335</b>, 1110–1114 (2012).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR15" class="c-article-references__text">Bock, L., Miller, G. H., Schaper, K. J. &amp; Seydel, J. K. Sulfonamide structure-activity relationships in a cell-free system. 2. Proof for the formation of a sulfonamide-containing folate analog.&nbsp;<i>J. Med Chem.</i>&nbsp;<b>17</b>, 23–28 (1974).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR16" class="c-article-references__text">Palmer, A. C. &amp; Kishony, R. Opposing effects of target overexpression reveal drug mechanisms.&nbsp;<i>Nat. Commun.</i>&nbsp;<b>5</b>, 4296 (2014).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR17" class="c-article-references__text">Thiede, J. M. et al. Targeting intracellular p-aminobenzoic acid production potentiates the anti-tubercular action of antifolates.&nbsp;<i>Sci. Rep.</i>&nbsp;<b>6</b>, 38083 (2016).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR18" class="c-article-references__text">Gabelli, S. B. et al. Structure and function of the&nbsp;<i>E. coli</i>&nbsp;dihydroneopterin triphosphate pyrophosphatase: a Nudix enzyme involved in folate biosynthesis.&nbsp;<i>Structure</i>&nbsp;<b>15</b>, 1014–1022 (2007).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR19" class="c-article-references__text">Ogwang, S. et al. Bacterial conversion of folinic acid is required for antifolate resistance.&nbsp;<i>J. Biol. Chem.</i>&nbsp;<b>286</b>, 15377–15390 (2011).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR20" class="c-article-references__text">Nichols, R. J. et al. Phenotypic landscape of a bacterial cell.&nbsp;<i>Cell</i>&nbsp;<b>144</b>, 143–156 (2011).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR21" class="c-article-references__text">Henry, R. J. The mode of action of sulfonamides.&nbsp;<i>Bacteriol. Rev.</i>&nbsp;<b>7</b>, 175–262 (1943).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR22" class="c-article-references__text">Hitchings, G. H. Folate antagonists as antibacterial and antiprotozoal agents.&nbsp;<i>Ann. N. Y. Acad. Sci.</i>&nbsp;<b>186</b>, 444–451 (1971).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR23" class="c-article-references__text">Quinlivan, E. P., McPartlin, J., Weir, D. G. &amp; Scott, J. Mechanism of the antimicrobial drug trimethoprim revisited.&nbsp;<i>FASEB J.</i>&nbsp;<b>14</b>, 2519–2524 (2000).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR24" class="c-article-references__text">Kwon, Y. K. et al. A domino effect in antifolate drug action in&nbsp;<i>Escherichia coli</i>.&nbsp;<i>Nat. Chem. Biol.</i>&nbsp;<b>4</b>, 602–608 (2008).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR25" class="c-article-references__text">Thijssen, H. H. A simple method for preparing 2-amino-4-hydroxy-6-formylpteridine, a precursor of the pteridine substrate of dihydropteroate biosynthesis.&nbsp;<i>Anal. Biochem.</i>&nbsp;<b>54</b>, 609–611 (1973).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR26" class="c-article-references__text">Furrer, H-J, Bieri J. H., &amp; Viscontini, M. Conformational analysis of 5,6,7,8-tetrahydropteroic acid and 5,6,7,8-tetrahydro-L-folic acid.&nbsp;<i>Helvetica Chimica Acta</i>&nbsp;<b>61,</b>&nbsp;2744–2751 (1978).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR27" class="c-article-references__text">Rabinowitz, J. D. &amp; Kimball, E. Acidic acetonitrile for cellular metabolome extraction from&nbsp;<i>Escherichia coli</i>.&nbsp;<i>Anal. Chem.</i>&nbsp;<b>79</b>, 6167–6173 (2007).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR28" class="c-article-references__text">Dhananjeyan, M. R. et al. Simultaneous determination of procaine and para-aminobenzoic acid by LC-MS/MS method.&nbsp;<i>J. Chromatogr. B Anal. Technol. Biomed. Life Sci.</i>&nbsp;<b>847</b>, 224–230 (2007).</p>
</li>
<li class="c-article-references__item js-c-reading-companion-references-item">
<p id="ref-CR29" class="c-article-references__text">Kwon, Y. K., Higgins, M. B. &amp; Rabinowitz, J. D. Antifolate-induced depletion of intracellular glycine and purines inhibits thymineless death in E. coli.&nbsp;<i>ACS Chem. Biol.</i>&nbsp;<b>5</b>, 787–795 (2010).</p>
</li>
</ol>
<p>&nbsp;</p>
<h2>Source</h2>
<hr>
<p>&nbsp;</p>
<p><a href="https://www.nature.com/articles/s41467-018-03447-x">https://www.nature.com/articles/s41467-018-03447-x</a></p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/01/14/mutual-potentiation-drives-synergy-between-trimethoprim-and-sulfamethoxazole/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/01/14/mutual-potentiation-drives-synergy-between-trimethoprim-and-sulfamethoxazole/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><div class="btPagination boldSection gutter" bis_skin_checked="1"><div class="port" bis_skin_checked="1"><div class="paging onLeft" bis_skin_checked="1"><p class="pagePrev"><a href="/../../../../category/articles/page/2/">Newer Posts</a></p></div><div class="paging onRight" bis_skin_checked="1"><p class="pageNext"><a href="/../../../../category/articles/page/4/">Older Posts</a></p></div></div></div>
</div>
</div>
</div>
<!--PAGE-CONTENT-END-HERE-->

<div class="bt_bb_wrapper"><section id="bt_section610e3a31c4f1c" data-parallax="0.7" data-parallax-offset="0" class="boldSection btDivider topSpaced bottomSemiSpaced btDarkSkin gutter boxed inherit btParallax" style="background-color:#1a86d3  !important;"><div class="port"><div class="boldCell"><div class="boldCellInner"><div class="boldRow "><div class="boldRowInner">
<div class="rowItem col-md-3 col-sm-6 col-ms-12 btTextLeft" data-width="3"><div class="rowItemContent">
<header class="header btClear small btDash bottomDash  regular"><div class="btSuperTitle"><span>HONG KONG</span></div>
<div class="dash"><h4><span class="headline">Headquarter</span></h4></div></header><span class="btIco btIcoDefaultType btIcoSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../index.html" target="no_target" data-ico-es="&#xe964;" class="btIcoHolder"><span>+852 3575 9046 </span></a></span><div class="btClear btSeparator noBorder"><hr></div>
<span class="btIco btIcoDefaultType btIcoSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../index.html" target="_self" data-ico-fa="&#xf0c1;" class="btIcoHolder"><span>www.ikigaicorporation.com</span></a></span><div class="btClear btSeparator noBorder"><hr></div>
<div class="bpgPhoto btDefaultHoverType">
<a href="./../../../../index.html" target="_self" title=""></a>
<div class="boldPhotoBox"><div class="bpbItem"><div class="btImage">
<img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="" title="" data-lazy-src="./../../../../wp-content/uploads/2020/05/HK-e1588760431256.png"><noscript><img src="./../../../../wp-content/uploads/2020/05/HK-e1588760431256.png" alt="" title=""></noscript>
</div></div></div>
<div class="captionPane btDarkSkin btTextCenter">
<div class="captionTable">
<div class="captionCell">
<div class="captionTxt"></div>
</div>
</div>
</div>
</div>
</div></div>
<div class="rowItem col-md-6 col-sm-12 btTextLeft" data-width="6"><div class="rowItemContent">
<header class="header btClear small btDash bottomDash  regular"><div class="btSuperTitle"><span>LOCATIONS</span></div>
<div class="dash"><h4><span class="headline">Our network</span></h4></div></header><div class="btClear btSeparator bottomSmallSpaced noBorder"><hr></div>
<div class="boldRow "><div class="boldRowInner">
<div class="rowItem rowInnerItem col-sm-6  btTextLeft"><div class="rowItemContent">
<div class="bpgPhoto btDefaultHoverType"><div class="btImage">
<img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="" title="						" data-lazy-src="./../../../../wp-content/uploads/2016/10/world-dot-map-gray-320x156.png"><noscript><img src="./../../../../wp-content/uploads/2016/10/world-dot-map-gray-320x156.png" alt="" title="						"></noscript>
</div></div>
<div class="btClear btSeparator topSmallSpaced noBorder"><hr></div>
</div></div>
<div class="rowItem rowInnerItem col-sm-6  btTextLeft"><div class="rowItemContent">
<header class="header btClear small  "><div class="btSuperTitle"><span>OUR NETWORK</span></div></header><div class="btClear btSeparator bottomExtraSmallSpaced noBorder"><hr></div>
<span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Asia</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Americas</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Middle East</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Europe</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Africa</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Oceania</span></a></span>
</div></div>
</div></div>
<div class="btClear btSeparator bottomExtraSmallSpaced noBorder"><hr></div>
<div class="btClear btSeparator bottomSemiSpaced noBorder"><hr></div>
</div></div>
<div class="rowItem col-md-3 col-sm-6 col-ms-12 btTextLeft" data-width="3"><div class="rowItemContent">
<header class="header btClear small btDash bottomDash  regular"><div class="btSuperTitle"><span>GET IN TOUCH</span></div>
<div class="dash"><h4><span class="headline">Follow us</span></h4></div></header><div class="btClear btSeparator bottomSmallSpaced noBorder"><hr></div>
<span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://www.facebook.com/ikigaicorporationcom" target="no_target" data-ico-fa="&#xf09a;" class="btIcoHolder"></a></span><span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://www.instagram.com/ikigaicorporation" target="no_target" data-ico-fa="&#xf16d;" class="btIcoHolder"></a></span><span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://www.google.com/maps/place/IKIGAI+CORPORATION+LTD/@22.3937048,113.9694348,17z/data=!3m1!4b1!4m5!3m4!1s0x3403fb18add189e3:0xccf4eec041856f0d!8m2!3d22.3936999!4d113.9716288" target="no_target" data-ico-fa="&#xf1a0;" class="btIcoHolder"></a></span><span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://wa.me/message/UZHAWI3JZQDVB1" target="no_target" data-ico-fa="&#xf232;" class="btIcoHolder"></a></span><div class="btClear btSeparator bottomSemiSpaced noBorder"><hr></div>
</div></div>
</div></div></div></div></div></section></div>
<footer>
  <section class="boldSection gutter btSiteFooter btGutter">
<div class="port">
<div class="boldRow">
<div class="rowItem btFooterCopy col-md-6 col-sm-12 btTextLeft">
<p class="copyLine">Ikigai Corporation Company is a leading pharmaceutical contract development and manufacturing organisation (CDMO) for both APIs and finished dose forms.</p> </div>
<div class="rowItem btFooterMenu col-md-6 col-sm-12 btTextRight">
<ul id="menu-primary-menu-1" class="menu">
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-3253"><a title="						" href="./../index.html">Home</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3403"><a href="./../about-us/index.html">About us</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-3451 current_page_item menu-item-3459"><a href="./index.html" aria-current="page">Our Technology</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3256"><a title="						" href="./../services/index.html">Product Portfolio</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3872"><a href="./../policies/index.html">Policies</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3594"><a href="./../services/partner_with_us/index.html">Partner with us</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3494"><a href="./../careers/index.html">Careers</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4734"><a href="./../library/index.html">Library</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3438"><a href="./../contact/index.html">Contact</a></li>
</ul> </div>
</div>
</div>
</section>
</footer>
</div>
<script >window.addEventListener('DOMContentLoaded', function() {
				(function( $ ) {
					$( document ).ready(function() {
						
						var time_notation = '24';
						
						var time = function() {
							
							if ( time_notation == '12' ) {
								var time = moment().tz( 'Asia/Hong_Kong' ).format( 'h:mm A' );
							} else {
								var time = moment().tz( 'Asia/Hong_Kong' ).format( 'H:mm' );
							}

							$( '#time610e3a31c10e7 .btIconWidgetText' ).html( time );
						}
						setInterval( function() {
							time();
						}, 1000 );
						time();
					});
				})( jQuery );
			});</script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-includes/js/comment-reply.min.js?ver=5.8" id="comment-reply-js" defer></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" id="buttonizer_frontend_javascript-js-extra">
/* <![CDATA[ */
var buttonizer_ajax = {"ajaxurl":".\/wp-admin\/admin-ajax.php","version":"2.4.3","buttonizer_path":".\/wp-content\/plugins\/buttonizer-multifunctional-button","buttonizer_assets":".\/wp-content\/plugins\/buttonizer-multifunctional-button\/assets\/","base_url":".","current":[],"in_preview":"","is_admin":"","cache":"ec7e88ea4f3f1891d22d4075828b5b63","enable_ga_clicks":"1"};
/* ]]> */
</script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/buttonizer-multifunctional-button/assets/frontend.min.js?v=7ab4fd8a7cd8bd136942183145de39a0&#038;ver=5.8" id="buttonizer_frontend_javascript-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/modal-for-elementor/js/bootstrap.js?ver=1620657753" id="bootstrap-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/modal-for-elementor/js/popup.js?ver=1620657753" id="modal-popup-js-js" defer></script>
<script  data-rocket-type="text/javascript" id="rocket-browser-checker-js-after">
"use strict";var _createClass=function(){function defineProperties(target,props){for(var i=0;i<props.length;i++){var descriptor=props[i];descriptor.enumerable=descriptor.enumerable||!1,descriptor.configurable=!0,"value"in descriptor&&(descriptor.writable=!0),Object.defineProperty(target,descriptor.key,descriptor)}}return function(Constructor,protoProps,staticProps){return protoProps&&defineProperties(Constructor.prototype,protoProps),staticProps&&defineProperties(Constructor,staticProps),Constructor}}();function _classCallCheck(instance,Constructor){if(!(instance instanceof Constructor))throw new TypeError("Cannot call a class as a function")}var RocketBrowserCompatibilityChecker=function(){function RocketBrowserCompatibilityChecker(options){_classCallCheck(this,RocketBrowserCompatibilityChecker),this.passiveSupported=!1,this._checkPassiveOption(this),this.options=!!this.passiveSupported&&options}return _createClass(RocketBrowserCompatibilityChecker,[{key:"_checkPassiveOption",value:function(self){try{var options={get passive(){return!(self.passiveSupported=!0)}};window.addEventListener("test",null,options),window.removeEventListener("test",null,options)}catch(err){self.passiveSupported=!1}}},{key:"initRequestIdleCallback",value:function(){!1 in window&&(window.requestIdleCallback=function(cb){var start=Date.now();return setTimeout(function(){cb({didTimeout:!1,timeRemaining:function(){return Math.max(0,50-(Date.now()-start))}})},1)}),!1 in window&&(window.cancelIdleCallback=function(id){return clearTimeout(id)})}},{key:"isDataSaverModeOn",value:function(){return"connection"in navigator&&!0===navigator.connection.saveData}},{key:"supportsLinkPrefetch",value:function(){var elem=document.createElement("link");return elem.relList&&elem.relList.supports&&elem.relList.supports("prefetch")&&window.IntersectionObserver&&"isIntersecting"in IntersectionObserverEntry.prototype}},{key:"isSlowConnection",value:function(){return"connection"in navigator&&"effectiveType"in navigator.connection&&("2g"===navigator.connection.effectiveType||"slow-2g"===navigator.connection.effectiveType)}}]),RocketBrowserCompatibilityChecker}();
</script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" id="rocket-preload-links-js-extra">
/* <![CDATA[ */
var RocketPreloadLinksConfig = {"excludeUris":"\/(.+\/)?feed\/?.+\/?|\/(?:.+\/)?embed\/|\/(index\\.php\/)?wp\\-json(\/.*|$)|\/wp-admin\/|\/logout\/|\/pudra\/","usesTrailingSlash":"1","imageExt":"jpg|jpeg|gif|png|tiff|bmp|webp|avif","fileExt":"jpg|jpeg|gif|png|tiff|bmp|webp|avif|php|pdf|html|htm","siteUrl":".","onHoverDelay":"100","rateThrottle":"3"};
/* ]]> */
</script>
<script  data-rocket-type="text/javascript" id="rocket-preload-links-js-after">
(function() {
"use strict";var r="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},e=function(){function i(e,t){for(var n=0;n<t.length;n++){var i=t[n];i.enumerable=i.enumerable||!1,i.configurable=!0,"value"in i&&(i.writable=!0),Object.defineProperty(e,i.key,i)}}return function(e,t,n){return t&&i(e.prototype,t),n&&i(e,n),e}}();function i(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}var t=function(){function n(e,t){i(this,n),this.browser=e,this.config=t,this.options=this.browser.options,this.prefetched=new Set,this.eventTime=null,this.threshold=1111,this.numOnHover=0}return e(n,[{key:"init",value:function(){!this.browser.supportsLinkPrefetch()||this.browser.isDataSaverModeOn()||this.browser.isSlowConnection()||(this.regex={excludeUris:RegExp(this.config.excludeUris,"i"),images:RegExp(".("+this.config.imageExt+")$","i"),fileExt:RegExp(".("+this.config.fileExt+")$","i")},this._initListeners(this))}},{key:"_initListeners",value:function(e){-1<this.config.onHoverDelay&&document.addEventListener("mouseover",e.listener.bind(e),e.listenerOptions),document.addEventListener("mousedown",e.listener.bind(e),e.listenerOptions),document.addEventListener("touchstart",e.listener.bind(e),e.listenerOptions)}},{key:"listener",value:function(e){var t=e.target.closest("a"),n=this._prepareUrl(t);if(null!==n)switch(e.type){case"mousedown":case"touchstart":this._addPrefetchLink(n);break;case"mouseover":this._earlyPrefetch(t,n,"mouseout")}}},{key:"_earlyPrefetch",value:function(t,e,n){var i=this,r=setTimeout(function(){if(r=null,0===i.numOnHover)setTimeout(function(){return i.numOnHover=0},1e3);else if(i.numOnHover>i.config.rateThrottle)return;i.numOnHover++,i._addPrefetchLink(e)},this.config.onHoverDelay);t.addEventListener(n,function e(){t.removeEventListener(n,e,{passive:!0}),null!==r&&(clearTimeout(r),r=null)},{passive:!0})}},{key:"_addPrefetchLink",value:function(i){return this.prefetched.add(i.href),new Promise(function(e,t){var n=document.createElement("link");n.rel="prefetch",n.href=i.href,n.onload=e,n.onerror=t,document.head.appendChild(n)}).catch(function(){})}},{key:"_prepareUrl",value:function(e){if(null===e||"object"!==(void 0===e?"undefined":r(e))||!1 in e||-1===["http:","https:"].indexOf(e.protocol))return null;var t=e.href.substring(0,this.config.siteUrl.length),n=this._getPathname(e.href,t),i={original:e.href,protocol:e.protocol,origin:t,pathname:n,href:t+n};return this._isLinkOk(i)?i:null}},{key:"_getPathname",value:function(e,t){var n=t?e.substring(this.config.siteUrl.length):e;return n.startsWith("/")||(n="/"+n),this._shouldAddTrailingSlash(n)?n+"/":n}},{key:"_shouldAddTrailingSlash",value:function(e){return this.config.usesTrailingSlash&&!e.endsWith("/")&&!this.regex.fileExt.test(e)}},{key:"_isLinkOk",value:function(e){return null!==e&&"object"===(void 0===e?"undefined":r(e))&&(!this.prefetched.has(e.href)&&e.origin===this.config.siteUrl&&-1===e.href.indexOf("?")&&-1===e.href.indexOf("#")&&!this.regex.excludeUris.test(e.href)&&!this.regex.images.test(e.href))}}],[{key:"run",value:function(){"undefined"!=typeof RocketPreloadLinksConfig&&new n(new RocketBrowserCompatibilityChecker({capture:!0,passive:!0}),RocketPreloadLinksConfig).init()}}]),n}();t.run();
}());
</script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/slick.min.js?ver=5.8" id="slick-min-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/jquery.magnific-popup.min.js?ver=5.8" id="jquery-magnific-popup-min-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/iscroll.js?ver=1620657753" id="iscroll-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/fancySelect.js?ver=1620657753" id="fancySelect-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/misc.js?ver=1620657753" id="industrial-misc-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/dir.hover.js?ver=1620657753" id="industrial-dir-hover-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/sliders.js?ver=1620657753" id="industrial-sliders-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/bt_parallax.js?ver=1620657753" id="industrial-bt-parallax-js" defer></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" id="cookie-notice-front-js-extra">
/* <![CDATA[ */
var cnArgs = {"ajaxUrl":".\/wp-admin\/admin-ajax.php","nonce":"870ef1de7b","hideEffect":"fade","position":"bottom","onScroll":"1","onScrollOffset":"100","onClick":"0","cookieName":"cookie_notice_accepted","cookieTime":"604800","cookieTimeRejected":"604800","cookiePath":"\/","cookieDomain":"","redirection":"0","cache":"1","refuse":"0","revokeCookies":"0","revokeCookiesOpt":"automatic","secure":"1"};
/* ]]> */
</script>
<script  async data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/cookie-notice/includes/../js/front.min.js?ver=2.1.0" id="cookie-notice-front-js"></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" src="./../../../../wp-includes/js/wp-embed.min.js?ver=5.8" id="wp-embed-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/moment.js?ver=1620657753" id="bt_moment-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/moment-timezone-with-data.js?ver=1620657753" id="bt_moment_timezone-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/industrial/imagesloaded.pkgd.min.js?ver=5.8" id="boldthemes_imagesloaded-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/industrial/packery.pkgd.min.js?ver=5.8" id="boldthemes_packery-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/bt_grid_tweak.js?ver=1620658021" id="boldthemes_grid_tweak-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/bt_grid.js?ver=1620658021" id="boldthemes_grid-js" defer></script>

<div id="cookie-notice" role="banner" class="cookie-notice-hidden cookie-revoke-hidden cn-position-bottom" aria-label="Cookie Notice" style="background-color: rgba(0,0,0,1);">
<div class="cookie-notice-container" style="color: #fff;">
<span id="cn-notice-text" class="cn-text-container">We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.</span><span id="cn-notice-buttons" class="cn-buttons-container"><a href="#" id="cn-accept-cookie" data-cookie-set="accept" class="cn-set-cookie cn-button bootstrap" aria-label="I AGREE, thank you.">I AGREE, thank you.</a><a href="./../../../../services/privacy-policy/index.html" target="_blank" id="cn-more-info" class="cn-more-info cn-button bootstrap" aria-label="Privacy policy">Privacy policy</a></span><a href="javascript:void(0);" id="cn-close-notice" data-cookie-set="accept" class="cn-close-icon" aria-label="I AGREE, thank you."></a>
</div>
</div>
 <script  data-rocket-type="text/javascript">window.addEventListener('DOMContentLoaded', function() {
        jQuery(document).ready(function ($) {
            //$( document ).ajaxStart(function() {
            //});

			
            for (var i = 0; i < document.forms.length; ++i) {
                var form = document.forms[i];
				if ($(form).attr("method") != "get") { $(form).append('<input type="hidden" name="kNEuIGs" value="ToGFEeP2A" />'); }
if ($(form).attr("method") != "get") { $(form).append('<input type="hidden" name="-rgtSF" value="PeoHbQdFwGR2kU" />'); }
            }

			
            $(document).on('submit', 'form', function () {
				if ($(this).attr("method") != "get") { $(this).append('<input type="hidden" name="kNEuIGs" value="ToGFEeP2A" />'); }
if ($(this).attr("method") != "get") { $(this).append('<input type="hidden" name="-rgtSF" value="PeoHbQdFwGR2kU" />'); }
                return true;
            });

			
            jQuery.ajaxSetup({
                beforeSend: function (e, data) {

                    //console.log(Object.getOwnPropertyNames(data).sort());
                    //console.log(data.type);

                    if (data.type !== 'POST') return;

                    if (typeof data.data === 'object' && data.data !== null) {
						data.data.append("kNEuIGs", "ToGFEeP2A");
data.data.append("-rgtSF", "PeoHbQdFwGR2kU");
                    }
                    else {
                        data.data =  data.data + '&kNEuIGs=ToGFEeP2A&-rgtSF=PeoHbQdFwGR2kU';
                    }
                }
            });

        });
	});</script>
<script src="./../../../../live_search.js"></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript">window.lazyLoadOptions={elements_selector:"img[data-lazy-src],.rocket-lazyload",data_src:"lazy-src",data_srcset:"lazy-srcset",data_sizes:"lazy-sizes",class_loading:"lazyloading",class_loaded:"lazyloaded",threshold:300,callback_loaded:function(element){if(element.tagName==="IFRAME"&&element.dataset.rocketLazyload=="fitvidscompatible"){if(element.classList.contains("lazyloaded")){if(typeof window.jQuery!="undefined"){if(jQuery.fn.fitVids){jQuery(element).parent().fitVids()}}}}}};window.addEventListener('LazyLoad::Initialized',function(e){var lazyLoadInstance=e.detail.instance;if(window.MutationObserver){var observer=new MutationObserver(function(mutations){var image_count=0;var iframe_count=0;var rocketlazy_count=0;mutations.forEach(function(mutation){for(i=0;i<mutation.addedNodes.length;i++){if(typeof mutation.addedNodes[i].getElementsByTagName!=='function'){continue}
if(typeof mutation.addedNodes[i].getElementsByClassName!=='function'){continue}
images=mutation.addedNodes[i].getElementsByTagName('img');is_image=mutation.addedNodes[i].tagName=="IMG";iframes=mutation.addedNodes[i].getElementsByTagName('iframe');is_iframe=mutation.addedNodes[i].tagName=="IFRAME";rocket_lazy=mutation.addedNodes[i].getElementsByClassName('rocket-lazyload');image_count+=images.length;iframe_count+=iframes.length;rocketlazy_count+=rocket_lazy.length;if(is_image){image_count+=1}
if(is_iframe){iframe_count+=1}}});if(image_count>0||iframe_count>0||rocketlazy_count>0){lazyLoadInstance.update()}});var b=document.getElementsByTagName("body")[0];var config={childList:!0,subtree:!0};observer.observe(b,config)}},!1)</script><script data-no-minify="1" async src="./../../../../wp-content/plugins/wp-rocket/assets/js/lazyload/16.1/lazyload.min.js" type="06cd7e663a0e46d4271fe72d-text/javascript"></script><script src="./../../../../cdn-cgi/scripts/7d0fa10a/cloudflare-static/rocket-loader.min.js" data-cf-settings="06cd7e663a0e46d4271fe72d-|49" defer></script><script type="text/javascript">(function(){window['__CF$cv$params']={r:'67b14aa0bd2192f8',m:'43df34172ca0f4f68ebbecbcf9a5a00029aba502-1628347556-1800-AVTlhDW4t9yA80xF5UdjoXKJiq7B7xNjRkAuPvixBxFixLosCDHCFG2h63XgOhBwRiCIDj2P9TKIHYBnV4kRgrcIoT5BrroyHzIFxwvjgkVmd115AGEcIIJPkP66qAQCQm/6tYO8Bkqd31TIv3OlW/z8inBUFtnaZsPjnH1RBzcf',s:[0xc47a4f690a,0xb1c6885590],}})();</script><script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67b14aa0bd2192f8","version":"2021.7.0","r":1,"token":"e3b748a178054eff95051ca851daefa1","si":10}'></script>
</body>
</html>